

FOR



ORDS

FACILITY
ONCOLOGY
REGISTRY
DATA
STANDARDS



Commission
on Cancer

FORDS

Facility Oncology Registry Data Standards Revised for 2016

(Incorporates all updates since FORDS was originally published in July 2002)

Includes updates to January 1, 2016

See Appendix C for a summary of changes since 2010.



**© 2016 AMERICAN COLLEGE OF SURGEONS
All Rights Reserved**

Table of Contents

| | |
|--|-------------|
| PREFACE 2016 | x |
| SECTION ONE: CASE ELIGIBILITY AND OVERVIEW OF CODING PRINCIPLES | 1–34 |
| CASE ELIGIBILITY | 3 |
| TUMORS REQUIRED BY THE COC TO BE ACCESSIONED, ABSTRACTED, FOLLOWED AND SUBMITTED TO THE NATIONAL CANCER DATA BASE (NCDB)..... | 3 |
| REPORTABLE-BY-AGREEMENT CASES | 3 |
| AMBIGUOUS TERMS AT DIAGNOSIS | 4 |
| CLASS OF CASE | 5 |
| DATE OF FIRST CONTACT | 5 |
| OVERVIEW OF CODING PRINCIPLES | 7 |
| UNIQUE PATIENT IDENTIFIER CODES | 7 |
| NATIONAL PROVIDER IDENTIFIER..... | 7 |
| CODING DATES | 7 |
| CANCER IDENTIFICATION..... | 8 |
| PATIENT ADDRESS AND RESIDENCY RULES..... | 18 |
| IN UTERO DIAGNOSIS AND TREATMENT | 19 |
| COMORBIDITIES AND COMPLICATIONS / SECONDARY DIAGNOSES | 19 |
| STAGE OF DISEASE AT INITIAL DIAGNOSIS | 20 |
| AJCC TNM STAGING..... | 21 |
| COLLABORATIVE STAGE DATA COLLECTION SYSTEM | 22 |
| FIRST COURSE OF TREATMENT | 23 |
| TREATMENT, PALLIATIVE, AND PROPHYLACTIC CARE | 31 |
| EMBOLIZATION..... | 32 |
| OUTCOMES | 32 |
| CASE ADMINISTRATION | 34 |
| SECTION TWO: INSTRUCTIONS FOR CODING | 36 |
| PATIENT IDENTIFICATION | 37 |
| ACCESSION NUMBER..... | 38 |
| SEQUENCE NUMBER | 39 |
| MEDICAL RECORD NUMBER..... | 41 |
| SOCIAL SECURITY NUMBER | 42 |

PATIENT IDENTIFICATION (CONTINUED)

LAST NAME.....43
FIRST NAME.....44
MIDDLE NAME45
PATIENT ADDRESS (NUMBER AND STREET) AT DIAGNOSIS46
PATIENT ADDRESS AT DIAGNOSIS–SUPPLEMENTAL47
CITY/TOWN AT DIAGNOSIS48
STATE AT DIAGNOSIS49
POSTAL CODE AT DIAGNOSIS..... 51
ADDRESS AT DX--COUNTRY52
COUNTY AT DIAGNOSIS53
PATIENT ADDRESS (NUMBER AND STREET) CURRENT54
PATIENT ADDRESS CURRENT–SUPPLEMENTAL55
CITY/TOWN–CURRENT56
STATE–CURRENT57
POSTAL CODE–CURRENT (ZIP CODE).....59
ADDRESS CURRENT--COUNTRY60
TELEPHONE61
BIRTHPLACE--STATE.....62
BIRTHPLACE--COUNTRY63
DATE OF BIRTH.....64
DATE OF BIRTH FLAG65
RACE 1.....67
RACE 2.....69
RACE 4.....71
RACE 5.....72
SPANISH ORIGIN–ALL SOURCES (SPANISH/HISPANIC ORIGIN).....73
SEX.....74
PRIMARY PAYER AT DIAGNOSIS75
COMORBIDITIES AND COMPLICATIONS #177
COMORBIDITIES AND COMPLICATIONS #279
COMORBIDITIES AND COMPLICATIONS #481

| | |
|--|----------------|
| COMORBIDITIES AND COMPLICATIONS #6..... | 83 |
| COMORBIDITIES AND COMPLICATIONS #7..... | 84 |
| COMORBIDITIES AND COMPLICATIONS #8..... | 85 |
| COMORBIDITIES AND COMPLICATIONS #9..... | 86 |
| COMORBIDITIES AND COMPLICATIONS #10..... | 87 |
| SECONDARY DIAGNOSIS #1 | 88 |
| SECONDARY DIAGNOSIS #2 | 90 |
| SECONDARY DIAGNOSIS #3 | 92 |
| SECONDARY DIAGNOSIS #4 | 94 |
| SECONDARY DIAGNOSIS #5 | 96 |
| SECONDARY DIAGNOSIS #6 | 98 |
| SECONDARY DIAGNOSIS #7 | 100 |
| SECONDARY DIAGNOSIS #8 | 102 |
| SECONDARY DIAGNOSIS #9 | 104 |
| SECONDARY DIAGNOSIS #10 | 106 |
| NPI–MANAGING PHYSICIAN | 108 |
| NPI–FOLLOWING PHYSICIAN..... | 109 |
| NPI–PRIMARY SURGEON | 110 |
| NPI–PHYSICIAN #3 (Radiation Oncologist–CoC Preferred)..... | 111 |
| NPI–PHYSICIAN #4 (Medical Oncologist–CoC Preferred)..... | 112 |
| CANCER IDENTIFICATION | 113-133 |
| CLASS OF CASE | 113 |
| NPI–INSTITUTION REFERRED FROM..... | 116 |
| NPI–INSTITUTION REFERRED TO..... | 117 |
| DATE OF FIRST CONTACT | 118 |
| DATE OF FIRST CONTACT FLAG | 119 |
| DATE OF INITIAL DIAGNOSIS | 120 |
| PRIMARY SITE | 121 |
| LATERALITY | 122 |
| HISTOLOGY | 123 |
| BEHAVIOR CODE | 124 |
| GRADE/DIFFERENTIATION..... | 126 |
| LYMPH-VASCULAR INVASION..... | 128 |
| DIAGNOSTIC CONFIRMATION | 129 |

| | |
|---|----------------|
| REGIONAL LYMPH NODES EXAMINED..... | 132 |
| REGIONAL LYMPH NODES POSITIVE | 133 |
| STAGE OF DISEASE AT DIAGNOSIS..... | 134-228 |
| DATE OF SURGICAL DIAGNOSTIC AND STAGING PROCEDURE..... | 135 |
| RX DATE–DX/STG PROC FLAG | 136 |
| SURGICAL DIAGNOSTIC AND STAGING PROCEDURE..... | 138 |
| SURGICAL DIAGNOSTIC AND STAGING PROCEDURE AT THIS FACILITY..... | 140 |
| TUMOR SIZE SUMMARY | 142 |
| METS AT DIAGNOSIS – BONE | 145 |
| METS AT DIAGNOSIS – BRAIN..... | 147 |
| METS AT DIAGNOSIS – DISTANT LYMPH NODES | 149 |
| METS AT DIAGNOSIS – LIVER | 151 |
| METS AT DIAGNOSIS – LUNG..... | 153 |
| METS AT DIAGNOSIS – OTHER..... | 155 |
| CLINICAL T | 157 |
| CLINICAL N..... | 159 |
| CLINICAL M | 160 |
| CLINICAL STAGE GROUP | 160 |
| CLINICAL STAGE (PREFIX/SUFFIX) DESCRIPTOR..... | 162 |
| STAGED BY (CLINICAL STAGE) | 163 |
| PATHOLOGIC T | 165 |
| PATHOLOGIC N | 167 |
| PATHOLOGIC M | 168 |
| PATHOLOGIC STAGE GROUP..... | 169 |
| PATHOLOGIC STAGE (PREFIX/SUFFIX) DESCRIPTOR..... | 170 |
| STAGED BY (PATHOLOGIC STAGE) | 171 |
| SEER SUMMARY STAGE 2000 | 173 |
| COLLABORATIVE STAGE INPUT DATA ITEMS | 174-185 |
| CS TUMOR SIZE..... | 175 |
| CS EXTENSION | 176 |
| CS TUMOR SIZE/EXT EVAL | 177 |
| CS LYMPH NODES | 178 |
| CS LYMPH NODES EVAL..... | 179 |
| CS METS AT DX..... | 180 |
| CS METS AT DX–BONE | 181 |
| CS METS AT DX–BRAIN | 182 |

| | |
|--|----------------|
| STAGE OF DISEASE AT DIAGNOSIS (CONTINUED) | |
| CS METS AT DX–LIVER..... | 183 |
| CS METS AT DX–LUNG | 184 |
| CS METS EVAL..... | 185 |
| COLLABORATIVE STAGE SITE-SPECIFIC FACTORS | 186-211 |
| CS SITE-SPECIFIC FACTOR 1..... | 187 |
| CS SITE-SPECIFIC FACTOR 2..... | 188 |
| CS SITE-SPECIFIC FACTOR 3..... | 189 |
| CS SITE-SPECIFIC FACTOR 4..... | 190 |
| CS SITE-SPECIFIC FACTOR 5..... | 191 |
| CS SITE-SPECIFIC FACTOR 6..... | 192 |
| CS SITE-SPECIFIC FACTOR 7..... | 193 |
| CS SITE-SPECIFIC FACTOR 8..... | 194 |
| CS SITE-SPECIFIC FACTOR 9..... | 195 |
| CS SITE-SPECIFIC FACTOR 10..... | 196 |
| CS SITE-SPECIFIC FACTOR 12..... | 198 |
| CS SITE-SPECIFIC FACTOR 13..... | 199 |
| CS SITE-SPECIFIC FACTOR 14..... | 200 |
| CS SITE-SPECIFIC FACTOR 15..... | 201 |
| CS SITE-SPECIFIC FACTOR 16..... | 202 |
| CS SITE-SPECIFIC FACTOR 17..... | 203 |
| CS SITE-SPECIFIC FACTOR 18..... | 204 |
| CS SITE-SPECIFIC FACTOR 19..... | 205 |
| CS SITE-SPECIFIC FACTOR 20..... | 206 |
| CS SITE-SPECIFIC FACTOR 21..... | 207 |
| CS SITE-SPECIFIC FACTOR 22..... | 208 |
| CS SITE-SPECIFIC FACTOR 23..... | 209 |
| CS SITE-SPECIFIC FACTOR 24..... | 210 |
| CS SITE-SPECIFIC FACTOR 25..... | 211 |
| COLLABORATIVE STAGE DERIVED DATA ITEMS..... | 212-228 |
| DERIVED AJCC-6 T..... | 213 |
| DERIVED AJCC-6 T DESCRIPT | 214 |
| DERIVED AJCC-6 N | 215 |
| DERIVED AJCC-6 N DESCRIPT..... | 216 |
| DERIVED AJCC-6 M DESCRIPT | 218 |
| DERIVED AJCC-6 STAGE GROUP | 219 |

STAGE OF DISEASE AT DIAGNOSIS (CONTINUED)

| | |
|----------------------------------|-----|
| DERIVED AJCC-7 T | 220 |
| DERIVED AJCC-7 T DESCRIPT | 221 |
| DERIVED AJCC-7 N | 222 |
| DERIVED AJCC-7 N DESCRIPT | 223 |
| DERIVED AJCC-7 M | 224 |
| DERIVED AJCC-7 M DESCRIPT | 225 |
| DERIVED AJCC-7 STAGE GROUP | 226 |
| DERIVED SS1977 | 227 |
| DERIVED SS2000 | 228 |

FIRST COURSE OF TREATMENT 229-319

| | |
|---|-----|
| DATE OF FIRST COURSE OF TREATMENT | 230 |
| DATE 1ST CRS RX FLAG | 231 |
| RX SUMM – TREATMENT STATUS | 233 |
| DATE OF FIRST SURGICAL PROCEDURE | 234 |
| RX DATE–SURGERY FLAG | 235 |
| DATE OF MOST DEFINITIVE SURGICAL RESECTION | 237 |
| RX DATE MST DEFN SRG FLAG | 238 |
| SURGICAL PROCEDURE OF PRIMARY SITE | 240 |
| APPROACH – SURGERY OF THE PRIMARY SITE AT THIS FACILITY | 242 |
| SURGICAL MARGINS OF THE PRIMARY SITE | 243 |
| SCOPE OF REGIONAL LYMPH NODE SURGERY | 244 |
| SCOPE OF REGIONAL LYMPH NODE SURGERY AT THIS FACILITY | 248 |
| SURGICAL PROCEDURE/OTHER SITE | 252 |
| SURGICAL PROCEDURE/OTHER SITE AT THIS FACILITY | 254 |
| DATE OF SURGICAL DISCHARGE | 255 |
| RX DATE SURG DISCH FLAG | 256 |
| READMISSION TO THE SAME HOSPITAL WITHIN 30 DAYS OF SURGICAL DISCHARGE | 258 |
| REASON FOR NO SURGERY OF PRIMARY SITE | 259 |
| DATE RADIATION STARTED | 260 |
| RX DATE–RADIATION FLAG | 261 |
| LOCATION OF RADIATION TREATMENT | 263 |
| RADIATION TREATMENT VOLUME | 264 |
| REGIONAL TREATMENT MODALITY | 268 |
| REGIONAL DOSE: CGY | 271 |
| BOOST TREATMENT MODALITY | 272 |

| | |
|---|----------------|
| FIRST COURSE OF TREATMENT (CONTINUED) | |
| BOOST DOSE: CGY | 275 |
| NUMBER OF TREATMENTS TO THIS VOLUME | 277 |
| RADIATION/SURGERY SEQUENCE | 278 |
| DATE RADIATION ENDED..... | 280 |
| RX DATE RAD ENDED FLAG | 281 |
| REASON FOR NO RADIATION | 283 |
| DATE SYSTEMIC THERAPY STARTED | 284 |
| RX DATE SYSTEMIC FLAG..... | 285 |
| DATE CHEMOTHERAPY STARTED..... | 287 |
| RX DATE-CHEMO FLAG | 288 |
| CHEMOTHERAPY | 290 |
| CHEMOTHERAPY AT THIS FACILITY | 292 |
| DATE HORMONE THERAPY STARTED..... | 294 |
| RX DATE-HORMONE FLAG | 295 |
| HORMONE THERAPY | 297 |
| HORMONE THERAPY AT THIS FACILITY | 299 |
| DATE IMMUNOTHERAPY STARTED..... | 301 |
| RX DATE-BRM FLAG | 302 |
| IMMUNOTHERAPY AT THIS FACILITY | 306 |
| HEMATOLOGIC TRANSPLANT AND ENDOCRINE PROCEDURES | 308 |
| SYSTEMIC/SURGERY SEQUENCE..... | 310 |
| DATE OTHER TREATMENT STARTED..... | 312 |
| RX DATE-OTHER FLAG | 313 |
| OTHER TREATMENT | 315 |
| OTHER TREATMENT AT THIS FACILITY | 316 |
| PALLIATIVE CARE..... | 317 |
| PALLIATIVE CARE AT THIS FACILITY | 319 |
| OUTCOMES..... | 320-333 |
| DATE OF FIRST RECURRENCE | 321 |
| RECURRENCE DATE-1st FLAG | 322 |
| TYPE OF FIRST RECURRENCE..... | 324 |
| DATE OF LAST CONTACT OR DEATH | 327 |
| DATE OF LAST CONTACT FLAG | 328 |
| VITAL STATUS..... | 329 |
| CANCER STATUS..... | 330 |

| | |
|--|----------------|
| NPI-FOLLOWING REGISTRY | 331 |
| FOLLOW-UP SOURCE..... | 332 |
| NEXT FOLLOW-UP SOURCE | 333 |
| CASE ADMINISTRATION..... | 334-374 |
| ABSTRACTED BY..... | 335 |
| FACILITY IDENTIFICATION NUMBER (FIN) | 336 |
| NPI-REPORTING FACILITY..... | 337 |
| ARCHIVE FIN | 338 |
| NPI-ARCHIVE FIN..... | 339 |
| DATE CASE COMPLETED – COC..... | 340 |
| OVERRIDE ACSN/CLASS/SEQ..... | 341 |
| OVERRIDE HOSPSEQ/DXCONF | 342 |
| OVERRIDE COC–SITE/TYPE..... | 343 |
| OVERRIDE HOSPSEQ/SITE | 344 |
| OVERRIDE SITE/TNM-STAGE GROUP | 345 |
| OVERRIDE AGE/SITE/MORPH | 346 |
| OVERRIDE SURG/DXCONF | 347 |
| OVERRIDE SITE/TYPE..... | 348 |
| OVERRIDE HISTOLOGY | 349 |
| OVERRIDE LEUK, LYMPHOMA | 351 |
| OVERRIDE SITE/BEHAVIOR | 352 |
| OVERRIDE SITE/LAT/MORPH..... | 353 |
| COC CODING SYSTEM–CURRENT..... | 354 |
| COC CODING SYSTEM–ORIGINAL..... | 356 |
| RACE CODING SYSTEM–CURRENT | 358 |
| RACE CODING SYSTEM–ORIGINAL | 359 |
| SITE CODING SYSTEM–CURRENT | 360 |
| SITE CODING SYSTEM–ORIGINAL..... | 361 |
| MORPHOLOGY CODING SYSTEM–CURRENT..... | 362 |
| MORPHOLOGY CODING SYSTEM–ORIGINAL | 363 |
| ICD-O-2 CONVERSION FLAG | 364 |
| ICD-O-3 CONVERSION FLAG | 365 |
| TNM EDITION NUMBER | 366 |
| RX CODING SYSTEM–CURRENT | 367 |
| DERIVED AJCC–FLAG..... | 368 |
| DERIVED SS1977–FLAG | 369 |

CASE ADMINISTRATION (CONTINUED)

| | |
|--------------------------------|-----|
| DERIVED SS2000-FLAG..... | 370 |
| CS VERSION INPUT ORIGINAL..... | 371 |
| CS VERSION INPUT CURRENT | 372 |
| CS VERSION DERIVED | 373 |
| OVER-RIDE CS 1-19 | 374 |

| | |
|--|----------------|
| APPENDIX A: Cases DX Prior to 2010 Hematopoietic and Lymphatic Table <i>(only for use prior to January 1, 2010, diagnoses)</i> | 374-381 |
| APPENDIX B: Site-Specific Surgery Codes | 382-449 |
| APPENDIX C: FORDS Page Revisions | 450-507 |
| APPENDIX D: FORDS Items Required to be Complete to Enter “Date Case Completed- CoC” | 508-513 |
| APPENDIX E: Country and State Codes | 514-523 |

Preface 2016

For all cases diagnosed on or after January 1, 2016, the Commission on Cancer will require its accredited programs to use Facility Oncology Registry Data Standards (FORDS): Revised for 2016; Collaborative Stage Data Collection System Version 02.05 for the collection of Site-specific Factors only; continued use of 7th Edition of the AJCC Cancer Staging Manual; the most current multiple primary and histology rules; the Hematopoietic rules; and, the SEER*RX systemic therapy application.

Revisions to CoC reporting requirements for 2016 are minimal and are primarily due to the discontinued use of Collaborative Stage to stage cancer cases. Other than the below-specified revisions, CoC data reporting requirements remain the same as for 2015. The CoC's transition away from use of Collaborative Stage includes the requirement of AJCC clinical and pathologic stage (requirement of both now enforced via edits), SEER Summary Stage 2000, and new Tumor Size Summary and Mets at Diagnosis data items. The CoC will continue to use the Collaborative Stage Data Collection System Version 02.05 for cases diagnosed 2004-2015, and only for the collection of Site-specific Factors (SSF) for cases diagnosed 1/1/2016 and forward. The majority of CS input data items are no longer required.

New Data Items

Eight new data items are introduced in **FORDS: Revised for 2016** and required for cases diagnosed January 1, 2016 and later.

- Tumor Size Summary [756]
- Mets at Diagnosis - Distant Lymph Nodes [1114]
- Mets at Diagnosis – Bone [1112]
- Mets at Diagnosis – Brain [1113]
- Mets at Diagnosis – Liver [1115]
- Mets at Diagnosis – Lung [1116]
- Mets at Diagnosis – Other [1117]
- SEER Summary Stage 2000 [759]

Discontinued Data Items (No Longer Required)

Beginning with cases diagnosed in 2016, the following Collaborative Stage input data items are no longer required. They must continue to be abstracted for cases diagnosed from 2004 through 2015.

- CS Tumor Size [2800]
- CS Extension [2810]
- CS Tumor Size/Ext Eval [2820]
- CS Lymph Nodes [2830]
- CS Lymph Nodes Eval [2840]
- CS Mets at DX Data Items [2850-2854] (Required 2009-2015)
- CS Mets Eval [2860]
- CS Version Derived [2936]
- Derived AJCC-6 Data Items [2940-3000]
- Derived SS and Flag Data Items [3010-3050]
- Derived AJCC-7 Data Items [3400-3430]

Specific Stage Data Items with Continuing Requirement

The following data items were considered as Collaborative Stage input data items for the purposes of Collaborative Stage, but are now are continued to be required for AJCC staffing and research purposes. They are required for all cases diagnosed in 2004 and later:

- Regional Nodes Positive [820]
- Regional Nodes Examined [830]
- Lymph-vascular Invasion [1182] (Required 2009+)
- CS Site-specific Factors [2861-2880, 2890-2930]
- CS Version Input Original [2935]
- CS Version Input Current [2937]

Note: CoC's requirements for the Site-specific Factors have **not changed from 2015**; the data items of CS Version Input Original and Current continue to be required to accommodate continued collection of the SSFs.

Implementation of New AJCC T, N, and M Categories:

According to the AJCC manual and trainings, the appropriate T, N, and M categories should be assigned based on clinical and pathologic staging/classification timeframes. This may entail allowing, for example, the pathologic staging M category to be properly assigned as cM1 when existence of distant metastasis is found upon imaging after surgery. However, historically cancer registry abstracting software has been set up to code two separate and mutually exclusive clinical and pathologic strings of T, N, M, and stage categories, with an implied "c" in the clinical TNM string, and an implied "p" in the pathologic TNM string. Upon abstraction, the registrar had no way of recording the appropriate M category for the pathologic stage if it is cM1. This discrepancy between registry software data items and AJCC staging classification rules caused a dilemma for registrars when abstracting the T, N, and M data items and resulted in inconsistent coding practices and data loss.

As a result, this issue will be addressed upon implementation of NAACCR version 16-compliant software with the addition of new AJCC T, N, and M categories for the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of 'c' and 'p' to existing valid clinical and pathologic T, N, and M categories respectively. The revisions will be incorporated into software look ups to allow for selection of necessary 'p' values within the clinical codes and selection of necessary 'c' values within the pathologic codes when abstracting. For example, the addition of pTis to the clinical classification T category will enable its use for in situ tumors in accordance with the AJCC rules (serves as a reminder that the in situ diagnosis cannot be made on imaging alone). This implementation will allow registrars to comply with AJCC rules while abstracting, thus reducing stage assignment confusion and increasing registrar confidence in assigning AJCC stage, increasing data integrity, and reducing the time and resources that registrars and standard setters currently spend addressing these issues.

CoC will require CoC-approved Cancer Programs to use the new T, N, and M categories and convert historical data upon upgrading to NAACCR version 16-compliant software (Please see the [NAACCR 2016 Implementation Guidelines](#) for complete details). The new category options will be implemented for cases of all diagnosis years abstracted using NAACCR version 16-compliant software. Conversion of historical data for the diagnosis years of 2015 and earlier is being carried out for the purposes of formatting the data

to accommodate consistent viewing, abstraction, and editing of the data across all diagnosis years. Please note that the prefixes included in the new categories are only intended to reflect clinical significance for cases diagnosed January 1, 2016 and later, and should not be analyzed in any fashion for cases diagnosed earlier. Existing T, N, and M values will not be converted for any cases diagnosed in 2016 that are initially abstracted using NAACCR Version 15-compliant software. As a result, the T, N, and M categories will need to be reviewed for these cases upon upgrade to NAACCR Version 16-compliant software. The registrar will have to accurately re-assign the new T, N, and M categories (that include c and p designations).

Clinical and Pathologic AJCC Stage Required

Beginning with cases diagnosed January 1, 2016 and later, both clinical and pathologic AJCC stage will be required for data submission to the NCDB. The requirement will be enforced via edits. Collaborative Stage is no longer required (required historically for cases diagnosed from 2004 – 2015).

No Submission of Derived Stage to the NCDB for Cases Diagnosed 2016 and Later

For cases diagnosed 2016 and later, no software-derived values should be submitted in the directly-assigned AJCC Stage data items [910, 970]. Registrars are encouraged to fully understand how their vendor software functions, and should never manually copy over any derived values into the directly-assigned data items. Algorithms are under development to identify derived values submitted in the directly-assigned data items. Programs will receive a deficiency on CoC Program Standard 5.6 if submission of derived values in the directly-assigned AJCC Stage data items is detected.

Documenting Clinical and Pathologic AJCC Stage

The hospital registrar will be responsible for recording the physician-assigned stage in the registry database.

- a) If the stage assigned by the physician is inconsistent with the documentation in the medical record, the registrar should assign the stage and record the registrar-assigned stage in the registry database. The registrar should verify the case information with the physician, as he or she may have additional information that would aid in the assignment of a stage. However, it is outside the realm of the responsibility of the registrar to educate the physician. **The registrar should inform the registry physician advisor and refer identified coding issues to the Cancer Committee for quality improvement activities.**
- b) If no physician-assigned stage can be found in the medical record, the registrar should assign the stage and record it in the registry database. **The registrar should inform the registry physician advisor and refer identified documentation issues to the Cancer Committee for quality improvement activities.**
- c) CoC Program Standard 1.10, Clinical Educational Activity states that the required cancer-related educational activity offered to physicians, nurses, and other allied health professionals is to be focused on the use of AJCC (or other appropriate) staging. The cancer committee is encouraged to use AJCC-developed materials for this purpose.

Revision of TNM Staged By Data Items

The length of the TNM Path Staged By [930] and TNM Clin Staged By [990] data items has been expanded to 2 digits to accommodate new codes. The historic 1 character codes will be converted to the new codes upon upgrade to NAACCR Version 16-compliant software.

Non-FORDS Code Modifications

ICD-O-3

The NAACCR Guidelines for ICD-O-3 Update Implementation (published December 2013) included a table of new ICD-O-3 codes and terms effective for 2015; however, the use of the new codes was postponed due to issues with adding these codes to the CSV2 software. For diagnosis year 2016, all standard setters have agreed to postpone these codes once again, and to use the alternate codes published in Table 2 of the [Guidelines for ICD-O-3 Update Implementation](#). It is anticipated that these codes will be implemented in 2017 when the AJCC-TNM 8th Edition goes into effect.

Newly-reportable Conditions/Tumors:

- Non-invasive mucinous cystic neoplasm of the pancreas with high-grade dysplasia replaces mucinous cystadenocarcinoma, non-invasive (8470/2).
- Solid pseudopapillary neoplasm of pancreas (8452/3) is synonymous with solid pseudopapillary carcinoma (C25._).
- Cystic pancreatic endocrine neoplasm (CPEN). Assign 8150/3 unless specified as a neuroendocrine tumor, Grade 1 (8240/3) or neuroendocrine tumor, Grade 2 (8249/3).
- Mature teratoma of the testes in adults is malignant (assign 9080/3), but continues to be non-reportable in prepubescent children (9080/0). Report only if pubescence is explicitly stated in the medical record. **Do not report if there is no mention of pubescence in the medical record.**

Hematopoietic and Lymphoid Database and Manual. An updated version of the Hematopoietic and Lymphoid (Heme) Database was released by NCI SEER in January 2015. There were no updates to Heme Database for 2016. Registrars will continue to use the current posted manual that's on the website, see <http://seer.cancer.gov/tools/heme/>.

A small number of other modifications to **FORDS: Revised for 2016** were made for clarification. *Appendix C* lists all content changes made in **FORDS: Revised for 2016**. Note that the modifications for this edition resulted in pagination changes, and communications about **FORDS** content should refer to the *Section One* heading or the item definition in which the information is found rather than to page numbers.

Additional Coding References

The following references are required to code some items. Coding instructions for items from these sources are not reproduced in **FORDS: Revised for 2016** in order to avoid redundancy and possible conflict when the primary manuals are updated. For each, use the most current version applicable for the diagnosis year.

Fritz A, Percy C, Jack A, et al (eds). *ICD-O: International Classification of Diseases for Oncology*, 3rd ed. Geneva, World Health Organization: 2000.

Edge S, Byrd D, Compton C, et al (eds): *AJCC Cancer Staging Manual*, 7th ed. American Joint Committee on Cancer, Chicago IL. Springer: 2009. Errata exist and can be downloaded from www.cancerstaging.org.

Collaborative Stage Data Collection System, Version 02.05. Available at www.cancerstaging.org/cstage. Site-specific factor requirements by schema, diagnosis year and standard-setter (including CoC) are available at <http://seer.cancer.gov/csreqstatus/>.

Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB), most current version. Available at <http://seer.cancer.gov/registrars/>.

The 2007 Multiple Primary and Histology Coding Rules, revised 2012. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD: 2007. Available for download at <http://seer.cancer.gov/tools/mphrules/>.

*SEER*Rx – Interactive Drug Database*. National Cancer Institute, Surveillance, Epidemiology and End Results Program, Bethesda MD. Available for download at <http://seer.cancer.gov/tools/seerrx/>.

The following references also may be useful.

NAACCR Inc. 2016 Implementation Guidelines and Recommendations. North American Association of Central Cancer Registries, Springfield IL: 2015. Available at <http://www.naacr.org/StandardsandRegistryOperations/ImplementationGuidelines.aspx>

NAACCR, Inc. Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, version 16. North American Association of Central Cancer Registries, Springfield IL: 2015. Available at <http://www.naacr.org/StandardsandRegistryOperations/VolumeII.aspx>.

SEER Program Coding and Staging Manual (<http://seer.cancer.gov/tools/codingmanuals/index.html>).

An interactive tool that incorporates many of the references above is provided free by The Centers for Disease Control and Prevention. The *Registry Plus Online Help* application has full copies of the **FORDS**, **Collaborative Stage**, and **Multiple Primary and Histology Coding** manuals as well as the **NAACCR Data Dictionary**, the **SEER Coding Manual**, and the introduction and histology sections of ICD-O-3. It also describes all standard edits with links to the item definitions they use and explanations for interpreting them. *Registry Plus Online Help* is free and available at <http://www.cdc.gov/cancer/npcr>. Select “Registry Plus” under “Software and Tools”; select “Online Help”; then select “Technical Information and Installation.” Follow the instructions to download and install.

SECTION ONE:

Case Eligibility and Overview of Coding Principles

CASE ELIGIBILITY

The American College of Surgeons Commission on Cancer (CoC) requires registries in accredited programs to accession, abstract, and conduct follow-up activities for required tumors diagnosed and/or initially treated at the abstracting facility. The tumors must meet the criteria for analytic cases (*Class of Case 00-22*), and pathologically and clinically diagnosed inpatients and outpatients must be included.

TUMORS REQUIRED BY THE CoC TO BE ACCESSIONED, ABSTRACTED, FOLLOWED AND SUBMITTED TO THE NATIONAL CANCER DATA BASE (NCDB)

Malignancies with an ICD-O-3 behavior code of 2 or 3 are required for all sites.

EXCEPTION 1: Juvenile astrocytoma, listed as 9421/1 in ICD-O-3, *is required* and should be recorded as 9421/3 in the registry.

EXCEPTION 2: Effective in 2015, code 8240/1 for Carcinoid tumor, NOS, of appendix (C18.1) becomes obsolete. Carcinoid tumors of the appendix (C18.1) must be coded to 8240/3, effective with 2015. This is *required* and must be coded with a behavior 3. Prior appendix primaries coded 8240/1 are converted to 8240/3 by the implementation conversions for 2015.

EXCEPTION 3: Malignant primary skin cancers (C44. _) with histology codes 8000–8110 *are not required* by the CoC. Skin primaries with those histologies diagnosed prior to January 1, 2003, were required to be accessioned and followed if the AJCC stage group at diagnosis was II, III, or IV. Those cases should remain in the registry data and continue to be followed.

EXCEPTION 4: Carcinoma in situ of the cervix (CIS), intraepithelial neoplasia grade III (8077/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), anus (AIN III), larynx (LIN III), and squamous intraepithelial neoplasia excluding cervix (SIN III) *are not required* by CoC. SIN III is a specific instance of intraepithelial neoplasia, grade III which is listed in ICD-O-3 as /2

Nonmalignant primary intracranial and central nervous system tumors diagnosed on or after January 1, 2004, with an ICD-O-3* behavior code of 0 or 1 are required for the following sites: meninges (C70. _), brain (C71. _), spinal cord, cranial nerves, and other parts of central nervous system (C72. _), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3).

Gastro-intestinal stromal tumors (GIST) and thymomas are frequently non-malignant. However, they must be abstracted and assigned a *Behavior Code* of 3 if they are noted to have multiple foci, metastasis or positive lymph nodes.

REPORTABLE-BY-AGREEMENT CASES

Registries may be requested to collect information about tumors that are not required to be abstracted by the CoC for accredited programs. Ordinarily, such requests will come from the facility's cancer committee or the central registry. The CoC does not require that reportable-by-agreement cases be accessioned, abstracted, followed, or submitted, but the requestor may identify the extent of information needed.

Examples of Reportable-by-Agreement Cases:

- The cancer committee requests abstracting and follow-up of *Class of Case 30* cases.

- The state central registry requests abstracting and reporting of pathology-only cases.

AMBIGUOUS TERMS AT DIAGNOSIS

As part of the registry case-finding activities, all diagnostic reports should be reviewed to confirm whether a case is required. If the terminology is ambiguous, use the following guidelines to determine whether a particular case should be included. Words or phrases that appear to be synonyms of these terms do not constitute a diagnosis. For example, “likely” alone does not constitute a diagnosis.

Ambiguous Terms that Constitute a Diagnosis

| | |
|-----------------|---|
| Apparent(ly) | Presumed |
| Appears | Probable |
| Comparable with | Suspect(ed) |
| Compatible with | Suspicious (for) |
| Consistent with | Tumor* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3) |
| Favors | Typical of |

Malignant appearing

Most likely

Neoplasm* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)

*additional terms for nonmalignant primary intracranial and central nervous system tumors only

EXCEPTION: If a cytology is identified only with an ambiguous term, do not interpret it as a diagnosis of cancer.

Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.

Examples of Diagnostic Terms:

- The inpatient discharge summary documents a chest X ray *consistent with carcinoma* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with carcinoma* is indicative of cancer.
- The pathology report states *suspicious for malignancy*. *Suspicious for malignancy* is indicative of cancer.

Ambiguous Terms That Do Not Constitute a Diagnosis without additional information

| | |
|-----------------------|--------------|
| Cannot be ruled out | Questionable |
| Equivocal | Rule out |
| Possible | Suggests |
| Potentially malignant | Worrisome |

Examples of Nondiagnostic Terms:

- The inpatient discharge summary documents a chest x-ray *consistent with neoplasm* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with neoplasm* is not indicative of cancer. While “consistent with” can indicate involvement, “neoplasm” without specification of

malignancy is not diagnostic except for non-malignant primary intracranial and central nervous system tumors.

- Final diagnosis is reported as *possible carcinoma* of the breast. *Possible* is not a diagnostic term for cancer.

Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

CLASS OF CASE

All accessioned cases are assigned a *Class of Case* (NAACCR Item #610) based on the nature of involvement of the facility in the care of the patient.

Analytic Cases

Cases diagnosed and/or administered any of the first course of treatment at the accessioning facility after the registry's reference date are analytic (*Class of Case* 00-22). A network clinic or outpatient center belonging to the facility is part of the facility.

Analytic cases *Class of Case* 10-22 are included in treatment and survival analysis.

Analytic cases *Class of Case* 00 are not required to be staged or followed, regardless of the year of diagnosis. *Class of Case* 00 is reserved for patients who are originally diagnosed by the reporting facility and receive all of their treatment elsewhere or a decision not to treat is made elsewhere. If the patient receives no treatment, either because the patient refuses recommended treatment or a decision is made not to treat, the *Class of Case* is 14. If there is no information about whether or where the patient was treated, the *Class of Case* is 10.

Nonanalytic Cases

Nonanalytic cases (*Class of Case* 30-99) are not usually included in routine treatment or survival statistics. The CoC does not require registries in accredited programs to accession, abstract, or follow these cases, but the program or central registry may require them.

Modifications to Class of Case in 2010

Class of Case was redefined for use beginning in 2010. The codes in this manual allow differentiation between analytic and nonanalytic cases and make additional distinctions. For analytic cases, the codes distinguish cases diagnosed in a staff physician's office from those diagnosed initially by the facility and patients fully treated at the facility from those partially treated by the reporting facility. Nonanalytic cases are distinguished by whether the patient received care at the facility or did not personally appear there. Patients who received care from the facility are distinguished by the reasons a case may not be analytic: diagnosed prior to the patient's reference date, type of cancer that is not required by CoC to be abstracted, consultation, in-transit care, and care for recurrent or persistent disease. Patients who did not receive care from the reporting facility are distinguished by care given in one or more staff physician offices, care given through an agency whose cancer cases are abstracted by the reporting facility but are not part of it, pathology only cases, and death certificate only cases. Treatment in staff physician offices is now coded "treated elsewhere" because the hospital has no more responsibility over this treatment than it would if the patient were treated in another hospital.

DATE OF FIRST CONTACT

The *Date of First Contact* (NAACCR Item #580) is the date of the facility's first inpatient or outpatient contact with the patient for diagnosis or treatment of the cancer. For analytic cases, the *Date of First Contact* is the date the patient qualifies as an analytic case *Class of Case* 00-22. Usually, the *Date of First Contact* is the date of admission for diagnosis or for treatment. If the patient was admitted for noncancer-related reasons, the *Date of First Contact* is the date the cancer was first suspected during the

hospitalization. If the patient's diagnosis or treatment is as an outpatient of the facility, the *Date of First Contact* is the date the patient first appeared at the facility for that purpose.

If the patient was initially diagnosed at the facility and went elsewhere for treatment (*Class of Case 00*), but then returned for treatment that was initially expected to occur elsewhere, the *Class of Case* is updated to 13 or 14 but the *Date of First Contact* is not changed because it still represents the date the patient became analytic. If the *Class of Case* changes from nonanalytic (for example, consult only, *Class of Case 30*) to analytic (for example, part of first course treatment administered at the facility, *Class of Case 21*), the *Date of First Contact* is updated to the date the case became analytic (the date the patient was admitted for treatment).

When a pathology specimen is collected off site and submitted to the facility to be read (and the specimen is positive for cancer), the case is not required by the Commission on Cancer to be abstracted unless the patient receives first course treatment from the facility.

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment; and the *Class of Case* (NAACCR Item #610) is 11 or 12 if the diagnosing physician is a staff physician at the reporting facility or 20 or 21 for any other physician. A staff physician is one who is employed by the facility, is under contract with it, or has routine admitting privileges there.

When a staff physician performs a biopsy off site and the specimen is not submitted to the facility to be read, the case is not required to be abstracted unless the patient receives some first course care at the facility.

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment and the *Class of Case* is 11 or 12.

For nonanalytic cases, the *Date of First Contact* is the date the patient's nonanalytic status begins with respect to the cancer. For example, for a patient diagnosed and treated entirely in a staff physician's office (*Class of Case 40*), the date the physician initially diagnosed the cancer is the *Date of First Contact*. For autopsy only cases, the *Date of First Contact* is the date of death.

If the state or regional registry requires pathology-only cases to be abstracted and reported, the *Date of First Contact* is the date the specimen was collected and the *Class of Case* is 43. If a patient whose tumor was originally abstracted as a *Class of Case 43* receives first course treatment subsequently as an inpatient or outpatient at the facility, update both *Class of Case* and *Date of First Contact* to reflect the patient's first in-person contact with the facility.

OVERVIEW OF CODING PRINCIPLES

UNIQUE PATIENT IDENTIFIER CODES

Accession Number (NAACCR Item #550) and *Sequence Number* (NAACCR Item #560) uniquely identify the patient and the tumor. Each cancer patient in a registry is assigned a unique accession number, and each primary diagnosed for that patient is assigned a sequence number. The accession number *never* changes.

- Accession numbers are never reassigned, even if a patient is removed from the registry.
- Once cases are submitted to RQRS or the NCDB, accession numbers are not to be changed for any reason. Even if there is a clerical error, or if cases are found in an out-of-order fashion when case finding (i.e., find an old case after abstraction of a newer one), the accession number serves as a permanent identifier for a patient at your facility. NCDB does not accommodate any requests for accession number changes for cases already submitted.
- The sequence number is the sequence of all tumors over the lifetime of a patient and is counted throughout the patient's lifetime.
- Only tumors that would have been reportable at the time of diagnosis for CoC or by agreement with a central registry or the program's cancer committee are required to be counted when assigning sequence numbers. A registry may contain a single abstract for a patient with a sequence number of 02, because the first tumor was not cared for by the program or was not otherwise required to be accessioned. Because of differences in requirements, it is possible for two registries with dissimilar eligibility requirements (for example, a facility registry and a state central registry) to assign different sequence numbers to the same tumor, even though the sequence number codes and instructions applied are the same.

NATIONAL PROVIDER IDENTIFIER

The National Provider Identifier (NPI) is a unique identification number for health care providers that was implemented in 2007 and 2008 by the Centers for Medicare and Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008. Individual item descriptions in Section Two of this volume should be consulted for specific coding instructions.

The NPI data items are:

| | |
|--------------------------------------|----------------------------|
| <i>NPI–Archive FIN</i> | <i>(NAACCR Item #3105)</i> |
| <i>NPI–Following Physician</i> | <i>(NAACCR Item #2475)</i> |
| <i>NPI–Following Registry</i> | <i>(NAACCR Item #2445)</i> |
| <i>NPI–Institution Referred From</i> | <i>(NAACCR Item #2415)</i> |
| <i>NPI–Institution Referred To</i> | <i>(NAACCR Item #2425)</i> |
| <i>NPI–Managing Physician</i> | <i>(NAACCR Item #2465)</i> |
| <i>NPI–Physician #3</i> | <i>(NAACCR Item #2495)</i> |
| <i>NPI–Physician #4</i> | <i>(NAACCR Item #2505)</i> |
| <i>NPI–Primary Surgeon</i> | <i>(NAACCR Item #2485)</i> |
| <i>NPI–Reporting Facility</i> | <i>(NAACCR Item #545)</i> |

CODING DATES

Beginning in 2010, the way dates are transmitted between facility registries and central registries or the National Cancer Data Base (NCDB) was changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format. Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In the traditional form, some dates also permit 88888888 or 00000000 for special meaning. Interoperable dates are displayed in CCYYMMDD form, with the unknown portions of the date filled

with blank spaces. If a date is entirely blank, an associated date flag is used to explain the missing date. The following table illustrates the relationship among these items for *Date of Most Definitive Surgical Resection of the Primary Site*, where each lower case 'b' represents a blank space. Flags are not used for software-generated dates.

| Description | Traditional Date of Most Definitive Surgical Resection of the Primary Site | Interoperable Date of Most Definitive Surgical Resection of the Primary Site | Rx Date Mst Defn Srg Flag |
|------------------------------------|---|--|---------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No surgery performed | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

CANCER IDENTIFICATION

The following instructions apply to *Primary Site* (NAACCR Item #400), *Laterality* (NAACCR Item #410), *Histology* (NAACCR Item #522), *Behavior Code* (NAACCR Item #523), and *Grade/Differentiation* (NAACCR Item #440).

Primary Site

The instructions for coding primary site are found in the “Topography” section of the **ICD-O-3** “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 23–26). The following guidelines should be followed for consistent analysis of primary sites for particular histologies.

Hematopoietic and Lymphoid Cancers

Beginning with cases diagnosed in 2010, the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** is to be used for coding primary site, histology, and grade of hematopoietic and lymphoid tumors (M-9590-9992) and to determine whether multiple conditions represent one or more tumors to be abstracted. *Appendix A* has the former table for use for tumors diagnosed prior to January 1, 2010, for determining unique or same hematopoietic tumors.

Kaposi Sarcoma

- Code Kaposi sarcoma to the site in which it arises.
- Code to Skin, NOS (C44.9) if Kaposi sarcoma arises simultaneously in the skin and another site or the primary site is not identified.

Melanoma

- Code to Skin, NOS (C44.9) if a patient is diagnosed with metastatic melanoma and the primary site is not identified.

Specific Tissues with Ill-Defined Sites

- If any of the following histologies appears only with an ill-defined site description (eg, “abdominal” or “arm”), code it to the tissue in which such tumors arise rather than the ill-defined region (C76._) of the body, which contains multiple tissues. Use the alphabetic index in **ICD-O-3** to assign the most specific site if only a general location is specified in the record.

| Histology | Description | Code to This Site |
|--|--|---|
| 8720–8790 | Melanoma | C44._, Skin |
| 8800–8811, 8813–8830, 8840–8921, 9040–9044 | Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma | C49._, Connective, Subcutaneous and Other Soft Tissues |
| 8990–8991 | Mesenchymoma | C49._, Connective, Subcutaneous and Other Soft Tissues |
| 9120–9170 | Blood vessel tumors, lymphatic vessel tumors | C49._, Connective, Subcutaneous and Other Soft Tissues |
| 9580–9582 | Granular cell tumor and alveolar soft part sarcoma | C49._, Connective, Subcutaneous and Other Soft Tissues |
| 9240–9252 | Mesenchymal chondrosarcoma and giant cell tumors | C40._, C41._ for Bone and Cartilage C49._, Connective, Subcutaneous and Other Soft Tissues |
| 8940–8941 | Mixed tumor, salivary gland type | C07._ for Parotid Gland C08._ for Other and Unspecified Major Salivary Glands |

Laterality

Laterality (NAACCR Item #410) must be recorded for the following paired organs as 1-5 or 9. Organs that are not paired, unless they are recorded “right” or “left” laterality, are coded 0. Midline origins are coded 5. “Midline” in this context refers to the point where the “right” and “left” sides of paired organs come into direct contact and a tumor forms at that point. Most paired sites can not develop midline tumors. For example, skin of the trunk can have a midline tumor, but the breasts can not.

Paired Organ Sites

| ICD-O-3 | Site |
|-------------|---|
| C07.9 | Parotid gland |
| C08.0 | Submandibular gland |
| C08.1 | Sublingual gland |
| C09.0 | Tonsillar fossa |
| C09.1 | Tonsillar pillar |
| C09.8 | Overlapping lesion of tonsil |
| C09.9 | Tonsil, NOS |
| C30.0 | Nasal cavity (excluding nasal cartilage and nasal septum) |
| C30.1 | Middle ear |
| C31.0 | Maxillary sinus |
| C31.2 | Frontal sinus |
| C34.0 | Main bronchus (excluding carina) |
| C34.1–C34.9 | Lung |

| | |
|-------------|---|
| C38.4 | Pleura |
| C40.0 | Long bones of upper limb and scapula |
| C40.1 | Short bones of upper limb |
| C40.2 | Long bones of lower limb |
| C40.3 | Short bones of lower limb |
| C41.3 | Rib and clavicle (excluding sternum) |
| C41.4 | Pelvic bones (excluding sacrum, coccyx, and symphysis pubis) |
| C44.1 | Skin of eyelid |
| C44.2 | Skin of external ear |
| C44.3 | Skin of other and unspecified parts of face |
| C44.5 | Skin of trunk |
| C44.6 | Skin of upper limb and shoulder |
| C44.7 | Skin of lower limb and hip |
| C47.1 | Peripheral nerves and autonomic nervous system of upper limb and shoulder |
| C47.2 | Peripheral nerves and autonomic nervous system of lower limb and hip |
| C49.1 | Connective, subcutaneous, and other soft tissues of upper limb and shoulder |
| C49.2 | Connective, subcutaneous, and other soft tissues of lower limb and hip |
| C50.0–C50.9 | Breast |
| C56.9 | Ovary |
| C57.0 | Fallopian tube |
| C62.0–C62.9 | Testis |
| C63.0 | Epididymis |
| C63.1 | Spermatic cord |
| C64.9 | Kidney, NOS |
| C65.9 | Renal pelvis |
| C66.9 | Ureter |
| C69.0–C69.9 | Eye and lacrimal gland |
| C70.0 | Cerebral meninges, NOS (excluding diagnoses prior to 2004) |
| C71.0 | Cerebrum (excluding diagnoses prior to 2004) |
| C71.1 | Frontal lobe (excluding diagnoses prior to 2004) |
| C71.2 | Temporal lobe (excluding diagnoses prior to 2004) |
| C71.3 | Parietal lobe (excluding diagnoses prior to 2004) |
| C71.4 | Occipital lobe (excluding diagnoses prior to 2004) |
| C72.2 | Olfactory nerve (excluding diagnoses prior to 2004) |
| C72.3 | Optic nerve (excluding diagnoses prior to 2004) |
| C72.4 | Acoustic nerve (excluding diagnoses prior to 2004) |
| C72.5 | Cranial nerve, NOS (excluding diagnoses prior to 2004) |
| C74.0–C74.9 | Adrenal gland |
| C75.4 | Carotid body |

Morphology: Histology Code

The instructions for coding histology and behavior of solid tumors are found in the “Morphology” section of the **ICD-O-3** “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 27-30)

To code multiple or mixed histologies present in one primary, the most recent **SEER 2007 Multiple Primary and Histology Coding Rules** (<http://seer.cancer.gov/tools/mphrules/>) replaces all previous multiple histology rules, effective for cases diagnosed January 1, 2007; do not use them to abstract cases diagnosed before January 1, 2007.

Use the SEER *Hematopoietic and Lymphoid Neoplasm Coding Manual* and Database at <http://seer.cancer.gov/tools/heme/> to code hematopoietic and lymphatic histologies.

Morphology: Grade

The word “grade” is used to indicate several distinct continua of cellular variability in cancer. Cancer registries have collected *Grade/Differentiation* (NAACCR Item #440) for many years, and in recent years registrars have become familiar with other grade systems. These are coding instructions for **cases diagnosed 1/1/2014** and forward. For diagnoses prior to that date, consult the applicable **FORDS** edition based on the diagnosis date of the cancer.

**Hematopoietic and Lymphoid Neoplasms
Cell Indicator (Codes 5, 6, 7, 8, 9)**

Cell Indicator (Codes 5, 6, 7, 8) describes the lineage or phenotype of the cell. Codes 5, 6, 7, and 8 are used only for hematopoietic and lymphoid neoplasms. Code 9 indicates cell type not determined, not stated, or not applicable.

Coding Grade for Hematopoietic and Lymphoid Neoplasms

1. **Determine the histology based on the current Hematopoietic and Lymphoid Neoplasm Manual**
[\[http://seer.cancer.gov/tools/heme/Hematopoietic Instructions and Rules/\]](http://seer.cancer.gov/tools/heme/Hematopoietic%20Instructions%20and%20Rules/).
2. **Determine the Cell Indicator by applying the “Grade of Tumor Rules” within the current Hematopoietic and Lymphoid Neoplasm Manual**
[\[http://seer.cancer.gov/tools/heme/Hematopoietic Instructions and Rules/\]](http://seer.cancer.gov/tools/heme/Hematopoietic%20Instructions%20and%20Rules/) to code the grade.

Grade codes for hematopoietic and lymphoid neoplasms

| Terminology | Grade Code |
|--|------------|
| T-cell; T-precursor | 5 |
| B-Cell; Pre-B; B-precursor | 6 |
| Null cell; Non T-non B | 7 |
| NK cell (natural killer cell) | 8 |
| Grade unknown, not stated, or not applicable | 9 |

Solid tumors**Grade, Differentiation (Codes 1, 2, 3, 4, 9)**

Pathologic examination determines the grade, or degree of differentiation, of the tumor. For these cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). Well-differentiated tumor cells closely resemble the tissue from the organ of origin. Poorly differentiated and undifferentiated tumor cells are disorganized and abnormal looking; they bear little (poorly differentiated) or no (undifferentiated) resemblance to the tissue from the organ of origin. These similarities/differences may be based on pattern (architecture), cytology, nuclear (or nucleolar) features, or a combination of these elements, depending upon the grading system that is used. Some grading systems

use only pattern, for example Gleason grading in prostate. Others use only a nuclear grade (usually size, amount of chromatin, degree of irregularity, and mitotic activity). Fuhrman's grade for kidney is based only on nuclear features. Most systems use a combination of pattern and cytologic and nuclear features; for example Nottingham's for breast combines numbers for pattern, nuclear size and shape, and mitotic activity. The information from this data item is useful for determining prognosis and treatment.

Pathologists describe the tumor grade using three systems or formats:

1. Two levels of similarity; also called a two-grade system
2. Three levels of similarity; also called a three-grade system (code according to "Coding for solid tumors."
 - a. Grade I, well
 - b. Grade II, moderately
 - c. Grade III, poorly (undifferentiated carcinoma is usually separated from this system, since "poorly" bears some, albeit little, similarity to the host tissue, while "undifferentiated" has none, e.g. Undifferentiated carcinoma).
3. Four levels of similarity; also called a four-grade system. The four-grade system describes the tumor as
 - a. Grade I; also called well-differentiated
 - b. Grade II; also called moderately differentiated
 - c. Grade III; also called poorly differentiated
 - d. Grade IV; also called undifferentiated or anaplastic

Breast and prostate grades may convert differently than other sites. These exceptions are noted in "Coding for Solid Tumors", #7-8 below.

Coding for Solid Tumors

1. Systemic treatment and radiation can alter a tumor's grade. Therefore, it is important to code grade based on information prior to neoadjuvant therapy even if grade is unknown.
2. Code the grade from the primary tumor only.
 - a. Do NOT code grade based on metastatic tumor or recurrence. In the rare instance that tumor tissue extends contiguously to an adjacent site and tissue from the primary site is not available, code grade from the contiguous site.
 - b. If primary site is unknown, code grade to 9.
3. Code the grade shown below (6th digit) for specific histologic terms that imply a grade.
 - Carcinoma, undifferentiated (8020/34)
 - Carcinoma, anaplastic (8021/34)
 - Follicular adenocarcinoma, well differentiated (8331/31)
 - Thymic carcinoma, well differentiated (8585/31)
 - Sertoli-Leydig cell tumor, poorly differentiated (8631/33)
 - Sertoli-Leydig cell tumor, poorly differentiated with heterologous elements (8634/33)
 - Undifferentiated sarcoma (8805/34)
 - Liposarcoma, well differentiated (8851/31)
 - Seminoma, anaplastic (9062/34)
 - Malignant teratoma, undifferentiated (9082/34)
 - Malignant teratoma, intermediate type (9083/32)
 - Intraosseous osteosarcoma, well differentiated (9187/31)
 - Astrocytoma, anaplastic (9401/34)
 - Oligodendroglioma, anaplastic (9451/34)
 - Retinoblastoma, differentiated (9511/31)
 - Retinoblastoma, undifferentiated (9512/34)
4. In situ and/or combined in situ/invasive components:
 - a. If a grade is given for an in situ tumor, code it. Do NOT code grade for dysplasia such as high grade dysplasia.

- b. If there are both in situ and invasive components, code only the grade for the invasive portion even if its grade is unknown.
5. If there is more than one grade, code the highest grade within the applicable system. Code the highest grade even if it is only a focus. Code grade in the following priority order using the first applicable system:
- special grade systems for the sites listed in Coding for Solid Tumors #6
 - differentiation: use Coding for Solid Tumors #7: 2-, 3-, or 4- grade system
 - nuclear grade: use Coding for Solid Tumors #7: 2-, 3-, or 4- grade system
 - If it isn't clear whether it is a differentiation or nuclear grade and a 2-, 3-, or 4- grade system was used, code it.
 - Terminology (use Coding for Solid Tumors #8)
6. Use the information from the special grade systems first. If no special grade can be coded, continue with Coding for Solid Tumors #7-9.

Special grade systems for solid tumors

Grade information based on CS Site-specific factors for breast, prostate, heart, mediastinum, peritoneum, retroperitoneum, soft tissue, and kidney parenchyma is used to code grade. See **Special Grade System Rules** section below for details on how to use this information to code grade.

| CS Schema | Special grade system |
|---------------------------|---|
| Breast | Nottingham or Bloom-Richardson (BR) Score/Grade (SSF7) |
| Prostate | Gleason's Score on Needle Core Biopsy/Transurethral Resection of Prostate (TURP) (SSF 8) |
| Prostate | Gleason's Score on Prostatectomy/Autopsy (SSF 10) |
| Heart, Mediastinum | Grade for Sarcomas (SSF 1) |
| Peritoneum | Grade for Sarcomas (SSF 1) |
| Retroperitoneum | Grade for Sarcomas (SSF 1) |
| Soft Tissue | Grade for Sarcomas (SSF 1) |
| Kidney Parenchyma | Fuhrman Nuclear Grade (SSF 6) |

Do not use these tables to code grade for any other groups including WHO (CNS tumors), WHO/ISUP (bladder, renal pelvis), or FIGO (female gynecologic sites) grades.

7. Use the Two-, Three- or Four-grade system information
- Two-grade system

| Term | Description | Grade Code | Exception for Breast and Prostate Grade Code |
|------------|-------------|------------|--|
| 1/2, I/II | Low grade | 2 | 1 |
| 2/2, II/II | High grade | 4 | 3 |

In transitional cell carcinoma for bladder, the terminology high grade TCC and low grade TCC are coded in the two-grade system.

- Three-grade system

| Term | Description | Grade Code | Exception for Breast and Prostate Grade Code |
|------|--------------------|------------|--|
| 1/3 | Low grade | 2 | 1 |
| 2/3 | Intermediate grade | 3 | 2 |
| 3/3 | High grade | 4 | 3 |

- Four-grade system: Any four-grade system including Edmondson and Steiner grade for liver.

| Term | Description | Grade Code |
|------|-------------|------------|
|------|-------------|------------|

| | | |
|-----|-------------------------------------|---|
| 1/4 | Grade I; Well differentiated | 1 |
| 2/4 | Grade II; Moderately differentiated | 2 |
| 3/4 | Grade III; Poorly differentiated | 3 |
| 4/4 | Grade IV; Undifferentiated | 4 |

8. Terminology: use the 'Description' column or the 'Grade' column to code grade. Breast & Prostate use the same grade code with a few noted exceptions.

| Description | Grade | Assign Grade Code | Exception for Breast and Prostate Grade Code |
|--|--------|-------------------|--|
| Differentiated, NOS | I | 1 | |
| Well differentiated | I | 1 | |
| Only stated as 'Grade I' | I | 1 | |
| | | | |
| Fairly well differentiated | II | 2 | |
| Intermediate differentiation | II | 2 | |
| Low grade | I-II | 2 | 1 |
| Mid differentiated | II | 2 | |
| Moderately differentiated | II | 2 | |
| Moderately well differentiated | II | 2 | |
| Partially differentiated | II | 2 | |
| Partially well differentiated | I-II | 2 | 1 |
| Relatively or generally well differentiated | II | 2 | |
| Only stated as 'Grade II' | II | 2 | |
| | | | |
| Medium grade, intermediate grade | II-III | 3 | 2 |
| Moderately poorly differentiated | III | 3 | |
| Moderately undifferentiated | III | 3 | |
| Poorly differentiated | III | 3 | |
| Relatively poorly differentiated | III | 3 | |
| Relatively undifferentiated | III | 3 | |
| Slightly differentiated | III | 3 | |
| Dedifferentiated | III | 3 | |
| Only stated as 'Grade III' | III | 3 | |
| | | | |
| High grade | III-IV | 4 | 3 |
| Undifferentiated, anaplastic, not differentiated | IV | 4 | |
| Only stated as 'Grade IV' | IV | 4 | |
| Non-high grade | | 9 | |

9. If no description fits or grade is unknown prior to neoadjuvant therapy, code as a 9 (unknown).

SPECIAL GRADE SYSTEMS RULES

Breast (site: breast excluding lymphomas; CS schema: breast)

Use Bloom Richardson (BR) or Nottingham score/grade to code grade based on CSv2 site-specific factor 7 (SSF) as stated below. If your registry does not collect this SSF, use the description in the table below to determine grade. If you collect this SSF, codes 030-130 could be automatically converted into the grade field.

BR could also be referred to as: Bloom-Richardson, modified Bloom-Richardson, BR, BR grading,

Scarff-Bloom-Richardson, SBR grading, Elston-Ellis modification of Bloom-Richardson score, Nottingham modification of Bloom-Richardson score, Nottingham modification of Scarff-Bloom-Richardson, Nottingham-Tenovus grade, or Nottingham grade.

Code the tumor grade using the following priority order

- a. BR scores 3-9
- b. BR grade (low, intermediate, high)

BR score may be expressed as a range, 3-9. The score is based on three morphologic features: degree of tubule formation/histologic grade, mitotic activity, nuclear pleomorphism/nuclear grade of tumor cells. If a report uses words such as low, intermediate, or high rather than numbers, use the table below to code grade.

If only a grade of 1 through 4 is given with no information on the score and it is unclear if it is a Nottingham or BR Grade, do not use the table below. Continue with the next priority according to “Coding for Solid Tumors” #7 above.

Code the highest score if multiple scores are reported (exclude scores from tests after neoadjuvant therapy began). Examples: different scores may be reported on multiple pathology reports for the same primary cancer; different scores may be reported for multiple tumors assigned to the same primary cancer.

| CS Site-Specific Factor 7 | | |
|--|----------------|-------------------|
| Nottingham or Bloom-Richardson (BR) Score/Grade | | |
| Description | CS Code | Grade Code |
| Score of 3 | 030 | 1 |
| Score of 4 | 040 | 1 |
| Score of 5 | 050 | 1 |
| Score of 6 | 060 | 2 |
| Score of 7 | 070 | 2 |
| Score of 8 | 080 | 3 |
| Score of 9 | 090 | 3 |
| Low Grade, Bloom-Richardson (BR) grade 1, score not given | 110 | 1 |
| Medium (Intermediate) Grade, BR grade 2, score not given | 120 | 2 |
| High Grade, BR grade 3, score not given | 130 | 3 |

Kidney Parenchyma (Site: kidney parenchyma excluding lymphomas; CS schema: KidneyParenchyma): Fuhrman Nuclear Grade

The Fuhrman Nuclear Grade should be used to code grade for kidney parenchyma only based on CSv2 SSF 6 as stated below. Do not use for kidney renal pelvis. If your registry does not collect this SSF, use the description in the table to determine grade. If you collect this SSF, the information could be automatically converted into the grade field if it is coded 010-040. Fuhrman nuclear grade is a four-grade system based on nuclear diameter and shape, the prominence of nucleoli, and the presence of chromatin clumping in the highest grade.

| Description | CS Code | Grade Code |
|--------------------|----------------|-------------------|
| Grade 1 | 010 | 1 |
| Grade 2 | 020 | 2 |
| Grade 3 | 030 | 3 |
| Grade 4 | 040 | 4 |

SoftTissue (sites excluding lymphomas: soft tissue, heart, mediastinum, peritoneum, and retroperitoneum; for CS users: SoftTissue, HeartMediastinum, Peritoneum, Retroperitoneum schemas): Grade for Sarcomas

The Grade for Sarcomas should be used to code grade based on CSv2 SSF 1 as stated below. If your registry does not collect this SSF, use the description in the table to determine grade. If you collect this SSF, the information could be automatically converted into the grade field if it is coded 010-200. The grading system of the French Federation of Cancer Centers Sarcoma Group (FNCLCC) is the preferred system.

Record the grade from any three-grade sarcoma grading system the pathologist uses. For terms such as "well differentiated" or "poorly differentiated," go to Coding for Solid Tumors #8.

In some cases, especially for needle biopsies, grade may be specified only as "low grade" or "high grade." The numeric grade takes precedence over "low grade" or "high grade."

| Description | CS Code | Grade Code |
|---------------------------------|---------|------------|
| Specified as Grade 1 [of 3] | 010 | 2 |
| Specified as Grade 2 [of 3] | 020 | 3 |
| Specified as Grade 3 [of 3] | 030 | 4 |
| Grade stated as low grade, NOS | 100 | 2 |
| Grade stated as high grade, NOS | 200 | 4 |

Prostate (site: prostate excluding lymphomas; CS schema: prostate)

Use the highest Gleason score from the biopsy/TURP or prostatectomy/autopsy. Use a known value over an unknown value. Exclude results from tests performed after neoadjuvant therapy began.

This information is collected in CSv2 SSF 8 (Gleason score from biopsy/TURP) and SSF 10 (Gleason score from prostatectomy/autopsy) as stated below. Use the table below to determine grade even if your registry does not collect these SSFs. If you collect these SSFs, the information could be converted into the grade field automatically.

Usually prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10. If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score. If only one number is given on a particular test and it is less than or equal to 5 and not specified as a score, do not use the information because it could refer to either a score or a grade. If only one number is given and it is greater than 5, assume that it is a score and use it. If the pathology report specifies a specific number out of a total of 10, the first number given is the score. Example: The pathology report says Gleason 3/10. The Gleason score would be 3.

Historic Perspective

| Gleason score | Description | | | | | |
|---------------|-------------|------------|----------|----------------|----------|-----------------|
| | CS Code | Grade Code | AJCC 7th | SEER 2003-2013 | AJCC 6th | SEER prior 2003 |
| 2 | 002 | 1 | G1 | G1 | G1 | G1 |
| 3 | 003 | 1 | G1 | G1 | G1 | G1 |
| 4 | 004 | 1 | G1 | G1 | G1 | G1 |
| 5 | 005 | 1 | G1 | G2 | G2 | G2 |

| | | | | | | |
|----|-----|---|----|----|----|----|
| 6 | 006 | 1 | G1 | G2 | G2 | G2 |
| 7 | 007 | 2 | G2 | G3 | G3 | G2 |
| 8 | 008 | 3 | G3 | G3 | G3 | G3 |
| 9 | 009 | 3 | G3 | G3 | G3 | G3 |
| 10 | 010 | 3 | G3 | G3 | G3 | G3 |

Historical perspective on long term trends in prostate grade: The relationship of Gleason score to grade changed for 1/1/2014+ diagnoses in order to have the grade field in sync with AJCC 7th ed. Analysis of prostate grade before 2014 based solely on the grade field is not recommended. In Collaborative Stage (CS), Gleason score was originally coded in CSv1 in one field (SSF 6) and then it was split into two fields in CSv2 based on the tissue used for the test: needle biopsy/TURP (SSF 8) and prostatectomy/autopsy (SSF 10). For trends using data back to 2004, if one collected the various CS Gleason scores, one could design a recode to have the same criteria as the data collected 2014+. The original grade field would NOT be changed, but for analyses this recode could be based on the CS SSFs and the original grade code.

Multiple Primaries

The most recent **SEER Multiple Primary and Histology Coding Rules** contain site-specific rules for lung, breast, colon, melanoma of the skin, head and neck, kidney, renal pelvis/ureter/bladder, and malignant and nonmalignant brain primaries. A separate set of rules addresses the specific and general rules for all other sites. The multiple primary rules guide and standardize the process of determining the number of primaries. The histology rules contain detailed histology coding instructions.

If an invasive and an in situ tumor are identified as a single tumor according to the **SEER Multiple Primary and Histology Coding Rules** and they are located in different subsites, the primary site should be identified as the subsite in which the *invasive* tumor is located. If, however, the two tumors are both invasive, then code the subsite as “.9”.

The **SEER Multiple Primary and Histology Coding Rules** do not apply to hematopoietic and lymphoid tumors. Use the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** and the **Hematopoietic and Lymphoid Neoplasms Database** to code hematopoietic primaries (lymphoma and leukemia M9590-9989) diagnosed on January 1, 2010, or later. Use the tables in *Appendix A of FORDS Revised for 2011* only for hematopoietic and lymphoid cases diagnosed prior to 2010. Primary site and timing are not applicable for determining whether these malignancies represent one or more primaries.

Paired Organ Sites

A list of paired organ sites can be found earlier in this section. Refer to the **SEER Multiple Primary and Histology Coding Rules** to determine whether involvement of paired sites should be coded as one or two primaries.

Revising the Original Diagnosis

Data are gathered from multiple sources using the most recent and complete information available. Over time, the patient’s records may contain new information such as tests, scans, and consults. Change the primary site, laterality, histology, grade and stage as the information becomes more complete. If the primary site or histology is changed, it may also be necessary to revise site-specific staging and treatment codes. There is no time limit for making revisions that give better information about the original diagnosis or stage. However, if staging information is updated, it is important to adhere to the timing requirements for the respective staging system. Most cases that require revision are unknown primaries.

Example 1

The institution clinically diagnoses a patient with carcinomatosis. The registry enters the case as an unknown primary (C80.9), carcinoma, NOS (8010/3), stage of disease unknown. Nine months later, a paracentesis shows serous cystadenocarcinoma. The physician says that the patient has an ovarian primary. Change the primary site to ovary (C56.9), histology to serous cystadenocarcinoma (8441/3),

and diagnostic confirmation to positive cytologic study, no positive histology (code 2). If enough information is available that meets the AJCC timing requirements for staging, change the stage from not applicable (88) to the appropriate staging basis, TNM elements, and stage group, or to unknown. Update the Collaborative Stage input items and rerun the derivation program. If first course surgery was performed, the surgery codes should be reviewed.

Example 2

A physician decides that a previously clinically diagnosed malignancy is a benign lesion. The patient is referred from a nursing home to the facility. The chest X ray shows a cavitory lesion in the right lung. The family requests that the patient undergo no additional workup or treatment. Discharge diagnosis is “probable carcinoma of right lung.” The registry abstracts a lung primary (C34.9). Two years later a chest X ray shows an unchanged lesion. The physician documents “lung cancer ruled out.” Delete the case from the database. Adjust the sequence number(s) of any other primaries the patient may have. If the deleted case is the patient’s only primary, do not reuse the accession number.

PATIENT ADDRESS AND RESIDENCY RULES

The patient’s address at diagnosis is the patient’s place of residence at the time of original diagnosis. It does not change if the patient moves. If the patient has more than one primary tumor, the address at diagnosis may be different for each primary.

The current address initially is the patient’s residence at the time the patient was first seen at the accessioning facility for this primary. The current address is updated if the patient moves. If the patient has more than one primary tumor, the current address should be the same for each primary.

Normally a residence is the home named by the patient. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with the rules of the Census Bureau whenever possible. The registry can resolve residency questions by using the Census Bureau’s definition, “the place where he or she lives and sleeps most of the time or the place the person considers to be his or her usual home.” State Vital Statistics rules may differ from Census rules. Do not record residence from the death certificate. Review each case carefully.

Rules for Persons with Ambiguous Residences

Persons with More than One Residence (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.

Persons with No Usual Residence (transients, homeless): Use the address of the place the patient was staying when the cancer was diagnosed. This location may be a shelter or the diagnosing facility.

Persons Away at School: College students are residents of the school area. Boarding school students below the college level are residents of their parents’ homes.

Persons in Institutions: The Census Bureau states, “Persons under formally authorized, supervised care or custody” are residents of the institution. This classification includes the following:

- Incarcerated persons
- Persons in nursing, convalescent, and rest homes
- Persons in homes, schools, hospitals, or wards for the physically disabled, mentally retarded, or mentally ill.
- Long-term residents of other hospitals, such as Veterans Affairs (VA) hospitals.

Persons in the Armed Forces and on Maritime Ships: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their families. Military personnel may use the installation address or the surrounding community’s address. The Census Bureau has detailed

residency rules for Navy personnel, Coast Guard, and maritime ships. Refer to Census Bureau publications for the detailed rules.

Coding Country and State

Beginning in 2013, “country” fields accompany “state” fields in addresses. The following state and country address data items are found in **FORDS**:

State at Diagnosis (not changed)

Addr at Diagnosis--Country (new item, associated with *State at Diagnosis*)

State—Current (not changed)

Address Current – Country (new item, associated with *State—Current*)

Place of Birth (discontinued, replaced by *Birthplace—State* and *Birthplace—Country*)

Birthplace—State (new item, coded similarly to the other two “state” fields)

Birthplace—Country (new item, associated with *Birthplace—State*)

Appendix E has a list of all country codes and corresponding state codes. State codes for all U.S. states and possessions and all Canadian provinces are included in Appendix E. State codes for the United States and its possessions are those used by the United States Postal Service. Canadian province or territory codes are from Canada Post sources. Country codes are based on the International Standards Organization (IS) 3166-1 Country Three Character Codes. State and country codes also include some custom codes, which are included in Appendix E.

The list in Appendix E is divided into three parts.

- The first part is the preferred codes to use when sufficient detail is known to identify the U.S. state, Canadian province, or other country to assign precise codes.
- The second part consists of codes for more general regions for use when a precise code can not be assigned (for example, “Near East”). If there is no indication at all of location in the patient record, the country is coded ZZU and the state will be ZZ.
- The third section is a list of obsolete codes that may have been assigned when the registry data were upgraded from former codes. This information is provided to assist registries in interpreting their historic data, but the obsolete codes must not be assigned for current abstracting.

IN UTERO DIAGNOSIS AND TREATMENT

Beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born. The exact date may be used for cases diagnosed prior to 2009.

COMORBIDITIES AND COMPLICATIONS / SECONDARY DIAGNOSES

The CoC requires that the registry record include up to 10 comorbid conditions, factors influencing the health status of the patient, and treatment complications, to be copied from the patient record. All are secondary diagnoses. The information is recorded in the **International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9-CM or ICD-10-CM)** code form, typically on the patient’s discharge abstract or face sheet of the billing record. Most hospitals in the United States are expected to implement use of ICD-10-CM in 2015. Separate data item series are used to record the two series. ICD-10-CM codes can have up to 7 characters, whereas ICD-9-CM codes only have 5 characters or fewer. Both the specific codes and the rules for recording them differ. The underlying meanings of the codes are similar. That is, the concepts originally described as “comorbidities and complications” are also known as “secondary diagnoses”; in this instance, the separate names are given to distinguish the separate registry data items.

The items describing patient comorbid conditions and complications ICD-9-CM codes are:

Comorbidities and Complications #1 (NAACCR Item #3110)

Comorbidities and Complications #2 (NAACCR Item #3120)

Comorbidities and Complications #3 (NAACCR Item #3130)
Comorbidities and Complications #4 (NAACCR Item #3140)
Comorbidities and Complications #5 (NAACCR Item #3150)
Comorbidities and Complications #6 (NAACCR Item #3160)
Comorbidities and Complications #7 (NAACCR Item #3161)
Comorbidities and Complications #8 (NAACCR Item #3162)
Comorbidities and Complications #9 (NAACCR Item #3163)
Comorbidities and Complications #10 (NAACCR Item #3164)

The items describing patient comorbid secondary diagnoses ICD-10-CM codes are:

Secondary Diagnosis #1 (NAACCR Item #3780)
Secondary Diagnosis #2 (NAACCR Item #3782)
Secondary Diagnosis #3 (NAACCR Item #3784)
Secondary Diagnosis #4 (NAACCR Item #3786)
Secondary Diagnosis #5 (NAACCR Item #3788)
Secondary Diagnosis #6 (NAACCR Item #3790)
Secondary Diagnosis #7 (NAACCR Item #3792)
Secondary Diagnosis #8 (NAACCR Item #3794)
Secondary Diagnosis #9 (NAACCR Item #3796)
Secondary Diagnosis #10 (NAACCR Item #3798)

Three general categories of information are collected: comorbidities, complications, and factors influencing the health status of patients.

Comorbidities are preexisting medical conditions or conditions that were present at the time the patient was diagnosed with this cancer (for example, chronic conditions such as COPD, diabetes, and hypertension).

Complications are conditions that occur during the hospital stay, while the patient is being treated for the cancer (for example, postoperative urinary tract infection or pneumonia). Complications may also occur following the completion of therapy and be a cause for readmission to the hospital. Complications are identified by codes which classify environmental events, circumstances, and conditions as the cause of injury, poisoning, and other adverse effects. Only complication codes that describe adverse effects occurring during medical care are collected in this data item. They include misadventures to patients during surgical and medical care, and drugs and medicinal and biologic substances causing adverse effects in therapeutic use.

Factors influencing the health status of patients are circumstances or problems that are not themselves a current illness or injury (for example, women receiving postmenopausal hormone replacement therapy, or a history of malignant neoplasm). Only specific codes which describe health characteristics are collected in this data item. They include prophylactic measures, personal health history, pregnancy, contraception, artificial opening and other post surgical states, and prophylactic organ removal.

STAGE OF DISEASE AT INITIAL DIAGNOSIS

Surgical Diagnostic and Staging Procedures

Surgical Diagnostic and Staging Procedure (NAACCR Item #1350) and *Surgical Diagnostic and Staging Procedure at This Facility* (NAACCR Item #740) refer solely to surgical procedures performed specifically for diagnosis or staging of the tumor and do not apply to surgical treatment. *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280) refers to the date on which the surgical diagnostic and/or staging procedure was performed at any facility.

EXCEPTION: Do not code surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350). Use the data item *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) to code these procedures. Additionally, do not record the date of surgical procedures that aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical*

Diagnostic and Staging Procedure (NAACCR Item #1280). Record the date of this surgical procedure in the data item *Date of First Course of Treatment* (NAACCR Item #1270) and/or *Date of First Surgical Procedure* (NAACCR Item #1200), as appropriate.

AJCC TNM STAGING

AJCC TNM Stage is based on the clinical, operative, and pathologic assessment of the anatomic extent of disease and is used to make appropriate treatment decisions, determine prognosis, and measure end results. Use the rules in the current *AJCC Cancer Staging Manual* to assign AJCC T, N, M and Stage Group values. The following general rules apply to AJCC staging of all sites.

- *Clinical staging* includes any information obtained about the extent of cancer before initiation of definitive treatment (surgery, systemic or radiation therapy, active surveillance, or palliative care) or within four months after the date of diagnosis, whichever is *shorter*, as long as the cancer has not clearly progressed during that time frame.
- *Pathologic staging* includes any information obtained about the extent of cancer through completion of definitive surgery as part of first course treatment or identified within 4 months after the date of diagnosis, whichever is *longer*, as long as there is no systemic or radiation therapy initiated or the cancer has not clearly progressed during that time frame.

The AJCC items that must be coded for Class of Case 10–22 are:

Clinical T (NAACCR Item #940)

Clinical N (NAACCR Item #950)

Clinical M (NAACCR Item #960)

Clinical Stage Group (NAACCR Item #970)

Clinical Stage (Prefix/Suffix) Descriptor (NAACCR Item #980)

Staged By (Clinical Stage) (NAACCR Item #990)

Pathologic T (NAACCR Item #880)

Pathologic N (NAACCR Item #890)

Pathologic M (NAACCR Item #900)

Pathologic Stage Group (NAACCR Item #910)

Pathologic Stage (Prefix/Suffix) Descriptor (NAACCR Item #920)

Staged By (Pathologic Stage) (NAACCR Item #930)

- If a patient has multiple primaries, stage each primary independently.
- If the stage group cannot be determined from the recorded components, then record it as unknown.
- When a patient with multiple primaries develops metastases, a biopsy may distinguish the source of distant disease. Stage both primaries as having metastatic disease if the physician is unable to conclude which primary has metastasized. If, at a later time, the physician identifies which primary has metastasized, update the stage(s) as appropriate.
- If pediatric staging is used and AJCC staging is not applied, code 88 for clinical and pathologic T, N, and M as well as stage group. If either clinical or pathologic staging was applied for a pediatric tumor, enter the appropriate codes and do not code 88.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are considered as “impossible diagnoses” in the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- Beginning in 2016, new T, N, and M categories were implemented that include ‘c’ and ‘p’ designations to enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules.

Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual. For example, the new category of cN0 for the TNM Path N [890] data item is limited to in situ tumors only in 2016.

Ambiguous Terminology

If the wording in the patient record is ambiguous with respect to tumor spread, use the following guidelines:

Ambiguous Terms Describing Tumor Spread

| Terms that Constitute Tumor Involvement or Extension | | Terms that <i>Do Not</i> Constitute Tumor Involvement or Extension |
|--|------------|--|
| Adherent | Into | Approaching |
| Apparent | Onto | Equivocal |
| Compatible with | Out onto | Possible |
| Consistent with | Probable | Questionable |
| Encroaching upon | Suspect | Suggests |
| Fixation, fixed | Suspicious | Very close to |
| Induration | To | |

COLLABORATIVE STAGE DATA COLLECTION SYSTEM

For cases diagnosed beginning January 1, 2016, the *Collaborative Stage Data Collection System* (CS) has been retired. CS is to be used for staging cases diagnosed on or after January 1, 2004 through December 31, 2015. It is not to be used for cases diagnosed prior to, or after those dates. For cases diagnosed from 2004-2015 all CS items identified in FORDS are required to be completed for *Class of Case* 00-22. See the interactive application at <http://seer.cancer.gov/csreqstatus/application.html> for the specific Site-Specific Factors required by CoC by site and histology.

The following data items were considered as Collaborative Stage input data items for the purposes of Collaborative Stage, but are now are continued to be required for AJCC staffing and research purposes. They are required for all cases diagnosed in 2004 and later:

- Regional Nodes Positive [820]
- Regional Nodes Examined [830]
- Lymph-vascular Invasion [1182]
- CS Site-specific Factors [2861-2880, 2890-2930]
- CS Version Input Original [2935]
- CS Version Input Current [2937]

Note: CoC's requirements for the Site-specific Factors have not changed from 2015; the data items of CS Version Input Original and Current continue to be required to accommodate continued collection of the SSFs.

Differences between CS Derived Values and Directly-assigned AJCC

Some differences in the ways that the CS algorithm operates and how the AJCC stage assignment rules are made can result in dissimilarities between the derived values for some patients and the direct-coded stages. Because of those differences, the CS Derived AJCC values must never be copied into the equivalent directly-assigned AJCC data items. The dissimilarities of most interest to registrars are those that might explain discrepancies between the derived AJCC T, N, M, and Stage Group values and the

values recorded for the same cases when directly coded using the AJCC instructions, as described in the next paragraph.

As a “best stage” system, CS makes use of the most complete information available to stage the tumor. The *AJCC Cancer Staging Manual* distinguishes between clinical staging, based on information available prior to primary treatment, and pathologic staging, based on information gathered as a product of the treatment process (particularly surgery). It also has specific rules governing how the components gathered at different times in the process may be combined. The CS algorithm derives a clinical (c) or pathologic (p) descriptor for each of the T, N, and M stage components based on the source of information used to validate the most extensive spread of the tumor, and uses the components to derive a stage group without reference to the value of the descriptors. Some derived stage groups may involve combinations that are neither clinical nor pathologic according to AJCC rules, so a case that is unstageable for a physician applying AJCC rules may be assigned a Derived AJCC Stage Group value by the CS algorithm. Other cases may involve combinations that do not match either the physician-assigned clinical stage or the pathologic stage.

FIRST COURSE OF TREATMENT

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. “Active surveillance” is a form of planned treatment for some patients; its use is coded in the new *RX Summ–Treatment Status* item. “No therapy” is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, or the physician recommends no treatment be given. If the patient refuses all treatment, code “patient refused” (code 7 or 87) for all treatment modalities. Maintenance treatment given as part of the first course of planned care (for example, for leukemia) is first course treatment, and cases receiving that treatment are analytic.

Treatment Plan

A treatment plan describes the type(s) of therapies intended to modify, control, remove, or destroy proliferating cancer cells. The documentation confirming a treatment plan may be found in several different sources; for example, medical or clinic records, consultation reports, and outpatient records.

- All therapies specified in the physician(s) treatment plan are a part of the first course of treatment if they are actually administered to the patient.
- A discharge plan must be part of the patient’s record in a JCAHO-accredited hospital and may contain part or all of the treatment plan.
- An established protocol or accepted management guidelines for the disease can be considered a treatment plan in the absence of other written documentation.
- If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, use the principle: “initial treatment must begin within four months of the date of initial diagnosis.”

Time Periods for First Course of Treatment

If first course treatment was provided, the *Date of First Course of Treatment* (NAACCR Item #1270) is the earliest of *Date of First Surgical Procedure* (NAACCR Item #1200), *Date Radiation Started* (NAACCR Item #1210), *Date Systemic Therapy Started* (NAACCR Item #3230), or *Date Other Treatment Started* (NAACCR Item #1250).

- If no treatment is given, record the date of the decision not to treat, the date of patient refusal, or the date the patient expired if the patient died before treatment could be given.
- If active surveillance (“watchful waiting”) was selected, record the date of that decision.
- Additional data items further define the parameters for specific treatments and treatment modalities, as described in the following sections.

A new item, *RX Summ–Treatment Status* (NAACCR Item #1285), implemented in 2010, summarizes whether the patient received any first course treatment, no treatment, or is being managed by active surveillance.

All Malignancies except Leukemias

The first course of treatment includes all therapy planned and administered by the physician(s) during the first diagnosis of cancer. Planned treatment may include multiple modes of therapy and may encompass intervals of a year or more. Any therapy administered after the discontinuation of first course treatment is subsequent treatment.

Leukemias

The first course of treatment includes all therapies planned and administered by the physician(s) during the first diagnosis of leukemia. Record all remission-inducing or remission-maintaining therapy as the first course of treatment. Treatment regimens may include multiple modes of therapy. The administration of these therapies can span a year or more. A patient may relapse after achieving a first remission. All therapy administered after the relapse is secondary or subsequent treatment.

Surgery

First course surgery items describe the most definitive type of surgical treatment the patient received from any facility, when it was performed, and its efficacy. When no surgical treatment is given, the reason is recorded. Major aspects of surgical care provided by the individual facility are also recorded so that hospital cancer programs can evaluate local patient care.

Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions. The paragraphs below describe how the surgery items fit together.

The following summary items apply to all surgical procedures performed at this facility and at other facilities:

- Surgical Procedure of Primary Site* (NAACCR Item #1290)
- Radiation/Surgery Sequence* (NAACCR Item #1380)
- Scope of Regional Lymph Node Surgery* (NAACCR Item #1292)
- Surgical Procedure/Other Site* (NAACCR Item #1294)
- Surgical Margins of the Primary Site* (NAACCR Item #1320)
- Reason for No Surgery of Primary Site* (NAACCR Item #1340)
- Date of First Surgical Procedure* (NAACCR Item #1200)
- RX Date–Surgery Flag* (NAACCR Item #1201)
- Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170)
- RX Date Mst Defn Srg Flag* (NAACCR Item #3171)
- Date of Surgical Discharge* (NAACCR Item #3180)
- RX Date Surg Disch Flag* (NAACCR Item #3181)
- Readmission to the Same Hospital Within 30 Days of Surgical Discharge* (NAACCR Item #3190)

The following items apply to surgical procedures performed at this facility:

- Surgical Procedure of Primary Site at This Facility* (NAACCR Item #670)
- RX Hosp–Surg App 2010* (NAACCR Item #668)
- Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672)
- Surgical Procedure/Other Site at This Facility* (NAACCR Item #674)

Relationships among Surgical Items

Date of First Surgical Procedure is the date that the first *Surgical Procedure of Primary Site*, *Scope of Regional Lymph Node Surgery*, or *Surgical Procedure/Other Site* is performed as part of first course treatment.

- If surgery was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date of First Surgical Procedure* is the same as *Date of First Course of Treatment*. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Surgical Procedure of Primary Site, *Scope of Regional Lymph Node Surgery*, and *Surgical Procedure/Other Site* record three distinct aspects of first course therapeutic surgical procedures that may be performed during one or multiple surgical events. If multiple primaries are treated by a single surgical event, code the appropriate surgical items separately for each primary.

When multiple first course procedures coded under the same item are performed for a primary, the most extensive or definitive is the last performed, and the code represents the cumulative effect of the separate procedures. Do not rely on your registry software to accumulate separate surgeries into the correct code.

- *Surgical Procedure of Primary Site* is a site-specific item that describes the most invasive extent of local tumor destruction or surgical resection of the primary site and of surrounding tissues or organs that are removed in continuity with the primary site.
- *Scope of Regional Lymph Node Surgery* describes the removal, biopsy, or aspiration of sentinel nodes and other regional lymph nodes that drain the primary site and may include surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease as well as removal of nodes for treatment of the disease.
- *Surgical Procedure/Other Site* describes first course resection of distant lymph node(s) and/or regional or distant tissue or organs beyond the *Surgical Procedure of the Primary Site* range.

If surgery of the respective type was performed, the code that best describes the surgical procedure is recorded whether or not any cancer was found in the resected portion. Incidental removal of tissue or organs, when it is not performed as part of cancer treatment (for example, incidental removal of an appendix), does not alter code assignment.

The code ranges and corresponding descriptions for site-specific *Surgical Procedure of Primary Site* code are grouped according to the general nature of the procedure:

- Codes 10 through 19 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.
- Codes 20 through 80 are site-specific descriptions of resection procedures.
- The special code 98 applies to specific tumors that cannot be clearly defined in terms of primary nonprimary site. *Surgical Procedure of Primary Site* should be coded 98 for any tumor characterized by the specific sites and/or morphologies identified in the site-specific code instructions for *Unknown and Ill-Defined Primary Sites* and *Hematopoietic/ Reticuloendothelial/Immunoproliferating/ Myeloproliferative Disease*. The item *Surgical Procedure/Other Site* is used to indicate whether surgery was performed for these tumors.

Response categories are defined in logical sequence. Within groups of codes, procedures are defined with increasing degrees of descriptive precision. Succeeding groups of codes define progressively more extensive forms of resection.

For codes 00 through 79, the descriptions of the surgical procedures are hierarchical. Last-listed responses take precedence over earlier-listed responses (regardless of the code or numeric value).

To the extent possible, codes and their definitions are the same as those previously assigned in *ROADS* to accommodate analysis in registries that maintain unconverted data. As a result of added and modified codes, however, the numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed.

Example: A rectosigmoid primary surgically treated by polypectomy with electrocautery, which is listed *after* polypectomy alone, is coded 22.

| | |
|---------------------------------|----------------------------|
| 20 | Local tumor excision, NOS |
| 26 | Polypectomy |
| 27 | Excisional biopsy |
| Combination of 20 or 26–27 WITH | |
| 21 | Photodynamic therapy (PDT) |
| 22 | Electrocautery |
| 23 | Cryosurgery |
| 24 | Laser ablation |
| 25 | Laser excision |

Scope of Regional Lymph Node Surgery distinguishes between sentinel lymph node biopsy and removal of other regional lymph nodes and distinguishes removal of regional lymph nodes during the same surgical procedure as a sentinel node biopsy from subsequent removal.

- One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment to previously published treatment based on the former codes, or to data still unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. The compromise incorporated in the *Scope of Regional Lymph Node Surgery* codes separates removal of one to three nodes (code 4) from removal of four or more nodes in the response categories (code 5). It is **very important** to note that this distinction is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than four nodes was not reflected in surgery codes. The distinction between fewer than four nodes and four or more nodes removed is not intended to reflect clinical significance when applied to a particular surgical procedure.

Surgical Procedure/Other Site describes surgery performed on tissue or organs other than the primary site or regional lymph nodes. It is also used to describe whether surgery was performed for tumors having unknown or ill-defined primary sites or hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease morphologies. If any surgical treatment was performed on these cancers, *Surgical Procedure/Other Site* is coded 1.

Surgical Procedure of Primary Site at This Facility, *Scope of Regional Lymph Node Surgery at This Facility*, and *Surgical Procedure/Other Site at This Facility* are identical to *Surgical Procedure of Primary Site*, *Scope of Regional Lymph Node Surgery*, and *Surgical Procedure/Other Site*, respectively, except they each refer solely to surgery provided by the respective facility.

Six surgery items augment the information recorded in *Surgical Procedure of Primary Site*. The items *Date of Most Definitive Surgical Resection of the Primary Site*, *Surgical Margins of the Primary Site*, *Date of Surgical Discharge*, and *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* apply to the most definitive (most invasive) first course primary site surgery performed, that is, to the event recorded under *Surgical Procedure of Primary Site*. When no surgical procedure of the primary site is performed, the reason is recorded in the item *Reason for No Surgery of Primary Site*.

- *Date of Most Definitive Surgical Resection* is the date on which the specific procedure recorded in *Surgical Procedure of Primary Site* was performed. If only one first course surgical procedure was performed, then the date will be the same as that for *Date of First Surgical Procedure*.

- *Surgical Margins of the Primary Site* records the pathologist's determination of the presence of microscopic or macroscopic involvement of cancer at the margins of resection following the surgical resection described by *Surgical Procedure of Primary Site*.
- *RX Hosp–Surg App 2010* distinguishes among open surgery, laparoscopic surgery, and robotic assisted surgery when it is performed by the reporting facility. If more than one surgical procedure is performed by the facility, this item refers to the most definitive (most invasive) first course primary site surgery performed.
- *Date of Surgical Discharge* is the date the patient was discharged following the procedure recorded in *Surgical Procedure of Primary Site*. It is on or after the *Date of Most Definitive Surgical Resection*.
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* distinguishes a planned from an unplanned hospital admission and is used as a quality of care indicator.
- *Reason for No Surgery* identifies why surgical therapy was not provided to the patient and distinguishes a physician's not recommending surgical therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan.

Radiation

The radiation items in *FORDS* are clinically relevant and reflect contemporary practice. These items record regional and boost treatment information.

The following summary items apply to all radiation therapy administered at this facility and at other facilities:

- Date Radiation Started* (NAACCR Item #1210)
- RX Date–Radiation Flag* (NAACCR Item #1211)
- Location of Radiation Treatment* (NAACCR Item #1550)
- Radiation Treatment Volume* (NAACCR Item #1540)
- Regional Treatment Modality* (NAACCR Item #1570)
- Regional Dose: cGy* (NAACCR Item #1510)
- Boost Treatment Modality* (NAACCR Item #3200)
- Boost Dose: cGy* (NAACCR Item #3210)
- Number of Treatments to This Volume* (NAACCR Item #1520)
- Radiation/Surgery Sequence* (NAACCR Item #1380)
- Date Radiation Ended* (NAACCR Item #3220)
- RX Date Rad Ended Flag* (NAACCR Item #3221)
- Reason for No Radiation* (NAACCR Item #1430)

Relationships among Radiation Items

Date Radiation Started is the date that the first radiation therapy was delivered to the patient as part of all of the first course of therapy. This item in combination with *Date Radiation Ended* allows the duration of treatment to be calculated.

- If radiation was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date Radiation Started* is the same as *Date of First Course of Treatment*. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Location of Radiation Treatment can be used to assess where therapy was provided. This item allows for the distinction between summary treatment and treatment given at the accessioning facility. Codes are provided that allow the description of where regional and boost dose therapy were provided, whether all the therapy was provided at the accessioning facility or if all or some of the radiation therapy was referred out to another treatment location.

The targeted anatomic region is described by *Radiation Treatment Volume*. The treatment volume may be the same as the primary site of disease; however, the available code values provide descriptions of anatomic regions that may extend beyond the primary site of disease and may be used to describe the treatment of metastatic disease. If two distinct volumes are radiated, and one of those includes the primary site, record the radiation involving the primary site in all radiation fields.

The type of regional dose therapy and its concomitant dose are captured by the items *Regional Treatment Modality* and *Regional Dose: cGy*. These two items describe the type of radiation delivered to the patient and the most significant therapeutic dose delivered.

A boost treatment is provided to a smaller field within the same volume as regional radiation in order to enhance the effect of the regional treatment.

- The boost dose may or may not employ the same treatment modality. For example, external beam radiation may be used for regional treatment and be followed by brachytherapy to provide the boost dose.
- Not all patients who receive radiation therapy receive a boost dose radiation. For these cases, boost modality and dose should be coded as 00 and 00000, respectively.

In addition to knowing the duration of treatment and the modalities and doses involved, it is critical to know the number of treatments to be able to gauge the intensity of the dose delivered to the patient. The data item *Number of Treatments to This Volume* describes the total number of therapeutic treatments (regional and boost combined) delivered to the anatomic volume coded in *Radiation Treatment Volume*.

Two items augment the information recorded in the radiation modality, dose, volume, and number of treatment items.

- *Radiation/Surgery Sequence* identifies those instances where radiation therapy and the surgical management of the patient are not discrete and overlap with respect to time. Radiation therapy can precede the surgical resection of a tumor and then be continued after the patient's surgery, or radiation can be administered intraoperatively.
- *Reason for No Radiation* identifies why radiation therapy was not provided to the patient and distinguishes a physician's not recommending this therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan.

Systemic Therapy

Systemic therapy encompasses the treatment modalities captured by the items chemotherapy, hormone therapy, and immunotherapy. The systemic therapy items in **FORDS** separate the administration of systemic agents or drugs from medical procedures which affect the hormonal or immunologic balance of the patient.

The following summary items apply to all systemic therapy administered at this facility and at other facilities:

Date Systemic Therapy Started (NAACCR Item #3230)
RX Date Systemic Flag (NAACCR Item #3231)
Date Chemotherapy Started (NAACCR Item #1220)
RX Date-Chemo Flag (NAACCR Item #1221)
Date Hormone Therapy Started (NAACCR Item #1230)
RX Date-Hormone Flag (NAACCR Item #1231)
Date Immunotherapy Started (NAACCR Item #1240)
RX Date BRM Flag (NAACCR Item #1241)
Systemic/Surgery Sequence (NAACCR Item #1639)
Chemotherapy (NAACCR Item #1390)
Hormone Therapy (NAACCR Item #1400)

Immunotherapy (NAACCR Item #1410)

Hematologic Transplant and Endocrine Procedures (NAACCR Item #3250)

The following items describe systemic therapy performed at this facility:

Chemotherapy at This Facility (NAACCR Item #700)

Hormone Therapy at This Facility (NAACCR Item #710)

Immunotherapy at This Facility (NAACCR Item #720)

| Clarification of Systemic Therapy Terms | |
|---|---|
| Term | Definition |
| Chemotherapy | Cancer therapy that achieves its antitumor effect through the use of antineoplastic drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis. |
| Hormone therapy | Cancer therapy that achieves its antitumor effect through changes in hormonal balance. This type of therapy includes the administration of hormones, agents acting via hormonal mechanisms, antihormones, and steroids. |
| Immunotherapy | Cancer therapy that achieves its antitumor effect by altering the immune system or changing the host's response to the tumor cells. |
| Endocrine therapy | Cancer therapy that achieves its antitumor effect through the use of radiation or surgical procedures that suppress the naturally occurring hormonal activity of the patient (when the cancer occurs at another site) and, therefore, alter or affect the long-term control of the cancer's growth. |
| Hematologic transplants | Bone marrow or stem cell transplants performed to protect patients from myelosuppression or bone marrow ablation associated with the administration of high-dose chemotherapy or radiation therapy. |

Important information affecting classification of some systemic therapies. The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. This change is effective for cases diagnosed January 1, 2013, and forward. For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER*Rx Interactive Drug Database*.

| Drug Name(s) | Category Prior to 2013 | Category 2013 + |
|-----------------------|------------------------|-------------------|
| Alemtuzumab/Campath | Chemotherapy | BRM/Immunotherapy |
| Bevacizumab/Avastin | Chemotherapy | BRM/Immunotherapy |
| Rituximab | Chemotherapy | BRM/Immunotherapy |
| Trastuzumab/Herceptin | Chemotherapy | BRM/Immunotherapy |
| Pertuzumab/Perjeta | Chemotherapy | BRM/Immunotherapy |
| Cetuxumab/Erbix | Chemotherapy | BRM/Immunotherapy |

Chemotherapy and hormone therapy agents are administered in treatment cycles, either singly or in a combination regimen of two or more drugs. If a patient has an adverse reaction, the managing physician may change one of the agents in a combination regimen. If the replacement agent belongs to the same group as the original agent, there is no change in the regimen. However, if the replacement agent is of a different group than the original agent, the new regimen represents the start of subsequent therapy, *only the original agent or regimen is recorded as first course therapy*. Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of systemic therapy agents.

Systemic agents may be administered by intravenous infusion or given orally. Other methods of administration include the following:

| Method | Administration |
|---------------------|--|
| Intrathecal | Administered directly into the cerebrospinal fluid through a lumbar puncture needle into an implanted access device (for example, Ommaya reservoir). |
| Pleural/pericardial | Injected directly into pleural or pericardial space to control malignant effusions. |
| Intraperitoneal | Injected into the peritoneal cavity. |
| Hepatic artery | Injected into a catheter inserted into the artery that supplies blood to the liver. |

Relationships among Systemic Therapy Items

The data item *Date Systemic Therapy Started* describes the first date on which any first course systemic treatment was administered to the patient. Nine out of 10 patients treated with systemic therapy receive only a single class of drugs (chemotherapy, hormone therapy, or immunotherapy). Of the remaining patients who receive a combined regimen of systemic therapies, two-thirds begin these combined regimens simultaneously. For the purposes of clinical surveillance, the collection of multiple dates to describe the sequence of systemic therapy administration is not necessary.

The data items *Chemotherapy*, *Hormone Therapy*, and *Immunotherapy* describe whether or not each respective class of agent(s) or drug(s) were administered to the patient as part of first course therapy, based on *SEER*Rx*. In the case of chemotherapy, additional distinction is allowed for instances where single or multiagent regimens were administered. Each of these three items includes code values that describe the reason a particular class of drugs is not administered to the patient and distinguishes a physician's not recommending systemic therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan. The associated date items were previously defined by CoC, though discontinued in *FORDS* from 2003 through 2009 and the same fields may be used to collect them now, if allowed by the registry software.

Hematologic Transplant and Endocrine Procedures captures those infrequent instances in which a medical, surgical, or radiation procedure is performed on a patient that has an effect on the hormonal or immunologic balance of the patient. Hematologic procedures, such as bone marrow transplants or stem cell harvests, are typically employed in conjunction with administration of systemic agent(s), usually chemotherapy.

- Endocrine procedures, either radiologic or surgical, may be administered in combination with systemic agent(s), typically hormonal therapeutic agents.
- As first course therapy, hematologic procedures will rarely be administered in conjunction with endocrine radiation or surgery. The use of code 40 in response to this data item should be reviewed and confirmed with the managing physician(s).

Other Treatment

Other Treatment encompasses first course treatment that cannot be described as surgery, radiation, or systemic therapy according to the defined data items found in this manual.

This item is also used for supportive care treatment for reportable hematopoietic diseases that do not meet the usual definition in which treatment “modifies, controls, removes, or destroys proliferating cancer tissue.” Treatments such as phlebotomy, transfusions, and aspirin are recorded in *Other Treatment* data

item for certain hematopoietic diseases, and should be coded 1. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item.

The following items apply to all Other Treatment provided at this facility and at other facilities:

Date Other Treatment Started (NAACCR Item #1250)
RX Date–Other Flag (NAACCR Item #1251)
Other Treatment (NAACCR Item #1420)
Other Treatment at This Facility (NAACCR Item #730)

Palliative Care

Palliative care is provided to prolong the patient's life by controlling symptoms, to alleviate persistent pain, or to make the patient comfortable. Palliative care provided to relieve symptoms may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy. Palliative care is not used to diagnose or stage the primary tumor.

The following items apply to all palliative care provided at this facility and at other facilities:

Palliative Care (NAACCR #3270)
Palliative Care at This Facility (NAACCR Item #3280)

Any surgical procedure, radiation therapy, and/or systemic therapy that is provided to modify, control, remove, or destroy primary or metastatic cancer tissue, is coded in the respective first course of treatment fields and also identified in the *Palliative Care* items. Refer to the preceding discussion of the surgery, radiation and systemic therapy data items for specific coding guidelines. Because these treatments are less aggressive when given for palliation than for treatment, the treatment plan or treatment notes will indicate when they are performed for palliative purposes.

- Record as palliative care any of the treatment recorded in the first course therapy items that was provided to prolong the patient's life by managing the patient's symptoms, alleviating pain, or making the patient more comfortable.
- Palliative care can involve pain management that may not include surgery, radiation or systemic treatment.
- It is possible for a patient to receive one or a combination of treatment modalities in conjunction with palliative care intended to reduce the burden of pain. For example, a patient with metastatic prostate cancer may receive an orchiectomy and systemic hormone therapy in combination with palliative radiation for bone metastasis.

TREATMENT, PALLIATIVE, AND PROPHYLACTIC CARE

Any first course radiation or systemic treatment that acts to kill cancer cells is to be reported as treatment. For example, when total body irradiation (TBI) is given to prepare the patient for a bone marrow transplant (BMT), the TBI acts in two ways. First, it suppresses the immune system to reduce the body's ability to reject the BMT. Second, it contributes to the patient's treatment by destroying cancer cells in the bone marrow, though its use alone would generally not be sufficient to produce a cure. Both the TBI and the BMT should be coded as treatment. The situation is analogous to the use of breast-conserving surgery and adjuvant radiation when the surgery or radiation alone may not be sufficient to produce a cure, though together they are more effective.

When first course surgery, systemic treatment, or radiation is undertaken to reduce the patient's symptoms, that treatment should be coded as palliative care. An example is radiation to bone metastases

for prostate cancer to reduce bone pain, which is palliative when there is no expectation that the radiation will effectively reduce the cancer burden. Palliative care involving surgery, systemic treatment, or radiation is also coded as treatment. This treatment qualifies the patient as analytic if it is given as part of planned first course treatment.

The term “prophylactic” is used in medical practice in a variety of ways. An action taken to prevent cancer from developing (such as a double mastectomy for a healthy woman who has several relatives diagnosed with breast cancer when they were young) is not reportable; there is no cancer to report. Actions taken as part of planned first course treatment to prevent spread or recurrence of the cancer are sometimes characterized as “prophylactic” (for example, performing an oophorectomy or providing Tamoxifen to a breast cancer mastectomy patient). These treatments are to be coded as treatment.

EMBOLIZATION

The term *embolization* refers to the intentional blocking of an artery or vein. The mechanism and the reason for embolization determine how and whether it is to be recorded.

Chemoembolization is a procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This procedure permits a higher concentration of drug to be in contact with the tumor for a longer period of time. Code chemoembolization as *Chemotherapy* when the embolizing agent(s) is a chemotherapeutic drug(s) or when the term *chemoembolization* is used with no reference to the agent. Use *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/registrars/>) to determine whether the drugs used are classified as chemotherapeutic agents. Also code as *Chemotherapy* when the patient has primary or metastatic cancer in the liver and the only information about embolization is a statement that the patient had chemoembolization, tumor embolization or embolization of the tumor in the liver. However, if alcohol is specified as the embolizing agent, even in the liver, code the treatment as *Other Therapy*.

Radioembolization is embolization combined with injection of small radioactive beads or coils into an organ or tumor. Code *Radiation Modality* as brachytherapy when tumor embolization is performed using a radioactive agent or radioactive seeds.

Embolization is coded as *Other Therapy* (code 1) if the embolizing agent is alcohol, or if the embolized site is other than the liver and the only information in the record is that the patient was given “embolization” with no reference to the agent.

Do not code presurgical embolization of hypervascular tumors with particles, coils or alcohol. These presurgical embolizations are typically performed to make the resection of the primary tumor easier. Examples where presurgical embolization is used include meningiomas, hemangioblastomas, paragangliomas, and renal cell metastases in the brain.

OUTCOMES

The outcomes data items describe the known clinical and vital status of the patient. Follow-up information is obtained at least annually for all living Class of Case 10-22 patients included in a cancer registry’s database. Recorded follow-up data should reflect the most recent information available to the registry that originates from reported patient hospitalizations, known patient readmissions, contact with the patient’s physician, and/or direct contact with the patient.

Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions. The paragraphs below describe the range of follow-up information that should be obtained.

Follow-up items that are required to be in the facility’s database:

There may be times when first course treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the necessary treatment information is collected. This includes:

- Complete first course of treatment information when *Surgical Procedure of Primary Site* (NAACCR Item #1290) is delayed six months or more following the *Date of First Contact* (NAACCR Item #580).
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* (NAACCR Item #3190) following the most definitive surgery.
- Radiation, chemotherapy, hormone therapy, immunotherapy, hematologic transplant and endocrine procedures, or other treatment that had been indicated as being planned as part of first course of treatment, but not been started or completed as of the most recent follow-up date. Use “reason for no” treatment codes of 88 or 8 as ticklers to identify incomplete treatment information.
- When all planned first course treatment has been recorded, first course treatment items no longer need to be followed.
- The CoC does not require Class 00 cases to be followed.
- Follow-up for disease recurrence should be conducted until (a) evidence of disease recurrence is reported, or (b) the patient dies. If the *Type of First Recurrence* (NAACCR Item #1880) is coded 70 (never cancer free), when the patient was last seen, but treatment was still underway, then check at follow-up to see whether the patient subsequently became cancer-free. Occasionally, if first course treatment ends due to disease progression, it may be the second course or subsequent treatment that results in a cancer-free status. If the *Type of First Recurrence* is coded 00 (became cancer-free and has had no recurrence), then continue to follow for recurrence and record the type and date when it occurs.
- Definition
 - Local recurrence: recurs in initial primary organ
 - Trocar recurrence: organ removed, recurs in scar tissue from removal
 - Regional recurrence: recurs in adjacent organ or lymph nodes draining the organ
 - Distant recurrence: recurs in a location beyond regional

Once the first recurrence has been recorded, do not update recurrence items further.

While the patient is alive, be sure that contact information is kept current. Contact information includes:

Patient Address–Current (NAACCR Item #2350)
City/Town–Current (NAACCR Item #1810)
State–Current (NAACCR Item #1820)
Postal Code–Current (NAACCR Item #1830)
Telephone (NAACCR Item #2360)
Date of Last Contact (NAACCR Item #1750)
Follow-Up Source, (NAACCR Item #1790)
Next Follow-Up Source (NAACCR Item #1800).

Follow-up for *Vital Status* (NAACCR Item #1760) and *Cancer Status* (NAACCR Item #1770) should be conducted annually for all analytic cases in the cancer program’s registry. *Class of Case* 00 patients that are not followed will have the most recent information as of the *Date of Last Contact*.

Once the patient’s death has been recorded and all care given prior to death is recorded, no further follow-up is performed.

CASE ADMINISTRATION

Correct and timely management of case records in a registry data set are necessary to describe the nature of the data in the cancer record and to facilitate meaningful analysis of data, and it is necessary to understand each item's respective purpose to ensure their accuracy and how to use them in facility analysis.

Administrative Tracking

The following administrative tracking items are required to be in the facility's database:

Abstracted By (NAACCR Item #570)
Facility Identification Number (FIN) (NAACCR Item #540)
NPI-Reporting Facility (NAACCR Item #545)
Archive FIN (NAACCR Item #3100)
NPI-Archive FIN (NAACCR Item #3105)

Abstracted By, *Facility Identification Number (FIN)*, and *NPI-Reporting Facility* identify the individual and facility responsible for compiling the record. *Archive FIN* and *NPI-Archive FIN* store the identification numbers assigned to the original abstracting facility and are used to convey the original identity assigned to a facility that has since merged with another. In a registry with more than one abstractor or serving more than one facility, it will ordinarily be necessary to enter these three numbers only when they change. All of these items should be autocoded by the registry software.

Note: A complete list of FINs is available on the American College of Surgeons Web site at <https://www.facs.org/quality-programs/cancer/accredited/info/fin> NPI numbers are available through the facility's billing or accounting department or at <https://nppes.cms.hhs.gov/NPPES/Welcome.do>.

EDITS Overrides

Some of the CoC edits identify rare, but possible, code combinations. For these edits, an override flag can be set if, upon review, the unusual combination is verified as being correct. Once set, the error message will not be repeated on subsequent EDITS passes.

- When no error message is generated by an edit that uses an override item, no action by the registrar is needed.
- If an error message is generated, the problem can often be resolved by checking the accuracy of the entry for each item that contributes to the edit and correcting any problems identified. If correction of data entry errors resolves the problem, do not make an override entry. If the codes reflect the information in the patient record, check for physician notes indicating the unusual combination of circumstances (for example, a colon adenocarcinoma in a child) has been confirmed.
- Enter the override code according to the instructions for the data item. If no comment regarding the unusual circumstances can be found in the record, it may be necessary to check with the managing physician or pathologist to determine whether it is appropriate to override the edit.

The following override items are required to be in the facility's database:

Override Acsn/Class/Seq (NAACCR Item #1985)
Override Age/Site/Morph (NAACCR Item #1990)
Override CoC- Site/Type (NAACCR Item #1987)
Override Site/Type (NAACCR Item #2030)
Override Histology (NAACCR Item #2040)
Override Leuk/Lymphoma (NAACCR Item #2070)
Override Site/Behavior (NAACCR Item #2071)
Override Site/Lat/Morph (NAACCR Item #2074)
Override HospSeq/DxConf (NAACCR Item #1986)
Override HospSeq/Site (NAACCR Item #1988)

Override Site/TNM-StgGrp (NAACCR Item #1989)
Override Surg/DxConf (NAACCR Item #2020)
Over-ride CS 1-19 (NAACCR Items #3750-3768)

Code Versions Used

Fifteen items describe the version of codes applied to record information in the registry record. Because registries cover many years of cases, registry data will be recorded according to many different coding systems. These items are necessary for the analysis of registry data and for further conversions, so it is important that they be maintained accurately.

The following code version items are required to be in the facility's database:

CoC Coding System–Current (NAACCR Item #2140)
CoC Coding System–Original (NAACCR Item #2150)
Race Coding System–Current (NAACCR Item #170)
Race Coding System–Original (NAACCR Item #180)
Site Coding System–Current (NAACCR Item #450)
Site Coding System–Original (NAACCR Item #460)
Morphology Coding System–Current (NAACCR Item #470)
Morphology Coding System–Original (NAACCR Item #480)
ICD-O-2 Conversion Flag (NAACCR Item #1980)
ICD-O-3 Conversion Flag (NAACCR Item #2116)
TNM Edition Number (NAACCR Item #1060)
RX Coding System–Current (NAACCR Item #1460)
CS Version Input Original (NAACCR Item #2935)
CS Version Input Current (NAACCR Item #2937)
CS Version Derived (NAACCR Item # 2936; for cases diagnosed 2004 through 2015)

All of these items are capable of being autocoded. Registry software operations differ, but typically the registrar will need to update the version of CoC codes, race coding system, site coding system, and morphology coding system whenever it changes.

For newly abstracted cases, code version information will be applied both as the current and original code versions. When registry data are converted to an updated version for a coding system, the code for the current version should be updated automatically by the conversion.

It is not possible to convert from one version of AJCC TNM to another. The registrar should ascertain that the correct version number is recorded for autocoding.

RX Coding System–Current identifies whether the treatment information was recorded using CoC rules or SEER rules and the version of each applied. The CoC requires that the *FORDS* manual be followed for all cases diagnosed January 1, 2003, or later (*RX Coding System–Current* = 06).

The *ICD-O-3 Conversion Flag* identifies how conversion from ICD-O-2 to ICD-O-3 was accomplished, and the *ICD-O-2 Conversion Flag* identifies how conversion from ICD-O-1 to ICD-O-2 was accomplished. Both should be autocoded at the time of conversion. If the results of either conversion were verified by review for some cases, the conversion flag will need to be updated to indicate that the case was reviewed.

**SECTION TWO:
Instructions for Coding**

Patient Identification

ACCESSION NUMBER

Item Length: 9
 NAACCR Item #550
 Revised 01/04, 01/10

Description

Provides a unique identifier for the patient consisting of the year in which the patient was first seen at the reporting facility and the consecutive order in which the patient was abstracted.

Rationale

This data item protects the identity of the patient and allows cases to be identified on a local, state, and national level.

Instructions for Coding

- When a patient is deleted from the database, **do not** reuse the accession number for another patient.
- The first four numbers specify the year and the last five numbers are the numeric order in which the patient was entered into the registry database.
- Numeric gaps are allowed in accession numbers.
- A patient's accession number is never reassigned.
- If a patient is first accessioned into the registry, then the registry later changes its reference date and the patient is subsequently accessioned into the registry with a new primary, use the original accession number associated with the patient and code the data item *Sequence Number* (NAACCR Item #560) appropriately.

| Code | Definition |
|---------------|---|
| (fill spaces) | Nine-digit number used to identify the year in which the patient was first seen at the reporting facility for the diagnosis and/or treatment of cancer. |

Examples

| Code | Reason |
|-----------|--|
| 200300033 | Patient enters the hospital in 2003, and is diagnosed with breast cancer. The patient is the thirty-third patient accessioned in 2003. |
| 200300033 | A patient with the accession number 200300033 for a breast primary returns to the hospital with a subsequent colon primary in 2004. The accession number will remain the same. <i>Sequence Number</i> (NAACCR Item #560) will distinguish this primary. |
| 200300010 | Patient diagnosed in November 2002 at another facility enters the reporting facility in January 2003, and is the tenth case accessioned in 2003. |
| 200300012 | Patient diagnosed in staff physician office in December 2002 enters the reporting facility in January 2003, and is the twelfth case accessioned in 2003. |
| 199100067 | Patient enters the hospital in 1991 and is diagnosed with prostate cancer. The registry later sets a new reference date of January 1, 1997. The same patient presents with a diagnosis of lymphoma in 2005. <i>Sequence Number</i> (NAACCR Item #560) will distinguish this primary. |
| 200300001 | First patient diagnosed and/or treated and entered into the registry database for 2003. |
| 200300999 | Nine hundred ninety-ninth patient diagnosed and/or treated and entered into the registry database for 2003. |
| 200401504 | One thousand five hundred fourth patient diagnosed and/or treated and entered into the registry database for 2004. |

SEQUENCE NUMBER

Item Length: 2
 Allowable Values: 00–88, 99
 NAACCR Item #560
 Revised 06/05, 04/07, 01/10, 01/13

Description

Indicates the sequence of malignant and nonmalignant neoplasms over the lifetime of the patient.

Rationale

This data item is used to distinguish among cases having the same accession numbers, to select patients with only one malignant primary tumor for certain follow-up studies, and to analyze factors involved in the development of multiple tumors.

Instructions for Coding

- Codes 00–59 and 99 indicate neoplasms of malignant (*in situ* or invasive) behavior (*Behavior* equals 2 or 3). Codes 60–88 indicate neoplasms of non-malignant behavior (*Behavior* equals 0 or 1).
- Code 00 only if the patient has a single malignant primary. If the patient develops a subsequent invasive or *in situ* primary tumor, change the code for the first tumor from 00 to 01, and number subsequent tumors sequentially.
- Code 60 only if the patient has a single non-malignant primary. If the patient develops a subsequent non-malignant primary, change the code for the first tumor from 60 to 61, and assign codes to subsequent non-malignant primaries sequentially.
- If two or more invasive or *in situ* neoplasms are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.
- Any tumor in the patient's past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors. However, do not reassign sequence numbers if one of those tumors becomes non-reportable later.
- Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that affects the sequence.

Malignant or In Situ Primaries

| Code | Definition |
|------|---|
| 00 | One malignant or <i>in situ</i> primary only in the patient's lifetime |
| 01 | First of two or more independent malignant or <i>in situ</i> primaries |
| 02 | Second of two or more independent or <i>in situ</i> primaries |
| ... | |
| ... | (Actual sequence of this malignant or <i>in situ</i> primary) |
| ... | |
| 59 | Fifty-ninth of 59 or more independent malignant or <i>in situ</i> primaries |
| 99 | Unknown number of malignant or <i>in situ</i> primaries |

Non-Malignant Primaries

| Code | Definition |
|------|---|
| 60 | One nonmalignant primary only in the patient's lifetime |
| 61 | First of two or more independent nonmalignant primaries |
| 62 | Second of two or more independent nonmalignant primaries |
| ... | |
| ... | (Actual sequence of this nonmalignant primary) |
| ... | |
| 87 | Twenty-seventh of 27 or more independent nonmalignant primaries |
| 88 | Unspecified number of independent nonmalignant primaries |

Examples

| Code | Reason |
|------|--|
| 00 | Patient with no previous history of cancer diagnosed with <i>in situ</i> breast carcinoma on June 13, 2003 |
| 01 | The sequence number is changed when the patient with an <i>in situ</i> breast carcinoma diagnosed June 13, 2003, is diagnosed with a subsequent melanoma on August 30, 2003 |
| 02 | Sequence number assigned to the melanoma diagnosed on August 30, 2003, following a breast cancer <i>in situ</i> diagnosis on June 13, 2003 |
| 04 | A nursing home patient is admitted to the hospital for first course surgery for a colon adenocarcinoma. The patient has a prior history of three malignant cancers of the type the registry is required to accession, though the patient was not seen for these cancers at the hospital. No sequence numbers 01, 02 or 03 are accessioned for this patient. |
| 60 | The sequence number assigned to a benign brain tumor diagnosed on November 1, 2005, following a breast carcinoma diagnosed on June 13, 2003, and a melanoma on August 30, 2003. |
| 63 | Myeloproliferative disease (9975/1) is diagnosed by the facility in 2003 and accessioned as Sequence 60. A benign brain tumor was diagnosed and treated elsewhere in 2002; the patient comes to the facility with a second independent benign brain tumor in 2004. Unaccessioned earlier brain tumor is counted as Sequence 61, myeloproliferative disease is resequenced to 62, and second benign brain tumor is Sequence 63. |

MEDICAL RECORD NUMBER

Item Length: 11
Right Justified, Leading Blanks
NAACCR Item #2300
Revised 01/11

Description

Records the medical record number usually assigned by the reporting facility's health information management (HIM) department.

Rationale

This number identifies the patient within a reporting facility. It can be used to reference a patient record and it helps to identify multiple reports on the same patient.

Instructions for Coding

- Record the medical record number.

Examples

| Code | Reason |
|---|--|
| —NNNN | If the medical record number is fewer than 11 characters, right justify the characters and allow leading blanks. |
| —NNNNRT (Radiology) —NNSU (One-day surgery clinic) | Record standard abbreviations for departments that do not use HIM medical record numbers. |
| —UNK | Unknown |

SOCIAL SECURITY NUMBERItem Length: 9
NAACCR Item #2320**Description**

Records the patient's Social Security number.

Rationale

This data item can be used to identify patients with similar names.

Instructions for Coding

- Code the patient's Social Security number.
- A patient's Medicare claim number may not always be identical to the person's Social Security number.
- Code Social Security numbers that end with "B" or "D" as 999999999. The patient receives benefits under the spouse's number and this is the spouse's Social Security number.

| Code | Definition |
|---------------|---|
| (fill spaces) | Record the patient's Social Security number without dashes |
| 999999999 | Patient does not have a Social Security number; SSN is not available. |

LAST NAME

Item Length: 40
Mixed Case, Left Justified
NAACCR Item #2230
Revised 01/04, 01/10

Description

Identifies the last name of the patient.

Rationale

This data item is used by hospitals as a patient identifier.

Instructions for Coding

- Truncate name if more than 40 letters long. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
- Do not leave blank; code as UNKNOWN if the patient's last name is unknown.
- This field may be updated if the last name changes.

Examples

| Code | Reason |
|-------------|---|
| Mc Donald | Recorded with space as Mc Donald |
| O'Hara | Recorded with apostrophe as O'Hara |
| Smith-Jones | Janet Smith marries Fred Jones and changes her last name to Smith-Jones |
| UNKNOWN | Patient's last name is not known, use UNKNOWN |

FIRST NAME

Item Length: 40
Mixed Case, Left Justified
NAACCR Item #2240
Revised 01/10, 01/11

Description

Identifies the first name of the patient.

Rationale

This data item is used by hospitals to differentiate between patients with the same last names.

Instructions for Coding

- Truncate name if more than 40 letters long. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
- This field may be updated if the name changes.

Examples

| Code | Reason |
|---------------|---|
| Michael | Patient's name is Michael David Hogan |
| (leave blank) | If patient's first name is not known, do not fill in the space. |

**MIDDLE NAME
(MIDDLE INITIAL)**

Item Length: 40
Mixed Case, Left Justified
NAACCR Item #2250
Revised 01/10, 01/11

Description

Identifies the middle name or middle initial of the patient.

Rationale

This data item helps distinguish between patients with identical first and last names.

Instructions for Coding

- Truncate name if more than 40 letters long. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
- This field may be updated if the name changes.

Examples

| Code | Reason |
|---------------|---|
| David | Patient's name is Michael David Hogan |
| D | Patient's name is Michael D. Hogan |
| (leave blank) | If patient's middle name is not known or there is none, do not fill in the space. |

PATIENT ADDRESS (NUMBER AND STREET) AT DIAGNOSIS Item Length: 60
 Uppercase, Left Justified
 NAACCR Item #2330
 Revised 01/10, 01/12

Description

Identifies the patient's address (number and street) at the time of diagnosis.

Rationale

The address is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Instructions for Coding

- Record the number and street address or the rural mailing address of the patient's usual residence when the tumor was diagnosed.
- The address should be fully spelled out with standardized use of abbreviations and punctuation per U.S. Postal Service postal addressing standards. The USPS Postal Addressing Standards, Pub 28, November 2000 can be found on the Internet at <http://pe.usps.gov/cpim/ftp/pubs/pub28/pub28.pdf>.
- Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. They include, but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub 28.
- Punctuation is normally limited to periods (for example, 39.2 RD), slashes for fractional addresses (101 1/2 MAIN ST), and hyphens when a hyphen carries meaning (289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (425 FLOWER BLVD #72).
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Do not update this data item if the patient's address changes.
- See "Residency Rules" in Section One for further instructions.

Examples:

| Code | Definition |
|--------------------------|--|
| 103 FIRST AVE SW APT 102 | The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words. |
| UNKNOWN | If the patient's address is unknown, enter UNKNOWN. |

PATIENT ADDRESS AT DIAGNOSIS–SUPPLEMENTAL

Item Length: 60
 Uppercase, Left Justified
 NAACCR Item #2335
 Revised 09/06, 01/10, 01/12

Description

Provides the ability to store additional address information such as the name of a place or facility (for example, a nursing home or name of an apartment complex) at the time of diagnosis.

Rationale

A registry may receive the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding.

Instructions for Coding

- Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's usual residence when the tumor was diagnosed.
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Do not use this data item to record the number and street address of the patient.
- Do not update this data item if the patient's address changes.
- See "Residency Rules" in Section One for further instructions.

Examples:

| Code | Definition |
|-------------------------|--|
| VALLEYVIEW NURSING HOME | The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words. |
| (leave blank) | If this address space is not needed, then leave blank. |

**CITY/TOWN AT DIAGNOSIS
(CITY OR TOWN)**

Item Length: 50
Uppercase, Left Justified
NAACCR Item #70
Revised 01/10

Description

Identifies the name of the city or town in which the patient resides at the time the tumor is diagnosed and treated.

Rationale

The city or town is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Instructions for Coding

- If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.
- If the patient has multiple malignancies, the city or town may be different for subsequent primaries.
- Do not update this data item if the patient's city or town of residence changes.
- See "Residency Rules" in Section One for further instructions.

| Code | Definition |
|-------------|--|
| CITY NAME | Do not use punctuation, special characters, or numbers. The use of capital letters is preferred by the USPS; it also guarantees consistent results in queries and reporting. Abbreviate where necessary. |
| UNKNOWN | If the patient's city or town is unknown. |

**STATE AT DIAGNOSIS
(STATE)**

Item Length: 2
Uppercase
NAACCR Item #80
Revised 09/06, 01/10, 01/11, 01/12

Description

Identifies the patient's state of residence at the time of diagnosis.

Rationale

The state of residence is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Instructions for Coding

- Use U.S. Postal Service abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient resides at the time the tumor is diagnosed and treated.
- If the patient has multiple tumors, the state of residence may be different for subsequent primaries.
- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.
- Do not update this data item if the patient's state of residence changes.

Code Definition

| | |
|----|--|
| IL | If the state in which the patient resides at the time of diagnosis and treatment is Illinois, then use the USPS code for the state of Illinois. |
| XX | Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>known</i> . |
| YY | Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>unknown</i> . |
| US | Resident of the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i> . |
| CD | Resident of Canada and the province is <i>unknown</i> . |
| ZZ | Residence unknown. |

Common Abbreviations

United States State and Territory Abbreviations (refer to the ZIP Code directory for further listings):

| State | | State | | State | |
|----------------------|----|----------------|----|-----------------------------------|----|
| Alabama | AL | Massachusetts | MA | Tennessee | TN |
| Alaska | AK | Michigan | MI | Texas | TX |
| Arizona | AZ | Minnesota | MN | Utah | UT |
| Arkansas | AR | Mississippi | MS | Vermont | VT |
| California | CA | Missouri | MO | Virginia | VA |
| Colorado | CO | Montana | MT | Washington | WA |
| Connecticut | CT | Nebraska | NE | West Virginia | WV |
| Delaware | DE | Nevada | NV | Wisconsin | WI |
| District of Columbia | DC | New Hampshire | NH | Wyoming | WY |
| Florida | FL | New Jersey | NJ | United States, state unknown | US |
| Georgia | GA | New Mexico | NM | American Samoa | AS |
| Hawaii | HI | New York | NY | Guam | GU |
| Idaho | ID | North Carolina | NC | Puerto Rico | PR |
| Illinois | IL | North Dakota | ND | Virgin Islands | VI |
| Indiana | IN | Ohio | OH | Palau | PW |
| Iowa | IA | Oklahoma | OK | Micronesia | FM |
| Kansas | KS | Oregon | OR | Marshall Islands | MH |
| Kentucky | KY | Pennsylvania | PA | Outlying Islands | UM |
| Louisiana | LA | Rhode Island | RI | APO/FPO Armed Services America | AA |
| Maine | ME | South Carolina | SC | APO/FPO Armed Services Europe | AE |
| Maryland | MD | South Dakota | SD | APO/FPO Armed Services Pacific | AP |

Canadian Provinces and Territory Abbreviations

| Province/Territory | | Province/Territory | |
|---------------------------|----|--------------------------|----|
| Alberta | AB | Nunavut | NU |
| British Columbia | BC | Ontario | ON |
| Manitoba | MB | Prince Edward Island | PE |
| New Brunswick | NB | Quebec | QC |
| Newfoundland and Labrador | NL | Saskatchewan | SK |
| Northwest Territories | NT | Yukon | YT |
| Nova Scotia | NS | Canada, province unknown | CD |

POSTAL CODE AT DIAGNOSIS (ZIP CODE)

Item Length: 9
 Left Justified
 NAACCR Item #100
 Revised 01/04

Description

Identifies the postal code of the patient's address at diagnosis.

Rationale

The postal code is part of the patient's demographic data and has multiple uses. It will provide a referral pattern report and allow analysis of cancer clusters or environmental studies.

Instructions for Coding

- For U.S. residents, record the patient's nine-digit extended postal code at the time of diagnosis and treatment.
- For Canadian residents, record the six-character postal code.
- When available, record the postal code for other countries.
- If the patient has multiple malignancies, the postal code may be different for subsequent primaries.
- Do not update this data item if the patient's postal code changes.
- See "Residency Rules" in Section One for further instructions.

| Code | Definition |
|------------------------------|--|
| (fill spaces) | The patient's nine-digit U.S. extended postal code. Do not record hyphens. |
| 60611_ _ _ _ | When the nine-digit extended U.S. ZIP Code is not available, record the five-digit postal code, left justified, followed by four blanks. |
| M6G2S8_ _ _ | The patient's six-character Canadian postal code left justified, followed by three blanks. |
| 88888_ _ _ _ or 888888888 | Permanent address in a country other than Canada, United States, or U.S. possessions and postal code is unknown. |
| 99999_ _ _ _ or 999999999 | Permanent address in Canada, United States, or U.S. possession and postal code is unknown. |

ADDRESS AT DX--COUNTRY

Item Length: 3
Uppercase
NAACCR Item #102
Added 01/01/2013

Description

Identifies the country of the patient's residence at the time of diagnosis. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival.

Instructions for Coding

- This item corresponds to the other *Addr at DX* items (state, postal code).
- Do not change if the patient moves to another country. Patients with more than one tumor may have different countries at diagnosis, however.
- See Appendix E for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

Examples:

| Code | Country |
|------|---------------|
| USA | United States |
| CAN | Canada |

COUNTY AT DIAGNOSIS

Item Length: 3
 Allowable Values: 001–997, 998, 999
 NAACCR Item #90
 Revised 09/06, 01/10, 01/15

Description

Identifies the county of the patient's residence at the time the reportable tumor is diagnosed.

Rationale

This data item may be used for epidemiological purposes. For example, to measure the cancer incidence in a particular geographic area.

Instructions for Coding

- For U.S. residents, use codes issued by the Federal Information Processing Standards (FIPS) publication *Counties and Equivalent Entities of the United States, Its Possessions, and Associated areas*. This publication is available in a reference library or can be accessed on the Internet through the U.S. EPA's Envirofacts Data Warehouse and Applications Web site at <http://www.epa.gov/>.
- If the patient has multiple tumors, the county codes may be different for each tumor.
- If the patient is a non-U.S. resident, use code 999.
- Do not update this data item if the patient's county of residence changes.

| Code | Label | Definition |
|---------|-----------------------------------|---|
| 001–997 | County at diagnosis | Valid FIPS code. |
| 998 | Outside state/county code unknown | Known town, city, state, or country of residence, but county code not known and a resident outside of the state of the reporting institution (must meet all criteria). |
| 999 | County unknown | The county of the patient is unknown, or the patient is not a United States resident. County is not documented in the patient's medical record. |

PATIENT ADDRESS (NUMBER AND STREET) CURRENT

Item Length: 60

Uppercase, Left Justified

NAACCR Item #2350

Revised 09/04, 01/10, 01/12

Description

Identifies the patient's current address (number and street).

Rationale

This data item provides a current address used for follow-up purposes. It is different from *Patient Address at Diagnosis* (NAACCR #2330).

Instructions for Coding

- Record the number and street address or the rural mailing address of the patient's current usual residence.
- The address should be fully spelled out with standardized use of abbreviations and punctuation per U.S. Postal Service postal addressing standards. The USPS Postal Addressing Standards, Pub 28, November 2000 can be found on the Internet at <http://pe.usps.gov/cpim/ftp/pubs/pub28/pub28.pdf>.
- Abbreviations should be limited to those recognized by the Postal Service standard abbreviations. They include, but are not limited to: AVE (avenue), BLVD (boulevard), CIR (circle), CT (court), DR (drive), PLZ (plaza), PARK (park), PKWY (parkway), RD (road), SQ (square), ST (street), APT (apartment), BLDG (building), FL (floor), STE (suite), UNIT (unit), RM (room), DEPT (department), N (north), NE (northeast), NW (northwest), S (south), SE (southeast), SW (southwest), E (east), W (west). A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub 28.
- Punctuation is normally limited to periods (for example, 39.2 RD), slashes for fractional addresses (101 1/2 MAIN ST), and hyphens when a hyphen carries meaning (289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (425 FLOWER BLVD #72).
- Update this data item if the patient's address changes.
- Do not change this item when the patient dies.
- See "Residency Rules" in Section One for further instructions.

Examples:

| Code | Definition |
|--------------------------|--|
| 103 FIRST AVE SW APT 102 | The use of capital letters is preferred by the USPS; use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words. |
| UNKNOWN | The patient's street address is unknown. |

PATIENT ADDRESS CURRENT–SUPPLEMENTAL

Item Length: 60
 Uppercase, Left Justified
 NAACCR Item #2355
 Revised 09/06, 01/10, 01/12

Description

Provides the ability to store additional address information such as the name of a place or facility (for example, a nursing home or name of an apartment complex).

Rationale

A registry may receive the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding.

Instructions for Coding

- Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's current usual residence.
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Update this data item if a patient's address changes.
- Do not use this data item to record the number and street address of the patient.
- Do not change this item when the patient dies.
- See "Residency Rules" in Section One for further instructions.

Examples:

| Code | Definition |
|-------------------------|--|
| VALLEYVIEW NURSING HOME | The use of capital letters is preferred by the USPS. Use recognized USPS standardized abbreviations; do not use punctuation unless absolutely necessary to clarify an address; leave blanks between numbers and words. |
| (leave blank) | If this address space is not needed, then leave blank. |

CITY/TOWN-CURRENT

Item Length: 50
 Uppercase, Left Justified
 NAACCR Item #1810
 Revised 09/04

Description

Identifies the name of the city or town of the patient's current usual residence.

Rationale

This data item provides a current city or town used for follow-up purposes. It is different from *City/Town at Diagnosis* (NAACCR Item #70).

Instructions for Coding

- If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.
- If the patient has multiple malignancies, the current city or town should be the same for all tumors.
- Update this data item if the patient's city or town of residence changes.
- Do not change this item when the patient dies.
- See "Residency Rules" in Section One for further instructions.

| Code | Definition |
|-----------|--|
| CITY NAME | Do not use punctuation, special characters, or numbers. The use of capital letters is preferred by the USPS; it also guarantees consistent results in queries and reporting. Abbreviate where necessary. |
| UNKNOWN | The city in which the patient resides is unknown. |

STATE–CURRENT

Item Length: 2
 Uppercase
 NAACCR Item #1820
 Revised 09/06, 01/11, 01/12

Description

Identifies the patient's current state of residence.

Rationale

This item provides a current state of residence used for follow-up purposes. It is different from *State at Diagnosis* (NAACCR Item #80).

Instructions for Coding

- Use U.S. Postal Service abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory of the patient's current usual residence.
- If the patient has multiple tumors, the current state of residence should be the same for all tumors.
- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.
- Update this data item if the patient's state of residence changes.
- Do not change this item when the patient dies.

Examples:

| Code | Definition |
|------|--|
| IL | If the state in which the patient resides at the time of diagnosis and treatment is Illinois, then use the USPS code for the state of Illinois. |
| XX | Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is known</i> . |
| YY | Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is unknown</i> . |
| US | Resident of the U.S. (including its territories, commonwealths, or possessions) and the state <i>is unknown</i> . |
| CD | Resident of Canada and the province <i>is unknown</i> . |
| ZZ | Residence unknown. |

Common U.S. abbreviations (refer to the ZIP Code directory for further listings):

| State | | State | | State | |
|----------------------|----|----------------|----|-----------------------------------|----|
| Alabama | AL | Massachusetts | MA | Tennessee | TN |
| Alaska | AK | Michigan | MI | Texas | TX |
| Arizona | AZ | Minnesota | MN | Utah | UT |
| Arkansas | AR | Mississippi | MS | Vermont | VT |
| California | CA | Missouri | MO | Virginia | VA |
| Colorado | CO | Montana | MT | Washington | WA |
| Connecticut | CT | Nebraska | NE | West Virginia | WV |
| Delaware | DE | Nevada | NV | Wisconsin | WI |
| District of Columbia | DC | New Hampshire | NH | Wyoming | WY |
| Florida | FL | New Jersey | NJ | United States, state unknown | US |
| Georgia | GA | New Mexico | NM | American Samoa | AS |
| Hawaii | HI | New York | NY | Guam | GU |
| Idaho | ID | North Carolina | NC | Puerto Rico | PR |
| Illinois | IL | North Dakota | ND | Virgin Islands | VI |
| Indiana | IN | Ohio | OH | Palau | PW |
| Iowa | IA | Oklahoma | OK | Micronesia | FM |
| Kansas | KS | Oregon | OR | Marshall Islands | MH |
| Kentucky | KY | Pennsylvania | PA | Outlying Islands | UM |
| Louisiana | LA | Rhode Island | RI | APO/FPO Armed Services America | AA |
| Maine | ME | South Carolina | SC | APO/FPO Armed Services Europe | AE |
| Maryland | MD | South Dakota | SD | APO/FPO Armed Services Pacific | AP |

Canadian Provinces or Territory abbreviations:

| Province/Territory | | Province/Territory | |
|---------------------------|----|--------------------------|----|
| Alberta | AB | Nunavut | NU |
| British Columbia | BC | Ontario | ON |
| Manitoba | MB | Prince Edward Island | PE |
| New Brunswick | NB | Quebec | QC |
| Newfoundland and Labrador | NL | Saskatchewan | SK |
| Northwest Territories | NT | Yukon | YT |
| Nova Scotia | NS | Canada, province unknown | CD |

POSTAL CODE–CURRENT (ZIP CODE)

Item Length: 9
 Left Justified
 NAACCR Item #1830
 Revised 01/04

Description

Identifies the postal code of the patient's current address.

Rationale

This data item provides a current postal code for follow-up purposes and should be updated. It is different from *Postal Code at Diagnosis* (NAACCR Item #100).

Instructions for Coding

- For U.S. residents, record the nine-digit extended postal code for the patient's current usual residence.
- For Canadian residents, record the six-character postal code.
- When available, record the postal code for other countries.
- If the patient has multiple tumors, the postal code should be the same.
- Update this data item if the patient's postal code changes.

| Code | Definition |
|------------------------------|--|
| (fill spaces) | The patient's nine-digit U.S. extended postal code. Do not record hyphens. |
| 60611_ _ _ _ | When the nine-digit extended U.S. ZIP Code is not available, record the five-digit postal code, left justified, followed by four blanks. |
| M6G2S8_ _ _ | The patient's six-character Canadian postal code left justified, followed by three blanks. |
| 88888_ _ _ _ or 888888888 | Permanent address in a country other than Canada, United States, or U.S. possessions and postal code is unknown. |
| 99999_ _ _ _ or 999999999 | Permanent address in Canada, United States, or U.S. possession and postal code is unknown. |

ADDRESS CURRENT--COUNTRY

Item Length: 3
Uppercase
NAACCR Item #1832
Added 01/01/2013

Description

Identifies the country of the patient's current residence. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival, and is useful for follow-up.

Instructions for Coding

- This item corresponds to Address Current--State..
- See Appendix E for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

Common Country Codes

| Code | Country |
|-------------|----------------|
| USA | United States |
| CAN | Canada |

TELEPHONEItem Length: 10
NAACCR Item #2360**Description**

Records the current telephone number with area code for the patient.

Rationale

This data item may be used by the hospital registry to contact the patient for follow-up.

Instructions for Coding

- The telephone number should be the current number with area code of the patient.
- Update this data item if the patient's telephone number changes.

| Code | Definition |
|---------------|---|
| (fill spaces) | Number is entered without dashes. |
| 000000000 | Patient does not have a telephone. |
| 999999999 | Telephone number is unavailable or unknown. |

BIRTHPLACE--STATE

Item Length: 2
 Uppercase
 NAACCR Item #252
 Added 01/13

Description

Records the patient's state of birth.

Rationale

This data item is used to evaluate medical care delivery to special populations and to identify populations at special risk for certain cancers.

Instructions for Coding

- Use the most specific code.
- This item corresponds to Birthplace--Country.
- See Appendix E for a list of state codes and their respective country codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software from the former *Place of Birth*.

Examples:

| Code | Definition |
|------|--|
| IL | If the state in which the was born is Illinois, then use the USPS code for the state of Illinois. |
| XX | Born in a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is known</i> (code the country in <i>Birthplace-Country</i>). |
| YY | Born in a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is unknown</i> . |
| US | Born in the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i> |
| CD | Born in Canada and the province is <i>unknown</i> . |
| ZZ | Place of birth is unknown, not mentioned in patient record. |

BIRTHPLACE--COUNTRY

Item Length: 3
Uppercase
NAACCR Item #254
Added 01/01/2013

Description

Identifies the country where the patient was born. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival.

Instructions for Coding

- This item corresponds to Birthplace--State.
- See Appendix E for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

Examples

| Code | Country |
|-------------|---|
| USA | United States |
| CAN | Canada |
| ZZU | Place of birth is unknown, not mentioned in patient record. |

DATE OF BIRTH

Item Length: 8
NAACCR Item #240
Revised 1/10

Description

Identifies the date of birth of the patient.

Rationale

This data item is useful for patient identification. It is also useful when analyzing tumors according to age cohort.

Instructions for Coding

- Record the patient's date of birth as indicated in the patient record. For single-digit day or month, record with a lead 0 (for example, September is 09). Use the full four-digit year for year.
- For *in utero* diagnosis and treatment, record the actual date of birth. It will follow one or both dates for those events.
- If only the patient age is available, calculate the year of birth from age and the year of diagnosis and leave day and month of birth unknown (for example, a 60 year old patient diagnosed in 2010 is calculated to have been born in 1950).
- If month is unknown, the day is coded unknown. If the year cannot be determined, the day and month are both coded unknown.
- If the date of birth cannot be determined at all, record the reason in *Date of Birth Flag* (NAACCR Item #241)
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about date entry in their own systems. The traditional format for *Date of Birth* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Birth* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date. The *Date of Birth Flag* (NAACCR Item #241) is used to explain why *Date of Birth* is not a known date. See *Date of Birth Flag* for an illustration of the relationships among these items.

DATE OF BIRTH FLAG

Item Length: 2
 NAACCR Item #241
 Valid Codes: 12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Birth* (NAACCR Item #240).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate nondate information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of Birth* (NAACCR Item #240) has a full or partial date recorded.
- Code 12 if the *Date of Birth* cannot be determined at all.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software

| Code | Definition |
|---------|---|
| 12 | A proper value is applicable but not known (for example, birth date is unknown) |
| (Blank) | A valid date value is provided in item <i>Date of Birth</i> (NAACCR Item #240) |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Birth* (NAACCR Item #240) and *Date of Birth Flag* (NAACCR Item #241). ***In the table below, the lowercase letter “b” is used to represent each blank space.***

| Description | Traditional Birth Date | Interoperable Birth Date | Date of Birth Flag |
|----------------------|---|--|--------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown. | |
| Full date known | MMDDCCYY (example: 02181942) | CCYYMMDD (example: 19420218) | bb |
| Month and year known | MM99CCYY (example: 02991942) | CCYYMMbb (example: 194202bb) | bb |
| Year only known | 9999CCYY (example: 99991942) | CCYYbbbb (example: 1942bbbb) | bb |
| Unknown date | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

AGE AT DIAGNOSIS

Item Length: 3
Allowable Values: 000–120, 999
Right Justified, Zero-filled
NAACCR Item #230
Revised 09/01/08

Description

Records the age of the patient at his or her last birthday before diagnosis.

Rationale

This data item is useful for patient identification. It may also be useful when analyzing tumors according to specific patient age.

Instructions for Coding

If the patient has multiple primaries, then the age at diagnosis may be different for subsequent primaries.

| Code | Definition |
|-------------|---|
| 000 | Less than one year old; diagnosed <i>in utero</i> |
| 001 | One year old but less than two years old |
| 002 | Two years old |
| ... | Actual age in years |
| 120 | One hundred twenty years old |
| 999 | Unknown age |

RACE 1

Item length: 2

Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 96–99

NAACCR Item #160

Revised 01/04, 09/08, 01/10, 01/12

Description

Identifies the primary race of the person.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- Additional races reported by the person should be coded in *Race 2*, *Race 3*, *Race 4*, and *Race 5*.
- *Race 1* is the field used to compare with race data on cases diagnosed prior to January 1, 2000.
- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If the patient is multiracial, then code all races using *Race 2* (NAACCR Item #161) through *Race 5* (NAACCR Item #164), and code all remaining *Race* items 88.
- If the person is multiracial and one of the races is white, code the other race(s) first with white in the next race field.
- If the person is multiracial and one of the races is Hawaiian, code Hawaiian as *Race 1*, followed by the other race(s).
- A known race code (other than blank or 99) must not occur more than once. For example, do not code “Black” in *Race 1* for one parent and “Black” in *Race 2* for the other parent.
- If *Race 1* is coded 99, then *Race 2* through *Race 5* must all be coded 99.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- If *Race Coding System–Current* (NAACCR Item #170) is less than six (6) for cases diagnosed prior to January 1, 2000, then *Race 2* through *Race 5* must be blank.
- If a patient diagnosed prior to January 1, 2000, develops a subsequent primary after that date, then *Race Coding System–Current* must be six (6), and data items *Race 2* through *Race 5* that do not have specific race recorded must be coded 88.

| Code | Label | Code | Label |
|------|--|------|--|
| 01 | White | 20 | Micronesian, NOS |
| 02 | Black | 21 | Chamorro/Chamoru |
| 03 | American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) | 22 | Guamanian, NOS |
| 04 | Chinese | 25 | Polynesian, NOS |
| 05 | Japanese | 26 | Tahitian |
| 06 | Filipino | 27 | Samoan |
| 07 | Hawaiian | 28 | Tongan |
| 08 | Korean | 30 | Melanesian, NOS |
| 10 | Vietnamese | 31 | Fiji Islander |
| 11 | Laotian | 32 | New Guinean |
| 12 | Hmong | 96 | Other Asian, including Asian, NOS and Oriental, NOS |
| 13 | Kampuchean (Cambodian) | 97 | Pacific Islander, NOS |
| 14 | Thai | 98 | Other |
| 15 | Asian Indian or Pakistani, NOS (formerly code 09) | 99 | Unknown |
| 16 | Asian Indian | | |
| 17 | Pakistani | | |

Examples

| Code | Reason |
|------|---|
| 01 | A patient was born in Mexico of Mexican parentage. Code also <i>Spanish/Hispanic Origin</i> (NAACCR Item #190). |
| 02 | A black female patient. |
| 05 | A patient has a Japanese father and a Caucasian mother. (Caucasian will be coded in <i>Race 2</i>). |

RACE 2

Item Length: 2

Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 88, 96–99

NAACCR Item #161

Revised 01/04, 09/08, 01/10, 01/12

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 1* (NAACCR Item #160) is coded 99, then *Race 2* must be coded 99.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for *Race 1* (NAACCR Item #160) for coding sequences for entering multiple races.

| Code | Label | Code | Label |
|------|--|------|--|
| 01 | White | 20 | Micronesian, NOS |
| 02 | Black | 21 | Chamorro/Chamoru |
| 03 | American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) | 22 | Guamanian, NOS |
| 04 | Chinese | 25 | Polynesian, NOS |
| 05 | Japanese | 26 | Tahitian |
| 06 | Filipino | 27 | Samoan |
| 07 | Hawaiian | 28 | Tongan |
| 08 | Korean | 30 | Melanesian, NOS |
| 10 | Vietnamese | 31 | Fiji Islander |
| 11 | Laotian | 32 | New Guinean |
| 12 | Hmong | 88 | No additional races |
| 13 | Kampuchean (Cambodian) | 96 | Other Asian, including Asian, NOS and Oriental, NOS |
| 14 | Thai | 97 | Pacific Islander, NOS |
| 15 | Asian Indian or Pakistani, NOS (formerly code 09) | 98 | Other |
| 16 | Asian Indian | 99 | Unknown |
| 17 | Pakistani | | |

RACE 3

Item Length: 2

Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 88, 96–99

NAACCR Item #162

Revised 01/04, 09/08, 01/10,

01/12

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 2* (NAACCR Item #161) is coded 88 or 99, then *Race 3* must be coded with the same value.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for Race 1 (NAACCR Item #160) for coding sequences for entering multiple races.

| Code | Label | Code | Label |
|------|--|------|--|
| 01 | White | 20 | Micronesian, NOS |
| 02 | Black | 21 | Chamorro/Chamoru |
| 03 | American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) | 22 | Guamanian, NOS |
| 04 | Chinese | 25 | Polynesian, NOS |
| 05 | Japanese | 26 | Tahitian |
| 06 | Filipino | 27 | Samoan |
| 07 | Hawaiian | 28 | Tongan |
| 08 | Korean | 30 | Melanesian, NOS |
| 10 | Vietnamese | 31 | Fiji Islander |
| 11 | Laotian | 32 | New Guinean |
| 12 | Hmong | 88 | No additional races |
| 13 | Kampuchean (Cambodian) | 96 | Other Asian, including Asian, NOS and Oriental, NOS |
| 14 | Thai | 97 | Pacific Islander, NOS |
| 15 | Asian Indian or Pakistani, NOS (formerly code 09) | 98 | Other |
| 16 | Asian Indian | 99 | Unknown |
| 17 | Pakistani | | |

RACE 4

Item Length: 2
 Allowable Values: 01–08, 10–17, 20–22, 25–28, 30–32, 88, 96–99
 NAACCR Item #163
 Revised 01/04, 09/08, 01/10, 01/12

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 3* (NAACCR Item #162) is coded 88 or 99, then *Race 4* must be coded with the same value.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for *Race 1* (NAACCR Item #160) for coding sequences for entering multiple races.

| Code | Label | Code | Label |
|------|---|------|---|
| 01 | White | 20 | Micronesian, NOS |
| 02 | Black | 21 | Chamorro/Chamoru |
| 03 | American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) | 22 | Guamanian, NOS |
| 04 | Chinese | 25 | Polynesian, NOS |
| 05 | Japanese | 26 | Tahitian |
| 06 | Filipino | 27 | Samoan |
| 07 | Hawaiian | 28 | Tongan |
| 08 | Korean | 30 | Melanesian, NOS |
| 10 | Vietnamese | 31 | Fiji Islander |
| 11 | Laotian | 32 | New Guinean |
| 12 | Hmong | 88 | No additional races |
| 13 | Kampuchean (Cambodian) | 96 | Other Asian, including Asian, NOS and Oriental, NOS |
| 14 | Thai | 97 | Pacific Islander, NOS |
| 15 | Asian Indian or Pakistani, NOS (formerly code 09) | 98 | Other |
| 16 | Asian Indian | 99 | Unknown |
| 17 | Pakistani | | |

RACE 5

Item Length: 2

Allowable Values: 01–08, 10–17,
20–22, 25–28, 30–32, 88, 96–99

NAACCR Item #164

Revised 01/04, 09/08, 01/10, 01/12

Description

Identifies the patient's race.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Instructions for Coding

- “Race” is analyzed with *Spanish/Hispanic Origin* (NAACCR Item #190). Both items must be recorded. All tumors for the same patient should have the same race code.
- If *Race 4* (NAACCR Item #163) is coded 88 or 99, then *Race 5* must be coded with the same value.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- See the instructions for *Race 1* (NAACCR Item #160) for coding sequences for entering multiple races.

| Code | Label | Code | Label |
|------|--|------|--|
| 01 | White | 20 | Micronesian, NOS |
| 02 | Black | 21 | Chamorro/Chamoru |
| 03 | American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere) | 22 | Guamanian, NOS |
| 04 | Chinese | 25 | Polynesian, NOS |
| 05 | Japanese | 26 | Tahitian |
| 06 | Filipino | 27 | Samoan |
| 07 | Hawaiian | 28 | Tongan |
| 08 | Korean | 30 | Melanesian, NOS |
| 10 | Vietnamese | 31 | Fiji Islander |
| 11 | Laotian | 32 | New Guinean |
| 12 | Hmong | 88 | No additional races |
| 13 | Kampuchean (Cambodian) | 96 | Other Asian, including Asian, NOS and Oriental, NOS |
| 14 | Thai | 97 | Pacific Islander, NOS |
| 15 | Asian Indian or Pakistani, NOS (formerly code 09) | 98 | Other |
| 16 | Asian Indian | 99 | Unknown |
| 17 | Pakistani | | |

SPANISH ORIGIN–ALL SOURCES (SPANISH/HISPANIC ORIGIN)

Item Length: 1
 Allowable Values: 0–7, 9
 NAACCR Item #190
 Revised 09/04

Description

Identifies persons of Spanish or Hispanic origin.

Rationale

This code is used by hospital and central registries to identify whether or not the person should be classified as “Hispanic” for purposes of calculating cancer rates. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the 01 (White category) of *Race 1* through *Race 5* (NAACCR Item #s 160–164).

Instructions for Coding

- Persons of Spanish or Hispanic origin may be of any race, but these categories are generally not used for Native Americans, Filipinos, or others who may have Spanish names.
- Code 0 (Non-Spanish; non-Hispanic) for Portuguese and Brazilian persons.
- If the patient has multiple tumors, all records should have the same code.

| Code | Label |
|------|--|
| 0 | Non-Spanish; non-Hispanic |
| 1 | Mexican (includes Chicano) |
| 2 | Puerto Rican |
| 3 | Cuban |
| 4 | South or Central America (except Brazil) |
| 5 | Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic) |
| 6 | Spanish, NOS; Hispanic, NOS; Latino, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category of 1–5) |
| 7 | Spanish surname only (The only evidence of the person’s Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic) |
| 8 | Dominican Republic (for use with patients who were diagnosed with cancer on January 1, 2005, or later) |
| 9 | Unknown whether Spanish or not; not stated in patient record |

SEX

Item Length: 1
Allowable Values: 1–4, 9
NAACCR Item #220
Revised 01/15, 01/16

Description

Identifies the sex of the patient.

Rationale

This data item is used to compare cancer rates and outcomes by site. The same sex code should appear in each medical record for a patient with multiple tumors.

Instructions for Coding

- Record the patient's sex as indicated in the medical record.
- Natality for transsexuals was added for use in 2015, but may be applied for earlier diagnoses.
- The definition of code 3 was updated to "Other (intersex, disorders of sexual development/DSD)" in 2016.

| Code | Label |
|------|---|
| 1 | Male |
| 2 | Female |
| 3 | Other (intersex, disorders of sexual development/DSD) |
| 4 | Transsexual, NOS |
| 5 | Transsexual, natal male |
| 6 | Transsexual, natal female |
| 9 | Not stated in patient record |

PRIMARY PAYER AT DIAGNOSIS

Item Length: 2
 Allowable Values: 01, 02, 10,
 20, 21, 31, 35, 60–68, 99
 NAACCR Item #630
 Revised 06/05, 01/10

Description

Identifies the patient's primary payer/insurance carrier at the time of initial diagnosis and/or treatment.

Rationale

This item is used in financial analysis and as an indicator for quality and outcome analyses. Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requires the patient admission page to document the type of insurance or payment structure that will cover the patient while being cared for at the hospital.

Instructions for Coding

- If the patient is diagnosed at the reporting facility, record the payer at the time of diagnosis.
- If the patient is diagnosed elsewhere or the payer at the time of diagnosis is not known record the payer when the patient is initially admitted for treatment.
- Record the type of insurance reported on the patient's admission page.
- Codes 21 and 65–68 are to be used for patients diagnosed on or after January 1, 2006.
- If more than one payer or insurance carrier is listed on the patient's admission page record the first.
- If the patient's payer or insurance carrier changes, do not change the initially recorded code.

| Code | Label | Definition |
|------|---|--|
| 01 | Not insured | Patient has no insurance and is declared a charity write-off. |
| 02 | Not insured, self-pay | Patient has no insurance and is declared responsible for charges. |
| 10 | Insurance, NOS | Type of insurance unknown or other than the types listed in codes 20, 21, 31, 35, 60–68. |
| 20 | Private insurance: Managed Care, HMO, or PPO | An organized system of prepaid care for a group of enrollees usually within a defined geographic area. Generally formed as one of four types: a group model, an independent physician association (IPA), a network, or a staff model. "Gate-keeper model" is another term for describing this type of insurance. |
| 21 | Private insurance: Fee-for-Service | An insurance plan that does not have a negotiated fee structure with the participating hospital. Type of insurance plan not coded as 20. |
| 31 | Medicaid | State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than described in code 35. |
| 35 | Medicaid administered through a Managed Care plan | Patient is enrolled in Medicaid through a Managed Care program (for example, HMO or PPO). The Managed Care plan pays for all incurred costs. |
| 60 | Medicare without supplement, Medicare, NOS | Federal government funded insurance for persons who are 65 years of age or older, or are chronically disabled (Social Security insurance eligible). Not described in codes 61, 62, or 63. |
| 61 | Medicare with supplement, NOS | Patient has Medicare and another type of unspecified insurance to pay costs not covered by Medicare. |
| 62 | Medicare administered through a Managed Care plan | Patient is enrolled in Medicare through a Managed Care plan (for example, HMO or PPO). The Managed Care plan pays for all incurred costs. |

| Code | Label | Definition |
|------|------------------------------------|---|
| 63 | Medicare with private supplement | Patient has Medicare and private insurance to pay costs not covered by Medicare. |
| 64 | Medicare with Medicaid eligibility | Federal government Medicare insurance with State Medicaid administered supplement. |
| 65 | TRICARE | Department of Defense program providing supplementary civilian-sector hospital and medical services beyond a military treatment facility to military dependents, retirees, and their dependents. Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services). |
| 66 | Military | Military personnel or their dependents who are treated at a military facility. |
| 67 | Veterans Affairs | Veterans who are treated in Veterans Affairs facilities. |
| 68 | Indian/Public Health Service | Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service. Patient receives care at a Public Health Service facility or at another facility, and medical costs are reimbursed by the Public Health Service. |
| 99 | Insurance status unknown | It is unknown from the patient's medical record whether or not the patient is insured. |

Examples

| Code | Reason |
|------|--|
| 01 | An indigent patient is admitted with no insurance coverage. |
| 20 | A patient is admitted for treatment and the patient admission page states the primary insurance carrier is an HMO. |
| 62 | A 65-year-old male patient is admitted for treatment and the patient admission page states the patient is covered by Medicare with additional insurance coverage from a PPO. |

COMORBIDITIES AND COMPLICATIONS #1
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00000, 00100–13980,
 24000–99990, E8700–E8799, E9300–E9499,
 V0720–V0739, V1000–V1590, V2220–V2310,
 V2540, V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3110
 Revised 06/05, 01/11, 01/12, 01/13

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #1* (NAACCR Item #3780) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Comorbidities and Complications* ICD-9-CM codes appearing on the "readmission" discharge abstract.
- If no ICD-9-CM secondary diagnoses were documented, then code 00000 in this data item, and leave the remaining *Comorbidities and Complications* data items blank.
- If fewer than 10 ICD-9-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Comorbidities and Complications* data items blank.

| Code | Definition, specific instructions |
|--|---|
| 00000 | No comorbid conditions or complications documented. |
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

Examples

| Code | Reason |
|-------------|---|
| 49600 | COPD (ICD-9-CM code 496) |
| 25001 | Type 1 diabetes mellitus (ICD-9-CM code 250.01) |
| E8732 | The patient was inadvertently exposed to an overdose of external beam radiation (ICD-9-CM code E873.2) |
| E9300 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-9-CM code E930.0) |
| V1030 | The patient has a personal history of breast cancer (ICD-9-CM code V10.3) |

COMORBIDITIES AND COMPLICATIONS #2
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3120
 Revised 06/05, 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #2* (NAACCR Item #3782) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If only one comorbid condition or complication is listed, then leave this data item blank.
- If only two comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

**COMORBIDITIES AND COMPLICATIONS #3
(Secondary Diagnoses)**

Item Length: 5

Allowable Values: 00100–13980,
24000–99990, E8700–E8799, E9300–
E9499, V0720–V0739, V1000–
V1590, V2220–V2310, V2540,
V4400–V4589, V5041–V5049

Left Justified, Zero-filled

NAACCR Item #3130

Revised 06/05, 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #3* (NAACCR Item #3784) to record ICD-10-CM codes. During adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If fewer than three comorbid conditions or complications are listed, then leave this data item blank.
- If only three comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000– V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

COMORBIDITIES AND COMPLICATIONS #4
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3140
 Revised 06/05, 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #4* (NAACCR Item #3786) to record ICD-10-CM codes. During adoption of ICD-10-CM, it is possible both will appear in the same patient record.
- If fewer than four comorbid conditions or complications are listed, then leave this data item blank.
- If only four comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

**COMORBIDITIES AND COMPLICATIONS #5
(Secondary Diagnoses)**

Item Length: 5
 Allowable Values: 00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3150
 Revised 06/05, 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to risk adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #5* (NAACCR Item #3788) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If fewer than five comorbid conditions or complications are listed, then leave this data item blank.
- If only five comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

COMORBIDITIES AND COMPLICATIONS #6
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3160
 Revised 06/05, 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #6* (NAACCR Item #3790) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the patient record.
- If fewer than six comorbid conditions or complications are listed, then leave this data item blank.
- If only six comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

**COMORBIDITIES AND COMPLICATIONS #7
(Secondary Diagnoses)**

Item Length: 5

Allowable Values: 00100–13980,
24000–99990, E8700–E8799, E9300–
E9499, V0720–V0739, V1000–
V1590, V2220–V2310, V2540,
V4400–V4589, V5041–V5049

Left Justified, Zero-filled

NAACCR Item #3161

Revised 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #7 (NAACCR Item #3792) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- *Comorbidities and Complications #7* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than seven comorbid conditions or complications are listed, then leave this data item blank.
- If only seven comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.

For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000– V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

COMORBIDITIES AND COMPLICATIONS #8
(Secondary Diagnoses)

Item Length: 5
 Allowable Values: 00100–13980,
 24000–99990, E8700–E8799, E9300–
 E9499, V0720–V0739, V1000–
 V1590, V2220–V2310, V2540,
 V4400–V4589, V5041–V5049
 Left Justified, Zero-filled
 NAACCR Item #3162
 Revised 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #8* (NAACCR Item #3792) to record ICD-10-CM. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- *Comorbidities and Complications #8* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than eight comorbid conditions or complications are listed, then leave this data item blank.
- If only eight comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000– V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

**COMORBIDITIES AND COMPLICATIONS #9
(Secondary Diagnoses)**

Item Length: 5

Allowable Values: 00100–13980,
24000–99990, E8700–E8799, E9300–
E9499, V0720–V0739, V1000–
V1590, V2220–V2310, V2540,
V4400–V4589, V5041–V5049

Left Justified, Zero-filled

NAACCR Item #3163

Revised 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #9* (NAACCR Item #3796) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- *Comorbidities and Complications #9* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than nine comorbid conditions or complications are listed, then leave this data item blank.
- If only nine comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining *Comorbidities and Complications* items blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000– V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

COMORBIDITIES AND COMPLICATIONS #10
(Secondary Diagnoses)

Item Length: 5
Allowable Values: 00100–13980,
24000–99990, E8700–E8799, E9300–
E9499, V0720–V0739, V1000–
V1590, V2220–V2310, V2540,
V4400–V4589, V5041–V5049
Left Justified, Zero-filled
NAACCR Item #3164
Revised 01/11, 01/12, 01/13, 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-9-CM codes. Use *Secondary Diagnosis #10* (NAACCR Item #3798) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- *Comorbidities and Complications #10* is to be used for patients diagnosed on or after January 1, 2006.
- If fewer than 10 comorbid conditions or complications are listed, then leave this data item blank.
- For further Instructions for Coding, see *Comorbidities and Complications #1* (NAACCR Item #3110).

| Code | Definition, specific instructions |
|--|---|
| 00100–13980, 24000–99990 | Comorbid conditions: Omit the decimal point between the third and fourth characters. |
| E8700–E8799, E9300–E9499 | Complications: Omit the decimal point between the fourth and fifth characters |
| V0720–V0739, V1000– V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049 | Factors affecting health status: Omit the decimal point between the fourth and fifth characters |

SECONDARY DIAGNOSIS #1
(Secondary Diagnoses)

Item Length: 7
 Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
 Left Justified, omit decimals
 All alpha characters capitalized
 Trailing blanks allowed
 NAACCR Item #3780
 New 01/01/2013

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #1* (NAACCR Item #3110) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If no ICD-10-CM secondary diagnoses were documented, then code 0000000 in this data item, and leave the remaining *Secondary Diagnosis* data items blank.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| 0000000 | No applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #2
(Secondary Diagnoses)

Item Length: 7
 Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
 Left Justified, omit decimals
 All alpha characters capitalized
 Trailing blanks allowed
 NAACCR Item #3782
 Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #2* (NAACCR Item #3120) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than two applicable ICD-10-CM codes are recorded in this patient's record |

**SECONDARY DIAGNOSIS #3
(Secondary Diagnoses)**

Item Length: 7
Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
Left Justified, omit decimals
All alpha characters capitalized
Trailing blanks allowed
NAACCR Item #3784
Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #4* (NAACCR Item #3130) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than three applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #4
(Secondary Diagnoses)

Item Length: 7
 Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
 Left Justified, omit decimals
 All alpha characters capitalized
 Trailing blanks allowed
 NAACCR Item #3786
 Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #4* (NAACCR Item #3140) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than four applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #5
(Secondary Diagnoses)

Item Length: 7
Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
Left Justified, omit decimals
All alpha characters capitalized
Trailing blanks allowed
NAACCR Item #3788
Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #5* (NAACCR Item #3150) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| 0000000 | Fewer than five applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #6
(Secondary Diagnoses)

Item Length: 7
Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
Left Justified, omit decimals
All alpha characters capitalized
Trailing blanks allowed
NAACCR Item #3790
Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #6* (NAACCR Item #3160) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than six applicable ICD-10-CM codes are recorded in this patient's record |

**SECONDARY DIAGNOSIS #7
(Secondary Diagnoses)**

Item Length: 7
Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
Left Justified, omit decimals
All alpha characters capitalized
Trailing blanks allowed
NAACCR Item #3792
Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #7* (NAACCR Item #3161) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than seven applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #8
(Secondary Diagnoses)

Item Length: 7
Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
Left Justified, omit decimals
All alpha characters capitalized
Trailing blanks allowed
NAACCR Item #3794
Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #8* (NAACCR Item #3162) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than eight applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #9
(Secondary Diagnoses)

Item Length: 7

Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ

Left Justified, omit decimals

All alpha characters capitalized

Trailing blanks allowed

NAACCR Item #3796

Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #9* (NAACCR Item #3163) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than nine applicable ICD-10-CM codes are recorded in this patient's record |

SECONDARY DIAGNOSIS #10
(Secondary Diagnoses)

Item Length: 7
Allowable Values: 0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, Y62-Y849ZZZ, Z1401-Z229ZZZ, Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ
Left Justified, omit decimals
All alpha characters capitalized
Trailing blanks allowed
NAACCR Item #3798
Revised 01/15

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Instructions for Coding

- Use this item to record ICD-10-CM codes. Use *Comorbidities and Complications #10* (NAACCR Item #3164) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM *Comorbidities and Complications* codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for *Secondary Diagnosis* fields, leaving blanks beyond those characters.
- Omit the decimal points when coding
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item *Readmission To The Same Hospital Within 30 Days Of Surgical Discharge* (NAACCR Item #3190) is coded 1, 2, or 3, report *Secondary Diagnosis* ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining *Secondary Diagnosis* data items blank.

Examples

| Code | Reason |
|-------------|---|
| J449 | Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9) |
| E119 | Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9) |
| Y632 | The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2) |
| T360X5 | During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5) |
| Z853 | The patient has a personal history of breast cancer (ICD-10-CM code Z85.3) |
| blank | Fewer than ten applicable ICD-10-CM codes are recorded in this patient's record |

NPI-MANAGING PHYSICIAN

Item Length: 10
Allowable Value: 10 digits
NAACCR Item #2465
Revised 04/07, 09/08

Description

Identifies the physician who is responsible for the overall management of the patient during diagnosis and/or treatment of this cancer.

Rationale

The managing physician is responsible for the patient's work-up, plans the treatment, and directs the delivery of patient care in accordance with CoC Standards. In most cases, the managing physician is responsible for AJCC staging.

Instructions for Coding

- Record the 10-digit NPI for the physician responsible for managing the patient's care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a managing physician for the patient, this item should not be changed even if a different managing physician is assigned.

| Code | Definition |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the managing physician. |
| (leave blank) | NPI for the managing physician is unknown or not available. |

NPI-FOLLOWING PHYSICIAN

Item Length: 10
Allowable Value: 10 digits
NAACCR Item #2475
Revised 04/07, 09/08, 01/11

Description

Records the NPI for the physician currently responsible for the patient's medical care.

Rationale

The following physician is the first contact for obtaining information on a patient's status and subsequent treatment. This information may be used for outcomes studies.

Instructions for Coding

- Record the 10-digit NPI for the physician currently responsible for the patient's medical care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Change this data item when patient follow-up becomes the responsibility of another physician.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

| Code | Definition |
|---------------|--|
| (fill spaces) | 10-digit NPI number for the following physician. |
| (leave blank) | NPI for the following physician is unknown or not available. |

NPI-PRIMARY SURGEON

Item Length: 10
Allowable Value: 10 digits
NAACCR Item #2485
Revised 04/07, 09/08, 01/11

Description

Identifies the physician who performed the most definitive surgical procedure.

Rationale

Administrative, physician, and service referral reports are based on this item.

Instructions for Coding

- Record the 10-digit NPI for the physician who performed the most definitive surgical procedure.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a primary surgeon for the patient, the information should not be changed or updated even if the patient receives care from another surgeon.

| Code | Definitions |
|---------------|--|
| (fill spaces) | 10-digit NPI number for the primary surgeon. |
| (leave blank) | The patient did not have surgery. NPI for the primary surgeon is unknown or not Available. The physician who performed the surgical procedure was not a surgeon (for example, general practitioner). |

NPI-PHYSICIAN #3 (Radiation Oncologist–CoC Preferred)

Item Length: 10
 Allowable Value: 10 digits
 NAACCR Item #2495
 Revised 4/07, 9/08, 1/10, 1/11

Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this item identify the physician who performed the most definitive radiation therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

Instructions for Coding

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Do not update this item. If the registry has designated a primary radiation oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another radiation oncologist.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

| Code | Definition |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the primary radiation oncologist. |
| (leave blank) | NPI for the primary radiation oncologist is unknown or not available. |

NPI–PHYSICIAN #4 (Medical Oncologist–CoC Preferred) Item Length: 10
Allowable Value: Ten digits
NAACCR Item #2505
Revised 4/07, 9/08, 1/10, 1/11, 1/12

Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this data item identify the physician who gives the most definitive systemic therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

Instructions for Coding

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Do not update this item. If the registry has designated a primary medical oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another medical oncologist.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

| Code | Definition |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the primary medical oncologist. |
| (leave blank) | NPI for the primary medical oncologist is unknown or not available. |

Cancer Identification

CLASS OF CASE

Item Length: 2
 Allowable Values: 00, 10-14,
 20-22, 30-38, 40-43, 49, 99
 NAACCR Item #610
 Revised 09/08, 01/10, 05/10, 01/11,
 01/12, 01/14, 01/15

Description

Class of Case divides cases into two groups. Analytic cases (codes 00–22) are those that are required by CoC to be abstracted because of the program’s primary responsibility in managing the cancer. Analytic cases are grouped according to the location of diagnosis and first course of treatment. Nonanalytic cases (codes 30–49 and 99) may be abstracted by the facility to meet central registry requirements or in response to a request by the facility’s cancer program. Nonanalytic cases are grouped according to the reason a patient who received care at the facility is nonanalytic, or the reason a patient who never received care at the facility may have been abstracted.

Rationale

Class of Case reflects the facility’s role in managing the cancer, whether the cancer is required to be reported by CoC, and whether the case was diagnosed after the program’s Reference Date.

Instructions for Coding

- Code the *Class of Case* that most precisely describes the patient’s relationship to the facility.
- Code 00 applies only when it is known the patient went elsewhere for treatment. If it is not known that the patient actually went somewhere else, code *Class of Case* 10.
- It is possible that information for coding *Class of Case* will change during the patient’s first course of care. If that occurs, change the code accordingly.
- Document *NPI–Institution Referred To* (NAACCR Item #2425) or the applicable physician NPI (NAACCR #s 2585, 2495, 2505) for patients coded 00 to establish that the patient went elsewhere for treatment
- Code 34 or 36 if the diagnosis benign or borderline (*Behavior* 0 or 1) for any site diagnosed before 2004 or for any site other than meninges (C70._), brain (C71._), spinal cord, cranial nerves, and other parts of central nervous system (C72._), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3) that were diagnosed in 2004 or later.
- Code 34 or 36 for carcinoma in situ of the cervix (CIS) and intraepithelial neoplasia grade III (8077/2 or 8148/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), and anus (AIN III).
- Physicians who are not employed by the hospital but are under contract with it or have routine admitting privileges there are described in codes 10-12 and 41 as physicians with admitting privileges. Treatment provided in the office of a physician with admitting privileges is provided “elsewhere”. That is because care given in the physician’s office is not within the hospital’s realm of responsibility.
- If the hospital purchases a physician practice, it will be necessary to determine whether the practice is now legally considered part of the hospital (their activity is coded as the hospital’s) or not. If the practice is not legally part of the hospital, it will be necessary to determine whether the physicians involved have routine admitting privileges or not, as with any other physician.
- “In-transit” care is care given to a patient who is temporarily away from the patient’s usual practitioner for continuity of care. If these cases are abstracted, they are *Class of Case* 31. Monitoring of oral medication started elsewhere is coded *Class of Case* 31. If a patient begins first course radiation or chemotherapy infusion elsewhere and continues at the reporting facility, and the care is not in-transit, then the case is analytic (*Class of Case* 21).

Codes

| Analytic Classes of Case (Required by CoC to be abstracted by accredited programs) | |
|--|---|
| | <i>Initial diagnosis at reporting facility or in a staff physician's office</i> |
| 00 | Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere |
| 10 | Initial diagnosis at the reporting facility or in an office of a physician with admitting privileges AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS |
| 11 | Initial diagnosis in an office of a physician with admitting privileges AND part of first course treatment was done at the reporting facility |
| 12 | Initial diagnosis in an office of a physician with admitting privileges AND all first course treatment or a decision not to treat was done at the reporting facility |
| 13 | Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere. |
| 14 | Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility |
| | <i>Initial diagnosis elsewhere</i> |
| 20 | Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS |
| 21 | Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere. |
| 22 | Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility |
| Classes of Case not required by CoC to be abstracted (May be required by Cancer Committee, state or regional registry, or other entity) | |
| | <i>Patient appears in person at reporting facility</i> |
| 30 | Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere) |
| 31 | Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care; or hospital provided care that facilitated treatment elsewhere (for example, stent placement) |
| 32 | Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence (active disease) |
| 33 | Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (disease not active) |
| 34 | Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility |
| 35 | Case diagnosed before program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility |
| 36 | Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility |
| 37 | Case diagnosed before program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility |
| 38 | Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death |
| | <i>Patient does not appear in person at reporting facility</i> |
| 40 | Diagnosis AND all first course treatment given at the same staff physician's office |
| 41 | Diagnosis and all first course treatment given in two or more different offices of physicians with admitting privileges |
| 42 | Nonstaff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility) |
| 43 | Pathology or other lab specimens only |
| 49 | Death certificate only |
| 99 | Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases). |

Examples

| Code | Reason |
|-------------|---|
| 00 | Leukemia was diagnosed at the facility, and all care was given in an office of a physician with practice privileges. The treatment may be abstracted if the cancer committee desires, but the case is <i>Class of Case 00</i> . |
| 13 | Breast cancer was diagnosed at the reporting hospital and surgery performed there. Radiation was given at the hospital across the street with which the reporting hospital has an agreement. |
| 10 | Reporting hospital found cancer in a biopsy, but was unable to discover whether the homeless patient actually received any treatment elsewhere. |
| 32 | After treatment failure, the patient was admitted to the facility for supportive care |
| 11 | Patient was diagnosed by a physician with practice privileges, received neoadjuvant radiation at another facility, then underwent surgical resection at the reporting facility |
| 42 | Patients from an unaffiliated, free-standing clinic across the street that hospital voluntarily abstracts with its cases because many physicians work both at the clinic and the hospital. |
| 31 | Patient received chemotherapy while attending daughter's wedding in the reporting hospital's city, then returned to the originating hospital for subsequent treatments. |

NPI-INSTITUTION REFERRED FROM

Item Length: 10

Allowable Value: Ten digits

NAACCR Item #2415

Revised 04/07, 09/08, 01/11

Description

Identifies the facility that referred the patient to the reporting facility.

Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

Instructions for Coding

- Record the 10-digit NPI for the referring facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI, or search on <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

| Code | Definition |
|---------------|--|
| (fill spaces) | 10-digit NPI number for the facility. |
| (leave blank) | NPI for the referring facility is unknown or not available. |
| (leave blank) | If the patient was not referred to the reporting facility from another facility. |

NPI-INSTITUTION REFERRED TO

Item Length: 10
 Allowable Value: 10 digits
 NAACCR Item #2425
 Revised 04/07, 09/08, 01/11

Description

Identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

Instructions for Coding

- Record the 10-digit NPI for the facility to which the patient was referred.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI or search on <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

| Code | Definition |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the facility. |
| (leave blank) | NPI for the facility referred to is unknown or not available. |
| (leave blank) | If the patient was not referred to another facility. |

DATE OF FIRST CONTACT

Item Length: 8
 NAACCR Item #580
 Revised 09/06, 01/04, 01/10, 01/11

Description

Date of first contact with the reporting facility for diagnosis and/or treatment of this cancer.

Rationale

This data item can be used to measure the time between first contact and the date that the case was abstracted. It can also be used to measure the length of time between the first contact and treatment for quality of care reports.

Instructions for Coding

- Record the date the patient first had contact with the facility as either an inpatient or outpatient for diagnosis and/or first course treatment of a reportable tumor. The date may be the date of an outpatient visit for a biopsy, X ray, or laboratory test, or the date a pathology specimen was collected at the hospital.
- For analytic cases (*Class of Case* 00-22), the *Date of First Contact* is the date the patient became analytic. For non-analytic cases, it is the date the patient first qualified for the *Class of Case* that causes the case to be abstracted.
- If this is an autopsy-only or death certificate-only case, then use the date of death.
- When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Contact* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Contact* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date. The *Date of First Contact Flag* (NAACCR Item #581) is used to explain why *Date of First Contact* is not a known date. See *Date of First Contact Flag* for an illustration of the relationships among these items.

Examples

| | |
|--|---------------------|
| Patient undergoes a biopsy in a staff physician's office on September 8, 2009. The pathology specimen was sent to the reporting facility and was read as malignant melanoma. The patient enters that same reporting facility on September 14, 2009 for wide re-excision. | September 14, 2009 |
| Patient has an MRI of the brain on December 7, 2010, for symptoms including severe headache and disorientation. The MRI findings are suspicious for astrocytoma. Surgery on December 19 removes all gross tumor. | December 7, 2010 |
| Information is limited to the description "Spring," 2011. | April 2011 |
| Information is limited to the description "The middle of the year," 2011. | July 2011 |
| Information is limited to the description "Fall," 2011. | October 2011 |
| If information is limited to the description "Winter," try to determine if this means the beginning or the end of the year. | December or January |

DATE OF FIRST CONTACT FLAG

Item Length: 2
 NAACCR Item #581
 Valid codes: 12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Contact* (NAACCR Item #580).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate nondate information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of First Contact* (NAACCR Item #580) has a full or partial date recorded.
- Code 12 if the *Date of First Contact* can not be determined at all.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software

| Code | Definition |
|---------|--|
| 12 | A proper value is applicable but not known (that is, the date of first contact is unknown) |
| (blank) | A valid date value is provided in item <i>Date of First Contact</i> (NAACCR Item #580) |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Contact* (NAACCR Item #580) and *Date of First Contact Flag* (NAACCR Item #581). *In the table below, the lowercase letter “b” is used to represent each blank space.*

| Description | Traditional Date of First Contact | Interoperable Date of First Contact | Date of First Contact Flag |
|----------------------|---|--|----------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown. | |
| Full date known | MMDDCCYY (example: 02182010) | CCYYMMDD (example: 20100218) | bb |
| Month and year known | MM99CCYY (example: 02992010) | CCYYMMbb (example: 201002bb) | bb |
| Year only known | 9999CCYY (example: 99992010) | CCYYbbbb (example: 2010bbbb) | bb |
| Unknown date | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

DATE OF INITIAL DIAGNOSIS

Item Length: 8
 NAACCR Item #390
 Revised 09/04, 09/08, 1/10, 01/11

Description

Records the date of initial diagnosis by a physician for the tumor being reported.

Rationale

The timing for staging and treatment of cancer begins with the date of initial diagnosis for cancer.

Instructions for Coding

- Use the first date of diagnosis whether clinically or histologically established.
- If the physician states that in retrospect the patient had cancer at an earlier date, use the earlier date as the date of diagnosis.
- Refer to the list of “Ambiguous Terms” in Section One for language that represents a diagnosis of cancer.
- Use the date treatment was started as the date of diagnosis if the patient receives a first course of treatment before a diagnosis is documented.
- The date of death is the date of diagnosis for a *Class of Case* (NAACCR Item #610) 38 (diagnosed at autopsy) or 49 (death certificate only).
- Use the actual date of diagnosis for an *in utero* diagnosis, for cases diagnosed on January 1, 2009, or later.
- If the year of diagnosis cannot be identified, it must be approximated. In that instance, the month and day are unknown.

Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Initial Diagnosis* MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Initial Diagnosis* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date.

Examples

| Date | Reason |
|--------------|--|
| July 2, 2010 | Cytology “suspicious” for cancer June 12, 2010; pathology positive July 2, 2010. Do not consider cytology with ambiguous terms to be diagnostic. |
| May 17, 2010 | Pathology “suspicious” for cancer May 17, 2010; confirmed positive May 22, 2010 |
| April 2010 | Physician’s referral notes dated July 5, 2010, indicate the patient was diagnosed with cancer spring of 2010. Use April for “spring”, July for “summer” or “mid-year”, October for “fall” or “autumn”. In winter, attempt to determine whether the diagnosis was “late in the year” (use December with the applicable year) or “early in year” (use January with the respective year). |

PRIMARY SITE

Item Length: 4
 NAACCR Item #400
 Revised 01/04, 09/08, 01/10

Description

Identifies the primary site.

Rationale

Primary site is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

Instructions for Coding

- Record the ICD-O-3 topography code for the site of origin.
- Consult the physician advisor to identify the primary site or the most definitive site code if the medical record does not contain that information.
- Topography codes are indicated by a “C” preceding the three-digit code number. Do not record the decimal point.
- Follow the Instructions for Coding in ICD-O-3, pages 20–40 and in the current *SEER Multiple Primary and Histology Coding Rules* to assign site for solid tumors.
- Follow the instructions in *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB) for assigning site for lymphomas, leukemia and other hematopoietic neoplasms.
- Use subcategory 8 for single tumors that overlap the boundaries of two or more sub-sites and the point of origin is not known.
- Use subcategory 9 for multiple tumors that originate in different subsites of one organ.

Examples

| Code | Reason |
|------|--|
| C108 | Overlapping lesion of oropharynx. Code overlapping lesion when a large tumor involves both the lateral wall of the oropharynx (C10.2) and the posterior wall of the oropharynx (C10.3) and the point of origin is not stated. |
| C678 | Overlapping lesion of bladder. Code overlapping lesion of the bladder when a single lesion involves the dome (C67.1) and the lateral wall (C67.2) and the point of origin is not stated. |
| C189 | Colon, NOS. Familial polyposis with carcinoma and carcinoma in situ throughout the transverse (C18.4) and descending colon (C18.6) would be one primary and coded to colon, NOS (C18.9). For a full explanation see the <i>SEER 2007 Multiple Primary and Histology Coding Rules</i> . |
| C16– | Stomach (sub-site as identified). An extranodal lymphoma of the stomach is coded to C16.– (sub-site as identified). |

LATERALITY

Item Length: 1
 Allowable Values: 0–4, 9
 NAACCR Item #410
 Revised 01/10, 05/10, 01/13

Description

Identifies the side of a paired organ or the side of the body on which the reportable tumor originated. This applies to the primary site only.

Rationale

Laterality supplements staging and extent of disease information and defines the number of primaries involved.

Instructions for Coding

- Code laterality for all paired sites. (See Section One for additional information.)
- Do not code metastatic sites as bilateral involvement.
- If both lungs have nodules or tumors and the lung of origin is not known, assign code 4.
- Where the right and left sides of paired sites are contiguous (come into contact) and the lesion is at the point of contact of the right and left sides, use code 5, midline. Note that “midline of the right breast” is coded 1, right; midline in this usage indicates the primary site is C50.8 (overlapping sites).
- Non-paired sites may be coded right or left, if appropriate. Otherwise, code non-paired sites 0.

| Code | Definition |
|------|---|
| 0 | Organ is not a paired site. |
| 1 | Origin of primary is right. |
| 2 | Origin of primary is left. |
| 3 | Only one side involved, right or left origin not specified. |
| 4 | Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors |
| 5 | Paired site: midline tumor |
| 9 | Paired site, but no information concerning laterality |

HISTOLOGY

Item Length: 4
 NAACCR Item #522
 Revised 09/06, 01/10, 03/10

Description

Identifies the microscopic anatomy of cells.

Rationale

Histology is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

Instructions for Coding

- ICD-O-3 identifies the morphology codes with an “M” preceding the code number. Do not record the “M.”
- Record histology using the ICD-O-3 codes in the Numeric Lists/Morphology section (ICD-O-3, pp. 69–104) and in the Alphabetic Index (ICD-O-3, pp. 105–218).
- Follow the coding rules outlined on pages 20 through 40 of ICD-O-3.
- Use the current *Multiple Primary and Histology Coding Rules* when coding the histology for all reportable solid tumors. These rules are effective for cases diagnosed January 1, 2007, or later. Do not use these rules to abstract cases diagnosed prior to January 1, 2007.
- Review all pathology reports.
- Code the **final** pathologic diagnosis for solid tumors.
- For lymphomas, leukemias and other hematopoietic tumors, follow the instructions in *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB)
- The codes for cancer, NOS (8000) and carcinoma, NOS (8010) are **not** interchangeable. If the physician says that the patient has carcinoma, then code carcinoma, NOS (8010).

Examples

| Code | Label | Definition |
|------|-------------------------------|---|
| 8140 | Adenocarcinoma | Final pathologic diagnosis is carcinoma, NOS (8010) of the prostate. Microscopic diagnosis specifies adenocarcinoma (8140) of the prostate. |
| 9680 | Diffuse large B-cell lymphoma | Diffuse large B-cell lymphoma, per the WHO Classification of Hematopoietic and Lymphoid Neoplasms. |

BEHAVIOR CODE

Item Length: 1

Allowable Values: 0–3

NAACCR Item #523

Revised 04/04, 01/10, 01/12, 01/13, 01/15

Description

Records the behavior of the tumor being reported. The fifth digit of the morphology code is the behavior code.

Rationale

The behavior code is used by pathologists to describe whether tissue samples are benign (0), borderline (1), in situ (2), or invasive (3).

Instructions for Coding

- Code 3 if any *malignant* invasion is present, no matter how limited.
- Code 3 if any *malignant* metastasis to nodes or tissue beyond the primary is present.
- If the specimen is from a metastatic site, code the histology of the metastatic site and code 3 for behavior.

Note: The ICD-O-3 behavior code for juvenile astrocytoma (9421/1) is coded as 3 by agreement of North American registry standard-setters. Refer to “Case Eligibility” in Section One for information. **Gastro-intestinal stromal tumors (GIST) and thymomas are frequently non-malignant. However, they must be abstracted and assigned a Behavior Code of 3 if they are noted to have multiple foci, metastasis or positive lymph nodes.**

| Code | Label | Definition |
|-----------------------------|-------------------------------------|--|
| 0 | Benign | Benign |
| 1 | Borderline | Uncertain whether benign or malignant |
| | | Borderline malignancy |
| | | Low malignant potential |
| | | Uncertain malignant potential |
| 2 | In situ and synonymous with in situ | Adenocarcinoma in an adenomatous polyp with no invasion of stalk |
| | | Bowen disease (not reportable for C44._) |
| | | Clark level 1 for melanoma (limited to epithelium) |
| | | Comedocarcinoma, noninfiltrating (C50.–) |
| | | Confined to epithelium |
| | | Hutchinson melanotic freckle, NOS (C44.–) |
| | | Intracystic, noninfiltrating.(carcinoma) |
| | | Intraductal.(carcinoma) |
| | | Intraepidermal, NOS (carcinoma) |
| | | Intraepithelial, NOS (carcinoma) |
| | | Involvement up to, but not including the basement membrane |
| | | Lentigo maligna (C44.–) |
| | | Lobular neoplasia (C50.–) |
| | | Lobular, noninfiltrating (C50.–) (carcinoma) |
| Noninfiltrating (carcinoma) | | |

| Code | Label | Definition |
|------|---|---|
| 2 | In situ and synonymous with in situ (continued) | Noninvasive (carcinoma only) |
| | | No stromal invasion or involvement |
| | | Papillary, noninfiltrating or intraductal (carcinoma) |
| | | Precancerous melanosis (C44.–) |
| | | Queyrat erythroplasia (C60.–) |
| 3 | Invasive | Invasive or microinvasive. |

Examples

| Code | Reason |
|------|---|
| 3 | Intraductal carcinoma (8500/2) with focal areas of invasion |
| 3 | Atypical thymoma (8585/1) with malignant metastasis in one lymph node |
| 1 | Atypical meningioma (9539/1) invading bone of skull (the meninges, which line the skull, are capable of invading into the bone without being malignant; do not code as malignant unless it is specifically mentioned) |
| 1 | GIST (with no mention whether malignant or benign) |
| 3 | Malignant GIST |

GRADE/DIFFERENTIATION

Item Length: 1

Allowable Values: 1–9

NAACCR Item #440

Revised 01/04, 09/08, 01/10, 01/11, 01/12, 01/13, 01/15

Description

Describes the tumor's resemblance to normal tissue. Well differentiated (Grade 1) is the most like normal tissue, and undifferentiated (Grade 4) is the least like normal tissue. Grades 5–8 define particular cell lines for lymphomas and leukemias.

Rationale

This data item is useful for prognosis.

Instructions for Coding

- See “Morphology: Grade” in the “Cancer Identification” of *Section I* for instructions for coding this item for cases diagnosed in 2014 or subsequently. Consult the applicable version of **FORDS** for cases for instructions for cases diagnosed prior to 2014.
- When there is no tissue diagnosis, it may be possible to establish grade through magnetic resonance imaging (MRI) or positron emission tomography (PET). When available, code grade based on the recorded findings from these imaging reports.

| Code | Label |
|-------------|--|
| 1 | Well differentiated; differentiated, NOS |
| 2 | Moderately differentiated; moderately well differentiated; intermediate differentiation |
| 3 | Poorly differentiated; dedifferentiated |
| 4 | Undifferentiated; anaplastic |
| 5 | T cell; T-precursor |
| 6 | B cell; pre-B; B-precursor |
| 7 | Null cell; non T-non B |
| 8 | NK (natural killer) cell (effective with diagnosis 1/1/95 and after) |
| 9 | Cell type not determined, not stated or not applicable; unknown primary; high grade dysplasia (adenocarcinoma in situ) |

LYMPH-VASCULAR INVASION

Item Length: 1
Allowable Values: 0-1, 8-9
NAACCR Item #1182
Revised 01/11

Description

Indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.

Rationale

Lymph-vascular invasion is an indicator of prognosis. This field is used by the CS algorithm to map AJCC T for some primary sites.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

DIAGNOSTIC CONFIRMATION

Item Length: 1

Allowable Values: 1, 2, 4–9

NAACCR Item #490

Revised 01/04, 01/10, 01/11, 01/12, 01/13

Description

Records the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history. The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.

Rationale

This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases.

Instructions for Coding Solid Tumors (all tumors *except* M9590-9992)

- These instructions apply to “Codes for Solid Tumors” below. See the section following this one for “Coding Hematopoietic or Lymphoid Tumors (9590-9992)”.
- The codes are in **priority order**; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods. This data item must be changed to the lower (higher priority) code if a more definitive method confirms the diagnosis *at any time during* the course of the disease.
- Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, autopsy or D&C or from aspiration of biopsy of bone marrow specimens.
- Assign code 2 when the microscopic diagnosis is based on cytologic examination of *cells* such as sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.
- Code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer.
- Code 6 when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy or from gross autopsy findings in the absence of tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

Instructions for Coding Hematopoietic or Lymphoid Tumors (9590-9992)

- These instructions apply to “Codes for Hematopoietic and Lymphoid Neoplasms” below. See the preceding section for instructions “Coding Solid Tumors”.
- There is no priority hierarchy for coding *Diagnostic Confirmation* for hematopoietic and lymphoid tumors. Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing. See the *Hematopoietic Database (DB)* for information on the definitive diagnostic confirmation for specific types of tumors.
- Code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, or autopsy or bone marrow specimens from aspiration or biopsy.
- For leukemia only, code 1 when the diagnosis is based only on the complete blood count (CBC), white blood count (WBC) or peripheral blood smear. Do not use code 1 if the diagnosis was based on immunophenotyping or genetic testing using tissue, bone marrow, or blood.

- Use code 2 when the microscopic diagnosis is based on cytologic examination of *cells* (rather than tissue) including but not limited to spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.
- Assign code 3 when there is a histology positive for cancer AND positive immunophenotyping and/or positive genetic testing results. Do not use code 3 for neoplasms diagnosed prior to January 1, 2010.
- Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer, but no positive histologic confirmation.
- Assign code 6 when the diagnosis is based only on the surgeon's report from a surgical exploration or endoscopy or from gross autopsy findings without tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

Codes for Solid Tumors

| Code | Label | Definition |
|------|---|---|
| 1 | Positive histology | Histologic confirmation (tissue microscopically examined). |
| 2 | Positive cytology | Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined). |
| 4 | Positive microscopic confirmation, method not specified | Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology. |
| 5 | Positive laboratory test/marker study | A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer. Examples include alpha-fetoprotein for liver primaries. Elevated PSA is not diagnostic of cancer. However, if the physician uses the PSA as a basis for diagnosing prostate cancer with no other workup, record as code 5. |
| 6 | Direct visualization without microscopic confirmation | The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination. |
| 7 | Radiography and other imaging techniques without microscopic confirmation | The malignancy was reported by the physician from an imaging technique report only. |
| 8 | Clinical diagnosis only, other than 5, 6 or 7 | The malignancy was reported by the physician in the medical record. |
| 9 | Unknown whether or not microscopically confirmed | A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed (usually nonanalytic). |

The codes for hematopoietic and lymphoid neoplasms are on the next page.

Codes for Hematopoietic and Lymphoid Neoplasms

| Code | Label | Definition |
|-------------|---|---|
| 1 | Positive histology | Histologic confirmation (tissue microscopically examined). |
| 2 | Positive cytology | Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined). |
| 3 | Positive histology PLUS <ul style="list-style-type: none"> • Positive immunophenotyping AND/OR • Positive genetic studies | Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results. For example, bone marrow examination is positive for acute myeloid leukemia. (9861/3) Genetic testing shows AML with inv(16)(p13.1q22) (9871/3). |
| 4 | Positive microscopic confirmation, method not specified | Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology. |
| 5 | Positive laboratory test/marker study | A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer. |
| 6 | Direct visualization without microscopic confirmation | The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination. |
| 7 | Radiography and other imaging techniques without microscopic confirmation | The malignancy was reported by the physician from an imaging technique report only. |
| 8 | Clinical diagnosis only, other than 5, 6 or 7 | The malignancy was reported by the physician in the medical record. |
| 9 | Unknown whether or not microscopically confirmed | A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed (usually nonanalytic). |

REGIONAL LYMPH NODES EXAMINED

Item Length: 2

Allowable Values: 00–90, 95–99

NAACCR Item #830

Revised 09/06, 01/10

Description

Records the total number of regional lymph nodes that were removed and examined by the pathologist. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS). In 2016 use of CS was discontinued, however this data item continued to be required.

Rationale

This data item serves as a quality measure of the pathologic and surgical evaluation and treatment of the patient.

Instructions for Coding

- Refer to the site/histology-specific instructions in the current *CS Manual* for codes and Instructions for Coding.
- When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual use the AJCC definition.

REGIONAL LYMPH NODES POSITIVE

Item Length: 2
Allowable Values: 00–99
Right Justified, Zero-filled
NAACCR Item #820
Revised 09/06, 01/10

Description

Records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS). In 2016 use of CS was discontinued, however this data item continued to be required.

Rationale

This data item is necessary for pathologic staging, and it serves as a quality measure for pathology reports and the extent of the surgical evaluation and treatment of the patient.

Instructions for Coding

- Refer to the site/histology-specific instructions in the current *CS Manual* for codes and Instructions for Coding.
- When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual use the AJCC definition.

Stage of Disease at Diagnosis

**DATE OF SURGICAL DIAGNOSTIC
AND STAGING PROCEDURE**Item Length: 8
NAACCR Item #1280
Revised 01/10, 01/11

Description

Records the date on which the surgical diagnostic and/or staging procedure was performed.

Rationale:

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Coding Instructions:

- Record the date on which the surgical diagnostic and/or staging procedure described in *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) was performed at this or any facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this modification does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Surgical Diagnostic and Staging Procedure* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Surgical Diagnostic and Staging Procedure* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date-DX/Stg Proc Flag* (NAACCR Item #1281) is used to explain why *Date of Surgical Diagnostic and Staging Procedure* is not a known date. See *RX Date-DX/Stg Proc Flag* for an illustration of the relationships among these items.

RX DATE–DX/STG PROC FLAG

Item Length: 2
 NAACCR Item 1281
 Valid codes 10–12, Blank
 Revised 01/12

Description

This flag explains why there is no appropriate value in the corresponding date data item, *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280).

Rationale

As part of an initiative to standardize date data items, date flag data items were introduced to accommodate non-date information that had previously been transmitted in date data items.

Coding Instructions

- Leave this item blank if *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280) has a full or partial date recorded.
- Code 10 if it is unknown whether a surgical diagnostic or staging procedure was performed.
- Code 11 if no surgical diagnostic or staging procedure was performed.
- Code 12 if the *Date of Surgical Diagnostic and Staging Procedure* cannot be determined, but a surgical diagnostic or staging procedure was performed for the patient.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Definition |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any diagnostic or staging procedure performed). |
| 11 | No proper value is applicable in this context (for example, no diagnostic or staging procedure performed; autopsy only case). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (for example, diagnostic or staging procedure performed but date is unknown). |
| (blank) | A valid date value is provided in item <i>Date of Surgical Diagnostic and Staging Procedure</i> (NAACCR Item #1280). Case was diagnosed prior to January 1, 2007. |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280-) and *RX Date–DX/Stg Proc Flag* (NAACCR Item #1281). *In this table, the lower-case letter “b” is used to represent each blank space.*

| Description | Traditional Date of Surgical Diagnostic or Staging Procedure | Interoperable Date of Surgical Diagnostic or Staging Procedure | RX Date–DX/Stg Proc Flag |
|--|--|---|--------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 Date entry MMDDCCYY (example: 02182007) | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. Date entry CCYYMMDD (example: 20070218) | Flag value bb |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if procedure done | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| Procedure not done | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, procedure done | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

**SURGICAL DIAGNOSTIC AND STAGING
PROCEDURE**

Item Length: 2
Allowable Values: 00–07, 09
NAACCR Item #1350
Revised 09/06, 09/08, 01/12, 01/15

Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Instructions for Coding:

- Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility.
- Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage *lymphoma*, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item *Surgical Procedure of Primary Site* (NAACCR Item #1290) to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove *regional lymph nodes* in an effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280). See instructions for *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292).
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation* (NAACCR Item #490). These are not considered surgical procedures and should not be coded in this item.
- Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item *Surgical Procedure of Primary Site* (NAACCR Item #1290) to code these procedures.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* data item (NAACCR Item #1290).
- Do not code palliative surgical procedures in this data item. Use the data item *Palliative Procedure* (NAACCR Item #3270) to code these procedures.

| Code | Definition |
|------|--|
| 00 | No surgical diagnostic or staging procedure was performed. |
| 01 | A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done. |
| 02 | A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma. |
| 03 | A surgical exploration only. The patient was not biopsied or treated. |
| 04 | A surgical procedure with a bypass was performed, but no biopsy was done. |
| 05 | An exploratory procedure was performed, and a biopsy of either the primary site or another site was done. |
| 06 | A bypass procedure was performed, and a biopsy of either the primary site or another site was done. |
| 07 | A procedure was done, but the type of procedure is unknown. |
| 09 | No information of whether a diagnostic or staging procedure was performed. |

Examples:

| Code | Reason |
|------|---|
| 00 | A lung cancer primary was diagnosed by CT scan. The patient expired. No surgical diagnostic or staging surgical procedure was performed. |
| 00 | A sputum sample is examined cytologically to confirm a diagnosis of suspected lung cancer. The procedure is not surgical. |
| 01 | A needle biopsy of a liver metastasis in a patient with suspected widespread colon cancer was done. Gross residual tumor is left at the biopsy site. |
| 03 | During abdominal exploratory surgery, a gastric lesion and suspicious retroperitoneal lymph nodes were observed. No biopsy or treatment was done. |
| 04 | An abdominal exploration of a patient revealed pancreatic carcinoma with extension into surrounding organs and arteries. No attempt to treat. A bypass was performed to alleviate symptoms. |
| 05 | An exploratory procedure was performed for primary colon carcinoma with biopsy of suspicious liver lesions. |
| 06 | Esophagogastrostomy was performed for infiltrating gastric tumor following a biopsy of the primary site. |
| 07 | Stage III lung carcinoma was diagnosed and staged prior to admission. |
| 09 | A patient expires in the emergency room with recently diagnosed metastatic melanoma. It is unknown whether a diagnostic or staging procedure was done. |

**SURGICAL DIAGNOSTIC AND STAGING
PROCEDURE AT THIS FACILITY**

Item Length: 2
Allowable Values: 00–07, 09
NAACCR Item #740
Revised 01/04, 09/08, 01/12

Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Instructions for Coding

- Record the type of procedure performed as part of the initial diagnosis and workup at this facility.
- Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage *lymphoma*, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item *Surgical Procedure of Primary Site at This Facility* (NAACCR Item #670) to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove *regional lymph nodes* in an effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672) to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* (NAACCR Item #1280). See instructions for *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation* (NAACCR Item #490). These are not considered surgical procedures and should not be coded in this item.
- Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item *Surgical Procedure of Primary Site at This Facility* (NAACCR Item #670) to code these procedures.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure at this Facility* (NAACCR Item #740) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site at this Facility* data item (NAACCR Item #670).
- Do not code palliative surgical procedures in this data item. Use the data item *Palliative Procedure at This Facility* (NAACCR Item #3280) to code these procedures.

| Code | Definition |
|-------------|--|
| 00 | No surgical diagnostic or staging procedure was performed. |
| 01 | A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done. |
| 02 | A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma. |
| 03 | A surgical exploration only. The patient was not biopsied or treated. |
| 04 | A surgical procedure with a bypass was performed, but no biopsy was done. |
| 05 | An exploratory procedure was performed, and a biopsy of either the primary site or another site was done. |
| 06 | A bypass procedure was performed, and a biopsy of either the primary site or another site was done. |
| 07 | A procedure was done, but the type of procedure is unknown. |
| 09 | No information of whether a diagnostic or staging procedure was performed. |

TUMOR SIZE SUMMARY

Item Length: 3
Allowable Values: 000-990, 998, 999
NAACCR Item #756
Revised 01/16

Description

This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen.

Rationale

Tumor size is one indication of the extent of disease. As such, it is used by both clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts.

Instructions for Coding

Note: All measurements should be in millimeters (mm).

Record size in specified order:

1. Size measured on the surgical resection specimen, when **surgery is administered as the first definitive treatment, i.e., no pre-surgical treatment administered.**
 - a. If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report (also known as CAP protocol or pathology report checklist). If only a text report is available, use: final diagnosis, microscopic, or gross examination, in that order.
Example: Chest x-ray shows 3.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 2.8 cm. Record tumor size as 028 (28 mm).
Example: Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record tumor size as 032 (32 mm).
2. If neoadjuvant therapy followed by surgery, do not record the size of the pathologic specimen. Code the largest size of tumor prior to neoadjuvant treatment; if unknown code size as 999.
Example: Patient has a 2.2 cm mass in the oropharynx; fine needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination chemotherapy. Pathologic size after total resection is 2.8 cm. Record tumor size as 022 (22mm).
3. If no surgical resection, then largest measurement of the tumor from physical exam, imaging, or other diagnostic procedures prior to any other form of treatment (See Coding Rules below).
4. If 1, 2, and 3 do not apply, the largest size from all information available within four months of the date of diagnosis, in the absence of disease progression.

Coding Rules:

1. Tumor size is the **diameter** of the tumor, **not the depth or thickness** of the tumor.
2. **Recording less than/greater than Tumor Size:**
 - a. If tumor size is reported as less than x mm or less than x cm, the reported tumor size should be 1 mm less; for example if size is <10 mm, code size as 009. Often these are given in cm such as < 1 cm which is coded as 009, < 2 cm is coded as 019, < 3 cm is coded as 029, < 4 cm is coded as 039, < 5 cm is coded as 049. If stated as less than 1 mm, use code 001.
 - b. If tumor size is reported as more than x mm or more than x cm, code size as 1 mm more; for example if size is >10 mm, size should be coded as 011. Often these are given in cm such as > 1 cm, which is coded as 011, > 2 cm is coded as 021, > 3 cm is coded as 031, > 4 cm is coded as 041, > 5 cm is coded as 051. If described as anything greater than 989 mm (98.9 cm) code as 989.

- c. If tumor size is reported to be between two sizes, record tumor size as the midpoint between the two: i.e., add the two sizes together and then divide by two (“between 2 and 3 cm” is coded as 025).
3. **Rounding:** Round the tumor size only if it is described in fractions of millimeters. If the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9 mm), record size as 001 (do not round down to 000). If tumor size is greater than 1 millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter, and round tenths of millimeters in the 5-9 range up to the nearest whole millimeter. Do not round tumor size expressed in centimeters to the nearest whole centimeter (rather, move the decimal point one space to the right, converting the measurement to millimeters).

Examples:

Breast cancer described as 6.5 millimeters in size. Round up *Tumor Size as 007.*

Cancer in polyp described as 2.3 millimeters in size. Round down *Tumor Size as 002.*

Focus of cancer described as 1.4 mm in size. *Round down as 001.*

5.2 mm breast cancer. *Round down to 5 mm and code as 005.*
4. **Priority of imaging/radiographic techniques:** Information on size from imaging/radiographic techniques can be used to code size when there is no more specific size information from a pathology or operative report, but it should be taken as low priority, over a physical exam.
5. **Tumor size discrepancies among imaging and radiographic reports:** If there is a difference in reported tumor size among imaging and radiographic techniques, unless the physician specifies which imaging is most accurate, record the largest size in the record, regardless of which imaging technique reports it.
6. **Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis.** However, if the tumor is described as a “cystic mass,” and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.
7. **Record the size of the invasive component, if given.**
 - a. If both an in situ and an invasive component are present and the invasive component is measured, record the size of the invasive component even if it is smaller.

Example: Tumor is mixed in situ and invasive adenocarcinoma, total 3.7 cm in size, of which 1.4 cm is invasive. Record tumor size as 014 (14 mm)
 - b. If the size of the invasive component is not given, record the size of the entire tumor from the surgical report, pathology report, radiology report or clinical examination.

Example: A breast tumor with infiltrating duct carcinoma with extensive in situ component; total size 2.3 cm. Record tumor size as 023 (23 mm).

Example: Duct carcinoma in situ measuring 1.9 cm with an area of invasive ductal carcinoma. Record tumor size as 019 (19 mm).
8. **Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor.**

Example: Tumor is described as 2.4 x 5.1 x 1.8 cm in size. Record tumor size as 051 (51 mm).
9. **Record the size as stated for purely in situ lesions.**
10. **Disregard microscopic residual or positive surgical margins when coding tumor size.** Microscopic residual tumor does not affect overall tumor size. The status of primary tumor margins may be recorded in a separate data item.

11. **Do not add the size of pieces or chips together to create a whole**; they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if the pathologist states an aggregate or composite size (determined by fitting the tumor pieces together and measuring the total size), record that size. If the only measurement describes pieces or chips, record tumor size as 999.
12. **Multifocal/multicentric tumors:** If the tumor is multi-focal or if multiple tumors are reported as a single primary, code the size of the largest invasive tumor or if all of the tumors are in situ, code the size of the largest in situ tumor.
13. **Tumor size code 999 is used when size is unknown or not applicable.** Sites/morphologies where tumor size is not applicable are listed here.

Hematopoietic, Reticuloendothelial, and Myeloproliferative neoplasms: histology codes 9590-9992

Kaposi Sarcoma
Melanoma Choroid
Melanoma Ciliary Body
Melanoma Iris

14. **Document the information to support coded tumor size in the appropriate text data item of the abstract.**

| Code | Description |
|---------|--|
| 000 | No mass/tumor found |
| 001 | 1 mm or described as less than 1 mm |
| 002-988 | Exact size in millimeters (2 mm to 988 mm) |
| 989 | 989 millimeters or larger |
| 990 | Microscopic focus or foci only and no size of focus is given |
| 998 | <p>SITE-SPECIFIC CODES Alternate descriptions of tumor size for specific sites:</p> <p>Familial/multiple polyposis: Rectosigmoid and rectum (C19.9, C20.9) Colon (C18.0, C18.2-C18.9)</p> <p>If no size is documented: Circumferential: Esophagus (C15.0-C15.5, C15.8-C15.9)</p> <p>Diffuse; widespread: 3/4s or more; linitis plastica: Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)</p> <p>Diffuse, entire lung or NOS: Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)</p> <p>Diffuse: Breast (C50.0-C50.6, C50.8-C50.9)</p> |
| 999 | <p>Unknown; size not stated Not documented in patient record Size of tumor cannot be assessed Not applicable (See Section 15, below.)</p> |

METS AT DIAGNOSIS – BONE

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #1112
Revised 01/16

Description

This data item identifies whether bone is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited cancer program cancer registries beginning with cases diagnosed January 1, 2016.

Instructions for Coding

1. **Code information about bone metastases only** (discontinuous or distant metastases to bone) identified at the time of diagnosis. This data item should not be coded for bone marrow involvement.
 - a. Bone involvement may be single or multiple
 - b. Information about bone involvement may be clinical or pathologic
 - c. Code this data item for bone metastases even if the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites

2. **Use of codes.** Assign the code that best describes whether the case has bone metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no bone metastases
 - iii. includes imaging reports that are negative for bone metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but bone is not mentioned as an involved site
Example: use code 0 when the patient has lung and liver metastases but not bone
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and bone is mentioned as an involved site
 - ii. indicates that bone is the primary site and there are metastases in a different bone or bones
 1. do not assign code 1 for a bone primary with multifocal bone involvement of the same bone
 - iii. indicates that the patient is diagnosed as an unknown primary (C80.9) and bone is mentioned as a distant metastatic site

- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

| ICD-O-3 Site | ICD-O-3 Histology | |
|--|-----------------------------|--|
| C000-C809 | 9740-9809, 9840-9992 | Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site |
| C420, C421, C424 | 9811-9818, 9823, 9827, 9837 | Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9820, 9826, 9831-9834 | Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9731, 9732, 9734 | Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has bone metastases; for example, when there is documentation of carcinomatosis but bone is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include bone.

| Code | Description |
|------|---|
| 0 | None; no bone metastases |
| 1 | Yes; distant bone metastases |
| 8 | Not applicable |
| 9 | Unknown whether bone is an involved metastatic site Not documented in patient record |

METS AT DIAGNOSIS – BRAIN

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #1113
Revised 01/16

Description

This data item identifies whether brain is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited cancer program cancer registries beginning with cases diagnosed January 1, 2016.

Instructions for Coding

1. **Code information about brain metastases only** (discontinuous or distant metastases to brain) identified at the time of diagnosis. This data item should not be coded for involvement of spinal cord or other parts of the central nervous system.
 - a. Brain involvement may be single or multiple
 - b. Information about brain involvement may be clinical or pathologic
 - c. Code this data item whether or not the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites

2. **Use of codes.** Assign the code that best describes whether the case has brain metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no brain metastases
 - iii. includes imaging reports that are negative for brain metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but brain is not mentioned as an involved site
Example: use code 0 when the patient has lung and liver metastases but not brain
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and brain is mentioned as an involved site
 - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and brain is mentioned as a distant metastatic site

- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

| ICD-O-3 Site | ICD-O-3 Histology | |
|--|-----------------------------|--|
| C000-C809 | 9740-9809, 9840-9992 | Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site |
| C420, C421, C424 | 9811-9818, 9823, 9827, 9837 | Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9820, 9826, 9831-9834 | Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9731, 9732, 9734 | Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has brain metastases; for example, when there is documentation of carcinomatosis but brain is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include brain.

| Code | Description |
|------|---|
| 0 | None; no brain metastases |
| 1 | Yes; distant brain metastases |
| 8 | Not applicable |
| 9 | Unknown whether brain is involved metastatic site Not documented in patient record |

METS AT DIAGNOSIS – DISTANT LYMPH NODES

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #1114
Revised 01/16

Description

This data item identifies whether distant lymph node(s) are an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited cancer program cancer registries beginning with cases diagnosed January 1, 2016.

Instructions for Coding

1. **Code information about distant lymph node(s) metastases only** (metastases to distant lymph nodes) identified at the time of diagnosis.
 - a. Distant lymph node involvement may be single or multiple
 - b. Information about distant lymph node involvement may be clinical or pathologic
 - c. Code this data item whether or not the patient had any preoperative systemic therapy
 - d. This data item should not be coded for regional lymph node involvement with the exception of lymph nodes for placenta which are M1
 - e. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites.
2. **Use of codes.** Assign the code that best describes whether the case has distant lymph node metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no distant lymph node metastases
 - iii. includes imaging reports that are negative for distant lymph node metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but distant lymph node(s) are not mentioned as an involved site
Example: use code 0 when the patient has lung and liver metastases but not distant lymph node(s)
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and distant lymph node(s) are mentioned as an involved site
 - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and distant lymph node(s) are mentioned as a metastatic site

- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

| ICD-O-3 Site | ICD-O-3 Histology | |
|--|-----------------------------|--|
| C000-C809 | 9740-9809, 9840-9992 | Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site |
| C420, C421, C424 | 9811-9818, 9823, 9827, 9837 | Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9820, 9826, 9831-9834 | Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9731, 9732, 9734 | Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has distant lymph node metastases; for example, when there is documentation of carcinomatosis but distant lymph node(s) are not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include distant lymph node(s).

| Code | Description |
|------|--|
| 0 | None; no distant lymph node metastases |
| 1 | Yes; distant lymph node metastases |
| 8 | Not applicable |
| 9 | Unknown whether distant lymph node(s) are involved metastatic site Not documented in patient record |

METS AT DIAGNOSIS – LIVER

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #1115
Revised 01/16

Description

This data item identifies whether liver is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited cancer program cancer registries beginning with cases diagnosed January 1, 2016.

Instructions for Coding

1. **Code information about liver metastases only** (discontinuous or distant metastases to liver) identified at the time of diagnosis.
 - a. Liver involvement may be single or multiple
 - b. Information about liver involvement may be clinical or pathologic
 - c. Code this data item whether or not the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites

2. **Use of codes.** Assign the code that best describes whether the case has liver metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no liver metastases
 - iii. includes imaging reports that are negative for liver metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but liver is not mentioned as an involved site
Example: use code 0 when the patient has lung and brain metastases but not liver
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and liver is mentioned as an involved site
 - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and liver is mentioned as a distant metastatic site

- c. Use code 8 (Not applicable) for the following site/histology/combinations for which a code for distant metastasis is not clinically relevant.

| ICD-O-3 Site | ICD-O-3 Histology | |
|--|-----------------------------|--|
| C000-C809 | 9740-9809, 9840-9992 | Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site |
| C420, C421, C424 | 9811-9818, 9823, 9827, 9837 | Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9820, 9826, 9831-9834 | Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9731, 9732, 9734 | Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has liver metastases; for example, when there is documentation of carcinomatosis but liver is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include liver.

| Code | Description |
|------|---|
| 0 | None; no liver metastases |
| 1 | Yes; distant liver metastases |
| 8 | Not applicable |
| 9 | Unknown whether liver is involved metastatic site Not documented in patient record |

METS AT DIAGNOSIS – LUNG

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #1116
Revised 01/16

Description

This data item identifies whether lung is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited cancer program cancer registries beginning with cases diagnosed January 1, 2016.

Instructions for Coding

1. **Code information about lung metastases only** (discontinuous or distant metastases to lung) identified at the time of diagnosis. This data item should not be coded for pleural or pleural fluid involvement.
 - a. Lung involvement may be single or multiple
 - b. Information about lung involvement may be clinical or pathologic
 - c. Code this data item whether or not the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites

2. **Use of codes.** Assign the code that best describes whether the case has lung metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no lung metastases
 - iii. includes imaging reports that are negative for lung metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but lung is not mentioned as an involved site.
Example: use code 0 when the patient has liver and brain metastases but not lung
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and lung is mentioned as an involved site
 - ii. indicates that lung is the primary site and there are metastases in the contralateral lung
 1. do not assign code 1 for a lung primary with multifocal involvement of the same lung
 - iii. indicates that the patient is diagnosed as an unknown primary (C80.9) and lung is mentioned as a distant metastatic site

- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

| ICD-O-3 Site | ICD-O-3 Histology | |
|--|-----------------------------|--|
| C000-C809 | 9740-9809, 9840-9992 | Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site |
| C420, C421, C424 | 9811-9818, 9823, 9827, 9837 | Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9820, 9826, 9831-9834 | Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9731, 9732, 9734 | Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has lung metastases; for example, when there is documentation of carcinomatosis but lung is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include lung.

| Code | Description |
|------|--|
| 0 | None; no lung metastases |
| 1 | Yes; distant lung metastases |
| 8 | Not applicable |
| 9 | Unknown whether lung is involved metastatic site Not documented in patient record |

METS AT DIAGNOSIS – OTHER

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #1117
Revised 01/16

Description

This data item identifies whether other metastatic involvement, other than bone, brain, liver, lung or distant lymph nodes exists. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, peritoneum and skin. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited cancer program cancer registries beginning with cases diagnosed January 1, 2016.

Instructions for Coding

1. **Code information about other metastases only** (discontinuous or distant metastases) identified at the time of diagnosis. This data item should not be coded for bone, brain, liver, lung or distant lymph node metastases.
 - a. Other involvement may be single or multiple
 - b. Information about other involvement may be clinical or pathologic.
 - c. Code this data item whether or not the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites.

2. **Use of codes.** Assign the code that best describes whether the case has other metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no other metastases
 - iii. includes imaging reports that are negative for other metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but other sites are not mentioned as involved
Example: use code 0 when the patient has lung and liver metastases only
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases in any site(s) other than bone, brain, liver, lung or distant lymph node(s)

- c. Use code 8 (Not applicable) for the following site/histology combination for which a code for distant metastasis is not clinically relevant.

| ICD-O-3 Site | ICD-O-3 Histology | |
|--|-----------------------------|--|
| C000-C809 | 9740-9809, 9840-9992 | Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site |
| C420, C421, C424 | 9811-9818, 9823, 9827, 9837 | Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9820, 9826, 9831-9834 | Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |
| C000-C440, C442-C689, C691-C694, C698-C809 | 9731, 9732, 9734 | Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS |

- d. Use code 9 when it cannot be determined from the medical record whether the patient has metastases other than bone, brain, liver, lung and distant lymph node(s); for example, when there is documentation of carcinomatosis but a specified site is not mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known specifically what they are.

| Code | Description |
|------|---|
| 0 | None; no other metastases |
| 1 | Yes; distant metastases in known site(s) other than bone, brain, liver, lung or distant lymph nodes |
| 8 | Not applicable |
| 9 | Unknown whether any other metastatic site Not documented in patient record |

CLINICAL T

Item Length: 4
Upper-case Alphanumeric
Left Justified
NAACCR Item #940
Revised 9/06, 1/08, 9/8, 1/10, 1/16

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories will be expanded with the implementation of the AJCC 8th Edition Manual.

Instructions for Coding

- The clinical T staging data item must be recorded for *Class of Case* 10-22.
- It is strongly recommended that the clinical T staging data item be recorded for *Class of Case* 00 cases if the patient’s workup at the facility allows coding of clinical T.
- Code clinical T as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical T, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For lung, occult carcinoma is coded cTX.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition |
|---------|---------------|
| (blank) | Not recorded |
| cX | cTX |
| c0 | cT0 |
| pA | pTa |
| pIS | pTis |
| pISU | pTispu |
| pISD | pTispd |
| c1MI | cT1mi, cT1mic |
| c1 | cT1 |
| c1A | cT1a |
| c1A1 | cT1a1 |
| c1A2 | cT1a2 |

| Code | Definition |
|------|------------|
| c1B | cT1b |
| c1B1 | cT1b1 |
| c1B2 | cT1b2 |
| c1C | cT1c |
| c1D | cT1d |
| c2 | cT2 |
| c2A | cT2a |
| c2A1 | cT2a1 |
| c2A2 | cT2a2 |
| c2B | cT2b |
| c2C | cT2c |
| c2D | cT2d |

| Code | Definition |
|------|----------------|
| c3 | cT3 |
| c3A | cT3a |
| c3B | cT3b |
| c3C | cT3c |
| c3D | cT3d |
| c4 | cT4 |
| c4A | cT4a |
| c4B | cT4b |
| c4C | cT4c |
| c4D | cT4d |
| c4E | cT4e |
| 88 | Not applicable |

CLINICAL N

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #950
 Revised 9/06, 1/08, 9/08, 1/10, 1/16

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories will be expanded with the implementation of the AJCC 8th Edition Manual.

Instructions for Coding

- The clinical N staging data item must be recorded for *Class of Case* 10-22.
- It is strongly recommended that the clinical N staging data item be recorded for *Class of Case* 00 cases if the patient’s workup at the facility allows coding of clinical N.
- Record clinical N as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical N, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| cX | cNX |
| c0 | cN0 |
| c0A | cN0a |
| c0B | cN0b |
| c1 | cN1 |
| c1A | cN1a |

| Code | Definition |
|------|------------|
| c1B | cN1b |
| c1C | cN1c |
| c2 | cN2 |
| c2A | cN2a |
| c2B | cN2b |
| c2C | cN2c |
| c3 | cN3 |

| Code | Definition |
|------|----------------|
| c3A | cN3a |
| c3B | cN3b |
| c3C | cN3c |
| c4 | cN4 |
| 88 | Not applicable |

CLINICAL M

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #960
 Revised 9/06, 1/08, 9/08, 1/10, 1/11, 1/16

Description

Identifies the presence or absence of distant metastasis (M) of the tumor known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories will be expanded with the implementation of the AJCC 8th Edition Manual.

Instructions for Coding

- The clinical M staging data item must be recorded for *Class of Case* 10-22.
- It is strongly recommended that the clinical M staging data item be recorded for *Class of Case* 00 cases if the patient’s workup at the facility allows coding of clinical M.
- Record clinical M as documented by the first treating physician or managing physician in the medical record.
- If the managing physician has not recorded clinical M, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| c0 | cM0 |
| c0I+ | cM0(i+) |
| c1 | cM1 |
| c1A | cM1a |
| c1B | cM1b |
| c1C | cM1c |
| c1D | cM1d |
| c1E | cM1e |

| Code | Definition |
|------|----------------|
| p1 | pM1 |
| p1A | pM1a |
| p1B | pM1b |
| p1C | pM1c |
| p1D | pM1d |
| p1E | pM1e |
| 88 | Not applicable |

CLINICAL STAGE GROUP

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #970
 Revised 9/06, 1/08, 9/08, 1/10, 1/11, 1/16

Description

Identifies the anatomic extent of disease based on the T, N, and M data items known *prior* to the start of any therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the clinical stage group as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the clinical stage, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- To assign stage group when some, but not all, T, N and/or M components can be determined, interpret missing components as "X".
- If the value does not fill all 4 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition | Code | Definition | Code | Definition |
|------|------------|------|------------|------|----------------|
| 0 | Stage 0 | 1S | Stage IS | 3C1 | Stage IIIC1 |
| 0A | Stage 0A | 2 | Stage II | 3C2 | Stage IIIC2 |
| 0IS | Stage 0is | 2A | Stage IIA | 4 | Stage IV |
| 1 | Stage I | 2A1 | Stage IIA1 | 4A | Stage IVA |
| 1A | Stage IA | 2A2 | Stage IIA2 | 4A1 | Stage IVA1 |
| 1A1 | Stage IA1 | 2B | Stage IIB | 4A2 | Stage IVA2 |
| 1A2 | Stage IA2 | 2C | Stage IIC | 4B | Stage IVB |
| 1B | Stage IB | 3 | Stage III | 4C | Stage IVC |
| 1B1 | Stage IB1 | 3A | Stage IIIA | OC | Occult |
| 1B2 | Stage IB2 | 3B | Stage IIIB | 88 | Not applicable |
| 1C | Stage IC | 3C | Stage IIIC | 99 | Unknown |

CLINICAL STAGE (PREFIX/SUFFIX) DESCRIPTOR

Item Length: 1

Allowable Values: 0-3, 5, 9

NAACCR Item #980

Revised 09/06, 01/08, 09/08, 01/10, 02/10,
05/10, 01/11, 01/16**Description**

Identifies the AJCC clinical stage (prefix/suffix) descriptor of the tumor *prior* to the start of any therapy. Stage descriptors identify special cases that need separate analysis. The descriptors are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the clinical stage (prefix/suffix) descriptor as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the descriptor, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC manual, leave this data item blank.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.
- Previous editions of FORDS included a code 4 for y-classification, and a note that it was not applicable for clinical stage. Code 4 has been removed from the list of valid codes.

| Code | Label | Description |
|------|--|---|
| 0 | None | There are no prefix or suffix descriptors that would be used for this case. |
| 1 | E–Extranodal, lymphomas only | A lymphoma case involving an extranodal site. |
| 2 | S– Spleen, lymphomas only | A lymphoma case involving the spleen. |
| 3 | M–Multiple primary tumors in a single site | This is one primary with multiple tumors in the primary site at the time of diagnosis. |
| 5 | E&S–Extranodal and spleen, lymphomas only | A lymphoma case with involvement of both an extranodal site and the spleen. |
| 9 | Unknown; not stated in patient record | A prefix or suffix would describe this stage, but it is not known which would be correct. |

STAGED BY (CLINICAL STAGE)

Item Length: 1

Allowable Values: 00, 10-15, 20, 30, 40,
50, 60, 88, 99

NAACCR Item #990

Revised 09/06, 01/08, 09/08, 01/10, 01/16

Description

Identifies the person who assigned the clinical AJCC staging data items and the Stage Group.

Rationale

Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries. Data captured in this data item can be used to evaluate the accuracy and completeness of staging recorded in the registry and form the basis for quality management and improvement studies.

In 2016, this data item was expanded to 2 characters and additional categories were added to document additional, more detailed sources of staging assignment and help in targeting training. The implementation of the new codes included data conversion and redefinition of “unknown” from “unknown stage” to unknown who assigned the stage (“9 - Unknown; not stated in patient record” was converted to “99 - Staged but unknown who assigned stage”.

Instructions for Coding

- Record the role of the person who documented the clinical AJCC staging data items and the Stage Group.
- If code 10-20 is used, then all of the staging elements (T, N, and M) and Stage Group must be assigned by the same person.
- If the tumor was not staged, or stage is unknown, use code 00.
- If the physician who assigned the stage cannot be identified as a surgeon, radiation oncologist, or medical oncologist, use code 10. Examples include: dentist, gynecologist, urologist.
- If it is clear from the treatment provided that the physician providing the stage information is a surgeon use code 11. Example: Urologist provides stage information from surgical resection of tumor – code as surgeon – 11.
- If a pathologist assigns T and/or N, and the registrar determines M and determines the stage group from other portions of the record use code 30.
- If staging was obtained from outside the facility, code the role of the person who staged it if known (codes 10-40); otherwise use code 50.
- If applicable, the Staging Elements (T, N, M) and the Stage Group must be recorded.
 - Exception: Lymphoma does not have TNM elements – only assigning Stage Group is applicable
- The staging source may be different for clinical vs. pathologic stage.

| Code | Label | Definition |
|------|---|---|
| 00 | Not staged | Clinical staging was not assigned ; no information was found in the medical record to assign clinical stage |
| 10 | Physician, NOS, or physician type not specified in codes 11-15 | Clinical staging assigned by a physician not described under codes 11-15 (i.e., cancer committee chair, cancer liaison physician or registry physician advisor) |
| 11 | Surgeon | Clinical staging assigned by the surgeon only. |
| 12 | Radiation Oncologist | Clinical staging assigned by the radiation oncologist only. |
| 13 | Medical Oncologist | Clinical staging assigned by the medical oncologist only. |
| 14 | Pathologist | Clinical staging assigned by the pathologist only. |
| 15 | Multiple Physicians; tumor board, etc. | Clinical staging assigned by multiple physicians such as during a tumor board meeting. |
| 20 | Cancer registrar | Clinical staging assigned by the cancer registrar only. |
| 30 | Cancer registrar and physician | Clinical staging assigned by the cancer registrar and any of the physicians specified in codes 10-15. This would include the cancer registrar assigning the stage and a physician approving it. |
| 40 | Nurse, physician assistant, or other non-physician medical staff | Clinical staging assigned by medical non-physician staff such as a nurse or physician assistant (PA). |
| 50 | Staging assigned at another facility | Clinical staging assigned at another facility, person's role unknown. |
| 60 | Staging by Central Registry including consolidation of multiple sources | Clinical staging assigned by Central Registry personnel based on information from one facility or multiple facilities. |
| 88 | Case is not eligible for staging | The site/histology combination is not defined in the AJCC Manual. |
| 99 | Staged but unknown who assigned stage | A stage was found in the medical record but it is unknown who assigned it. |

Examples:

| | |
|----|--|
| 10 | Initial staging is assigned by the Primary Care General Practitioner. |
| 15 | During tumor conference after discussion among pathologist, radiologist and surgeon the facilitator announces the final TNM and stage group. |
| 30 | Only information on staging in medical record states, T1, nodes negative, registrar enters the listed T, N0 and adds the M and stage group in the abstract. |
| 40 | Nurse practitioner documents all staging elements. |
| 40 | Staging is entered into the medical record by a physician assistant (PA). |
| 50 | Patient transfers to your facility, there is a completed staging form in the chart copies received from the transferring facility, but the staging form is not signed. |
| 60 | Uploaded data to central registry from two facilities; there is no documentation listing staging just a comment saying the patient has a late stage cancer. The central registry enters the TNM and stage group based on the consolidated records from the two facilities. |
| 88 | A child is diagnosed with Neuroblastoma. |

PATHOLOGIC T**Item Length: 4**

Upper-case Alphanumeric

Left Justified

NAACCR Item #880

Revised 9/06, 1/08, 9/08, 1/10, 1/15, 1/16

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories will be expanded with the implementation of the AJCC 8th Edition Manual.

Instructions for Coding

- The pathologic T staging data item must be recorded for *Class of Case* 10-22.
- Code pathologic T as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathologic T, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- Truncate the least significant subdivision of the category from the right as needed.
- For lung, occult carcinoma is coded TX.

| Code | Definition |
|---------|----------------|
| (blank) | Not recorded |
| pX | pTX |
| p0 | pT0 |
| pA | pTa |
| pIS | pTis |
| pISU | pTispu |
| pISD | pTispd |
| p1MI | pT1mi, pT1 mic |
| p1 | pT1 |
| p1A | pT1a |
| p1A1 | pT1a1 |
| p1A2 | pT1a2 |

| Code | Definition |
|------|------------|
| p1B | pT1b |
| p1B1 | pT1b1 |
| p1B2 | pT1b2 |
| p1C | pT1c |
| p1D | pT1d |
| p2 | pT2 |
| p2A | pT2a |
| p2A1 | pT2a1 |
| p2A2 | pT2a2 |
| p2B | pT2b |
| p2C | pT2c |
| p2D | pT2d |

| Code | Definition |
|------|----------------|
| p3 | pT3 |
| p3A | pT3a |
| p3B | pT3b |
| p3C | pT3c |
| p3D | pT3d |
| p4 | pT4 |
| p4A | pT4a |
| p4B | pT4b |
| p4C | pT4c |
| p4D | pT4d |
| p4E | pT4e |
| 88 | Not applicable |

PATHOLOGIC N

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #890
 Revised 9/06, 1/08, 9/08, 1/10, 1/15, 1/16

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories will be expanded with the implementation of the AJCC 8th Edition Manual.

Instructions for Coding

- The pathologic N staging data item must be recorded for *Class of Case* 10-22.
- Code pathologic N as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded pathologic N, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are considered as “impossible diagnoses” in the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- Use of the new category of cN0 for this data item is limited to in situ tumors only in 2016.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| pX | pNX |
| c0 | cN0 |
| p0 | pN0 |
| p0I- | pN0i- |
| p0I+ | pN0i+ |
| p0M- | pN0m- |
| p0M+ | pN0m+ |
| p1MI | pN1mi |

| Code | Definition |
|------|------------|
| p0A | pN0a |
| p0B | pN0b |
| p1 | pN1 |
| p1A | pN1a |
| p1B | pN1b |
| p1C | pN1c |
| p2 | pN2 |
| p2A | pN2a |
| p2B | pN2b |

| Code | Definition |
|------|----------------|
| p2C | pN2c |
| p3 | pN3 |
| p3A | pN3a |
| p3B | pN3b |
| p3C | pN3c |
| p4 | pN4 |
| 88 | Not applicable |

PATHOLOGIC M

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #900
 Revised 9/06, 1/08, 9/08, 1/10, 1/15, 1/16

Description

Identifies the presence or absence of distant metastasis (M) of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories will be expanded with the implementation of the AJCC 8th Edition Manual.

Instructions for Coding

- The pathologic M staging data item must be recorded for *Class of Case* 10-22.
- Code pathologic M as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathologic M, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are considered as “impossible diagnoses” in the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| c0 | cM0 |
| c0I+ | cM0(i+) |
| p1 | pM1 |
| p1A | pM1a |
| p1B | pM1b |

| Code | Definition |
|------|------------|
| p1C | pM1c |
| p1D | pM1d |
| p1E | pM1e |
| c1 | cM1 |
| c1A | cM1a |
| c1B | cM1b |

| Code | Definition |
|------|----------------|
| c1C | cM1c |
| c1D | cM1d |
| c1E | cM1e |
| 88 | Not applicable |

PATHOLOGIC STAGE GROUP

Item Length: 4
 Upper-case Alphanumeric
 Left Justified
 NAACCR Item #910
 Revised 09/06, 01/08, 09/08, 01/10, 01/11, 01/15

Description

Identifies the anatomic extent of disease based on the T, N, and M data items known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the pathologic stage group as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the pathologic stage, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- To assign stage group when some, but not all, T, N and/or M components can be determined, interpret missing components as "X".
- If pathologic M (NAACCR Item #900) is coded as either X or blank and clinical M (NAACCR Item #960) is coded as 0, 1, 1A, 1B, or 1C, then the combination of staging data items pT, pN, and cM (NAACCR Item #880, 890, 960) may be used to complete the pathologic stage group.
- If the value does not fill all 4 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Definition | Code | Definition | Code | Definition |
|------|------------|------|------------|------|----------------|
| 0 | Stage 0 | 1S | Stage IS | 3C1 | Stage IIIC1 |
| 0A | Stage 0A | 2 | Stage II | 3C2 | Stage IIIC2 |
| 0IS | Stage 0is | 2A | Stage IIA | 4 | Stage IV |
| 1 | Stage I | 2A1 | Stage IIA1 | 4A | Stage IVA |
| 1A | Stage IA | 2A2 | Stage IIA2 | 4A1 | Stage IVA1 |
| 1A1 | Stage IA1 | 2B | Stage IIB | 4A2 | Stage IVA2 |
| 1A2 | Stage IA2 | 2C | Stage IIC | 4B | Stage IVB |
| 1B | Stage IB | 3 | Stage III | 4C | Stage IVC |
| 1B1 | Stage IB1 | 3A | Stage IIIA | OC | Occult |
| 1B2 | Stage IB2 | 3B | Stage IIIB | 88 | Not applicable |
| 1C | Stage IC | 3C | Stage IIIC | 99 | Unknown |

PATHOLOGIC STAGE (PREFIX/SUFFIX) DESCRIPTOR

Item Length: 1
 Allowable Values: 0–6, 9
 NAACCR Item #920
 Revised 9/06, 1/08, 1/10, 1/14, 1/16

Description

Identifies the AJCC pathologic stage (prefix/suffix) descriptor known *following* the completion surgical therapy.

Rationale

Stage descriptors identify special cases that need separate analysis. The descriptors are adjuncts to and do not change the stage group. The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Instructions for Coding

- Record the pathologic stage (prefix/suffix) descriptor as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the descriptor, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- If the tumor is not staged using AJCC rules, leave this data item blank.
- Refer to the current *AJCC Cancer Staging Manual* for staging rules.

| Code | Label | Definition |
|------|---|--|
| 0 | None | There are no prefix or suffix descriptors that would be used for this case. |
| 1 | E–Extranodal, lymphomas only | A lymphoma case involving an extranodal site. |
| 2 | S–Spleen, lymphomas only | A lymphoma case involving the spleen. |
| 3 | M–Multiple primary tumors in a single site | This is one primary with multiple tumors in the organ of origin at the time of diagnosis . |
| 4 | Y–Classification after initial multimodality therapy | Neoadjuvant treatment given before staging |
| 5 | E&S–Extranodal and spleen, lymphomas only | A lymphoma case with involvement of both an extranodal site and the spleen. |
| 6 | M&Y–Multiple primary tumors and initial multimodality therapy | A case meeting the parameters of both codes 3 (multiple primary tumors in a single site) and 4 (classification after initial multimodality therapy). |
| 9 | Unknown; not stated in patient record | A prefix or suffix would describe this stage, but it is not known which would be correct. |

STAGED BY (PATHOLOGIC STAGE)

Item Length: 1

Allowable Values: 0–9

NAACCR Item #930

Revised 09/06, 01/08, 09/08, 01/10, 01/16

Description

Identifies the person who recorded the pathologic AJCC staging data items.

Rationale

Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. Data captured in this data item can be used to evaluate the accuracy and completeness of staging recorded in the registry and form the basis for quality management and improvement studies.

In 2016, this data item was expanded to 2 characters and additional categories were added to document additional, more detailed sources of staging assignment and help in targeting training. The implementation of the new codes included data conversion and redefinition of “unknown” from “unknown stage” to unknown who assigned the stage (“9 - Unknown; not stated in patient record” was converted to “99 - Staged but unknown who assigned stage”).

Instructions for Coding

- Record the role of the person who documented the pathologic AJCC staging data items and the Stage Group.
- If the case does not meet the criteria for pathologic staging, the tumor was not staged, or stage is unknown, use code 00.
- If code 10-20 is used, then all of the staging elements (T, N, and M) and Stage Group must be assigned by the same person.
- If the physician who assigned the stage cannot be identified as a surgeon, radiation oncologist, or medical oncologist, use code 10. Examples include: dentist, gynecologist, urologist.
- If it is clear from the treatment provided that the physician providing the stage information is a surgeon use code 11. Example: Urologist provides stage information from surgical resection of tumor – code as surgeon – 11.
- If a pathologist assigns T and/or N, and the registrar determines M and determines the stage group from other portions of the record use code 30.
- If staging was obtained from outside the facility, code the role of the person who staged it if known (codes 10-40); otherwise use code 50.
- If applicable, the Staging Elements (T, N, M) and the Stage Group must be recorded.
 - Exception: Lymphoma does not have TNM elements – only assigning Stage Group is applicable
- The staging source may be different for clinical vs. pathologic stage.

| Code | Label | Definition |
|------|---|---|
| 00 | Not staged | Pathologic staging was not assigned; no information was found in the medical record to assign pathologic stage |
| 10 | Physician, NOS, or physician type not specified in codes 11-15 | Pathologic staging assigned by a physician not described under codes 11-15 (i.e., cancer committee chair, cancer liaison physician or registry physician advisor) |
| 11 | Surgeon | Pathologic staging assigned by the surgeon only. |
| 12 | Radiation Oncologist | Pathologic staging assigned by the radiation oncologist only. |
| 13 | Medical Oncologist | Pathologic staging assigned by the medical oncologist only. |
| 14 | Pathologist | Pathologic staging assigned by the pathologist only. |
| 15 | Multiple Physicians; tumor board, etc. | Pathologic staging assigned by multiple physicians such as during a tumor board meeting. |
| 20 | Cancer registrar | Pathologic staging assigned by the cancer registrar only. |
| 30 | Cancer registrar and physician | Pathologic staging assigned by the cancer registrar and any of the physicians specified in codes 10-15. This would include the cancer registrar assigning the stage and a physician approving it. |
| 40 | Nurse, physician assistant, or other non-physician medical staff | Pathologic staging assigned by medical non-physician staff such as a nurse or physician assistant (PA). |
| 50 | Staging assigned at another facility | Pathologic staging assigned at another facility, person's role unknown. |
| 60 | Staging by Central Registry including consolidation of multiple sources | Pathologic staging assigned by Central Registry personnel based on information from one facility or multiple facilities. |
| 88 | Case is not eligible for staging | An AJCC staging scheme has not been developed for this site. The histology is excluded from an AJCC site scheme. |
| 99 | Staged but unknown who assigned stage | A stage was found in the medical record but it is unknown who assigned it. |

SEER SUMMARY STAGE 2000

Item Length: 1
 Allowable Values: 0-5, 7, 8, 9
 NAACCR Item #759
 Revised 01/16

Description

Code for summary stage at the initial diagnosis or treatment of the reportable tumor. Summary stage should include all information available through completion of surgery(ies) in the first course of treatment or within 4 months of diagnosis in the absence of disease progression, whichever is longer.

Rationale

Stage information is important when evaluating the effects of cancer control programs. It is crucial in understanding whether changes over time in incidence rates or outcomes are due to earlier detection of the cancers. In addition, cancer treatment cannot be studied without knowing the stage at diagnosis.

From 2004 through 2015, CoC relied on the item Derived SS2000 [3020] for the value of SEER Summary Stage 2000 as generated by the collaborative Staging algorithm. Effective with cases diagnosed January 1, 2016 the CoC requires that directly-assigned SEER Summary Stage be recorded in its accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific definitions of categories and coding instructions in the [SEER Summary Staging Manual 2000](#).
- Use Code 8 for benign and borderline brain/CNS cases

| Code | Description |
|------|---|
| 0 | In situ |
| 1 | Localized |
| 2 | Regional, direct extension only |
| 3 | Regional, regional lymph nodes only |
| 4 | Regional, direct extension and regional lymph nodes |
| 5 | Regional, NOS |
| 7 | Distant |
| 8 | Not applicable |
| 9 | Unstaged |

Collaborative Stage Input Data Items

Recorded for Cases Diagnosed 2004 through 2015 Only

CS TUMOR SIZE

Item Length: 3

Allowable Values: 000–995, 999

NAACCR Item #2800

Revised 09/06, 09/08, 01/10, 01/11

Description

Records the largest dimension or diameter of the **primary tumor** in millimeters.

Rationale

Tumor size at diagnosis is an independent prognostic indicator for many tumors and it is used by Collaborative Stage to derive some TNM-T codes. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS EXTENSION

Item Length: 2

Allowable Values: 00–80, 95, 99

NAACCR Item #2810

Revised 09/06, 09/08, 01/10, 01/11

Description

Identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs. For certain sites such as ovary, discontinuous metastasis is coded in *CS Extension*.

Rationale

Tumor extension at diagnosis is a prognostic indicator used by Collaborative Stage to derive some TNM-T codes and some SEER Summary Stage codes. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS TUMOR SIZE/EXT EVAL

Item Length: 1

Allowable Values: 0–3, 5, 6, 8, 9

NAACCR Item #2820

Revised 09/06, 09/08, 01/10, 01/11

Description

Records how the codes for the two items *CS Tumor Size* (NAACCR Item #2800) and *CS Extension* (NAACCR Item #2810) were determined, based on the diagnostic methods employed.

Rationale

This item is used by Collaborative Stage to describe whether the staging basis for the TNM-T code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS LYMPH NODES

Item Length: 2

Allowable Values: 00–80, 90

NAACCR Item #2830

Revised 09/06, 09/08, 01/10, 01/11

Description

Identifies the regional lymph nodes involved with cancer at the time of diagnosis.

Rationale

The involvement of specific regional lymph nodes is a prognostic indicator used by Collaborative Stage to derive some TNM-N codes and SEER Summary Stage codes. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

**CS LYMPH NODES EVAL
(CS REG NODES EVAL)**

Item Length: 1
Allowable Values: 0–3, 5, 6, 8, 9
NAACCR Item #2840
Revised 09/06, 09/08, 01/10, 01/11

Description

Records how the code for *CS Lymph Nodes* (NAACCR Item #2830) was determined, based on the diagnostic methods employed.

Rationale

This data item is used by Collaborative Stage to describe whether the staging basis for the TNM-N code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX

Item Length: 2

Allowable Values: site-specific

NAACCR Item #2850

Revised 09/06, 09/08, 01/10, 01/11, 01/14

Description

Identifies the distant site(s) of metastatic involvement at time of diagnosis.

Rationale

The presence of metastatic disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage to derive TNM-M codes and SEER Summary Stage codes. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–BONE

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #2851
Revised 01/11

Description

Identifies the presence of distant metastatic involvement of bone at time of diagnosis.

Rationale

The presence of metastatic bone disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage to derive TNM-M codes and SEER Summary Stage codes for some sites. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–BRAIN

Item Length: 1
Allowable Values: 0, 1, 8, 9
NAACCR Item #2852
Revised 01/11

Description

Identifies the presence of distant metastatic involvement of the brain at time of diagnosis.

Rationale

The presence of metastatic brain disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage to derive TNM-M codes and SEER Summary Stage codes for some sites. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–LIVER

Item Length: 1

Allowable Values: 0, 1, 8, 9

NAACCR Item #2853

Revised 01/11

Description

Identifies the presence of distant metastatic involvement of the liver at time of diagnosis.

Rationale

The presence of metastatic liver disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage to derive TNM-M codes and SEER Summary Stage codes for some sites. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS AT DX–LUNG

Item Length: 1

Allowable Values: 0, 1, 8, 9

NAACCR Item #2854

Revised 01/11

Description

Identifies the presence of distant metastatic involvement of the lung at time of diagnosis.

Rationale

The presence of metastatic lung disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage to derive TNM-M codes and SEER Summary Stage codes for some sites. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

CS METS EVAL

Item Length: 1

Allowable Values: 0–3, 5, 6, 8, 9

NAACCR Item #2860

Revised 09/06, 09/08, 01/10, 01/11

Description

Records how the code for *CS Mets at Dx* (NAACCR Item #2850) was determined based on the diagnostic methods employed.

Rationale

This data item is used by Collaborative Stage to describe whether the staging basis for the TNM-M code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging. Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.

Collaborative Stage Site-Specific Factors

Recorded for Cases Diagnosed 2004+

CS SITE-SPECIFIC FACTOR 1

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2880
Revised 04/07, 09/08, 01/10, 02/10,
03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 2

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2890

Revised 09/06, 09/08, 01/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 3

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2900

Revised 04/07, 09/08, 01/10, 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 4

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2910
Revised 09/06, 09/08, 01/10, 02/10,
03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 5

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2920
Revised 09/06, 09/08, 01/10, 02/10,
03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 6

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2930
Revised 09/06, 09/08, 01/10, 02/10,
03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 7

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2861

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 8

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2862
Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 9

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2863

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 10

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2864

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 11

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2865

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 12

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2866

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 13

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2867

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 14

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2868

Revised 02/10, 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 15

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2869

Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 16

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2870
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 17

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2871
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 18

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2872
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 19

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2873
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 20

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2874
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 21

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2875
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 22

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2876
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 23

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2877
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 24

Item Length: 3
Allowable Values: 000–999
NAACCR Item #2878
Revised 03/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- CoC does not require that registrars report information for this item that is not readily available in the facility's records. However, if that information is obtained along with other material from another source, it may be used.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

CS SITE-SPECIFIC FACTOR 25

Item Length: 3

Allowable Values: 000–999

NAACCR Item #2879

Revised 02/10, 01/11, 01/12

Description

Identifies additional information needed to generate stage, or prognostic factors that have an effect on stage or survival.

Rationale

CS Site-Specific Factor 25 is used to discriminate between CS staging schema (for cases diagnosed from 2004 through 2015 only) or between AJCC chapters for cases where site and histology alone are insufficient to identify the tumor type or location to identify the applicable staging method. Use of this item is limited to specific subsites and histologies as shown below.

Instructions for Coding

- Refer to the site and histology-specific instructions in the current *CS Manual* for coding instructions.
- Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

Collaborative Stage Derived Data Items

Derived and Recorded for Cases Diagnosed 2004-2015

DERIVED AJCC-6 T

Item Length: 2
NAACCR Item #2940
Revised 09/08, 01/10

Description

This item is the derived AJCC “T” staging data item from coded data items using the CS algorithm.

Rationale

Derived AJCC-6 T can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “T” descriptions.

DERIVED AJCC-6 T DESCRIPT

Item Length: 1
 NAACCR Item #2950
 Revised 09/04, 01/10

Description

This item is the derived AJCC “T Descriptor” from coded data items using the CS algorithm.

Rationale

Derived AJCC-6 T Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

| Code | Description |
|------|--|
| c | Clinical stage. |
| p | Pathologic stage. |
| a | Autopsy stage. |
| y | Surgical resection performed after pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence. |
| N | Not applicable. |
| 0 | Not derived. |

DERIVED AJCC-6 N

Item Length: 2
NAACCR Item #2960
Revised 01/10

Description

This item is the derived AJCC “N” staging data item from coded data items using the CS algorithm.

Rationale

The CS *Derived AJCC-6 N* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “N” descriptions.

DERIVED AJCC-6 N DESCRIPT

Item Length: 1
 NAACCR Item #2970
 Revised 09/04, 01/10

Description

This item is the derived AJCC “N Descriptor” from coded data items using the CS algorithm.

Rationale

Derived AJCC-6 N Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

| Code | Description |
|------|---|
| c | Clinical stage. |
| p | Pathologic stage. |
| a | Autopsy stage. |
| y | Lymph nodes removed for examination after pre-surgical systemic treatment or radiation and lymph node evaluation based on pathologic evidence. |
| N | Not applicable. |
| 0 | Not derived. |

DERIVED AJCC-6 M

Item Length: 2
NAACCR Item #2980
Revised 01/10

Description

This item is the derived AJCC “M” staging data item from coded data items using the CS algorithm.

Rationale

Derived AJCC-6 M can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific “M” descriptions.

DERIVED AJCC-6 M DESCRIPT

Item Length: 1
 NAACCR Item #2990
 Revised 09/04, 01/10

Description

This item is the derived AJCC “M Descriptor” from coded data items using the CS algorithm.

Rationale

Derived AJCC-6 M Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

| Code | Description |
|------|---|
| c | Clinical stage. |
| p | Pathologic stage. |
| a | Autopsy stage. |
| y | Pathologic examination of metastatic tissue performed after pre-surgical systemic treatment or radiation and extension based on pathologic evidence. |
| N | Not applicable. |
| 0 | Not derived. |

DERIVED AJCC-6 STAGE GROUP

Item Length: 2
NAACCR Item #3000
Revised 01/10, 01/11

Description

This item is the derived AJCC “Stage Group” from coded data items using the CS algorithm.

Rationale

The *CS Derived AJCC-6 Stage Group* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 6th Edition* for the site-specific Stage Group descriptions.

DERIVED AJCC-7 T

Item Length: 2
NAACCR Item #3400
New Item 01/10, 01/16

Description

This item is the derived AJCC “T” staging data item from coded data items using the CS algorithm.

Rationale

Derived AJCC-7 T can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “T” descriptions.

DERIVED AJCC-7 T DESCRIPT

Item Length: 1
 NAACCR Item #3402
 New Item 01/10, 01/16

Description

This item is the derived AJCC “T Descriptor” from coded data items using the CS algorithm.

Rationale

Derived AJCC-7 T Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

| Code | Description |
|------|--|
| c | Clinical stage. |
| p | Pathologic stage. |
| a | Autopsy stage. |
| y | Surgical resection performed after pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence. |
| N | Not applicable. |
| 0 | Not derived. |

DERIVED AJCC-7 N

Item Length: 2
NAACCR Item #3410
New Item 01/10, 01/16

Description

This item is the derived AJCC “N” staging data item from coded data items using the CS algorithm.

Rationale

The CS *Derived AJCC-7 N* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “N” descriptions.

DERIVED AJCC-7 N DESCRIPT

Item Length: 1
 NAACCR Item #3412
 New Item 01/10, 01/16

Description

This item is the derived AJCC “N Descriptor” from coded data items using the CS algorithm.

Rationale

Derived AJCC-7 N Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

| Code | Description |
|------|---|
| c | Clinical stage. |
| p | Pathologic stage. |
| a | Autopsy stage. |
| y | Lymph nodes removed for examination after pre-surgical systemic treatment or radiation and lymph node evaluation based on pathologic evidence. |
| N | Not applicable. |
| 0 | Not derived. |

DERIVED AJCC-7 M

Item Length: 2
NAACCR Item #3420
New Item 01/10, 01/16

Description

This item is the derived AJCC “M” staging data item from coded data items using the CS algorithm.

Rationale

Derived AJCC-7 M can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific “M” descriptions.

DERIVED AJCC-7 M DESCRIPT

Item Length: 1
 NAACCR Item #3422
 New Item 01/10, 01/16

Description

This item is the derived AJCC “M Descriptor” from coded data items using the CS algorithm.

Rationale

Derived AJCC-7 M Descript can be used in analysis to differentiate the timing of staging with respect to the treatment process.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for prefix definitions for codes c, p, a, and y.
- Refer to the current *CS Manual* for the calculation procedures for all codes.

| Code | Description |
|------|---|
| c | Clinical stage. |
| p | Pathologic stage. |
| a | Autopsy stage. |
| y | Pathologic examination of metastatic tissue performed after pre-surgical systemic treatment or radiation and extension based on pathologic evidence. |
| N | Not applicable. |
| 0 | Not derived. |

DERIVED AJCC-7 STAGE GROUP

Item Length: 2
NAACCR Item #3430
Revised 01/11, 01/16

Description

This item is the derived AJCC “Stage Group” from coded data items using the CS algorithm.

Rationale

The CS *Derived AJCC-7 Stage Group* can be used to evaluate disease spread at diagnosis, plan and track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- This data item is autocoded and is not recorded by registry staff.
- The two-digit storage codes are designed for analytic purposes.
- Refer to the current *CS Manual* for the display equivalent of the storage codes.
- Refer to the *AJCC Cancer Staging Manual, 7th Edition* for the site-specific Stage Group descriptions.

DERIVED SS1977

Item Length: 1
 Allowable Values: 0–5, 7, 9
 NAACCR Item #3010
 Revised 09/08, 01/10, 01/16

Description

This item is the derived “SEER Summary Stage 1977” from the CS algorithm.

Rationale

Derived SS1977 can be used to evaluate patterns of disease spread at diagnosis, track treatment patterns, and analyze outcomes, especially when comparing or combining cases diagnosed prior to 2001 (when an updated version was implemented) with those diagnosed later.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- Refer to the *SEER Summary Staging Manual, 1977* for descriptions of the site-specific categories.
- Refer to the current *CS Manual* for the calculation procedures for this item.

| Code | Description |
|---------|--|
| 0 | In situ |
| 1 | Localized |
| 2 | Regional, direct extension only. |
| 3 | Regional, regional lymph nodes only. |
| 4 | Regional, direct extension and regional lymph nodes. |
| 5 | Regional, NOS. |
| 7 | Distant metastases/systemic disease. |
| 8 | Not applicable |
| 9 | Unstaged, unknown, or unspecified. |
| (blank) | Not derived. |

DERIVED SS2000

Item Length: 1
 Allowable Values: 0–5, 7, 9
 NAACCR Item #3020
 Revised 09/08, 01/10, 01/16

Description

This item is the derived “SEER Summary Stage 2000” from the CS algorithm.

Rationale

Derived SS2000 can be used to evaluate patterns of disease spread at diagnosis, track treatment patterns, and analyze outcomes.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

- Refer to the *SEER Summary Staging Manual, 2000* for descriptions of the site-specific categories.
- Refer to the current *CS Manual* for the calculation procedures for this item.

| Code | Description |
|---------|--|
| 0 | In situ |
| 1 | Localized |
| 2 | Regional, direct extension only. |
| 3 | Regional, regional lymph nodes only. |
| 4 | Regional, direct extension and regional lymph nodes. |
| 5 | Regional, NOS. |
| 7 | Distant metastases/systemic disease. |
| 8 | Not applicable |
| 9 | Unstaged, unknown, or unspecified. |
| (blank) | Not derived. |

First Course of Treatment

DATE OF FIRST COURSE OF TREATMENT

Item Length: 8
 NAACCR Item #1270
 Revised 01/10, 01/11

Description

Records the date on which treatment (surgery, radiation, systemic, or other therapy) of the patient began at any facility.

Rationale

It is important to be able to measure the delay between diagnosis and the onset of treatment. A secondary use for this date is as a starting point for survival statistics (rather than using the diagnosis date). This date cannot be calculated from the respective first course treatment modality dates if no treatment was given. Therefore, providing the date on which active surveillance is chosen, a physician decides not to treat a patient, or a patient's family or guardian declines treatment is important.

Instructions for Coding

- Record the earliest of the following dates: *Date of First Surgical Procedure* (NAACCR Item #1200), *Date Radiation Started* (NAACCR Item #1210), *Date Systemic Therapy Started* (NAACCR Item #3230), or *Date Other Treatment Started* (NAACCR Item #1250).
- If active surveillance or watchful waiting is selected as the first course of treatment (*RX Summ–Treatment Status* [NAACCR Item #1285] = 2) record the date this decision is made.
- In cases of nontreatment (*RX Summ–Treatment Status* [NAACCR Item #1285] = 0), in which a physician decides not to treat a patient or a patient's family or guardian declines all treatment, the date of first course of treatment is the date this decision was made.
- Leave this item blank if the cancer was diagnosed at autopsy and not suspected prior to that.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Course of Treatment* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Course of Treatment* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Date 1st Crs Rx Flag* (NAACCR Item #1271) is used to explain why *Date of First Course of Treatment* is not a known date. See *Date 1st Crs Rx Flag* for an illustration of the relationships among these items.

Examples

| | |
|---|-------------------|
| A patient has a core biopsy on February 12, 2004, and subsequently undergoes an excisional biopsy on February 14, 2004 | February 14, 2004 |
| A patient begins receiving preoperative radiation therapy elsewhere on April 21, 2005, and subsequent surgical therapy at this facility on June 2, 2005 | April 21, 2005 |

DATE 1st CRS RX FLAG

Item Length: 2
 NAACCR Item #1271
 Valid Codes: 10-12, Blank
 Revised 01/12, 01/15

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Course of Treatment* (NAACCR Item #1270).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of First Course of Treatment* (NAACCR Item #1270) has a full or partial date recorded.
- Code 12 if the *Date of First Course of Treatment* can not be determined at all, but the patient did receive first course treatment.
- Code 12 if a decision not to treat was made, but the date is totally unknown.
- Code 12 if a decision to use active surveillance was made, but the date is totally unknown.
- Code 10 if it is unknown whether any treatment was administered.
- Code 11 if the initial diagnosis was at autopsy.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Definition |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any treatment was given). |
| 11 | No proper value is applicable in this context (that is, autopsy only). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (for example, treatment was given but the date is unknown). |
| (blank) | A valid date value is provided in item <i>Date of First Course of Treatment</i> (NAACCR Item #1270). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Course of Treatment* (NAACCR Item #1270) and *Date 1st Crs Rx Flag* (NAACCR Item #1271). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date of First Course of Treatment | Interoperable Date of First Course of Treatment | Date 1 st Crs Rx Flag |
|----------------------------------|---|--|----------------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any treatment given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| Diagnosis at autopsy only | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, treatment given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

RX SUMM – TREATMENT STATUS

Item Length: 1
 Allowable Values: 0-2, 9
 NAACCR Item #1285
 Revised 01/11

Description

This data item summarizes whether the patient received any treatment or the tumor was under active surveillance.

Rationale

This item documents active surveillance (watchful waiting) and eliminate searching each treatment modality to determine whether treatment was given. It is used in conjunction with *Date of First Course of Treatment* [NAACCR Item #1270] to document whether treatment was or was not given, it is unknown if treatment was given, or treatment was given on an unknown date.

Instructions for Coding

- This item may be left blank for cases diagnosed prior to 2010.
- Treatment given after a period of active surveillance is considered subsequent treatment and it not coded in this item.
- Use code 0 when treatment is refused or the physician decides not to treat for any reason such as the presence of comorbidities.

| Code | Definition |
|------|--|
| 0 | No treatment given |
| 1 | Treatment given |
| 2 | Active surveillance (watchful waiting) |
| 9 | Unknown if treatment was given |

Examples:

| Code | Reason |
|------|---|
| 0 | An elderly patient with pancreatic cancer requested no treatment. |
| 0 | Patient is expected to receive radiation, but it has not occurred yet (<i>Reason for No Radiation</i> [NAACCR Item #1430] = 8) |
| 2 | Treatment plan for a lymphoma patient is active surveillance. |

DATE OF FIRST SURGICAL PROCEDURE

Item Length: 8
 NAACCR Item #1200
 Revised 01/10, 01/11

Description

Records the earliest date on which any first course surgical procedure was performed. Formerly called “Date of Cancer-Directed Surgery.”

Rationale

This item can be used to sequence multiple treatment modalities and to evaluate the time intervals between treatments.

Instructions for Coding

- Record the date of the first surgical procedure of the types coded as *Surgical Procedure of Primary Site* (NAACCR Item #1290), *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Surgical Procedure/Other Site* (NAACCR Item #1294) performed at this or any facility.
- The date in this item may be the same as that in *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170), if the patient received only one surgical procedure and it was a resection of the primary site.
- If surgery is the first or only treatment administered to the patient, then the date of surgery should be the same as the date entered into the item *Date of First Course Treatment* (NAACCR Item #1270).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Surgical Procedure* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Surgical Procedure* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Rx Date–Surgery Flag* (NAACCR Item #1201) is used to explain why *Date of First Surgical Procedure* is not a known date. See *Rx Date–Surgery Flag* for an illustration of the relationships among these items.

Examples

| | |
|--|-------------------|
| A melanoma patient had an excisional biopsy on March 23, 2008, then a wide excision on March 28, 2008. | March 23, 2008 |
| The patient had a small (0.5 cm) lump removed from her breast on November 16, 2009. | November 16, 2009 |
| The patient’s primary tumor was treated with radiation beginning on April 16, 2007, after a distant metastasis was removed surgically on March 27, 2007. | March 27, 2007 |

RX DATE–SURGERY FLAG

Item Length: 2
 NAACCR Item #1201
 Valid Codes: 10-12, Blank
 New Item: 1/1/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Surgical Procedure* (NAACCR Item #1200).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of First Surgical Procedure* (NAACCR Item #1200) has a full or partial date recorded.
- Code 12 if the *Date of First Surgical Procedure* can not be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Definition |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery performed). |
| 11 | No proper value is applicable in this context (for example, no surgery performed). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown). |
| (blank) | A valid date value is provided in item <i>Date of First Surgical Procedure</i> (NAACCR Item #1200). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Surgical Procedure* (NAACCR Item #1200) and *Rx Date–Surgery Flag* (NAACCR Item #1201). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date of First Surgical Procedure | Interoperable Date of First Surgical Procedure | Rx Date–Surgery Flag |
|------------------------------------|---|--|----------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No surgery performed | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

**DATE OF MOST DEFINITIVE SURGICAL RESECTION
OF THE PRIMARY SITE**

Item Length: 8
NAACCR Item #3170
Revised 09/08, 01/10, 01/11

Description

Records the date of the most definitive surgical procedure of the primary site performed as part of the first course of treatment.

Rationale

This item is used to measure the lag time between diagnosis and the most definitive surgery of the primary site. It is also used in conjunction with *Date of Surgical Discharge* (NAACCR Item #3180) to calculate the duration of hospitalization following the most definitive primary site surgical procedure. This can then be used to evaluate treatment efficacy.

Instructions for Coding

- Record the date on which the surgery described by *Surgical Procedure of Primary Site* (NAACCR Item #1290) was performed at this or any facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Most Definitive Surgical Resection of the Primary Site* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Most Definitive Surgical Resection of the Primary Site* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date Mst Defn Srg Flag* (NAACCR Item #3171) is used to explain why *Date of Most Definitive Surgical Resection of the Primary Site* is not a known date. See *RX Date Mst Defn Srg Flag* for an illustration of the relationships among these items.

RX DATE MST DEFN SRG FLAG

Item Length: 2
 NAACCR Item #3171
 Valid Codes: 10-12, Blank
 Revised 01/11

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170) has a full or partial date recorded.
- Code 12 if the *Date of Most Definitive Surgical Resection of the Primary Site* can not be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2003.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery performed). |
| 11 | No proper value is applicable in this context (for example, no surgery performed). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown). |
| (blank) | A valid date value is provided in item <i>Date of Most Definitive Surgical Resection of the Primary Site</i> (NAACCR Item #3170). Case was diagnosed prior to January 1, 2003. |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170) and *Rx Date Mst Defn Srg Flag* (NAACCR Item #3171). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date of Most Definitive Surgical Resection of the Primary Site | Interoperable Date of Most Definitive Surgical Resection of the Primary Site | Rx Date Mst Defn Srg Flag |
|---|---|--|---------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No surgery performed | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

SURGICAL PROCEDURE OF PRIMARY SITE

Item Length: 2

Allowable Values: 00, 10B80, 90, 98, 99

L/R Justified, Zero-filled

NAACCR Item #1290

Revised 06/05, 01/10, 01/12, 01/15

Description

Records the surgical procedure(s) performed to the primary site.

Rationale

This data item can be used to compare the efficacy of treatment options.

Instructions for Coding

- Site-specific codes for this data item are found in Appendix B.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* data item (NAACCR Item #1290).
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in Appendix B.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

| Code | Label | Definition |
|-------|--|---|
| 00 | None | No surgical procedure of primary site. Diagnosed at autopsy. |
| 10–19 | Site-specific codes; tumor destruction | Tumor destruction, no pathologic specimen produced. Refer to Appendix B for the correct site-specific code for the procedure. |
| 20–80 | Site-specific codes; resection | Refer to Appendix B for the correct site-specific code for the procedure. |
| 90 | Surgery, NOS | A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided. |
| 98 | Site-specific codes; special | Special code. Refer to Appendix B for the correct site-specific code for the procedure. |
| 99 | Unknown | Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only. |

SURGICAL PROCEDURE OF PRIMARY SITE AT THIS FACILITY Item Length: 2

Allowable Values: 00, 10-80, 90, 98, 99

L/R Justified, Zero-filled

NAACCR Item #670

Revised 09/04, 01/10, 01/12, 01/15

Description

Records the surgical procedure(s) performed to the primary site at this facility.

Rationale

This data item can be used to compare the efficacy of treatment options.

Instructions for Coding

- Site-specific codes for this data item are found in Appendix B.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be collected, this item refers to the most invasive surgical procedure for the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* data item (NAACCR Item #1290).
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* (NAACCR Item #3280).

| Code | Label | Definition |
|-------|--|---|
| 00 | None | No surgical procedure of primary site. Diagnosed at autopsy. |
| 10–19 | Site-specific codes; tumor destruction | Tumor destruction, no pathologic specimen produced. Refer to Appendix B for the correct site-specific code for the procedure. |
| 20–80 | Site-specific codes; resection | Refer to Appendix B for the correct site-specific code for the procedure. |
| 90 | Surgery, NOS | A surgical procedure to primary site was done, but no information on the type of surgical procedure is provided. |
| 98 | Site-specific codes; special | Special code. Refer to Appendix B for the correct site-specific code for the procedure. |
| 99 | Unknown | Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only. |

**APPROACH – SURGERY OF THE PRIMARY SITE AT THIS FACILITY
(RX HOSP – SURG APP 2010)**

Item Length: 1
Allowable Values: 0-5, 9
NAACCR Item #668
Revised 05/10, 01/11, 01/13, 01/15

Description

This item is used to describe the surgical method used to approach the primary site for patients undergoing surgery of the primary site at this facility.

Rationale

This item is used to monitor patterns and trends in the adoption and utilization of minimally-invasive surgical techniques.

Instructions for Coding

- This item may be left blank for cases diagnosed prior to 2010.
- If the patient has multiple surgeries of the primary site, this item describes the approach used for the most invasive, definitive surgery.
- For ablation procedures, assign code 3.
- Assign code 2 or 4 if the surgery began as robotic assisted or endoscopic and was converted to open.
- If both robotic and minimally invasive (for example, endoscopic or laparoscopic) surgery are used, code to robotic (codes 1 or 2).
- This item should not be confused with the obsolete item published in Registry Operations and Data Standards (ROADS), *Surgical Approach* (NAACCR Item #1310)

| Code | Definition |
|------|--|
| 0 | No surgical procedure of primary site at this facility; Diagnosed at autopsy |
| 1 | Robotic assisted |
| 2 | Robotic converted to open |
| 3 | Minimally invasive (such as endoscopic or laparoscopic) |
| 4 | Minimally invasive (endoscopic or laparoscopic) converted to open. |
| 5 | Open or approach unspecified |
| 9 | Unknown whether surgery was performed at this facility |

Examples:

| Code | Reason |
|------|--|
| 0 | Patient received radiation at this facility after having surgery elsewhere |
| 3 | Endoscopic surgery was performed |
| 3 | Patient treated with RFA of kidney |
| 5 | The surgical report described conventional open surgery, but did not use the term “open” |

SURGICAL MARGINS OF THE PRIMARY SITE

Item Length: 1

Allowable Values: 0–3, 7–9

NAACCR Item #1320

Revised 08/02, 01/10, 02/10, 01/13

Description

Records the final status of the surgical margins after resection of the primary tumor.

Rationale

This data item serves as a quality measure for pathology reports and is used for staging, and may be a prognostic factor in recurrence.

Instructions for Coding

- Record the margin status as it appears in the pathology report.
- Codes 0–3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- Code 7 if the pathology report indicates the margins could not be determined.
- If no surgery of the primary site was performed, code 8.
- Code 9 if the pathology report makes no mention of margins or no tissue was sent to pathology.
- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9), code 9.
- For an unknown or ill-defined primary site (C76.0–C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4, or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.

| Code | Label | Definition |
|------|----------------------------|---|
| 0 | No residual tumor | All margins are grossly and microscopically negative. |
| 1 | Residual tumor, NOS | Involvement is indicated, but not otherwise specified. |
| 2 | Microscopic residual tumor | Cannot be seen by the naked eye. |
| 3 | Macroscopic residual tumor | Gross tumor of the primary site which is visible to the naked eye. |
| 7 | Margins not evaluable | Cannot be assessed (indeterminate). |
| 8 | No primary site surgery | No surgical procedure of the primary site. Diagnosed at autopsy. |
| 9 | Unknown or not applicable | It is unknown whether a surgical procedure to the primary site was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease. |

Example:

| Code | Reason |
|------|---|
| 3 | (C18-Colon) The pathology report from a colon resection describes the proximal margin as grossly involved with tumor (code 3) and the distal margin as microscopically involved (code 2). Code macroscopic involvement (code 3). |

SCOPE OF REGIONAL LYMPH NODE SURGERY

Item Length: 1
Allowable Values: 0–7, 9
NAACCR Item #1292
Revised 01/04, 09/08, 02/10, 01/11, 01/12,
04/12, 01/13, 01/15

Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

Rationale

This data item can be used to compare and evaluate the extent of surgical treatment.

Instructions for Coding

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- Record surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose or stage disease in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* (NAACCR Item #1270) and/or *Date of First Surgical Procedure* (NAACCR Item #1200) if applicable.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.
- For intracranial and central nervous system primaries (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9, C75.1–C75.3), code 9.
- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9), code 9.
- For an unknown or ill-defined primary site (C76.0–C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. Distant nodes are coded in the data field *Surgical Procedure/Other Site* (NAACCR Item #1294).
- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).

Note: One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

Codes and Labels

The following instructions should be applied to all surgically treated cases for all types of cancers. The treatment of breast and skin cancer is where the distinction between sentinel lymph node biopsies (SLNBx) and more extensive dissection of regional lymph nodes is most frequently encountered. For all other sites, non-sentinel regional node dissections are typical, and codes 2, 6 and 7 are infrequently used.

| Code | Label | General Instructions Applying to All Sites | Additional Notes Specific to Breast (C50.x) |
|------|--|---|--|
| | | Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection. | Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a ALND. |
| 0 | No regional lymph node surgery | No regional lymph node surgery. | |
| 1 | Biopsy or aspiration of regional lymph node(s) | Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed. If additional procedures were performed on the lymph nodes, use the appropriate code 2-7. | Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7. |
| 2 | Sentinel Lymph Node Biopsy | <ul style="list-style-type: none"> The operative report states that a SLNBx was performed. Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination. When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes may be discovered by the pathologist or selectively removed (or harvested) as part of the SLNBx procedure by the surgeon. Code this as a | <ul style="list-style-type: none"> If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND). Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made and a node exploration was conducted. Patients undergoing |

| | | | |
|---|---|--|---|
| | | SLNBx (code 2). If review of the operative report confirms that a regional lymph node dissection followed the SLNBx, code these cases as 6. | SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items <i>Regional Lymph Nodes Examined</i> (NAACCR Item #830) and <i>Regional Lymph Nodes Positive</i> (NAACCR Item #820). |
| 3 | Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS | <ul style="list-style-type: none"> The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure). Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SNLBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event. | Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7). |
| 4 | 1-3 regional lymph nodes removed | | |
| 5 | 4 or more regional lymph nodes removed | | |
| 6 | Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated | <ul style="list-style-type: none"> SNLBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However it is possible for these procedures to harvest only a few nodes. | <ul style="list-style-type: none"> Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a |

| | | | |
|---|---|---|---|
| | | <ul style="list-style-type: none"> If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only. Infrequently, a SNLBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6. | SLNBx, or whether a SLNBx plus an ALND was performed. |
| 7 | Sentinel node biopsy and code 3, 4, or 5 at different times | <ul style="list-style-type: none"> SNLBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events. Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only. | <ul style="list-style-type: none"> Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx plus an ALND was performed. |
| 9 | Unknown or not applicable | <ul style="list-style-type: none"> The status of regional lymph node evaluation should be known for surgically-treated cases (i.e., cases coded 19-90 in the data item <i>Surgery of Primary Site</i> [NAACCR Item #1290]). Review surgically treated cases coded 9 in <i>Scope of Regional Lymph Node Surgery</i> to confirm the code. | |

Examples

| Code | Reason |
|------|--|
| 0 | No effort was made to locate sentinel lymph nodes, and no nodes were found in pathologic analysis. |
| 2 | (C50.1-Breast) There was an attempt at sentinel lymph node dissection, but no lymph nodes were found in the pathological specimen. |
| 1 | (C14.0-Pharynx) Aspiration of regional lymph node to confirm histology of widely metastatic disease. |
| 2 | (C44.5-Skin of Back) Patient has melanoma of the back. A sentinel lymph node dissection was done with the removal of one lymph node. This node was negative for disease. |
| 3 | (C61.9-Prostate) Bilateral pelvic lymph node dissection for prostate cancer. |
| 6 | (C50.3-Breast) Sentinel lymph node biopsy (SLNBx) of right axilla, followed by right axillary lymph node dissection (ALND) during the same surgical event. |
| 7 | (50.4-Breast) Sentinel lymph node biopsy (SLNBx) of left axilla, followed in a second procedure 5 days later by a left axillary lymph node dissection (ALND). |
| 9 | (C34.9-Lung) Patient was admitted for radiation therapy following surgery for lung cancer. There is no documentation on the extent of lymph node surgery in patient record. |

SCOPE OF REGIONAL LYMPH NODE SURGERY AT THIS FACILITY Item Length: 1

Allowable Values: 0–7, 9

NAACCR Item #672

Revised 1/04, 9/08, 2/10, 1/12

Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event at this facility.

Rationale

This item can be used to compare and evaluate the extent of surgical treatment.

Instructions for Coding

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- If a surgical procedure which aspirates, biopsies, or removes regional lymph nodes to diagnose or stage this cancer, record the scope of regional lymph nodes surgery in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* (NAACCR Item #1270) and/or *Date of First Surgical Procedure* (NAACCR Item #1200) as appropriate.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.
- For primaries of the meninges, brain, spinal cord, cranial nerves, and other parts of the central nervous system (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9, C75.1–C75.3), code 9.
- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9), code 9.
- For all unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. They are coded in the data field *Surgical Procedure/Other Site* (NAACCR Item #1294).
- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* (NAACCR Item #3280).

Note: One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. *It is important to avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

Codes and Labels

The following instructions should be applied to all surgically treated cases for all types of cancers. The treatment of breast and skin cancer is where the distinction between sentinel lymph node biopsies (SLNBx) and more extensive dissection of regional lymph nodes is most frequently encountered. For all other sites, non-sentinel regional node dissections are typical, and codes 2, 6 and 7 are infrequently used.

| Code | Label | General Instructions Applying to All Sites | Additional Notes Specific to Breast (C50.x) |
|------|--|---|--|
| | | Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection. | Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a ALND. |
| 0 | No regional lymph node surgery | No regional lymph node surgery. | |
| 1 | Biopsy or aspiration of regional lymph node(s) | Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed. If additional procedures were performed on the lymph nodes, use the appropriate code 2-7. | Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7. |
| 2 | Sentinel Lymph Node Biopsy | <ul style="list-style-type: none"> The operative report states that a SLNBx was performed. Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination. When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes may be discovered by the pathologist or selectively removed (or harvested) as part of the SLNBx procedure by the surgeon. Code this as a | <ul style="list-style-type: none"> If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND). Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made and a node exploration was conducted. Patients undergoing |

| | | | |
|---|---|--|--|
| | | SLNBx (code 2). If review of the operative report confirms that a regional lymph node dissection followed the SLNBx, code these cases as 6. | SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items <i>Regional Lymph Nodes Examined</i> (NAACCR Item #830) and <i>Regional Lymph Nodes Positive</i> (NAACCR Item #820). |
| 3 | Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS | <p>The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure).</p> <ul style="list-style-type: none"> Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). <p>Infrequently, a SNLBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</p> | Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7). |
| 4 | 1-3 regional lymph nodes removed | | |
| 5 | 4 or more regional lymph nodes removed | | |
| 6 | Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated | <ul style="list-style-type: none"> SNLBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However it is possible for these procedures to harvest only a few nodes. If relatively few nodes are | <ul style="list-style-type: none"> Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx, or whether a SLNBx plus an |

| | | | |
|---|---|---|--|
| | | <p>pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</p> <ul style="list-style-type: none"> • Infrequently, a SNLBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6. | ALND was performed. |
| 7 | Sentinel node biopsy and code 3, 4, or 5 at different times | <ul style="list-style-type: none"> • SNLBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events. • Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. • If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only. | <ul style="list-style-type: none"> • Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes. • If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only, or whether a SLNBx plus an ALND was performed. |
| 9 | Unknown or not applicable | The status of regional lymph node evaluation should be known for surgically-treated cases (i.e., cases coded 19-90 in the data item <i>Surgery of Primary Site</i> [NAACCR Item #1290]). Review surgically treated cases coded 9 in <i>Scope of Regional Lymph Node Surgery</i> to confirm the code. | |

SURGICAL PROCEDURE/OTHER SITE

Item Length: 1

Allowable Values: 0–5, 9

NAACCR Item #1294

Revised 01/04, 09/08, 01/10, 02/10, 01/12,
01/13**Description**

Records the surgical removal of *distant lymph nodes* or other tissue(s) or organ(s) removed beyond the primary site

Rationale

The removal of nonprimary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

Instructions for Coding

- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- If other tissue or organs are removed during primary site surgery that are not specifically defined by the site-specific *Surgical Procedure of the Primary Site* (NAACCR Item #1290 or #670) code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code. Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* (NAACCR Item #3270).

| Code | Label | Definition |
|------|---|--|
| 0 | None | No surgical procedure of nonprimary site was performed. Diagnosed at autopsy. |
| 1 | Nonprimary surgical procedure performed | Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant. |
| 2 | Nonprimary surgical procedure to other regional sites | Resection of regional site. |
| 3 | Nonprimary surgical procedure to <i>distant lymph node(s)</i> | Resection of <i>distant lymph node(s)</i> . |
| 4 | Nonprimary surgical procedure to distant site | Resection of distant site. |
| 5 | Combination of codes | Any combination of surgical procedures 2, 3, or 4. |
| 9 | Unknown | It is unknown whether any surgical procedure of a nonprimary site was performed. Death certificate only. |

Examples

| Code | Reason |
|------|--|
| 0 | (C18.1–Colon) The incidental removal of the appendix during a surgical procedure to remove a primary malignancy in the right colon. |
| 1 | Surgical removal of metastatic lesion from liver; unknown primary. |
| 2 | (C18.3–Colon) Surgical ablation of solitary liver metastasis, hepatic flexure primary. |
| 4 | (C34.9–Lung) Removal of solitary brain metastasis. |
| 5 | (C21.0–Anus) Excision of solitary liver metastasis and one large hilar lymph node. |

SURGICAL PROCEDURE/OTHER SITE AT THIS FACILITY

Item Length: 1

Allowable Values: 0–5, 9

NAACCR Item #674

Revised 01/04, 01/10, 02/10, 01/12

Description

Records the surgical removal of *distant lymph nodes* or other tissue(s)/organ(s) beyond the primary site at this facility.

Rationale

The removal of non-primary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

Instructions for Coding

- If other tissue or organs are removed during primary site surgery that are not specifically defined by the site-specific *Surgical Procedure of the Primary Site* (NAACCR Item #1290 or #670) code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* (NAACCR Item #3280).

| Code | Label | Definition |
|------|---|--|
| 0 | None | No nonprimary surgical site resection was performed. Diagnosed at autopsy. |
| 1 | Nonprimary surgical procedure performed | Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant. |
| 2 | Nonprimary surgical procedure to other regional sites | Resection of regional site. |
| 3 | Nonprimary surgical procedure to <i>distant lymph node(s)</i> | Resection of <i>distant lymph node(s)</i> . |
| 4 | Nonprimary surgical procedure to distant site | Resection of distant site. |
| 5 | Combination of codes | Any combination of surgical procedures 2, 3, or 4. |
| 9 | Unknown | It is unknown whether any surgical procedure of a nonprimary site was performed. Death certificate only. |

DATE OF SURGICAL DISCHARGE

Item Length: 8
NAACCR Item #3180
Revised 01/10, 01/11

Description

Records the date the patient was discharged following primary site surgery. The date corresponds to the event recorded in *Surgical Procedure of Primary Site* (NAACCR Item #1290), and *Date of Most Definitive Surgical Resection* (NAACCR Item #3170).

Rationale

Length of stay is an important quality of care and financial measure among hospital administrations, those who fund public and private health care, and public health users. This date, in conjunction with the data item *Date of Most Definitive Surgical Resection* (NAACCR Item #3170), will allow for the calculation of a patient's length of hospitalization associated with primary site surgery.

Instructions for Coding

- Record the date the patient was discharged from the hospital following the event recorded in *Surgical Procedure of Primary Site* (NAACCR Item #1290).
- If the patient died following the event recorded in *Surgical Procedure of Primary Site* (NAACCR Item #1290), but before being discharged from the treating facility, then the *Date of Surgical Discharge* is the same as the date recorded in the data item *Date of Last Contact or Death* (NAACCR Item #1750).
- If the patient received out-patient surgery, then the date of surgical discharge is the same as the date recorded in the data item *Date of Most Definitive Surgical Resection of the Primary Site* (NAACCR Item #3170).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Surgical Discharge* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Surgical Discharge* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date Surg Disch Flag* (NAACCR ITEM #3181) is used to explain why *Date of Surgical Discharge* is not a known date. See *RX Date Surg Disch Flag* for an illustration of the relationships among these items.

RX DATE SURG DISCH FLAG

Item Length: 2
 NAACCR Item #3181
 Valid Codes: 10-12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Surgical Discharge* (NAACCR Item #3180).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date of Surgical Discharge* (NAACCR Item #3180) has a full or partial date recorded.
- Code 12 if the *Date of Surgical Discharge* can not be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2003.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery was performed). |
| 11 | No proper value is applicable in this context (for example, no surgery performed). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown). |
| (blank) | A valid date value is provided in item <i>Date of Surgical Discharge</i> (NAACCR Item #3180). The case was diagnosed prior to January 1, 2003. |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Surgical Discharge* (NAACCR Item #3180) and *Rx Date Surg Disch Flag* (NAACCR Item #3181). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date of Surgical Discharge | Interoperable Date of Surgical Discharge | Rx Date Surg Disch Flag |
|---|---|--|-------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No primary site surgery performed | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, primary site surgery performed | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

READMISSION TO THE SAME HOSPITAL WITHIN 30 DAYS OF SURGICAL DISCHARGE

Item Length: 1

Allowable Values: 0–3, 9

NAACCR Item #3190

Revised 06/05, 01/10

Description

Records a readmission to the same hospital, for the same illness, within 30 days of discharge following hospitalization for surgical resection of the primary site.

Rationale

This data item provides information related to the quality of care. A patient may have a readmission related to the primary diagnosis on discharge if the length of stay was too short, and then he/she needed to return due to problems or complications. A patient may also need to be readmitted if discharge planning and/or follow-up instructions were ineffective. It is important to distinguish a planned from an unplanned readmission, since a planned readmission is not an indicator of quality of care problems.

Instructions for Coding

- Consult patient record or information from the billing department to determine if a readmission to the same hospital occurred within 30 days of the date recorded in the item *Date of Surgical Discharge* (NAACCR Item #3180).
- Only record a readmission related to the treatment of this cancer.
- Review the treatment plan to determine whether the readmission was planned.
- If there was an unplanned admission following surgical discharge, check for an ICD-9-CM “E” code and record it, space allowing, as an additional *Comorbidities and Complications* (NAACCR Item #3110, 3120, 3130, 3140, 3150, 3160, 3161, 3162, 3163, 3124).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

| Code | Definition |
|------|--|
| 0 | No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge. |
| 1 | A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned. |
| 2 | A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned (chemotherapy port insertion, revision of colostomy, etc.) |
| 3 | A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital. |
| 9 | It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge. Death certificate only. |

Examples

| Code | Reason |
|------|---|
| 0 | A patient does not return to the hospital following a local excision for a Stage I breast cancer. |
| 0 | A patient was surgically treated and, upon discharge from acute hospital care, was admitted/transferred to an extended care ward of the hospital. |
| 1 | A patient is readmitted to the hospital three weeks (21 days) following a colon resection due to unexpected perirectal bleeding. |
| 2 | Following surgical resection the patient returns to the hospital for the insertion of a chemotherapy port. |

REASON FOR NO SURGERY OF PRIMARY SITE

Item Length: 1

Allowable Values: 0–2, 5–9

NAACCR Item #1340

Revised 01/04, 01/13

Description

Records the reason that no surgery was performed on the primary site.

Rationale

This data item provides information related to the quality of care and describes why primary site surgery was not performed.

Instructions for Coding

- If *Surgical Procedure of Primary Site* (NAACCR Item #1290) is coded 00, then record the reason based on documentation in the patient record.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include surgery of the primary site, or if the option of “no treatment” was accepted by the patient.
- Code 1 if *Surgical Procedure of Primary Site* (NAACCR Item #1290) is coded 98.
- Code 7 if the patient refused recommended surgical treatment, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended primary site surgery, but no further documentation is available yet to determine whether surgery was performed.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple choices, but it is unknown which treatment, if any was provided.

| Code | Definition |
|------|---|
| 0 | Surgery of the primary site was performed. |
| 1 | Surgery of the primary site was not performed because it was not part of the planned first course treatment. Diagnosed at autopsy. |
| 2 | Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery etc.) |
| 5 | Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery. |
| 6 | Surgery of the primary site was not performed; it was recommended by the patient’s physician, but was not performed as part of the first course of therapy. No reason was noted in patient record. |
| 7 | Surgery of the primary site was not performed; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in patient record. |
| 8 | Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended. |
| 9 | It is unknown whether surgery of the primary site was recommended or performed. Death certificate only. |

Examples

| Code | Reason |
|------|--|
| 2 | A patient with a primary tumor of the liver is not recommended for surgery due to advanced cirrhosis. |
| 8 | A patient is referred to another facility for recommended surgical resection of a gastric carcinoma, but further information from the facility to which the patient was referred is not available. |

DATE RADIATION STARTED

Item Length: 8

NAACCR Item #1210

Revised 06/05, 01/10, 01/11

Description

Records the date on which radiation therapy began at any facility that is part of the first course of treatment.

Rationale

It is important to be able to sequence the use of multiple treatment modalities and to evaluate the time intervals between the treatments. For some diseases, the sequence of radiation and surgical therapy is important when determining the analytic utility of pathologic stage information.

Instructions for Coding

- If radiation therapy is the first or only treatment administered to the patient, then the date radiation started should be the same as the date entered into the item *Date of First Course of Treatment* (NAACCR Item #1270).
- The date when treatment started will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Radiation Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Radiation Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Radiation Flag* (NAACCR ITEM #1211) is used to explain why *Date Radiation Started* is not a known date. See *RX Date–Radiation Flag* for an illustration of the relationships among these items.

Examples

| | |
|---|-------------------|
| A patient has external beam radiation on December 15, 2003. | December 15, 2003 |
| A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on October 12, 2003. | October 12, 2003 |
| A patient enters the facility for interstitial radiation boost for prostate cancer that is performed on August 6, 2003. Just prior to this, the patient had external beam therapy to the lower pelvis that was started on June 2, 2003 at another facility. | June 2, 2003 |

RX DATE–RADIATION FLAG

Item Length: 2
 NAACCR Item #1211
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Radiation Started* (NAACCR Item #1210).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Radiation Started* (NAACCR Item #1210) has a full or partial date recorded.
- Code 12 if the *Date Radiation Started* can not be determined, but the patient did receive first course radiation.
- Code 10 if it is unknown whether any radiation was given.
- Code 11 if no radiation is planned or given.
- Code 15 if radiation is planned, but has not yet started and the start date is not yet available. Follow this patient for radiation treatment and update this item, *Date Radiation Started*, and all other radiation items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any radiation was given). |
| 11 | No proper value is applicable in this context (for example, no radiation given). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, radiation was given but the date is unknown). |
| 15 | Information is not available at this time, but it is expected that it will be available later (for example, radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up). |
| (blank) | A valid date value is provided in item <i>Date Radiation Started</i> (NAACCR Item #1210). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Radiation Started* (NAACCR Item #1210) and *Rx Date–Radiation Flag* (NAACCR Item #1211). *In this table, the lower-case letter “b” is used to represent each blank space.*

| Description | Traditional Date Radiation Started | Interoperable Date Radiation Started | Rx Date–Radiation Flag |
|----------------------------------|---|--|------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any radiation given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No radiation given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, radiation given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |
| Radiation not started yet | 88888888 (example: 88888888) | bbbbbbbb (example: bbbbbbbb) | 15 |

LOCATION OF RADIATION TREATMENT

Item Length: 1
 Allowable Values: 0–4, 8, 9
 NAACCR Item #1550
 Revised 01/04, 01/12

Description

Identifies the location of the facility where radiation therapy was administered during the first course of treatment.

Rationale

This data item provides information useful to understanding the referral patterns for radiation therapy services and for assessing the quality and outcome of radiation therapy by delivery site.

Instructions for Coding

If the radiation treatment was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the radiation administered in the items *Palliative Care* (NAACCR Item #3270) and/or *Palliative Care at This Facility* (NAACCR Item #3280), as appropriate.

In this context, “regional” is used to distinguish from “boost”; it does not refer to “regional” as used to identify stage or disease spread.

| Code | Label | Definition |
|------|--|--|
| 0 | No radiation treatment | No radiation therapy was administered to the patient. Diagnosed at autopsy. |
| 1 | All radiation treatment at this facility | All radiation therapy was administered at the reporting facility. |
| 2 | Regional treatment at this facility, boost elsewhere | Regional treatment was administered at the reporting facility; a boost dose was administered elsewhere. |
| 3 | Boost radiation at this facility, regional elsewhere | Regional treatment was administered elsewhere; a boost dose was administered at the reporting facility. |
| 4 | All radiation treatment elsewhere | All radiation therapy was administered elsewhere. |
| 8 | Other | Radiation therapy was administered, but the pattern does not fit the above categories. |
| 9 | Unknown | Radiation therapy was administered, but the location of the treatment facility is unknown or not stated in patient record; it is unknown whether radiation therapy was administered. Death certificate only. |

Examples

| Code | Reason |
|------|---|
| 2 | A patient received radiation therapy to the entire head and neck region at the reporting facility and is then referred to another facility for a high-dose-rate (HDR) intracavitary boost. |
| 3 | A patient was diagnosed with breast cancer at another facility and received surgery and regional radiation therapy at that facility before being referred to the reporting facility for boost dose therapy. |
| 8 | Regional treatment was initiated at another facility and midway through treatment the patient was transferred to the reporting facility to complete the treatment regime. |
| 9 | Patient is known to have received radiation therapy, but records do not define the facility or facility(s) where the treatment was administered. |

RADIATION TREATMENT VOLUME

Item Length: 2

Allowable Values: 00–41, 50, 60, 98, 99

NAACCR Item #1540

Revised 01/04, 01/11, 01/12, 01/15

Description

Identifies the volume or anatomic target of the most clinically significant radiation therapy delivered to the patient during the first course of treatment.

Rationale

This data item provides information describing the anatomical structures targeted by the regional radiation therapy and can be used to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility (local analysis of physician practices) and on a regional or national basis.

Instructions for Coding

- Radiation treatment volume will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the exact treatment volume may require assistance from the radiation oncologist for consistent coding.
- If two discrete volumes are treated and one of those includes the primary site, record the treatment to the primary site.

| Code | Label | Definition |
|------|-------------------------|--|
| 00 | No radiation treatment | Radiation therapy was not administered to the patient. Diagnosed at autopsy. |
| 01 | Eye/orbit | The radiation therapy target volume is limited to the eye and/or orbit. |
| 02 | Pituitary | The target volume is restricted to the pituitary gland and all adjacent volumes are irradiated incidentally. |
| 03 | Brain (NOS) | Treatment is directed at tumors lying within the substance of the brain, or its meninges. |
| 04 | Brain (limited) | The treatment volume encompasses less than the total brain, or less than all of the meninges. |
| 05 | Head and neck (NOS) | The treatment volume is directed at a primary tumor of the oropharyngeal complex, usually encompassing regional lymph nodes. |
| 06 | Head and neck (limited) | Limited volume treatment of a head and neck primary with the exception of glottis (code 7), sinuses (code 8), or parotid (code 9). |
| 07 | Glottis | Treatment is limited to a volume in the immediate neighborhood of the vocal cords. |
| 08 | Sinuses | The primary target is one or both of the maxillary sinuses, the ethmoidal, and/or the frontal sinuses. In some cases, the adjacent lymph node regions may be irradiated. |
| 09 | Parotid | The primary target is one of the parotid glands. There may be secondary regional lymph node irradiation as well. |
| 10 | Chest/lung (NOS) | Radiation therapy is directed to some combination of hilar, mediastinal, and/or supraclavicular lymph nodes, and/or peripheral lung structures. |
| 11 | Lung (limited) | Radiation therapy is directed at one region of the lung without nodal irradiation. |
| 12 | Esophagus | The primary target is some portion of the esophagus. Regional lymph nodes may or may not be included in the treatment. Include tumors of the gastroesophageal junction. |

| Code | Label | Definition |
|------|------------------------|---|
| 13 | Stomach | The primary malignancy is in the stomach. Radiation is directed to the stomach and possibly adjacent lymph nodes. |
| 14 | Liver | The primary target is all or a portion of the liver, for either primary or metastatic disease. |
| 15 | Pancreas | The primary tumor is in the pancreas. The treatment field encompasses the pancreas and possibly adjacent lymph node regions. |
| 16 | Kidney | The target is primary or metastatic disease in the kidney or the kidney bed after resection of a primary kidney tumor. Adjacent lymph node regions may be included in the field. |
| 17 | Abdomen (NOS) | Include all treatment of abdominal contents that do not fit codes 12–16. |
| 18 | Breast | The primary target is the intact breast and no attempt has been made to irradiate the regional lymph nodes. Intact breast includes breast tissue that either was not surgically treated or received a lumpectomy or partial mastectomy (C50.0–C50.9, Surgical Procedure of Primary Site [NAACCR Item #1290] codes 0–24). |
| 19 | Breast/lymph nodes | A deliberate attempt has been made to include regional lymph nodes in the treatment of an intact breast. See definition of intact breast above. |
| 20 | Chest wall | Treatment encompasses the chest wall (following mastectomy). |
| 21 | Chest wall/lymph nodes | Treatment encompasses the chest wall (following mastectomy) plus fields directed at regional lymph nodes. |
| 22 | Mantle, Mini-mantle | Treatment consists of a large radiation field designed to encompass all of the regional lymph nodes above the diaphragm, including cervical, supraclavicular, axillary, mediastinal, and hilar nodes (mantle), or most of them (mini-mantle). This code is used exclusively for patients with Hodgkin's or non-Hodgkin's lymphoma. |
| 23 | Lower extended field | The target zone includes lymph nodes below the diaphragm along the paraaortic chain. It may include extension to one side of the pelvis. This code includes the "hockey stick" field utilized to treat seminomas. |
| 24 | Spine | The primary target relates to the bones of the spine, including the sacrum. Spinal cord malignancies should be coded 40 (Spinal cord). |
| 25 | Skull | Treatment is directed at the bones of the skull. Any brain irradiation is a secondary consequence. |
| 26 | Ribs | Treatment is directed toward metastatic disease in one or more ribs. Fields may be tangential or direct. |
| 27 | Hip | The target includes the proximal femur for metastatic disease. In many cases there may be acetabular disease as well. |
| 28 | Pelvic bones | The target includes structures of the bones of the pelvis other than the hip or sacrum. |
| 29 | Pelvis (NOS) | Irradiation is directed at soft tissues within the pelvic region and codes 34–36 do not apply. |
| 30 | Skin | The primary malignancy originates in the skin and the skin is the primary target. So-called skin metastases are usually subcutaneous and should be coded 31 (Soft tissue). |

| Code | Label | Definition |
|------|------------------------|---|
| 31 | Soft tissue | All treatment of primary or metastatic soft tissue malignancies not fitting other categories. |
| 32 | Hemibody | A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. This is almost always administered for palliation of widespread bone metastasis in patients with prostate or breast cancer. |
| 33 | Whole body | Entire body included in a single treatment. |
| 34 | Bladder and pelvis | The primary malignancy originated in the bladder, all or most of the pelvis is treated as part of the plan, typically with a boost to the bladder. |
| 35 | Prostate and pelvis | The primary malignancy originated in the prostate, all or most of the pelvis is treated as part of the plan, typically with a boost to the prostate. |
| 36 | Uterus and cervix | Treatment is confined to the uterus and cervix or vaginal cuff, usually by intracavitary or interstitial technique. If entire pelvis is included in a portion of the treatment, then code 29 (Pelvis, NOS). |
| 37 | Shoulder | Treatment is directed to the proximal humerus, scapula, clavicle, or other components of the shoulder complex. This is usually administered for control of symptoms for metastases. |
| 38 | Extremity bone, NOS | Bones of the arms or legs. This excludes the proximal femur, code 27 (Hip). This excludes the proximal humerus, code 37 (Shoulder). |
| 39 | Inverted Y | Treatment has been given to a field that encompasses the paraaortic and bilateral inguinal or inguinofemoral lymph nodes in a single port. |
| 40 | Spinal cord | Treatment is directed at the spinal cord or its meninges. |
| 41 | Prostate | Treatment is directed at the prostate with or without the seminal vesicles, without regional lymph node treatment. |
| 50 | Thyroid | Treatment is directed at the thyroid gland. |
| 60 | Lymph node region, NOS | The target is a group of lymph nodes not listed above. Examples include isolated treatment of a cervical, supraclavicular, or inguinofemoral region. |
| 98 | Other | Radiation therapy administered, treatment volume other than those previously categorized. |
| 99 | Unknown | Radiation therapy administered, treatment volume unknown or not stated in patient record; it is unknown whether radiation therapy was administered. Death certificate only. |

Examples

| Code | Reason |
|------|---|
| 01 | Lymphoma of the orbit treated with 4 cm x 4 cm portals. |
| 02 | Pituitary adenomas receiving small opposed field or rotational treatment. |
| 03 | The entire brain is treated for metastatic disease. |

| Code | Reason |
|-------------|---|
| 04 | Limited field irradiation of an oligodendroglioma or glioblastoma. |
| 05 | Carcinoma of the left tonsil treated with opposed lateral fields to the neck and an anterior supraclavicular field. |
| 06 | Interstitial implant utilized to treat a small carcinoma of the lateral tongue. |
| 07 | Small lateral fields utilized to treat a T1 or T2 glottic tumor. |
| 11 | Small portal treatment is delivered to the right bronchial/hilar region to stop hemoptysis. |
| 17 | Irradiation for hypersplenism due to lymphoma. |
| 19 | Tangential fields deliberately arranged in a manner that will encompass internal mammary lymph nodes in a patient with a medial primary; breast tangential fields plus supraclavicular and/or axillary field in a patient with five positive lymph nodes. |
| 20 | Following mastectomy, a patient has prophylactic chest wall irradiation to prevent local recurrence; a thoracotomy scar is irradiated because of known contamination with tumor. |
| 24 | An inverted "T" field is utilized to treat painful metastases in the lumbar vertebrae and sacrum in a patient with prostate cancer. |
| 25 | Patient with myeloma receives total skull irradiation for numerous "punched out" lesions that are causing discomfort. |
| 33 | Patient with chronic lymphocytic leukemia receives five whole-body treatments of 10 cGy each to reduce adenopathy or lymphocyte count. |
| 33 | TBI (total body irradiation) is administered prior to a bone marrow transplant. Both the radiation and the chemotherapy that also is given with bone marrow transplants act to destroy cancer cells, and both are recorded as treatment. |
| 36 | Patient receives intracavitary therapy alone for a high-grade Stage IA carcinoma of the endometrium. |
| 38 | The distal forearm is treated for a metastatic lesion involving the radius. |
| 39 | Stage IA Hodgkin's disease presenting in an inguinal lymph node. |
| 40 | A portion of the spinal cord is treated for a primary ependymoma. |
| 60 | Ovarian carcinoma presenting with left supraclavicular lymphadenopathy as the only documented site of metastatic disease. The supraclavicular region is treated to prevent neurologic complications. |
| 98 | Anterior neck is treated for a primary thyroid lymphoma. |

REGIONAL TREATMENT MODALITY

Item Length: 2

Allowable Values: 00, 20–32, 40–43,
50–55, 60–62, 98, 99

NAACCR Item #1570

Revised 09/06, 09/08, 01/11, 01/15

Description

Records the dominant modality of radiation therapy used to deliver the most clinically significant regional dose to the primary volume of interest during the first course of treatment.

Rationale

Radiation treatment is frequently delivered in two or more phases which can be summarized as “regional” and “boost” treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding

- Radiation treatment modality will typically be found in the radiation oncologist’s summary letter for the first course of treatment. Segregation of treatment components into regional and boost and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- In the event multiple radiation therapy modalities were employed in the treatment of the patient, record only the dominant modality.
- Note that in some circumstances the boost treatment may precede the regional treatment.
- For purposes of this data item, photons and x-rays are equivalent.
- Code IMRT or conformal 3D whenever either is explicitly mentioned.
- Code radioembolization as brachytherapy.
- Note: do not confuse a radioiodine *scan* with treatment. Only treatment is recorded in this item.

| Code | Label | Definition |
|------|--------------------------|---|
| 00 | No radiation treatment | Radiation therapy was not administered to the patient. Diagnosed at autopsy. |
| 20 | External beam, NOS | The treatment is known to be by external beam, but there is insufficient information to determine the specific modality. |
| 21 | Orthovoltage | External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV). |
| 22 | Cobalt-60, Cesium-137 | External beam therapy using a machine containing either a Cobalt- 60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51. |
| 23 | Photons (2–5 MV) | External beam therapy using a photon producing machine with a beam energy in the range of 2–5 MV. |
| 24 | Photons (6–10 MV) | External beam therapy using a photon producing machine with a beam energy in the range of 6–10 MV. |
| 25 | Photons (11–19 MV) | External beam therapy using a photon producing machine with a beam energy in the range of 11–19 MV. |
| 26 | Photons (>19 MV) | External beam therapy using a photon producing machine with a beam energy of more than 19 MV. |
| 27 | Photons (mixed energies) | External beam therapy using more than one energy over the course of treatment. |
| 28 | Electrons | Treatment delivered by electron beam. |

| Code | Label | Definition |
|------|---|---|
| 29 | Photons and electrons mixed | Treatment delivered using a combination of photon and electron beams. |
| 30 | Neutrons, with or without photons/electrons | Treatment delivered using neutron beam. |
| 31 | IMRT | Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record. |
| 32 | Conformal or 3-D therapy | An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record. |
| 40 | Protons | Treatment delivered using proton therapy. |
| 41 | Stereotactic radiosurgery, NOS | Treatment delivered using stereotactic radiosurgery, type not specified in patient record. |
| 42 | Linac radiosurgery | Treatment categorized as using stereotactic technique delivered with a linear accelerator. |
| 43 | Gamma Knife | Treatment categorized as using stereotactic technique delivered using a Gamma Knife machine. |
| 50 | Brachytherapy, NOS | Brachytherapy, interstitial implants, molds, seeds, needles, radioembolization, or intracavitary applicators of radioactive materials not otherwise specified. |
| 51 | Brachytherapy, Intracavitary, LDR | Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator). |
| 52 | Brachytherapy, Intracavitary, HDR | Intracavitary (no direct insertion into tissues) radioisotope treatment using high dose rate after-loading applicators and isotopes. |
| 53 | Brachytherapy, Interstitial, LDR | Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources. |
| 54 | Brachytherapy, Interstitial, HDR | Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources. |
| 55 | Radium | Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy. |
| 60 | Radioisotopes, NOS | Iodine-131, Phosphorus-32, etc. |
| 61 | Strontium-89 | Treatment primarily by intravenous routes for bone metastases. |
| 62 | Strontium-90 | |
| 80* | Combination modality, specified* | Combination of external beam radiation and either radioactive implants or radioisotopes* |
| 85* | Combination modality, NOS* | Combination of radiation treatment modalities not specified in code 80.* |
| 98 | Other, NOS | Other radiation, NOS; Radiation therapy administered, but the treatment modality is not specified or is unknown. |
| 99 | Unknown | It is unknown whether radiation therapy was administered. |

Examples

| Code | Reason |
|-------------|--|
| 00 | A patient was treated for melanoma with PUVA (psoralen and long-wave ultraviolet radiation). Code this treatment as <i>Other Treatment</i> (NAACCR Item #1420, code 1). |
| 20 | A patient with prostate carcinoma receives pelvic irradiation at the reporting facility, and is then referred to a major medical center for experimental proton therapy boost. |
| 24 | A patient treated with breast conserving surgery has an interstitial boost at the time of the excisional biopsy. The implant uses Ir-192 and is left in place for three days. This is followed by 6 MV photon treatment of the entire breast. In this case, the “boost” precedes the regional treatment. |
| 25 | In an experimental program, a patient with as Stage III carcinoma of the prostate receives 4,500 cGy to the pelvis using 15 MV photons, and then the prostate receives a 600 cGy boost with neutrons. |
| 25 | Patient receives 15 MV external pelvic treatment to 4,500 cGy for cervical carcinoma, and then receives two Fletcher intracavitary implants. |
| 29 | A patient with carcinoma of the parotid receives daily treatments of which 60% are delivered by 15 MV photons and 40% of the dose is delivered by 16 MV electrons. |
| 53 | A prostate cancer patient is treated with I-125 seeds. I-125 is low dose brachytherapy. |
| 98 | A patient with a head and neck cancer underwent regional radiation treatment elsewhere and was referred to reported facility for an HDR brachytherapy boost. Detailed treatment records from the other facility are not available. |

***Note:** For cases diagnosed prior to January 1, 2003, the codes reported in this data item describe any radiation administered to the patient as part or all of the first course of therapy. Codes 80 and 85 describe specific converted descriptions of radiation therapy coded according to *Vol. II, ROADS*, and *DAM* rules and **should not** be used to record regional radiation for cases diagnosed on or later than January 1, 2003.

REGIONAL DOSE: cGy

Item Length: 5
 Right Justified, Zero-filled
 NAACCR Item #1510
 Revised 01/04, 01/15

Description

Records the dominant or most clinically significant total dose of regional radiation therapy delivered to the patient during the first course of treatment. The unit of measure is centiGray (cGy).

Rationale

To evaluate patterns of radiation oncology care, it is necessary to capture information describing the prescribed regional radiation dose. Outcomes are strongly related to the dose delivered.

Instructions for Coding

- The International Council for Radiation Protection (ICRP) recommends recording doses at the axis point where applicable (opposed fields, four field box, wedged pair, and so on). For maximum consistency in this data item, the ICRP recommendations should be followed whenever possible. Where there is no clear axis point, record the dose as indicated in the summary chart. Determining the exact dose may be highly subjective and require assistance from the radiation oncologist for consistent coding.
- Regional dose will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the total dose of regional radiation therapy may require assistance from the radiation oncologist for consistent coding.
- For proton treatment, dosage is reported in cGe units (Cobalt Gray Equivalent) rather than cGy. Please record 100x cGe for *Regional Dose: cGy* (note that it is necessary to multiply cGe by 100 to code this).
- Do not include the boost dose, if one was administered.
- Code 88888 when brachytherapy or radioisotopes—codes 50–62 for *Regional Treatment Modality* (NAACCR Item #1570)—were administered to the patient.
- Note that dose is still occasionally specified in “rads.” One rad is equivalent to one centiGray (cGy).

| Code | Definition |
|---------------|---|
| (fill spaces) | Record the actual regional dose delivered. |
| 00000 | Radiation therapy was not administered. Diagnosed at autopsy. |
| 88888 | Not applicable, brachytherapy or radioisotopes administered to the patient. |
| 99999 | Regional radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered. Death certificate only. |

Examples

| Code | Reason |
|-------|---|
| 05000 | A patient with Stage III prostate carcinoma received pelvic irradiation to 5,000 cGy followed by a prostate boost to 7,000 cGy. Record the regional dose as 5,000 cGy. |
| 06000 | A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region. The dose is calculated at a prescribed depth of 3 cm. A secondary calculation shows a D_{max} dose of 6,450 cGy. Record the regional dose reflecting the prescribed dose of 6,000 cGy. |
| 05500 | A patient with a Stage II breast carcinoma is treated with the breast intact. Tangent fields are utilized to bring the dose of the breast to 5,500 cGy. The supraclavicular lymph nodes are treated 4,500 cGy, calculated to a depth of 3 cm, and an interstitial boost in the primary tumor bed is delivered to a small volume in the breast. Record the primary target of the breast as 5,500cGy. |

BOOST TREATMENT MODALITY

Item Length: 2
 Allowable Values: 00, 20–32, 40–43,
 50–55, 60–62, 98, 99
 NAACCR Item #3200
 Revised 01/04, 09/08

Description

Records the dominant modality of radiation therapy used to deliver the most clinically significant boost dose to the primary volume of interest during the first course of treatment. This is accomplished with external beam fields of reduced size (relative to the regional treatment fields), implants, stereotactic radiosurgery, conformal therapy, or IMRT. External beam boosts may consist of two or more successive phases with progressively smaller fields generally coded as a single entity.

Rationale

Radiation treatment is frequently delivered in two or more phases which can be summarized as “regional” and “boost” treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding

- Radiation boost treatment modalities will typically be found in the radiation oncologist’s summary letter for the first course of treatment. Segregation of treatment components into regional and boost and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- In the event that multiple radiation therapy boost modalities were employed during the treatment of the patient, record only the dominant modality.
- Note that in some circumstances, the boost treatment may precede the regional treatment.
- For purposes of this field, photons and x-rays are equivalent.
- Code radioembolization as brachytherapy.

| Code | Label | Definition |
|------|--------------------------|---|
| 00 | No boost treatment | A boost dose was not administered to the patient. Diagnosed at autopsy. |
| 20 | External beam, NOS | The treatment is known to be by external beam, but there is insufficient information to determine the specific modality. |
| 21 | Orthovoltage | External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV). |
| 22 | Cobalt-60, Cesium-137 | External beam therapy using a machine containing either a Cobalt-60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51. |
| 23 | Photons (2–5 MV) | External beam therapy using a photon producing machine with a beam energy in the range of 2–5 MV. |
| 24 | Photons (6–10 MV) | External beam therapy using a photon producing machine with a beam energy in the range of 6–10 MV. |
| 25 | Photons (11–19 MV) | External beam therapy using a photon producing machine with a beam energy in the range of 11–19 MV. |
| 26 | Photons (>19 MV) | External beam therapy using a photon producing machine with a beam energy of more than 19 MV. |
| 27 | Photons (mixed energies) | External beam therapy using more than one energy over the course of treatment. |

| Code | Label | Definition |
|------|---|---|
| 28 | Electrons | Treatment delivered by electron beam. |
| 29 | Photons and electrons mixed | Treatment delivered using a combination of photon and electron beams. |
| 30 | Neutrons, with or without photons/electrons | Treatment delivered using neutron beam. |
| 31 | IMRT | Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record. |
| 32 | Conformal or 3-D therapy | An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record. |
| 40 | Protons | Treatment delivered using proton therapy. |
| 41 | Stereotactic radiosurgery, NOS | Treatment delivered using stereotactic radiosurgery, type not specified in patient record. |
| 42 | Linac radiosurgery | Treatment categorized as using stereotactic technique delivered with a linear accelerator. |
| 43 | Gamma Knife | Treatment categorized as using stereotactic technique delivered using a Gamma Knife machine. |
| 50 | Brachytherapy, NOS | Brachytherapy, interstitial implants, molds, seeds, needles, radioembolization, or intracavitary applicators of radioactive materials not otherwise specified. |
| 51 | Brachytherapy, Intracavitary, LDR | Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator). |
| 52 | Brachytherapy, Intracavitary, HDR | Intracavitary (no direct insertion into tissues) radioisotope treatment using high dose rate after-loading applicators and isotopes. |
| 53 | Brachytherapy, Interstitial, LDR | Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources. |
| 54 | Brachytherapy, Interstitial, HDR | Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources. |
| 55 | Radium | Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy. |
| 60 | Radioisotopes, NOS | Iodine-131, Phosphorus-32, etc. |
| 61 | Strontium-89 | Treatment primarily by intravenous routes for bone metastases. |
| 62 | Strontium-90 | |
| 98 | Other, NOS | Radiation therapy administered, but the treatment modality is not specified or is unknown. |
| 99 | Unknown | It is unknown whether radiation therapy was administered. Death certificate only. |

Examples

| Code | Reason |
|------|---|
| 29 | A patient with carcinoma of the tonsil receives 4,500 cGy to the head and neck region with 6 MV photons. The primary site and involved regional lymph nodes are then boosted, ie, taken to a maximum dose of 7,400 cGy, using a sequence of beam arrangements involving 6 MV photons, 15 MV photons, and 12 MV electrons. |
| 30 | In an experimental program, a patient with Stage III carcinoma of the prostate receives 4,500 cGy to the pelvis using 15 MV photons, and then the prostate receives a 600 cGy boost with neutrons. |
| 40 | A patient with prostate carcinoma receives pelvic irradiation at the reporting facility and is referred to a major medical center for experimental proton therapy boost. |

| Code | Reason |
|-------------|---|
| 51 | A patient receives external pelvic treatment to 4,500 cGy for cervical carcinoma, then receives two Fletcher intracavitary implants as boost treatment. |
| 55 | A patient treated with breast conserving surgery has an interstitial boost at the time of the excisional biopsy. The implant uses Ir-192 and is left in place for three days. |
| 99 | A patient with a head and neck cancer is referred to another institution for an HDR brachytherapy boost. Detailed treatment records from the other institution are not available. |

BOOST DOSE: cGy

Item Length: 5
 Right Justified, Zero-filled
 NAACCR Item #3210
 Revised 06/05, 01/2015

Description

Records the additional dose delivered to that part of the treatment volume encompassed by the boost fields or devices. The unit of measure is centiGray (cGy).

Rationale

To evaluate patterns of radiation oncology care, it is necessary to capture information describing the prescribed boost radiation dose. Outcomes are strongly related to the dose delivered.

Instructions for Coding

- The International Council for Radiation Protection (ICRP) recommends recording doses at the axis point where applicable (opposed fields, four field box, wedged pair, and so on). For maximum consistency in this data item, the ICRP recommendations should be followed whenever possible. Where there is no clear axis point, record the dose as indicated in the summary chart. Consult the radiation oncologist for the exact dose, if necessary.
- Radiation boost treatment dose will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the additional boost dose of radiation therapy may require assistance from the radiation oncologist for consistent coding.
- For proton treatment, dosage is reported in cGe units (Cobalt Gray Equivalent) rather than cGy. Please record 100x cGe for *Regional Dose: cGy* (note that it is necessary to multiply cGe by 100 to code this).
- Do not include the regional dose. In general, the boost dose will be calculated as the difference between the maximum prescribed dose and the regional dose. Many patients will not have a boost.
- Code 88888 when brachytherapy or radioisotopes—codes 50–62 for *Boost Treatment Modality* (NAACCR Item #3200)—were administered to the patient.
- Note that dose is still occasionally specified in “rads.” One rad is equivalent to one centiGray (cGy).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

| Code | Definition |
|---------------|--|
| (fill spaces) | Record the actual boost dose delivered. |
| 00000 | Boost dose therapy was not administered. Diagnosed at autopsy |
| 88888 | Not applicable, brachytherapy or radioisotopes administered to the patient. |
| 99999 | Boost radiation therapy was administered, but the dose is unknown. Death certificate only. |

Examples

| Code | Reason |
|-------|---|
| 02000 | A patient with Stage III prostate carcinoma receives pelvic irradiation to 5,000 cGy followed by a conformal prostate boost to 7,000 cGy. Record the prescribed (and delivered) boost dose, 2,000 cGy (7,000 cGy minus 5,000 cGy). |
| 00000 | A patient with a left supraclavicular metastasis from a gastric carcinoma receives 6,000 cGy to the left supraclavicular region. The dose is calculated at a prescribed depth of 3 cm. A secondary calculation shows a D_{max} dose (dose at depth of maximum dose) of 6,450 cGy. Do not confuse D_{max} doses with boost doses. In this case, there is no planned boost. Record the boost dose as 00000 cGy. |
| 88888 | A patient with a Stage II breast carcinoma is treated with the breast intact. Tangent fields are utilized to bring the central axis dose in the breast to 5,040 cGy. The supraclavicular lymph nodes are treated 4,500 cGy, calculated to a depth of 3 cm, and an interstitial boost in the primary tumor bed is delivered to a small volume in the breast. Record the boost dose as 88888. Note that standards for describing an interstitial or intracavitary treatment with a single number are somewhat variable. |

NUMBER OF TREATMENTS TO THIS VOLUME

Item Length: 3
 Allowable Values: 000–999
 Right Justified, Zero-filled
 NAACCR Item #1520
 Revised 09/04, 01/10, 05/10, 01/12

Description

Records the total number of treatment sessions (fractions) administered during the first course of treatment.

Rationale

This data item is used to evaluate patterns of radiation therapy and the treatment schedules.

Instructions for Coding

- The number of treatments or fractions will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the exact number of treatments or fractions delivered to the patient may require assistance from the radiation oncologist for consistent coding.
- Although a treatment session may include several treatment portals delivered within a relatively confined period of time—usually a few minutes—it is still considered one session.
- The total number of treatment sessions (fractions) is the sum of the number of fractions of regional treatment and the number of fractions of boost treatment.
- Count each separate administration of brachytherapy or implants as a single treatment or fraction.

| Code | Label | Definition |
|---------|----------------------|--|
| 000 | None | Radiation therapy was not administered to the patient. Diagnosed at autopsy. |
| 001–998 | Number of treatments | Total number of treatment sessions administered to the patient. |
| 999 | Unknown | Radiation therapy was administered, but the number of treatments is unknown. Or, it is unknown whether radiation therapy was administered. Death certificate only. |

Examples

| Code | Reason |
|------|--|
| 025 | A patient with breast carcinoma had treatment sessions in which treatment was delivered to the chest wall and separately to the ipsilateral supraclavicular region for a total of three treatment portals. Twenty-five treatment sessions were given. Record 25 treatments. |
| 035 | A patient with Stage IIIB bronchogenic carcinoma received 25 treatments to the left hilum and mediastinum, given in 25 daily treatments over five weeks. A left hilar boost was then given in 10 additional treatments. Record 35 treatments. |
| 050 | A patient with advanced head and neck cancer was treated using “hyperfractionation.” Three fields were delivered in each session, two sessions were given each day, six hours apart, with each session delivering a total dose of 150 cGy. Treatment was given for a total of 25 days. Record 50 treatments. |
| 010 | The patient was given Mammosite® brachytherapy, repeated in 10 separate sessions. Record 10 treatments. |
| 001 | Prostate cancer patient treated with a single administration of seeds. Code as 1 treatment. |

RADIATION/SURGERY SEQUENCE

Item Length: 1

Allowable Values: 0, 2–6, 9

NAACCR Item #1380

Revised 01/04, 01/10, 01/11, 01/12

Description

Records the sequencing of radiation and surgical procedures given as part of the first course of treatment.

Rationale

The sequence of radiation and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

Instructions for Coding

- Surgical procedures include *Surgical Procedure of Primary Site* (NAACCR Item #1290); *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292); *Surgical Procedure/Other Site* (NAACCR Item #1294). If all of these procedures are coded 0, or it is not known whether the patient received both surgery and radiation, then this item should be coded 0.
- If the patient received both radiation therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of Primary Site*, *Regional Lymph Node Surgery*, or *Surgical Procedure/Other Site*, then code this item 2–9, as appropriate.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies.

| Code | Label | Definition |
|------|--|--|
| 0 | No radiation therapy and/or surgical procedures | No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s) or it is unknown whether any surgery given. |
| 2 | Radiation therapy before surgery | Radiation therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 3 | Radiation therapy after surgery | Radiation therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 4 | Radiation therapy both before and after surgery | At least two courses of radiation therapy are given before and at least two more after surgery to the primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 5 | Intraoperative radiation therapy | Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 6 | Intraoperative radiation therapy with other therapy administered before or after surgery | Intraoperative radiation therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 7 | Surgery both before and after radiation | Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 9 | Sequence unknown | Administration of radiation therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of the treatment is not stated in the patient record. |

| Code | Reason |
|-------------|--|
| 0 | Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain. |
| 2 | A large lung lesion received radiation therapy prior to resection. |
| 3 | A patient received a wedge resection of a right breast mass with axillary lymph node dissection followed by radiation to right breast. |
| 4 | Preoperative radiation therapy was given to a large, bulky vulvar lesion and was followed by a lymph node dissection. This was then followed by radiation therapy to treat positive lymph nodes. |
| 5 | A cone biopsy of the cervix was followed by intracavitary implant for IIIB cervical carcinoma. |
| 6 | Stage IV vaginal carcinoma was treated with 5,000 cGy to the pelvis followed by a lymph node dissection and 2,500 cGy of intracavitary brachytherapy. |
| 9 | An unknown primary of the head and neck was treated with surgery and radiation prior to admission, but the sequence is unknown. The patient enters for chemotherapy. |

DATE RADIATION ENDED

Item Length: 8

NAACCR Item #3220

Revised 06/05, 01/10, 01/11, 01/12

Description

The date on which the patient completes or receives the last radiation treatment at any facility.

Rationale

The length of time over which radiation therapy is administered to a patient is a factor in tumor control and treatment morbidity. It is useful to evaluate the quality of care and the success of patient support programs designed to maintain continuity of treatment.

Instructions for Coding

- The date when treatment ended will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- For brachytherapy if the treatment is applied only once, this date will be the same as *Date Radiation Started* (NAACCR Item #1210).
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Radiation Ended* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Radiation Ended* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Radiation Flag* (NAACCR Item #1211) is used to explain why *Date Radiation Ended* is not a known date. See *RX Date–Rad Ended Flag* for an illustration of the relationships among these items.

Examples

| | |
|---|-----------------|
| A patient starts IMRT radiation treatment on December 15, 2004 and treatment continues until January 4, 2005. | January 4, 2005 |
| A patient receives one radiation treatment on October 2, 2009, then refuses further treatments. | October 2, 2009 |
| A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on April 4, 2006. | April 4, 2006 |

RX DATE RAD ENDED FLAG

Item Length: 2

NAACCR Item #3221

Valid Codes: 10-12, 15, Blank

New Item: 01/2010, revised 02/10, 03/10

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Radiation Ended* (NAACCR Item #3200).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Radiation Ended* (NAACCR Item #3200) has a full or partial date recorded.
- Code 12 if the *Date Radiation Ended* can not be determined, but the patient did receive first course radiation.
- Code 10 if it is unknown whether any radiation was given.
- Code 11 if no radiation is planned or given..
- Code 15 if radiation is ongoing. Follow this patient for radiation treatment and update this item, *Date Radiation Ended*, and all other radiation items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any radiation was given). |
| 11 | No proper value is applicable in this context (for example, no radiation was administered). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, radiation was given but the date is unknown). |
| 15 | Information is not available at this time, but it is expected that it will be available later (that is, radiation therapy had begun at the time of the most recent follow-up but was not yet completed). |
| (blank) | A valid date value is provided in item <i>Date Radiation Ended</i> (NAACCR Item #3200). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Radiation Ended* (NAACCR Item #3200) and *Rx Date Rad Ended Flag* (NAACCR ITEM #3201). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date Radiation Ended | Interoperable Date Radiation Ended | Rx Date–Rad Ended Flag |
|----------------------------------|---|--|------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any radiation given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No radiation given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, radiation given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |
| Radiation is ongoing | 88888888 (example: 88888888) | bbbbbbbb (example: bbbbbbbb) | 15 |

REASON FOR NO RADIATION

Item Length: 1
 Allowable Values: 0–2, 5–9
 NAACCR Item #1430
 Revised 09/04, 01/13

Description

Records the reason that no regional radiation therapy was administered to the patient.

Rationale

When evaluating the quality of care, it is useful to know the reason that various methods of therapy were not used, and whether the failure to provide a given type of therapy was due to the physician's failure to recommend that treatment, or due to the refusal of the patient, a family member, or the patient's guardian.

Instructions for Coding

- If *Regional Treatment Modality* (NAACCR Item #1570) is coded 00, then record the reason based on documentation in patient record.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include radiation therapy.
- Code 7 if the patient refused recommended radiation therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended radiation treatment, but no further documentation is available yet to confirm its administration.
- Code 8 to indicate referral to a radiation oncologist was made and the registry should follow to determine whether radiation was administered. If follow-up to the specialist or facility determines the patient was never there and no other documentation can be found, code 1.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple alternative treatment options, but it is unknown which treatment, if any, was provided.

| Code | Definition |
|------|--|
| 0 | Radiation therapy was administered. |
| 1 | Radiation therapy was not administered because it was not part of the planned first course treatment. Diagnosed at autopsy. |
| 2 | Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.). |
| 5 | Radiation therapy was not administered because the patient died prior to planned or recommended therapy. |
| 6 | Radiation therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record. |
| 7 | Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 8 | Radiation therapy was recommended, but it is unknown whether it was administered. |
| 9 | It is unknown if radiation therapy was recommended or administered. Death certificate cases only. |

Example

| Code | Reason |
|------|--|
| 1 | A patient with Stage I prostate cancer is offered either surgery or brachytherapy to treat his disease. The patient elects to be surgically treated. |

DATE SYSTEMIC THERAPY STARTED

Item Length: 8
 NAACCR Item #3230
 Revised 01/10, 01/11

Description

Records the date of initiation for systemic therapy that is part of the first course of treatment. Systemic therapy includes the administration of chemotherapy agents, hormonal agents, biological response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which systemic therapy was administered. Systemic therapy includes *Chemotherapy* (NAACCR Item #1390), *Hormone Therapy* (NAACCR Item #1400), *Immunotherapy* (NAACCR Item #1410), and *Hematologic Transplant and Endocrine Procedures* (NAACCR Item #3250).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Systemic Therapy Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Systemic Therapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date Systemic Flag* (NAACCR Item #3231) is used to explain why *Date Systemic Therapy Started* is not a known date. See *RX Date Systemic Flag* for an illustration of the relationships among these items.

Examples

| | |
|--|-------------------|
| A patient with breast cancer begins her regimen of chemotherapy on December 15, 2003, and is subsequently given Tamoxifen on January 20, 2004. | December 15, 2003 |
| A patient with Stage IV prostate cancer has an orchiectomy on June 2, 2003. He is then started on a regime of hormonal agents on June 9, 2003. | June 2, 2003 |

RX DATE SYSTEMIC FLAG

Item Length: 2
 NAACCR Item #3231
 Valid Codes: 10-12, 15, Blank
 Revised 01/12

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Systemic Therapy Started* (NAACCR Item #3230).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Systemic Therapy Started* (NAACCR Item #3230) has a full or partial date recorded.
- Code 12 if the *Date Systemic Therapy Started* can not be determined, but the patient did receive first course systemic therapy.
- Code 10 if it is unknown whether any systemic therapy was given.
- Code 11 if no systemic therapy is planned or given.
- Code 15 if systemic therapy is planned, but not yet started. Follow this patient for systemic therapy and update this item, *Date Systemic Therapy Started*, and all relevant systemic therapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any systemic therapy was given). |
| 11 | No proper value is applicable in this context (for example, no systemic therapy given). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, systemic therapy was given but the date is unknown). |
| 15 | Information is not available at this time, but it is expected that it will be available later (that is, systemic therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up). |
| (blank) | A valid date value is provided in item <i>Date Systemic Therapy Started</i> (NAACCR Item #3230). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Systemic Therapy Started* (NAACCR Item #3230) and *Rx Date Systemic Flag* (NAACCR Item #3231). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date Systemic Therapy Started | Interoperable Date Systemic Therapy Started | Rx Date Systemic Flag |
|--|---|--|-----------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any systemic therapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No systemic therapy given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, systemic therapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |
| Systemic therapy is planned, not yet begun | 88888888 (example: 88888888) | bbbbbbbb (example: bbbbbbbb) | 15 |

DATE CHEMOTHERAPY STARTED

Item Length: 8
NAACCR Item #1220
Revised 01/11

Description

Records the date of initiation of chemotherapy that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which chemotherapy was administered by any facility. This date corresponds to administration of the agents coded in *Chemotherapy* (NAACCR Item #1390).
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Chemotherapy Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Chemotherapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date-Chemo Flag* (NAACCR Item #1221) is used to explain why *Date Chemotherapy Started* is not a known date. See *RX Date-Chemo Flag* for an illustration of the relationships among these items.

RX DATE–CHEMO FLAG

Item Length: 2
 NAACCR Item #1221
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Chemotherapy Started* (NAACCR Item #1220).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Chemotherapy Started* (NAACCR Item #1220) has a full or partial date recorded.
- Code 12 if the *Date Chemotherapy Started* can not be determined, but the patient did receive first course chemotherapy.
- Code 10 if it is unknown whether any chemotherapy was given.
- Code 11 if no chemotherapy is planned or given.
- Code 15 if chemotherapy is planned, but not yet started. Follow this patient for chemotherapy and update this item, *Date Chemotherapy Started*, and the relevant chemotherapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 (inclusive) if this facility did not collect *Date Chemotherapy Started* at that time.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any chemotherapy was given). |
| 11 | No proper value is applicable in this context (for example, no chemotherapy given). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, chemotherapy was given but the date is unknown). |
| 15 | Information is not available at this time, but it is expected that it will be available later (that is, chemotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up). |
| (blank) | A valid date value is provided in item <i>Date Chemotherapy Started</i> (NAACCR Item #1220). Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Chemotherapy Started</i> (NAACCR Item #1220) at that time. |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Chemotherapy Started* (NAACCR Item #1220) and *Rx Date-Chemo Flag* (NAACCR Item #1221). *In this table, the lower-case letter “b” is used to represent each blank space.*

| Description | Traditional Date Chemotherapy Started | Interoperable Date Chemotherapy Started | Rx Date-Chemo Flag |
|--|---|--|--------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any chemotherapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No chemotherapy given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, chemotherapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |
| Chemotherapy is planned, not yet begun | 88888888 (example: 88888888) | bbbbbbbb (example: bbbbbbbb) | 15 |

CHEMOTHERAPY

Item Length: 2

Allowable Values: 00–03, 82, 85–88, 99

NAACCR Item #1390

Revised 06/05, 09/08, 01/10, 01/15

Description

Records the type of chemotherapy administered as first course treatment at this and all other facilities. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

Instructions for Coding

- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include chemotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Code 88 to indicate referral was made to a medical oncologist and the registry must follow to determine whether it was given. If follow-up with the specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and *only the original agent or regimen is recorded as first course therapy*.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of chemotherapeutic agents.
- If chemotherapy was provided as a radiosensitizer or radioprotectant DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer.
- If chemotherapy was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care (NAACCR Item #3270).

Important information affecting classification of some systemic therapies. The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER*Rx Interactive Drug Database*.

| Drug Name(s) | Category Prior to 2013 | Category 2013 + |
|-----------------------|------------------------|-------------------|
| Alemtuzumab/Campath | Chemotherapy | BRM/Immunotherapy |
| Bevacizumab/Avastin | Chemotherapy | BRM/Immunotherapy |
| Rituximab | Chemotherapy | BRM/Immunotherapy |
| Trastuzumab/Herceptin | Chemotherapy | BRM/Immunotherapy |
| Pertuzumab/Perjeta | Chemotherapy | BRM/Immunotherapy |
| Cetuxumab/Erbitux | Chemotherapy | BRM/Immunotherapy |

| Code | Definition |
|------|---|
| 00 | None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy. |
| 01 | Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record. |
| 02 | Single-agent chemotherapy administered as first course therapy. |
| 03 | Multiagent chemotherapy administered as first course therapy. |
| 82 | Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age progression of tumor prior to administration, etc.). |
| 85 | Chemotherapy was not administered because the patient died prior to planned or recommended therapy. |
| 86 | Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Chemotherapy was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. |

Examples

| Code | Reason |
|------|---|
| 01 | A patient with primary liver cancer is known to have received chemotherapy, however, the name(s) of agent(s) administered is not stated in patient record. |
| 02 | A patient with Stage III colon cancer is treated with a combination of fluorouracil and levamisole. Code the administration of fluorouracil as single agent chemotherapy, and levamisole as an immunotherapeutic agent. |
| 02 | A patient with non-Hodgkin's lymphoma is treated with fludarabine. |
| 03 | A patient with early stage breast cancer receives chemotherapy. The patient chart indicates that a regimen containing doxorubicin is to be administered. |
| 86 | After surgical resection of an ovarian mass the following physician recommends chemotherapy. The patient record states that chemotherapy was not subsequently administered to the patient, but the reason why chemotherapy was not administered is not given. |

CHEMOTHERAPY AT THIS FACILITY

Item Length: 2

Allowable Values: 00–03, 82, 85–88, 99

NAACCR Item #700

Revised 06/05, 09/08, 01/10, 01/12, 01/13, 01/15

Description

Records the type of chemotherapy administered as first course treatment at this facility. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

Instructions for Coding

- Record only chemotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include chemotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and *only the original agent or regimen is recorded as first course therapy*.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of chemotherapeutic agents.
- If chemotherapy was provided as a radiosensitizer or radioprotectant DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer.
- If chemotherapy was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item *Palliative Care at This Facility* (NAACCR Item #3280)..

Important information affecting classification of some systemic therapies. The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER*Rx Interactive Drug Database*.

| Drug Name(s) | Category Prior to 2013 | Category 2013 + |
|-----------------------|------------------------|-------------------|
| Alemtuzumab/Campath | Chemotherapy | BRM/Immunotherapy |
| Bevacizumab/Avastin | Chemotherapy | BRM/Immunotherapy |
| Rituximab | Chemotherapy | BRM/Immunotherapy |
| Trastuzumab/Herceptin | Chemotherapy | BRM/Immunotherapy |

| | | |
|--------------------|--------------|-------------------|
| Pertuzumab/Perjeta | Chemotherapy | BRM/Immunotherapy |
| Cetuxumab/Erbitux | Chemotherapy | BRM/Immunotherapy |

| Code | Definition |
|------|---|
| 00 | None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy. |
| 01 | Chemotherapy administered as first course therapy; but the type and number of agents is not documented in patient record. |
| 02 | Single-agent chemotherapy administered as first course therapy. |
| 03 | Multiagent chemotherapy administered as first course therapy |
| 82 | Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to planned administration). |
| 85 | Chemotherapy was not administered because the patient died prior to planned or recommended therapy. |
| 86 | Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Chemotherapy was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. |

DATE HORMONE THERAPY STARTED

Item Length: 8
NAACCR Item #1230
Revised 01/11, 01/12

Description

Records the date of initiation of hormone therapy that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which hormone therapy was administered by any facility. This date corresponds to administration of the agents coded in *Hormone Therapy* (NAACCR Item #1400).
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Hormone Therapy Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Hormone Therapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–Hormone Flag* (NAACCR Item #1231) is used to explain why *Date Hormone Therapy Started* is not a known date. See *RX Date–Hormone Flag* for an illustration of the relationships among these items.

RX DATE–HORMONE FLAG

Item Length: 2
 NAACCR Item #1231
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Hormone Therapy Started* (NAACCR Item #1230).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Hormone Therapy Started* (NAACCR Item #1230) has a full or partial date recorded.
- Code 12 if the *Date Hormone Therapy Started* can not be determined, but the patient did receive first course hormone therapy.
- Code 10 if it is unknown whether any hormone therapy was given.
- Code 11 if no hormone therapy is planned or given.
- Code 15 if hormone therapy is planned, but not yet started. Follow this patient for hormone therapy and update this item, *Date Hormone Therapy Started*, and the relevant hormone therapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 if this facility did not collect *Date Hormone Therapy Started* at that time.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any hormone therapy was given). |
| 11 | No proper value is applicable in this context (for example, no hormone therapy given). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, hormone therapy was given but the date is unknown). |
| 15 | Information is not available at this time, but it is expected that it will be available later (that is, hormone therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up). |
| (blank) | A valid date value is provided in item <i>Date Hormone Therapy Started</i> (NAACCR Item #1230). Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Hormone Therapy Started</i> (NAACCR Item #1230) at that time. |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Hormone Therapy Started* (NAACCR Item #1230) and *Rx Date–Hormone Flag* (NAACCR Item #1231). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date Hormone Therapy Started | Interoperable Date Hormone Therapy Started | Rx Date–Chemo Flag |
|---|---|--|--------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any hormone therapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No hormone therapy given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, hormone therapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |
| Hormone therapy is planned, not yet begun | 88888888 (example: 88888888) | bbbbbbbb (example: bbbbbbbb) | 15 |

**HORMONE THERAPY
(HORMONE/STEROID THERAPY)**

Item Length: 2
Allowable Values: 00, 01, 82,
85–88, 99
NAACCR Item #1400
Revised 06/05, 09/08, 01/10, 01/13

Description

Records the type of hormone therapy administered as first course treatment at this and all other facilities. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

Instructions for Coding

- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include hormone therapy or if the option of “no treatment” was accepted by the patient.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate the patient was referred to a medical oncologist and the registry should follow the case for hormone therapy. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why not.
- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of hormonal agents.
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* (NAACCR Item #3270).

| Code | Definition |
|------|--|
| 00 | None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy. |
| 01 | Hormone therapy administered as first course therapy. |
| 82 | Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.). |
| 85 | Hormone therapy was not administered because the patient died prior to planned or recommended therapy. |
| 86 | Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Hormone therapy was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. |

Examples

| Code | Reason |
|------|--|
| 00 | A patient has advanced lung cancer with multiple metastases to the brain. The physician orders Decadron to reduce the edema in the brain and relieve the neurological symptoms. Decadron is not coded as hormonal therapy. |
| 00 | A patient with breast cancer may be treated with aminoglutethimide (Cytadren, Elipten), which suppresses the production of glucocorticoids and mineralocorticoids. This patient must take glucocorticoid (hydrocortisone) and may also need a mineralocorticoid (Florinef) as a replacement therapy. |
| 00 | A patient with advanced disease is given prednisone to stimulate the appetite and improve nutritional status. Prednisone is not coded as hormone therapy. |
| 01 | A patient with metastatic prostate cancer is administered flutamide (an antiestrogen). |
| 87 | A patient with metastatic prostate cancer declines the administration of Megace (a progestational agent) and the refusal is noted in the patient record. |

**HORMONE THERAPY AT THIS FACILITY
(HORMONE/STEROID THERAPY)**

Item Length: 2
 Allowable Values: 00, 01, 82,
 85–88, 99
 NAACCR Item #710
 Revised 06/05, 09/08, 01/10, 01/13

Description

Records the type of hormone therapy administered as first course treatment at this facility. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

Instructions for Coding

- Record only hormone therapy received at this facility. Do not record procedures done at other facilities.
- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include hormone therapy or if the option of "no treatment" was accepted by the patient.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why not.
- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of hormonal agents.
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* (NAACCR Item #3270).

| Code | Definition |
|------|--|
| 00 | None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy. |
| 01 | Hormone therapy administered as first course therapy. |
| 82 | Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.). |
| 85 | Hormone therapy was not administered because the patient died prior to planned or recommended therapy. |

| Code | Definition |
|-------------|--|
| 86 | Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Hormone therapy was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. |

DATE IMMUNOTHERAPY STARTED

Item Length: 8
NAACCR Item #1240
Valid Codes: 10-12, 15, Blank
Revised 01/11

Description

Records the date of initiation of immunotherapy or a biologic response modifier (BRM) that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the first or earliest date on which immunotherapy or a biologic response modifier was administered by any facility. This date corresponds to administration of the agents coded in *Immunotherapy* (NAACCR Item #1410).
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Immunotherapy Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Immunotherapy Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date–BRM Flag* (NAACCR Item #1241) is used to explain why *Date Immunotherapy Started* is not a known date. See *RX Date–BRM Flag* for an illustration of the relationships among these items.

RX DATE–BRM FLAG

Item Length: 2
 NAACCR Item #1241
 Valid Codes: 10-12, 15, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Immunotherapy Started* (NAACCR Item #1240).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Immunotherapy Started* (NAACCR Item #1240) has a full or partial date recorded.
- Code 12 if the *Date Immunotherapy Started* can not be determined, but the patient did receive first course immunotherapy or a biologic response modifier.
- Code 10 if it is unknown whether any immunotherapy or a biologic response modifier was given.
- Code 11 if no immunotherapy or biologic response modifier is planned or given.
- Code 15 if immunotherapy or a biologic response modifier is planned, but not yet started. Follow this patient for immunotherapy and update this item, *Date Immunotherapy Started*, and the relevant immunotherapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 if this facility did not collect *Date Immunotherapy Started* at that time.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any immunotherapy was given). |
| 11 | No proper value is applicable in this context (for example, no immunotherapy given). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, immunotherapy was given but the date is unknown). |
| 15 | Information is not available at this time, but it is expected that it will be available later (that is, immunotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up). |
| (blank) | A valid date value is provided in item <i>Date Immunotherapy Started</i> (NAACCR Item #1240). Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Immunotherapy Started</i> (NAACCR Item #1240) at that time. |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Immunotherapy Started* (NAACCR Item #1240) and *Rx Date–BRM Flag* (NAACCR Item #1241). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date Immunotherapy Started | Interoperable Date Immunotherapy Started | Rx Date–BRM Flag |
|---|---|--|------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if any immunotherapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No immunotherapy given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, immunotherapy given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |
| Immunotherapy is planned, not yet begun | 88888888 (example: 88888888) | bbbbbbbb (example: bbbbbbbb) | 15 |

IMMUNOTHERAPY

Item Length: 2

Allowable Values: 00, 01, 82, 85–88, 99

NAACCR Item #1410

Revised 06/05, 09/08, 01/10, 01/13, 01/15

Description

Records the type of immunotherapy administered as first course treatment at this and all other facilities. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

Instructions for Coding

- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include immunotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- *Cases coded 88 should be followed and the code updated as appropriate. Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.*
- Refer to the SEER*Rx Interactive Drug Database (<http://seer.cancer.gov/>) for immunotherapeutic agents.
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item Palliative Care (NAACCR Item #3270).

Important information affecting classification of some systemic therapies. The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER*Rx Interactive Drug Database*.

| Drug Name(s) | Category Prior to 2013 | Category 2013 + |
|-----------------------|------------------------|-------------------|
| Alemtuzumab/Campath | Chemotherapy | BRM/Immunotherapy |
| Bevacizumab/Avastin | Chemotherapy | BRM/Immunotherapy |
| Rituximab | Chemotherapy | BRM/Immunotherapy |
| Trastuzumab/Herceptin | Chemotherapy | BRM/Immunotherapy |
| Pertuzumab/Perjeta | Chemotherapy | BRM/Immunotherapy |
| Cetuxumab/Erbitux | Chemotherapy | BRM/Immunotherapy |

| Code | Definition |
|-------------|--|
| 00 | None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy. |
| 01 | Immunotherapy administered as first course therapy. |
| 82 | Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.). |
| 85 | Immunotherapy was not administered because the patient died prior to planned or recommended therapy. |
| 86 | Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Immunotherapy was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. |

Examples

| Code | Reason |
|-------------|---|
| 01 | A patient with malignant melanoma is treated with interferon. |
| 85 | Before recommended immunotherapy could be administered, the patient died from cancer. |

IMMUNOTHERAPY AT THIS FACILITY

Item Length: 2
 Allowable Values: 00, 01, 82,
 85–88, 99
 NAACCR Item #720
 Revised 06/05, 09/08, 01/10, 01/13, 01/15

Description

Records the type of immunotherapy administered as first course treatment at this facility. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

Instructions for Coding

- Record only immunotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include immunotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received immunotherapy or why not.
- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of immunotherapeutic agents.
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item *Palliative Care at This Facility* (NAACCR Item #3280).

Important information affecting classification of some systemic therapies. The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER*Rx Interactive Drug Database*.

| Drug Name(s) | Category Prior to 2013 | Category 2013 + |
|-----------------------|------------------------|-------------------|
| Alemtuzumab/CamPATH | Chemotherapy | BRM/Immunotherapy |
| Bevacizumab/Avastin | Chemotherapy | BRM/Immunotherapy |
| Rituximab | Chemotherapy | BRM/Immunotherapy |
| Trastuzumab/Herceptin | Chemotherapy | BRM/Immunotherapy |
| Pertuzumab/Perjeta | Chemotherapy | BRM/Immunotherapy |
| Cetuxumab/Erbix | Chemotherapy | BRM/Immunotherapy |

| Code | Definition |
|-------------|--|
| 00 | None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy. |
| 01 | Immunotherapy administered as first course therapy. |
| 82 | Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age). |
| 85 | Immunotherapy was not administered because the patient died prior to planned or recommended therapy. |
| 86 | Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Immunotherapy was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. |

HEMATOLOGIC TRANSPLANT AND ENDOCRINE PROCEDURES Item Length: 2
Allowable Values: 00, 10–12, 20, 30,
40, 82, 85–88, 99
NAACCR Item #3250
Revised 06/05, 01/10, 01/12, 01/13

Description

Identifies systemic therapeutic *procedures* administered as part of the first course of treatment at this and all other facilities. If none of these *procedures* were administered, then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

Rationale

This data item allows the evaluation of patterns of treatment which involve the alteration of the immune system or change the patient's response to tumor cells but does not involve the administration of antineoplastic agents. In addition, when evaluating the quality of care, it is useful to know the reason if these *procedures* were not performed.

Instructions for Coding

- Bone marrow transplants should be coded as either autologous (bone marrow originally taken from the patient) or allogeneic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.
- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- Endocrine irradiation and/or endocrine surgery are procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long-term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.
- Code 00 if a transplant or endocrine procedure was not administered to the patient, and it is known that these procedures are not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include a transplant or endocrine procedure or if the option of "no treatment" was accepted by the patient.
- If it is known that a transplant or endocrine procedure is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused a recommended transplant or endocrine procedure, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended a hematologic transplant or endocrine procedure, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate referral to a specialist for hematologic transplant or endocrine procedures and the registry should follow the case. If follow-up to the specified specialist or facility determines the patient was never there, code 00.
- Use code 88 if a bone marrow or stem cell harvest was undertaken, but was not followed by a rescue or re-infusion as part of first course treatment.
- Cases coded 88 should be followed to determine whether they were given a hematologic transplant or endocrine procedure or why not.
- Code 99 if it is not known whether a transplant or endocrine procedure is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- If the hematologic transplant or endocrine procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hematologic transplant or endocrine procedure provided in the items *Palliative Care* (NAACCR Item #3270) and/or *Palliative Care at This Facility* (NAACCR Item #3280), as appropriate.

| Code | Definition |
|-------------|--|
| 00 | No transplant procedure or endocrine therapy was administered as part of first course therapy. Diagnosed at autopsy. |
| 10 | A bone marrow transplant procedure was administered, but the type was not specified. |
| 11 | Bone marrow transplant—autologous. |
| 12 | Bone marrow transplant—allogeneic. |
| 20 | Stem cell harvest and infusion. Umbilical cord stem cell transplant, with blood from one or multiple umbilical cords |
| 30 | Endocrine surgery and/or endocrine radiation therapy. |
| 40 | Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 and 10, 11, 12, or 20.) |
| 82 | Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of disease prior to administration, etc.). |
| 85 | Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy. |
| 86 | Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. |
| 87 | Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. |
| 88 | Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered. |
| 99 | It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record. Death certificate only. |

SYSTEMIC/SURGERY SEQUENCE

Item Length: 1

Allowable Values: 0, 2–6, 9

NAACCR Item #1639

Revised 01/10, 01/11, 01/12

Description

Records the sequencing of systemic therapy and surgical procedures given as part of the first course of treatment.

Rationale

The sequence of systemic therapy and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

Instructions for Coding

- *Systemic/Surgery Sequence* is to be used for patients diagnosed on or after January 1, 2006.
- Code the administration of systemic therapy in sequence with the first surgery performed, described in the item *Date of First Surgical Procedure* (NAACCR Item #1200).
- If none of the following surgical procedures was performed: *Surgical Procedure of Primary Site* (NAACCR Item #1290), *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292), *Surgical Procedure/Other Site* (NAACCR Item #1294), then this item should be coded 0.
- If the patient received both systemic therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of the Primary Site* (NAACCR Item #1290), *Scope of Regional Lymph Node Surgery* (NAACCR Item # 1292), or *Surgical Procedure/Other Site* (NAACCR Item # 1294), then code this item 2-9, as appropriate.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies. For example: the sequence, chemo then surgery then hormone therapy then surgery is coded 4 for “chemo then surgery then hormone”.

| Code | Label | Definition |
|------|--|--|
| 0 | No systemic therapy and/or surgical procedures | No systemic therapy was given; and/or no surgical procedure of primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s); or no reconstructive surgery was performed. It is unknown whether both surgery and systemic treatment were provided. |
| 2 | Systemic therapy before surgery | Systemic therapy was given before surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed. |
| 3 | Systemic therapy after surgery | Systemic therapy was given after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed. |
| 4 | Systemic therapy both before and after surgery | At least two courses of systemic therapy were given before and at least two more after a surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed. |
| 5 | Intraoperative systemic therapy | Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 6 | Intraoperative systemic therapy with other systemic therapy administered before or after surgery | Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) with other systemic therapy administered before or after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed. |
| 7 | Surgery both before and after systemic therapy | Systemic therapy was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s). |
| 9 | Sequence unknown | Both surgery and systemic therapy were provided, but the sequence is unknown. |

Examples

| Code | Reason |
|-------------|--|
| 0 | Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain. |
| 2 | Patient with prostate cancer received hormone therapy prior to a radical prostatectomy. |
| 3 | Patient underwent a colon resection followed by a 5-FU based chemotherapy regimen. |
| 4 | Patient with breast cancer receives pre-operative chemotherapy followed by post-operative Tamoxifen. |
| 5 | Patient with a intracranial primary undergoes surgery at which time a glial wafer is implanted into the resected cavity. |
| 6 | Patient with metastatic colon cancer receives intraoperative chemotherapy to the liver. |
| 9 | An unknown primary of the head and neck was treated with surgery and chemotherapy prior to admission, but the sequence is unknown. The patient enters for radiation therapy. |

DATE OTHER TREATMENT STARTED

Item Length: 8
 NAACCR Item #1250
 Revised 01/10, 01/11

Description

Records the date on which other treatment began at any facility.

Rationale

Collecting dates for each treatment modality allows for the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Instructions for Coding

- Record the date on which the care coded as *Other Treatment* [NAACCR Item #1420] was initiated.
- If other treatment is the first or only treatment administered to the patient, then the date other treatment started should be the same as the *Date of First Course of Treatment* (NAACCR Item #1270).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date Other Treatment Started* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date Other Treatment Started* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *RX Date-Other Flag* (NAACCR Item #1251) is used to explain why *Date Other Treatment Started* is not a known date. See *RX Date-Other Flag* for an illustration of the relationships among these items.

Examples

| | |
|---|--------------------|
| A patient with metastatic disease was started on an experimental therapy on March 16, 2010. | March 16, 2010 |
| Alcohol was used as an embolizing agent for a patient on August 1, 2009 | August 1, 2009 |
| A polycythemia vera patient was given several phlebotomies, the first being on September 17, 2008 | September 17, 2008 |

RX DATE–OTHER FLAG

Item Length: 2
 NAACCR Item #1251
 Valid Codes: 10-12, Blank
 Revised 01/15

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Other Treatment Started* (NAACCR Item #1250).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Coding Instructions

- Leave this item blank if *Date Other Treatment Started* (NAACCR Item #1250) has a full or partial date recorded.
- Code 12 if the *Date Other Treatment Started* can not be determined, but the patient did receive first course other treatment.
- Code 10 if it is unknown whether any other treatment was given (*Other Treatment* [NAACCR Item #1420] is 9).
- Code 11 if no other treatment is planned or given (*Other Treatment* [NAACCR Item #1420] is 0, 7 or 8).
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Description |
|---------|--|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if any Other Treatment was given). |
| 11 | No proper value is applicable in this context (for example, no Other Treatment given). |
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, Other Treatment was given but the date is unknown). |
| 15 | Other therapy is planned as part of the first course of treatment, but had not been started at the time of the most recent follow-up. |
| (blank) | A valid date value is provided in item <i>Date Other Treatment Started</i> (NAACCR Item #1250). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date Other Treatment Started* (NAACCR Item #1250) and *Rx Date–Other Flag* (NAACCR Item #1251). ***In this table, the lower-case letter “b” is used to represent each blank space.***

| Description | Traditional Date Other Treatment Started | Interoperable Date Other Treatment Started | Rx Date–Other Flag |
|--|---|--|--------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if other treatment given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No other treatment given | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, other treatment given | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

OTHER TREATMENT

Item Length: 1

Allowable Values: 0–3, 6–9

NAACCR Item #1420

Revised 06/05, 09/08, 01/10, 01/11, 01/12, 01/15

Description

Identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Instructions for Coding

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care* (NAACCR Item #3270).
- Code 8 if it is known that a physician recommended treatment coded as Other Treatment, and no further documentation is available yet to confirm its administration
- Code 8 to indicate referral to a specialist for Other Treatment and the registry should follow. If follow-up with the specialist or facility determines the patient was never there, code 0.

| Code | Label | Definition |
|------|--------------------------------------|---|
| 0 | None | All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy. |
| 1 | Other | Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy). |
| 2 | Other–Experimental | This code is not defined. It may be used to record participation in institution-based clinical trials. |
| 3 | Other–Double Blind | A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken. |
| 6 | Other–Unproven | Cancer treatments administered by nonmedical personnel. |
| 7 | Refusal | Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record. |
| 8 | Recommended; unknown if administered | Other treatment was recommended, but it is unknown whether it was administered. |
| 9 | Unknown | It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only. |

OTHER TREATMENT AT THIS FACILITY

Item Length: 1

Allowable Values: 0–3, 6–9

NAACCR Item #730

Revised 01/04, 09/08, 01/10, 01/12, 01/15

Description

Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Instructions for Coding

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care at This Facility* (NAACCR Item #3280).
- Code 8 if it is known that a physician recommended the patient receive treatment coded as Other Treatment, but no further documentation is available yet to confirm its administration.

| Code | Label | Definition |
|------|--------------------------------------|---|
| 0 | None | All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy. |
| 1 | Other | Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy). Use this code for treatment unique to hematopoietic diseases . |
| 2 | Other–Experimental | This code is not defined. It may be used to record participation in institution-based clinical trials. |
| 3 | Other–Double Blind | A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken. |
| 6 | Other–Unproven | Cancer treatments administered by nonmedical personnel. |
| 7 | Refusal | Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record. |
| 8 | Recommended; unknown if administered | Other treatment was recommended, but it is unknown whether it was administered. |
| 9 | Unknown | It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only. |

**PALLIATIVE CARE
(PALLIATIVE PROCEDURE)**

Item Length: 1
 Allowable Values: 0–7, 9
 NAACCR Item #3270
 Revised 01/04, 01/10

Description

Identifies any care provided in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Instructions for Coding

- Record the type of palliative care provided.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable should be coded palliative care and as first course therapy if that procedure removes or modifies either primary or metastatic malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.

| Code | Definition |
|------|---|
| 0 | No palliative care provided. Diagnosed at autopsy. |
| 1 | Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. |
| 2 | Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. |
| 3 | Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. |
| 4 | Patient received or was referred for pain management therapy with no other palliative care. |
| 5 | Any combination of codes 1, 2, and/or 3 without code 4. |
| 6 | Any combination of codes 1, 2, and/or 3 with code 4. |
| 7 | Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6. |
| 9 | It is unknown if palliative care was performed or referred; not stated in patient record. |

Examples

| Code | Reason |
|-------------|---|
| 0 | No palliative care was given. |
| 1 | A patient undergoes palliative surgical removal of brain metastasis. [Surgery recorded in <i>Surgical Procedure/Other Site</i> (NAACCR Item #1294)] |
| 1 | A patient with unresectable pancreatic carcinoma (no surgical procedure of the primary site is performed) receives bypass surgery to alleviate jaundice and pain. |
| 2 | A patient is diagnosed with Stage IV prostate cancer. His only symptoms are painful bony metastases in his right hip and lower spine. XRT is given to those areas. (Record all radiotherapy items also). |
| 2 | A patient with lung cancer with a primary tumor extending into the spine is treated with XRT to shrink tumor away from spine/nerves to provide pain relief. (Record all radiotherapy items also). |
| 3 | A patient is given palliative chemotherapy for Stage IIIB lung cancer. (Record all chemotherapy items also). |
| 4 | A 93-year old patient is diagnosed with multiple myeloma and enters a pain management clinic to treat symptoms. No other therapy is planned due to other medical problems. |
| 5 | A patient is diagnosed with widely disseminated small cell lung cancer. A palliative resection of a solitary brain metastasis is performed followed by XRT to the lower spine for painful bony metastasis. There is no known pain management. (Record all surgery and radiotherapy items also). |
| 6 | A patient diagnosed with colon cancer receives bypass surgery to alleviate symptoms and XRT to the liver for metastasis, and then enters a pain management clinic for treatment for unremitting abdominal pain. (Record all radiotherapy items also). |
| 7 | A patient enters the facility with a clinical diagnosis of unresectable carcinoma of the pancreas. A stent was inserted into the bile duct to relieve obstruction and improve the bile duct flow. |

**PALLIATIVE CARE AT THIS FACILITY
(PALLIATIVE PROCEDURE AT THIS FACILITY)**

Item Length: 1
Allowable Values: 0–7, 9
NAACCR Item #3280
Revised 01/04, 01/10

Description

Identifies care provided at this facility in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Instructions for Coding

- Record only the type of palliative care at this facility.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable at this facility should be coded as palliative care and as first course therapy if that procedure removes or modifies either primary or secondary malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.

| Code | Definition |
|------|---|
| 0 | No palliative care provided. Diagnosed at autopsy. |
| 1 | Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. |
| 2 | Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. |
| 3 | Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. |
| 4 | Patient received or was referred for pain management therapy with no other palliative care. |
| 5 | Any combination of codes 1, 2, and/or 3 without code 4. |
| 6 | Any combination of codes 1, 2, and/or 3 with code 4. |
| 7 | Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6. |
| 9 | It is unknown if palliative care was performed or referred; not stated in patient record. |

Outcomes

DATE OF FIRST RECURRENCE

Item Length: 8
NAACCR Item #1860
Revised 06/05, 01/10, 01/11, 01/12

Description

Records the date of the first recurrence.

Rationale

This data item is used to measure the efficacy of the first course of treatment.

Instructions for Coding

- Record the date the physician diagnoses the first progression, metastasis, or recurrence of disease after a disease-free period.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of First Recurrence* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of First Recurrence* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Recurrence Date–1st Flag* (NAACCR Item #1861) is used to explain why *Date of First Recurrence* is not a known date. See *Recurrence Date–1st Flag* for an illustration of the relationships among these items.

RECURRENCE DATE–1st FLAG

Item Length: 2
 NAACCR Item #1861
 Valid Codes: 10-12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Recurrence* (NAACCR Item #1860).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of First Recurrence* (NAACCR Item #1860) has a full or partial date recorded.
- Code 12 if the *Date of First Recurrence* can not be determined, but the patient did have a recurrence following a disease-free period.
- Code 10 if it is unknown whether the patient had a recurrence.
- Code 11 if the patient was never disease free, became disease free but had no recurrence, or was initially diagnosed at autopsy.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Description |
|---------|---|
| 10 | No information whatsoever can be inferred from this exceptional value (that is, unknown if the patient was ever disease-free or had a first recurrence) |
| 11 | No proper value is applicable in this context (that is, patient became disease-free after treatment and never had a recurrence; or patient was never disease-free; autopsy only case) |
| 12 | A proper value is applicable but not known (that is, there was a recurrence, but the date is unknown) |
| (blank) | A valid date value is provided in item <i>Date of First Recurrence</i> (NAACCR Item #1860). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of First Recurrence* (NAACCR Item #1860) and *Recurrence Date–1st Flag* (NAACCR Item #1861). *In this table, the lower-case letter “b” is used to represent each blank space.*

| Description | Traditional Date of First Recurrence | Interoperable Date of First Recurrence | Recurrence Date–1st Flag |
|--|---|--|--------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Unknown if patient had a recurrence | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 10 |
| No recurrence; never disease-free | 00000000 (example: 00000000) | bbbbbbbb (example: bbbbbbbb) | 11 |
| Date is unknown, but patient had a recurrence | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

TYPE OF FIRST RECURRENCE

Item Length: 2

Allowable Values: 00, 04, 06, 10,
13–17, 20–22, 25–27, 30, 36, 40,
46, 51–59, 60, 62, 70, 88, 99

NAACCR Item #1880

Revised 06/05, 01/10, 01/11, 01/13, 01/15

Description

Identifies the type of first recurrence after a period of documented disease-free intermission or remission.

Rationale

This item is used to evaluate treatment efficacy and as a long-term prognostic factor.

Instructions for Coding

- Code the type of first recurrence. First recurrence may occur well after completion of the first course of treatment or after subsequent treatment.
- Check the SEER *Multiple Primary and Histology Coding Rules Manual* to determine which subsequent tumors should be coded as recurrences.
- If the patient has never been disease-free (code 70), continue to track for disease-free status which may occur after subsequent treatment has been completed.
- If the patient is disease-free (code 00), continue to track until a recurrence occurs. First recurrence may occur well after completion of the first course of treatment.
- Once a recurrence has been recorded (code 04–62 or 88), subsequent recurrences are NOT to be recorded.
- Codes 00 through 70 are hierarchical; record the highest-numbered applicable response, with the following limits.. The first time a patient converts from disease status (70) to disease-free, change the code to 00. Then the first time a patient converts from 00 to a recurrence, then record the proper code for the recurrence. No further changes (other than corrections) should be made.
- If the tumor was originally diagnosed as in situ, code recurrence to 06, 16, 17, 26, 27, 36, or 46 only. Do not use those codes for any other tumors. Codes 00, 88, or 99 may apply to any tumor.
- Codes 51–59 (organ or organ system of distant recurrence) apply only if all first occurrences were in a single category. There may be multiple metastases (or “seeding”) within the distant location.
- Code lymphomas or leukemias that are in remission 00. If the patient relapses, then code recurrence as 59. If one of these is controlled by drugs (for example, Gleevec for CML), the patient is in remission.
- If there is more than one primary tumor and the physician is unable to decide which has recurred, code the recurrent disease for each tumor. If the recurrent primary is identified later, revise the codes appropriately.

| Code | Definition |
|------|--|
| 00 | Patient became disease-free after treatment and has not had a recurrence. |
| 04 | In situ recurrence of an invasive tumor. |
| 06 | In situ recurrence of an in situ tumor. |
| 10 | Local recurrence, and there is insufficient information available to code to 13–17. Local recurrence includes recurrence confined to the remnant of the organ of origin, to the organ of origin, to the anastomosis, or to scar tissue where the organ previously existed. |
| 13 | Local recurrence of an invasive tumor. |
| 14 | Trocar recurrence of an invasive tumor. Includes recurrence in the trocar path or entrance site following prior surgery. |
| 15 | Both local and trocar recurrence of an invasive tumor (both 13 and 14). |
| 16 | Local recurrence of an in situ tumor, NOS |

| Code | Definition |
|------|--|
| 17 | Both local and trocar recurrence of an in situ tumor. |
| 20 | Regional recurrence, and there is insufficient information available to code to 21–27. |
| 21 | Recurrence of an invasive tumor in adjacent tissue or organ(s) only. |
| 22 | Recurrence of an invasive tumor in regional lymph nodes only. |
| 25 | Recurrence of an invasive tumor in adjacent tissue or organ(s) and in regional lymph nodes (both 21 and 22) at the same time. |
| 26 | Regional recurrence of an in situ tumor, NOS. |
| 27 | Recurrence of an in situ tumor in adjacent tissue or organ(s) and in regional lymph nodes at the same time. |
| 30 | Both regional recurrence of an invasive tumor in adjacent tissue or organs(s) and/or regional lymph nodes (20–25) and local and/or trocar recurrence (10, 13, 14, or 15). |
| 36 | Both regional recurrence of an in situ tumor in adjacent tissue or organ(s) and/or regional lymph nodes (26 or 27) and local and/or trocar recurrence (16 or 17). |
| 40 | Distant recurrence, to a site not listed in 46–62 or there is insufficient information available to code to 46–62. |
| 46 | Distant recurrence of an in situ tumor. |
| 51 | Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid. |
| 52 | Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura. |
| 53 | Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid. |
| 54 | Distant recurrence of an invasive tumor in the liver only. |
| 55 | Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site. |
| 56 | Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye. |
| 57 | Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site. |
| 58 | Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site. |
| 59 | Distant systemic recurrence of an invasive tumor only. This includes lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease. |
| 60 | Distant recurrence of an invasive tumor in a single distant site (51–58) and local, trocar and/or regional recurrence (10–15, 20–25, or 30). |
| 62 | Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51–59). |
| 70 | Since diagnosis, patient has never been disease-free. This includes cases with distant metastasis at diagnosis, systemic disease, unknown primary, or minimal disease that is not treated. |
| 88 | Disease has recurred, but the type of recurrence is unknown. |
| 99 | It is unknown whether the disease has recurred or if the patient was ever disease-free. |

Examples

| Code | Reason |
|-------------|------------------------------------|
| 52 | Distant recurrence in the lung. |
| 62 | Recurrence in liver, lung and bone |

DATE OF LAST CONTACT OR DEATH

Item Length: 8
NAACCR #1750
Revised 06/05, 01/10, 01/11,01/15

Description

Records the date of last contact with the patient or the date of death.

Rationale

This information is used for patient follow-up and outcomes studies.

Instructions for Coding

- Record the last date on which the patient was known to be alive or the date of death.
 - Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.
- If a patient has multiple primaries, all records should have the same date of last contact.
- As of January 1, 2006, the CoC does not require *Class of Case* 00 cases to be followed.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Last Contact or Death* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Last Contact or Death* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The *Date of Last Contact Flag* (NAACCR Item #1751) is used to explain why *Date of Last Contact or Death* is not a known date. See *Date of Last Contact Flag* for an illustration of the relationships among these items.

DATE OF LAST CONTACT FLAG

Item Length: 2
 NAACCR #1751
 Valid Codes: 12, Blank
 New Item: 01/2010

Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Last Contact or Death* (NAACCR Item #1750).

Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding

- Leave this item blank if *Date of Last Contact or Death* (NAACCR Item #1750) has a full or partial date recorded.
- Code 12 if the *Date of Last Contact or Death* can not be determined
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

| Code | Description |
|---------|--|
| 12 | A proper value is applicable but not known. This event occurred, but the date is unknown (that is, the date of last contact is unknown). |
| (blank) | A valid date value is provided in item <i>Date of Last Contact or Death</i> (NAACCR Item #1750). |

The following table illustrates the use of the date flag and the traditional and interoperable date formats for coding *Date of Last Contact or Death* (NAACCR Item #1750) and *Date of Last Contact Flag* (NAACCR Item #1751). *In this table, the lower-case letter “b” is used to represent each blank space.*

| Description | Traditional Date of Last Contact or Death | Interoperable Date of Last Contact or Death | Date of Last Contact Flag |
|----------------------|---|--|---------------------------|
| | Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999 | Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces); omit the date if the date is completely unknown or not applicable. | |
| Full date known | MMDDCCYY (example: 02182007) | CCYYMMDD (example: 20070218) | bb |
| Month and year known | MM99CCYY (example: 02992007) | CCYYMMbb (example: 200702bb) | bb |
| Year only known | 9999CCYY (example: 99992007) | CCYYbbbb (example: 2007bbbb) | bb |
| Date is unknown | 99999999 (example: 99999999) | bbbbbbbb (example: bbbbbbbb) | 12 |

VITAL STATUS

Item Length: 1
 Allowable Values: 0, 1
 NAACCR Item #1760
 Revised 01/15

Description

Records the vital status of the patient as of the date entered in *Date of Last Contact or Death* (NAACCR Item #1750).

Rationale

This information is used for patient follow-up and outcomes studies.

Instructions for Coding

- This item is collected during the follow-up process with *Date of Last Contact or Death* (NAACCR Item #1750).
- Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.
- If a patient has multiple primaries, all records should have the same vital status.

| Code | Label |
|------|-------|
| 0 | Dead |
| 1 | Alive |

Example

| Code | Reason |
|------|--|
| 0 | Death clearance information obtained from a state central registry confirms the death of the patient within the past year. |
| 1 | In response to a follow-up letter to a patient's following physician, it is learned the patient is alive. |

CANCER STATUS

Item Length: 1
 Allowable Values: 1, 2, 9
 NAACCR Item #1770
 Revised 01/04

Description

Records the presence or absence of clinical evidence of the patient's malignant or non-malignant tumor as of the *Date of Last Contact or Death* (NAACCR Item #1750).

Rationale

This information is used for patient follow-up and outcomes studies.

Instructions for Coding

- Cancer status is based on information from the patient's physician or other official source such as a death certificate.
- The patient's cancer status should be changed **only** if new information is received from the patient's physician or other official source. If information is obtained from the patient, a family member, or other nonphysician, then cancer status is not updated.
- Cancer status changes if the patient has a recurrence or relapse.
- If a patient has multiple primaries, each primary could have a different cancer status.

| Code | Label |
|------|--|
| 1 | No evidence of this tumor |
| 2 | Evidence of this tumor |
| 9 | Unknown, indeterminate whether this tumor is present; not stated in patient record |

Example

| Code | Reason |
|------|--|
| 1 | Patient with hematopoietic disease who is in remission. |
| 1 | A patient is seen by the physician on February 2, 2004 with no evidence of this tumor. The patient did not return to the physician. The patient was then called by the registry on August 29, 2005. The <i>Date of Last Contact or Death</i> (NAACCR Item #1750) is updated, but the cancer status is not. |
| 2 | A patient with prostate cancer is diagnosed with bone metastasis in April 2003. The registrar finds an obituary documenting the patient's death in a nursing home in June 2003. |

NPI-FOLLOWING REGISTRY

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #2445
 Revised 04/07, 09/08, 01/11

Description

Records the registry responsible for following the patient.

Rationale

This data item is useful when the same patient is recorded in multiple registries.

Instructions for Coding

- Record the 10-digit NPI for the facility of the registry responsible for following the patient.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI, or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

| Code | Definition |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the facility. |
| (leave blank) | NPI for the facility of the following registry is unknown or not available. |

FOLLOW-UP SOURCE

Item Length: 1
 Allowable Values: 0–5, 7–9
 NAACCR Item #1790

Description

Records the source from which the latest follow-up information was obtained.

Rationale

This data item is used by registries to identify the most recent follow-up source.

Instructions for Coding

| Code | Label | Definition |
|------|---------------------------------------|---|
| 0 | Reported hospitalization | Hospitalization at another institution/hospital or first admission to the reporting facility. |
| 1 | Readmission | Hospitalization or outpatient visit at the reporting facility. |
| 2 | Physician | Information from a physician. |
| 3 | Patient | Direct contact with the patient. |
| 4 | Department of Motor Vehicles | The Department of Motor Vehicles confirmed the patient has a current license. |
| 5 | Medicare/Medicaid file | The Medicare or Medicaid office confirmed the patient is alive. |
| 7 | Death certificate | Information from the death certificate only. |
| 8 | Other | Friends, relatives, employers, other registries, or any sources not covered by other codes. |
| 9 | Unknown; not stated in patient record | The follow-up source is unknown or not stated in patient record. |

**NEXT FOLLOW-UP SOURCE
(NEXT FOLLOW-UP METHOD)**

Item Length: 1
Allowable Values: 0–5, 8, 9
NAACCR Item #1800
Revised 01/10

Description

Identifies the method planned for the next follow-up.

Rationale

This data item is used by registries to identify the method planned for the next follow-up.

Instructions for Coding

- Registries in CoC-accredited cancer programs are not required to follow foreign residents.
- As of January 1, 2006, the CoC does not require *Class of Case* 00 cases to be followed.

| Code | Definition |
|------|--|
| 0 | Chart requisition |
| 1 | Physician letter |
| 2 | Contact letter |
| 3 | Phone call |
| 4 | Other hospital contact |
| 5 | Other, NOS |
| 8 | Foreign residents (not followed) |
| 9 | Not followed. Other cases for which follow-up is not required. |

Case Administration

ABSTRACTED BY

Item Length: 3
Left Justified Alphanumeric
NAACCR Item #570

Description

Records the initials or assigned code of the individual abstracting the case.

Rationale

This item can be used for quality control and management in multistaffed registries.

Instructions for Coding

Code the initials of the abstractor.

| Code | Definition |
|---------------|---------------------------------|
| (fill spaces) | Initials or code of abstractor. |

FACILITY IDENTIFICATION NUMBER (FIN)

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #540
 Revised 09/08, 01/12

Description

Identifies the facility reporting the case.

Rationale

Each facility's identification number (FIN) is unique. The number is essential to the National Cancer Data Base (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

Instructions for Coding

- *Facility Identification Number* is automatically coded by the software provider.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.
- Facilities that are part of an Integrated Network Cancer Program (INCP) *must* use the hospital-specific FIN in their data for submission to the National Cancer Data Base.
- Facilities that merge are legally a single hospital. Consult NCDB for instructions for recording the FIN for newly-merged programs.

Examples

| Code | Reason |
|------------|---|
| 0006439999 | 6439999, General Hospital, Anytown, Illinois |
| 0010000099 | 10000099, Anytown Medical Center, Anytown, Illinois |

Note: A complete list of FINs is available on the American College of Surgeons Web site at <https://www.facs.org/quality-programs/cancer/accredited/info/fin>.

NPI-REPORTING FACILITY

Item Length: 10

Allowable Value: Ten digits

NAACCR Item #545

Revised 04/07, 09/08, 01/10, 01/12

Description

Identifies the facility whose data are in the record.

Rationale

Each facility's NPI is unique. The number is essential to the National Cancer Data Base (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

NPI-Reporting Facility is the NPI equivalent of *Facility Identification Number* (NAACCR Item #540). Both are required during a period of transition.

Instructions for Coding

- *NPI-Reporting Facility* is automatically coded by the software provider.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- The facility's NPI can be obtained from the billing or accounting department, or searched at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- If the facility has more than one NPI number assigned, use the "umbrella" number that applies to the entire facility.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number in their data for submission to the National Cancer Data Base.
- Facilities that merge are legally a single hospital. Use the NPI number for the merged hospital.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

| Code | Definitions |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the facility. |
| (leave blank) | NPI for the facility is unknown or not available. |

ARCHIVE FIN

Item Length: 10
 Right Justified, Zero-filled
 NAACCR Item #3100
 Revised 01/10, 01/12

Description

Identifies the facility that originally abstracted the case.

Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

Instructions for Coding

- *Archive FIN* is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- For facilities that have not merged, the *Archive FIN* and *FIN* (NAACCR Item #540) will be the same.
- If facilities merged after January 1, 2003, a new FIN was assigned to represent the merged facility. This new FIN was assigned to all cases in the *merged* registry, but the *Archive FIN* for cases from each registry prior to the merger **does not** change.
- If a merged program continues to operate multiple campuses, the Archive FIN is the historic FIN for the respective facilities that are now separate campuses of the same hospital.
- Facilities that are part of an Integrated Network Cancer Program (INCP) *must* use the hospital-specific FIN for the Archive FIN in their data for submission to the National Cancer Data Base.
- Programs that are not part of a merged facility or an INCP will use their hospital's FIN as the Archive FIN.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number. The Archive FIN must be recorded similarly.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number. The Archive FIN must be recorded similarly.

Examples

| Code | Reason |
|--------------------------------|---|
| 0006439999 | General Hospital, Anytown, Illinois (FIN: 6439999). Original diagnosis was made at this facility; both the FIN and the Archive FIN are the same. |
| 0006439999 or 0006430000 | General Hospital (FIN: 6439999) and Anytown Medical Center (FIN: 6430000) in Anytown IL merged; the two cancer registries were combined and now report as Anytown Medical Center. The new FIN for this reporting facility is 10000099. All cases from the merged General Hospital and Anytown Medical Center registry have the new FIN (0010000099) assigned to them. In addition, either the General Hospital Archive FIN (0006439999) or the Anytown Medical Center Archive FIN (0006430000) is retained in each record depending on which registry originally accessioned the case. |

NPI-ARCHIVE FIN

Item Length: 10
 Allowable Value: Ten digits
 NAACCR Item #3105
 Revised 01/10, 01/12

Description

Identifies the facility that originally abstracted the case.

Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

NPI-Archive FIN is the NPI equivalent of *Archive FIN* (NAACCR Item #3100). Both are required during a period of transition.

Instructions for Coding

- *NPI-Archive FIN* is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- For facilities that have not merged, the *NPI-Archive FIN* and the *NPI-Reporting Facility* (NAACCR Item #545) will be the same. Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number for the *NPI-Archive FIN* in their data for submission to the National Cancer Data Base.
- If the facility has more than one NPI number assigned, use the “umbrella” number that applies to the entire facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

| Code | Definition |
|---------------|---|
| (fill spaces) | 10-digit NPI number for the facility. |
| (leave blank) | NPI for the facility is unknown or not available. |

DATE CASE COMPLETED – COC

Item Length: 8
 NAACCR Item #2092
 Revised 01/12

Description

This data item identifies the date that specified items are completed, based on the *Class of Case*, and those items pass the relevant edits. Follow-up information, including delayed treatment received elsewhere, may be coded after the *Date Case Completed–CoC*. This item should be autocoded by the registry software. The CoC specifications will not necessarily be the same as those used for *Date Case Completed* [NAACCR Item #2090], which CoC does not require.

Rationale

This item was created to measure abstracting timeliness of information that should be available when the facility's main involvement in the patient's first course care is completed, based on *Class of Case*. CoC Standard 3.3 requires that 90% of all cases be abstracted within 6 months of the patient's first contact with the facility in CoC accredited programs. It is assumed that for all except some unusual cases, all required items, not just those used to determine *Date Case Completed – CoC*, will have been completed for all analytic cases by the time the NCDB annual Call for Data begins.

Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Follow-up information, information about delayed treatment received elsewhere, and information about multiple tumors diagnosed later may be coded after the *Date Case Completed – CoC*.
- Corrections and updates may be made after the *Date Case Completed – CoC*.
- Appendix D provides a list of items in each broad completion category below.
- After all required items identified below for the patient's *Class of Case* have been abstracted, the registrar should run the standard NAACCR edit set "Hosp: vs 12 CoC Required - All" using the registry software. The registry software will record the *Date Case Completed – CoC* when those items are abstracted and the case passes all edits in that set.

| Class of Case | Description | Items that Must Be Completed by Date Case Completed - CoC |
|----------------------|---|---|
| 00-22 | All analytic cases | Identification, demographic, diagnostic |
| 10-22 | Patient received part or all first course treatment from facility | Staging, hospital-specific treatment |
| 10, 12, 14, 20, 22 | Patient received all first course treatment from facility, or unspecified whether all or part | Summary treatment (treatment at any facility) |
| 00 | Patient diagnosed at facility, received all treatment elsewhere | NPI number for the facility the patient was referred to or a treating physician |
| 20-22 | Patient diagnosed elsewhere, received part or all of treatment from facility | NPI number for the facility the patient was referred to or from OR the physician who diagnosed or treated the patient |

OVERRIDE ACSN/CLASS/SEQ

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1985
 Revised 09/06, 09/08, 01/10

Description

Used with the EDITS software to override the edit *Accession Number, Class of Case, Seq Number (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

The edit, *Accession Number, Class of Case, Seq Number (CoC)*, checks the following:

- If the case is the only case or the first of multiple cases diagnosed at the facility (*Sequence Number–Hospital* = 00, 01, 60 or 61, and *Class of Case* = 00, 10, 12, 13, or 14), then the first 4 characters of the *Accession Number* (NAACCR Item #550) must equal the year of the *Date of First Contact* (NAACCR Item #580).
- If the case is first diagnosed at autopsy (*Class of Case* = 38), and the case is the only case or the first of multiple cases for a patient (*Sequence Number–Hospital* = 00, 01, 60, or 61), then the first 4 characters of the *Accession Number* must equal the year of the *Date of Last Contact or Death* (NAACCR Item #1750) AND must equal the year of the *Date of First Contact*.
- If the case is first diagnosed at autopsy (*Class of Case* = 38), and the case is the second or more case for a patient (*Sequence Number–Hospital* greater than 01 or greater than 61), then the year of the *Date of First Contact* must equal the year of *Date of Last Contact or Death*.

There are some exceptions to the above rules. *Override Acsn/Class/Seq* may be used to override the edit when the circumstances fit the following situation or one similar to it:

- The case may be the only or the first of multiple malignant cases for a patient (*Sequence Number–Hospital* = 00 or 01), but there is an earlier benign case (with an earlier year of the *Date of First Contact*) for which the *Accession Number* applies.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edit *Accession Number, Class of Case, Sequence Number (CoC)*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed and confirmed as reported. |

OVERRIDE HOSPSEQ/DXCONF

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1986
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edit *Diagnostic Confirm, Seq Num–Hosp (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

The edit, *Diagnostic Confirm, Seq Num–Hosp (CoC)*, does the following:

- If any case is one of multiple primaries and is not microscopically confirmed or positive lab test/marker study, i.e., *Diagnostic Confirmation* > 5 and *Sequence Number–Hospital* > 00 (more than one primary), review is required.
- If *Primary Site* (NAACCR Item #400) specifies an ill-defined or unknown primary (C76.0–C76.8, C80.9), no further checking is done. If *Sequence Number–Hospital* is in the range of 60-88, this edit is skipped.

It is important to verify that the non-microscopically-confirmed case is indeed a separate primary from any others that may have been reported. This edit forces review of multiple primary cancers when one of the primaries is coded to a site other than ill-defined or unknown and is not microscopically confirmed or confirmed by a positive lab test/marker study.

- If this edit is failed and the suspect case is confirmed accurate as coded, and the number of primaries is correct, set the *Override HospSeq/DxConf* to 1. Do not set the override flag on the patient's other primary cancers.
- However, if it turns out that the non-microscopically-confirmed cancer is considered a manifestation of one of the patient's other cancers, delete the non-microscopically-confirmed case. Check the sequence numbers of remaining cases, correcting them if necessary. Also check for other data items on the remaining cases that may need to be changed as a result of the corrections, such as stage and treatment.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edit *Diagnostic Confirm, Seq Num–Hosp (CoC)*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed and confirmed as reported. |

OVERRIDE COC–SITE/TYPE

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1987
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edits *Primary Site, Morphology-Type ICDO2 (CoC)*, *Primary Site, Morphology-Type ICDO3 (CoC)*, and/or *Primary Site, Morphology-Type, Behavior ICDO3 (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

There are multiple versions of edits of the type, *Primary Site, Morphology-Type*, which check for “usual” combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept Override CoC-Site/Type or Override Site/Type as equivalent.

- The Site/Histology Validation List (available on the SEER Web site) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations *not* listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if *Primary Site* (NAACCR Item #400) is in the range C44.0-C44.9 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis (See *Cancer Identification* in Section I). Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for edits of the type *Primary Site, Morphology-Type*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms they are correct and coded in conformance with coding rules.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed and confirmed as reported. |

OVERRIDE HOSPSEQ/SITE

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1988
 Revised 09/06 09/08, 02/10

Description

Used with the EDITS software to override the edit *Seq Num–Hosp, Primary Site, Morph ICDO2 (CoC)* and/or the edit *Seq Num–Hosp, Primary Site, Morph ICDO3 (CoC)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type, *Seq Num–Hosp, Primary Site, Morph*, differ in use of ICD-O-2 or ICD-O-3 morphology. They force review of multiple primary cancers when one of the primaries is coded to a site-morphology combination that could indicate a metastatic site rather than a primary site. If *Sequence Number–Hospital* indicates the person has had more than one primary, then any case with one of the following site-histology combinations requires review:

- C76.0–C76.8 (Ill-defined sites) or C80.9 (unknown primary) and ICD-O-2 or ICD-O-3 histology < 9590. (Look for evidence that the unknown or ill-defined primary is a secondary site from one of the patient's other cancers. For example, a clinical discharge diagnosis of “abdominal carcinomatosis” may be attributable to the patient's primary ovarian cystadenocarcinoma already in the registry, and should not be entered as a second primary.)
- Lymph node primary sites (C77.0–C77.9) for histologies other than lymphomas, or hematopoietic primary sites for histologies not in range for hematopoietic diseases. (That combination is most likely a metastatic lesion. Check whether the lesion could be a manifestation of one of the patient's other cancers.)
- Any site and ICD-O-2 histology in the range 9720–9723, 9740–9741 or ICD-O-3 histology in the range 9740–9758. (Verify that these diagnoses are coded correctly and are indeed separate primaries from the others.)

If it turns out that the suspect tumor is a manifestation of one of the patient's other cancers, delete the metastatic or secondary case, re-sequence remaining cases, and correct the coding on the original case as necessary.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for an edit of the type *Seq Num–Hosp, Primary Site, Morph*
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed and confirmed as reported. |

OVERRIDE SITE/TNM-STAGE GROUP

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1989
 Revised 09/04, 09/08, 01/10, 01/12

Description

Used with the EDITS software to override the edits of the type *Primary Site, AJCC Stage Group*, for AJCC staging editions 6 and later.

Rationale

This override flag allows identification of pediatric cancers that were staged according to a system other than the **AJCC** staging manual (which is predominantly directed toward adult staging) if they are not also **AJCC**-staged. In that situation an otherwise-stageable case may be coded 88 (not applicable) for all **AJCC** items.

EDITS Use

Edits of the type, *Primary Site, AJCC Stage Group*, check that the pathologic and clinical AJCC stage group codes are valid for the site and histology group according to the applicable *AJCC Cancer Staging Manual*, using the codes described for the items *Clinical Stage Group* (NAACCR Item #970) and *Pathologic Stage Group* (NAACCR Item #910). Combinations of site and histology not represented in any AJCC schema must be coded 88. Unknown codes must be coded 99. Blanks are not permitted.

Since pediatric cancers whose sites and histologies have an AJCC scheme may be coded according to a pediatric scheme instead, use *Override Site/TNM-Stage Group* to indicate the case was coded according to a pediatric staging system if it was not also coded according to the AJCC manual. Pediatric stage groups should *not* be recorded in the *Clinical Stage Group* or *Pathologic Stage Group* items. When neither clinical nor pathologic AJCC staging is used for pediatric cases, code all AJCC items 88. When any AJCC component is used to stage a pediatric case, follow the instructions for coding AJCC items and leave *Override Site/TNM-Stage Group* blank.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edits of the type, *Primary Site, AJCC Stage Group*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if the case is confirmed to be a pediatric case that was coded using a pediatric coding system.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed and confirmed as reported. |

OVERRIDE AGE/SITE/MORPH

Item Length: 1
 Allowable Values: 1
 NAACCR Item #1990
 Revised 04/07, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Age, Primary Site, Morphology*; *Age, Primary Site, Morph ICDO3–Adult*, and *Age, Primary Site, Morph ICDO3–Pediatric*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type *Age, Primary Site, Morphology*; *Age, Primary Site, Morph ICDO3–Adult*; and *Age, Primary Site, Morph ICDO3–Pediatric* require review if a site-morphology combination occurs in an age group for which it is extremely rare or if the cancer was diagnosed in utero.

If the edit generates an error or warning message, check that the primary site and histologic type are coded correctly and that the age, date of birth, and date of diagnosis are correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the *Age, Primary Site, Morphology*; *Age, Primary Site, Morph ICDO3–Adult*, and *Age, Primary Site, Morph ICDO3–Pediatric* edits.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 for an unusual occurrence of a particular age/site/histology combination for a given age has been confirmed by review to be correct.
- Code 2 if the case was diagnosed in utero.
- Code 3 if both conditions apply.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed; age, site, and morphology combination confirmed as reported. |
| 2 | Reviewed; diagnosis in utero. |
| 3 | Reviewed; both conditions apply. |

OVERRIDE SURG/DXCONF

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2020
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edits *RX Summ–Surg Prim Site, Diag Conf (SEER IF76)*; *RX Summ–Surgery Type, Diag Conf (SEER IF46)*; and/or the edit *RX Summ–Surg Site 98-02, Diag Conf (SEER 106)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type, *RX Summ–Surg Prim Site, Diag Conf*, check that cases with a primary site surgical procedure coded 20-90 are histologically confirmed.

If the patient had a surgical procedure, most likely there was a microscopic examination of the cancer.

- Verify the surgery and diagnostic confirmation codes, and correct any errors.
- Sometimes there are valid reasons why no microscopic confirmation is achieved with the surgery, for example, the tissue removed may be inadequate for evaluation.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for edits of the type, *RX Summ–Surg Prim Site, Diag Conf*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported. |

OVERRIDE SITE/TYPE

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2030
 Revised 09/06, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Primary Site, Morphology-Type* and *Primary Site, Morphology-Type, Behavior ICDO3*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

There are multiple versions of edits of the type, *Primary Site, Morphology-Type*, which check for “usual” combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept *Override CoC-Site/Type* or *Override Site/Type* as equivalent.

- The Site/Histology Validation List (available on the SEER website) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations *not* listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if *Primary Site* (NAACCR Item #400) is in the range C440-C449 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis (See *Cancer Identification* in Section I). Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for edits of the type *Primary Site, Morphology-Type*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported. |

OVERRIDE HISTOLOGY

Item Length: 1
Allowable Values: 1, 2, 3
NAACCR Item #2040
Revised 04/07, 09/08

Description

Used with the EDITS software to override any of five edits: *Diagnostic Confirmation, Behavior ICDO2 (SEER IF31)*; *Diagnostic Confirmation, Behavior ICDO3 (SEER IF31)*; *Morphology–Type/Behavior ICDO2 (SEER MORPH)*; *Morphology–Type/Behavior ICDO3 (SEER MORPH)*; and/or the edit *Morph (1973-91) ICD-O-1 (SEER MORPH)*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

I. Edits of the type, *Diagnostic Confirmation, Behavior Code*, differ in the use of ICD-O-2 or ICD-O-3 and check that, for in situ cases (Behavior = 2), *Diagnostic Confirmation* specifies microscopic confirmation (1, 2 or 4). The distinction between in situ and invasive is very important to a registry, since prognosis is so different. Since the determination that a neoplasm has not invaded surrounding tissue, i.e. is in situ, is made microscopically, cases coded in situ in behavior should have a microscopic confirmation code. Very rarely, a physician will designate a case noninvasive or in situ without microscopic evidence.

If an edit of the type, *Diagnostic Confirmation, Behavior Code*, gives an error message or warning, check that *Behavior Code* (NAACCR Item #523) and *Diagnostic Confirmation* (NAACCR Item #490) have been coded correctly. Check carefully for any cytologic or histologic evidence that may have been missed in coding.

II. Edits of the type, *Morphology–Type/Behavior*, perform the following overrideable check:

- Codes listed in ICD-O-2 or ICD-O-3 with behavior codes of only 0 or 1 are considered valid, since use of the behavior matrix of ICD-O-2 and ICD-O-3 allows for the elevation of the behavior of such histologies when the tumor is in situ or malignant. This edit forces review of these rare cases to verify that they are indeed in situ or malignant.

If a *Morphology-Type/Behavior* edit produces an error or warning message and the case is one in which the 4-digit morphology code is one that appears in ICD-O-2 or ICD-O-3 only with behavior codes of 0 or 1, verify the coding of morphology and that the behavior should be coded malignant or in situ. The registrar may need to consult a pathologist or medical advisor in problem cases.

Exceptions to the above: If year of *Date of Diagnosis* > 2000, then a behavior code of 1 is valid for the following ICD-O-2 histologies and no override flag is needed: 8931, 9393, 9538, 9950, 9960-9962, 9980-9984, 9989. Similarly, the following ICD-O-3 histologies are valid with a behavior code of 1: 8442, 8451, 8462, 8472, and 8473.

Note: The *Morphology-Type/Behavior* edits are complex and perform several additional types of checks. No other aspects of their checks are subject to override.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edits of the types *Diagnostic Confirmation* or *Morph* or *Morphology–Type/Behavior*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1, 2 or 3 as indicated if review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|---|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported for edits of the type <i>Morphology–Type/Behavior</i> . |
| 2 | Reviewed, confirmed as reported for edits of the type <i>Diagnostic Confirmation, Behavior Code</i> . |
| 3 | Reviewed: conditions 1 and 2 above both apply. |

OVERRIDE LEUK, LYMPHOMA

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2070
 Revised 09/06, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Diagnostic Confirmation, Histology*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type *Diagnostic Confirmation, Histology* differ in use of ICD-O-2 (NAACCR Item #420) or ICD-O-3 (NAACCR Item #522) and check the following:

- Since lymphoma and leukemia are almost exclusively microscopic diagnoses, this edit forces review of any cases of lymphoma that have diagnostic confirmation of direct visualization or clinical, and any leukemia with a diagnostic confirmation of direct visualization.
- For lymphomas, *Diagnostic Confirmation* (NAACCR Item #490) cannot be 6 (direct visualization) or 8 (clinical).
- For leukemia and other hematopoietic neoplasms, *Diagnostic Confirmation* cannot be 6 (direct visualization).

If an edit of the type, *Diagnostic Confirmation, Histology*, produces an error or warning message, check that the *Histology* and *Diagnostic Confirmation* items are correctly coded. Remember that positive hematologic findings and bone marrow specimens are included as histologic confirmation (code 1 in *Diagnostic Confirmation*) for leukemia.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the edits of the type *Diagnostic Confirmation, Histology*.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported. |

OVERRIDE SITE/BEHAVIOR

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2071
 Revised 09/06, 09/08

Description

Used with the EDITS software to override the edits of the type *Primary Site, Behavior Code*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type, *Primary Site, Behavior*, require review of the following primary sites with a behavior of in situ (ICD-O-2 or ICD-O-3 behavior = 2):

| | |
|-------------|---|
| C26.9 | Gastrointestinal tract, NOS |
| C39.9 | Ill-defined sites within respiratory system |
| C55.9 | Uterus, NOS |
| C57.9 | Female genital tract, NOS |
| C63.9 | Male genital organs, NOS |
| C68.9 | Urinary system, NOS |
| C72.9 | Nervous system, NOS |
| C75.9 | Endocrine gland, NOS |
| C76.0-C76.8 | Ill-defined sites |
| C80.9 | Unknown primary site |

Since the designation of in situ is very specific and almost always requires microscopic confirmation, ordinarily specific information should also be available regarding the primary site. Conversely, if inadequate information is available to determine a specific primary site, it is unlikely that information about a cancer being in situ is reliable.

- If a specific in situ diagnosis is provided, try to obtain a more specific primary site. A primary site within an organ system can sometimes be identified based on the diagnostic procedure or treatment given or on the histologic type. If a more specific site cannot be determined, it is usually preferable to code a behavior code of 3. In the exceedingly rare situation in which it is certain that the behavior is in situ and no more specific-site code is applicable, set *Override Site/Behavior* to 1.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for *Primary Site, Behavior* edits.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported. |

OVERRIDE SITE/LAT/MORPH

Item Length: 1
 Allowable Values: 1
 NAACCR Item #2074
 Revised 09/06, 09/08

Description

Used with the EDITS software to override edits of the type *Laterality*, *Primary Site*, *Morph*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

Edits of the type *Laterality*, *Primary Site*, *Morph* differ in whether they produce a warning or an error message and in use of ICD-O-2 or ICD-O-3 morphology and do the following:

- If the *Primary Site* (NAACCR Item #400) is a paired organ and *Behavior Code* (NAACCR Item #523) is in situ (2), then *Laterality* (NAACCR Item #410) must be 1, 2, 3 or 5.
- If diagnosis year is less than 1988 and *Histology* (NAACCR Item #522) is greater than or equal to 9590, then no further editing is performed. If diagnosis year is greater than 1987 and *Histology* equals 9140, 9700, 9701, 9590-9980, then no further editing is performed.

The intent of this edit is to force a review of in situ cases for which *Laterality* is coded 4 (bilateral) or 9 (unknown laterality) as to origin.

- In rare instances when the tumor is truly midline and the case was diagnosed prior to 2010 (when midline was coded 9), either change the *Laterality* code to 5 and leave the override blank, or enter code 1 for *Override Site/Lat/Morph*. For cases diagnosed in 2010 or later, *Laterality* must be coded 5 for midline tumors.
- If the rare combination is otherwise confirmed correct, enter code 1 for *Override Site/Lat/Morph*.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message for the *Laterality*, *Primary Site*, *Morphology* edits.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported. |

COC CODING SYSTEM–CURRENT

Item Length: 2
 Allowable Values: 00–08, 99
 NAACCR Item #2140
 Revised 01/10

Description

Indicates the Commission on Cancer coding system currently used in the record.

Rationale

Knowledge of the coding system that describes the meaning of the codes currently stored for each case is necessary for interpretation of the coded data. It is also necessary for correct conversion of the record to a different coding system or to a different registry software system. This item differs from *CoC Coding System–Original* (NAACCR Item #2150) if the record has been converted to a more recent coding system.

Instructions for Coding

- All fields in a case record should be coded according to the same Commission on Cancer coding system following record conversion.
- This code does not apply to patient race, primary site, histology, TNM stage and its components, Collaborative Stage, comorbidities and complications, or cause of death. The original coding systems for these items are recorded in other fields.
- This item should be updated every time the record is converted to another coding system.

| Code | Label | Definition |
|------|----------|---|
| 00 | None | No CoC coding system used. |
| 01 | Pre-1988 | Pre-1988 version (Cancer Program Manual Supplement) |
| 02 | 1988 | 1988 <i>Data Acquisition Manual</i> |
| 03 | 1989 | 1989 <i>Data Acquisition Manual</i> |
| 04 | 1990 | 1990 <i>Data Acquisition Manual</i> |
| 05 | 1994 | 1994 <i>Data Acquisition Manual</i> |
| 06 | 1996 | <i>Standards of the Commission on Cancer Volume II: Registry Operations and Data Standards (ROADS)</i> |
| 07 | 1998 | <i>Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> 1998 Revisions |
| 08 | 2003 | <i>Facility Oncology Registry Data Standards (FORDS)</i> |
| 99 | Unknown | Unknown coding system. |

Examples

| Code | Reason |
|------|---|
| 00 | A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program and no conversion of the record has occurred since its accession into the registry. |
| 08 | A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program. In 1989, the registry records were converted to conform to the codes defined in the 1989 <i>Data Acquisition Manual</i> . The registry data were subsequently converted in 1996, 1998, and 2003 with the publication of each manual. |

| Code | Reason |
|------|--|
| 08 | A case accessioned in 1997 was coded according to 1996 <i>Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> , and subsequently converted to correspond to the coding system expressed in <i>Facility Oncology Registry Data Standards (FORDS)</i> . |
| 08 | A new case was abstracted in 2010 using <i>Facility Oncology Registry Data Standards (FORDS) Revised for 2010</i> . |
| 99 | A case was accessioned in 1989, but it is unknown whether the 1988 or 1989 version of the <i>Data Acquisition Manual</i> was used to code the case. The conversion of this record to a more recent coding system is not possible due the uncertainty of its original coding system. |

COC CODING SYSTEM–ORIGINAL

Item Length: 2
 Allowable Values: 00–08, 99
 NAACCR Item #2150
 Revised 01/10

Description

Indicates the Commission on Cancer coding system used to originally code the items.

Rationale

The coding system used when a case is originally coded limits the possible categories that could have been applied to code the case. Because code categories may change over time as new coding systems are developed, this item is used to assist interpretation when cases that may have been coded originally according to multiple coding systems are analyzed.

Instructions for Coding

- All fields in a case record should be coded according to the same Commission on Cancer coding system.
- This code does not apply to patient race, primary site, histology, TNM stage and its components, Collaborative Stage, comorbidities or complications, or cause of death. The original coding systems for these items are recorded in other fields.
- This item must not be changed when the record is converted to another coding system. That information is reflected in the data item *CoC Coding System–Current* (NAACCR Item #2140).
- Code 99 for cases coded prior to 2003 if the correct CoC coding system is not known, or if multiple coding systems were used to code a single case. Ordinarily, it will not be necessary to use code 99 for cases accessioned in 2003 or later.

| Code | Label | Definition |
|------|----------|---|
| 00 | None | No CoC coding system used. |
| 01 | Pre-1988 | Pre-1988 version (Cancer Program Manual Supplement) |
| 02 | 1988 | 1988 <i>Data Acquisition Manual</i> |
| 03 | 1989 | 1989 <i>Data Acquisition Manual</i> |
| 04 | 1990 | 1990 <i>Data Acquisition Manual</i> |
| 05 | 1994 | 1994 <i>Data Acquisition Manual</i> |
| 06 | 1996 | <i>Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> |
| 07 | 1998 | <i>Standards of the Commission on Cancer Volume II: Registry Operations and Data Standards (ROADS) 1998 Revisions</i> |
| 08 | 2003 | <i>Facility Oncology Registry Data Standards (FORDS)</i> |
| 99 | Unknown | Original CoC coding system used is not known. |

Examples

| Code | Reason |
|-------------|---|
| 00 | A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program. |
| 00 | A case accessioned in 1980 was coded according to codes developed locally by the hospital before it became involved in the Commission on Cancer Approvals Program. In 1989, the registry records were converted to conform to the codes defined in the 1989 <i>Data Acquisition Manual</i> . The registry data were subsequently converted in 1996, 1998, and 2003 with the publication of each manual. |
| 06 | A case accessioned in 1997 was coded according to <i>1996 Standards of the Commission on Cancer, Volume II: Registry Operations and Data Standards (ROADS)</i> , and subsequently converted to correspond to the coding rules expressed in <i>Facility Oncology Registry Data Standards (FORDS)</i> . |
| 99 | A case was accessioned in 1989, but it is unknown whether the 1988 or 1989 version of the <i>Data Acquisition Manual</i> was used to code the case. |

RACE CODING SYSTEM–CURRENT

Item Length: 1
 Allowable Values: 1–6, 9
 NAACCR Item #170
 Revised 01/04, 01/10

Description

Describes how race is currently coded. If converted, this field shows the system to which it was converted.

Rationale

Race codes (NAACCR Items #160–164) have changed over time. To accurately group and analyze data, it is necessary to record the system used to record the race codes.

Instructions for Coding

This item is autocoded by the software provider.

| Code | Definition |
|------|---|
| 1 | 4-value coding: 1 = White, 2 = Black, 3 = Other, 9 = Unknown |
| 2 | <1988 (1-digit) |
| 3 | 1988 + (2-digit) |
| 4 | 1991 + (added codes 20–97) |
| 5 | 1994 + (added code 14) |
| 6 | 2000 + (no new codes added, new items <i>Race #2–Race #5</i> added) |
| 7 | 2010 + (added codes 15, 16, and 17; removed 09) |
| 9 | Other |

RACE CODING SYSTEM—ORIGINAL

Item Length: 1
 Allowable Values: 1–6, 9
 NAACCR Item #180
 Revised 01/04, 01/10

Description

Describes how race was originally coded.

Rationale

Race #1–#5 codes (NAACCR Items #160–164) have changed over time. Identifying both the original and current coding systems used to code race promotes accurate data grouping and analysis.

Instructions for Coding

- This item is autocoded by the software provider.
- For cases diagnosed on or after January 1, 2010, this data item must be coded 7.

| Code | Definition |
|------|---|
| 1 | 4-value coding: 1 = White, 2 = Black, 3 = Other, 9 = Unknown |
| 2 | <1988 (1-digit) |
| 3 | 1988 + (2-digit) |
| 4 | 1991 + (added codes 20–97) |
| 5 | 1994 + (added code 14) |
| 6 | 2000 + (no new codes added, new items <i>Race #2–Race #5</i> added) |
| 7 | 2010 + (added codes 15, 16, and 17; removed 09) |
| 9 | Other |

SITE CODING SYSTEM–CURRENT

Item Length: 1
Allowable Values: 1–6, 9
NAACCR Item #450

Description

Describes how the primary site is currently coded. If converted, this field shows the system to which it was converted.

Rationale

This information is used for some data analysis and for further item conversions.

Instructions for Coding

This item is autocoded by the software provider.

| Code | Definition |
|------|--|
| 1 | ICD-8 and Manual of Tumor Nomenclature and Coding (MOTNAC) |
| 2 | ICD-9 |
| 3 | ICD-O, First Edition |
| 4 | ICD-O, Second Edition |
| 5 | ICD-O, Third Edition |
| 6 | ICD-10 |
| 9 | Other |

SITE CODING SYSTEM–ORIGINAL

Item Length: 1
Allowable Values: 1–6, 9
NAACCR Item #460

Description

Describes how the primary site was originally coded.

Rationale

This information is used for some data analysis. Converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

This item is autocoded by the software provider.

| Code | Definition |
|------|--|
| 1 | ICD-8 and Manual of Tumor Nomenclature and Coding (MOTNAC) |
| 2 | ICD-9 |
| 3 | ICD-O, First Edition |
| 4 | ICD-O, Second Edition |
| 5 | ICD-O, Third Edition |
| 6 | ICD-10 |
| 9 | Other |

MORPHOLOGY CODING SYSTEM–CURRENT

Item Length: 1
 Allowable Values: 1–7, 9
 NAACCR Item #470
 Revised 01/10

Description

Describes how morphology is currently coded. If converted, this field shows the system to which it was converted.

Rationale

This information is used for some data analysis and for further item conversions. New versions of the codes used for recording histology and behavior reflect advances in medical and pathologic knowledge, and converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

This item is autocoded by the software provider.

| Code | Definition |
|------|---|
| 1 | ICD-O, First Edition |
| 2 | ICD-O, 1986 Field Trial |
| 3 | ICD-O, 1988 Field Trial |
| 4 | ICD-O, Second Edition |
| 5 | ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/95 |
| 6 | ICD-O, Second Edition, plus FAB codes effective 1/1/98 |
| 7 | ICD-O, Third Edition |
| 8 | ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms effective 1/1/2010 |
| 9 | Other |

MORPHOLOGY CODING SYSTEM–ORIGINAL

Item Length: 1
 Allowable Values: 1–7, 9
 NAACCR Item #480
 Revised 01/04, 01/10, 01/11

Description

Describes how morphology was originally coded. If later converted, this field shows the original codes used.

Rationale

This information is used for some data analysis and for further item conversions. New versions of the codes used for recording histology and behavior reflect advances in medical and pathologic knowledge, and converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

- This item is autocoded by the software provider.
- For cases diagnosed on or after January 1, 2010, this data item must be coded 8.

| Code | Definition |
|------|---|
| 1 | ICD-O, First Edition |
| 2 | ICD-O, 1986 Field Trial |
| 3 | ICD-O, 1988 Field Trial |
| 4 | ICD-O, Second Edition |
| 5 | ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/95 |
| 6 | ICD-O, Second Edition, plus FAB codes effective 1/1/98 |
| 7 | ICD-O, Third Edition |
| 8 | ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms effective 1/1/2010 |
| 9 | Other |

ICD-O-2 CONVERSION FLAG

Item Length: 1
 Allowable Values: 0–6, blank
 NAACCR Item #1980
 Revised 01/04

Description

Specifies whether or how site and morphology codes were converted to ICD-O-2.

Rationale

This information is used for some data analysis and for further item conversions.

Instructions for Coding

- Codes 0, 1, and 2 are autocoded by the software provider.
- Codes 3 and 4 are manually entered following a review of the automated morphology conversion from ICD-O-1 or ICD-O-3 to ICD-O-2.

| Code | Definition |
|---------------|---|
| (leave blank) | Not converted. |
| 0 | Primary site and morphology originally coded in ICD-O-2. |
| 1 | Primary site and morphology converted without review. |
| 2 | Primary site and morphology converted with review; morphology machine-converted without review. |
| 3 | Primary site machine-converted without review; morphology converted with review. |
| 4 | Primary site and morphology converted with review. |
| 5 | Morphology converted from ICD-O-3 without review. |
| 6 | Morphology converted from ICD-O-3 with review. |

ICD-O-3 CONVERSION FLAG

Item Length: 1
 Allowable Values: 0, 1, 3, blank
 NAACCR Item #2116
 Revised 01/04

Description

Identifies how the conversion of morphology codes from ICD-O-2 to ICD-O-3 was accomplished.

Rationale

This information is used for some data analysis and for further item conversions. New versions of the codes used for recording histology and behavior reflect advances in medical and pathologic knowledge, and converted codes have a slightly different distribution and meaning than codes entered directly. Cancer registries record case histories over many years, so not all cases will originally be assigned according to the same code version.

Instructions for Coding

- Codes 0 and 1 are autocoded by the software provider.
- Code 3 is manually entered following review of the automated morphology conversion from ICD-O-2 to ICD-O-3.

| Code | Definition |
|---------------|---|
| (leave blank) | Not converted. |
| 0 | Morphology (Morph–Type&Behav ICD-O-3, NAACCR Item #521) originally coded in ICD-O-3. |
| 1 | Morphology (Morph–Type&Behav ICD-O-3, NAACCR Item #521) converted from (Morph–Type&Behav ICD-O-2, NAACCR Item #419) without review. |
| 3 | Morphology (Morph–Type&Behav ICD-O-3, NAACCR Item #521) converted from (Morph–Type&Behav ICD-O-2, NAACCR Item #419) with review. |

TNM EDITION NUMBER

Item Length: 2
Allowable Values: 00–06, 88, 99
NAACCR Item #1060
Revised 01/04, 01/10

Description

Identifies the edition of the *AJCC Cancer Staging Manual* used to stage the case.

Rationale

AJCC stage and component T, N, and M codes and rules have changed over time. This item enables the analysis of cases grouped by edition number.

Instructions for Coding

This item is autocoded by the software provider.

| Code | Label |
|------|---|
| 00 | Not staged (cases that have an AJCC staging scheme and staging was not done). |
| 01 | First Edition |
| 02 | Second Edition |
| 03 | Third Edition |
| 04 | Fourth Edition |
| 05 | Fifth Edition |
| 06 | Sixth Edition |
| 07 | Seventh Edition |
| 88 | Not applicable (cases that do not have an AJCC staging scheme). |
| 99 | Staged, but the edition is unknown. |

RX CODING SYSTEM–CURRENT

Item Length: 2
 Allowable Values: 00–06, 99
 NAACCR Item #1460

Description

Describes how treatment for this case is now coded.

Rationale

This information is used for some data analysis and for further item conversions.

Instructions for Coding

- This item is autocoded by the software provider.
- The *FORDS* manual **must** be used to record treatment for all cases diagnosed January 1, 2003, or later and this item **must** be coded 06.

| Code | Definition |
|------|---|
| 00 | Treatment data not coded/transmitted, i.e., all treatment fields blank. |
| 01 | Treatment data coded using 1-digit surgery codes. |
| 02 | Treatment data coded according to 1983–1992 SEER manuals and CoC manuals 1983–1995. |
| 03 | Treatment data coded according to 1996 ROADS manual. |
| 04 | Treatment data coded according to 1998 ROADS supplement. |
| 05 | Treatment data coded according to 1998 SEER manual. |
| 06 | Treatment data coded according to FORDS. |
| 07 | Treatment data coded according to 2010 SEER manual. |
| 99 | Other coding, including partial or nonstandard coding. |

DERIVED AJCC-FLAG

Item Length: 1
Allowable Values: 1, 2
NAACCR Item #3030
Revised 01/10

Description

Indicates the source data items used to derive AJCC Stage descriptors and Stage Group. It also indicates the target AJCC edition described by the derived AJCC Stage descriptors and Stage Group.

Rationale

AJCC Stage and component T, N, and M codes and rules change over time as does the method of deriving them. This item enables the analysis of cases grouped by coding and derivation version.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

| Code | Description |
|---------------|---|
| (leave blank) | Not derived. |
| 1 | AJCC fields derived from Collaborative Stage. |
| 2 | AJCC fields derived from EOD (prior to 2004). |

DERIVED SS1977–FLAG

Item Length: 1
Allowable Values: 1, 2
NAACCR Item #3040
Revised 01/10

Description

Indicates the source data items used to derive SEER Summary Stage 1997.

Rationale

The derivation of SS1977 varies over time with the coding rules and codes in use when the components were coded. This item enables the analysis of cases grouped by coding and derivation version.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

| Code | Description |
|---------------|--|
| (leave blank) | Not derived. |
| 1 | SS1977 derived from Collaborative Stage. |
| 2 | SS1977 derived from EOD (prior to 2004). |

DERIVED SS2000–FLAG

Item Length: 1
Allowable Values: 1, 2
NAACCR Item #3050
Revised 01/10

Description

Indicates the source data items used to derive SEER Summary Stage 2000.

Rationale

The derivation of SS2000 varies over time with the coding rules and codes in use when the components were coded. This item enables the analysis of cases grouped by coding and derivation version.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

| Code | Description |
|---------------|--|
| (leave blank) | Not derived. |
| 1 | SS2000 derived from Collaborative Stage. |
| 2 | SS2000 derived from EOD (prior to 2004). |

**CS VERSION INPUT ORIGINAL
(CS VERSION FIRST)**

Item Length: 6
Numeric
NAACCR Item #2935
Revised 01/10

Description

This item indicates the number of the version initially used to code Collaborative Staging (CS) fields. The CS version number is returned as part of the output of the CS algorithm.

Rationale

Over time, the input codes and instructions for CS items may change. This item identifies the correct interpretation of input CS items.

Instructions for Coding

This item is autocoded by the software provider.

Codes

CS Version Input Original is a 6-digit code. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

CS VERSION INPUT CURRENT

Item Length: 6
Numeric
NAACCR Item #2937
New Item 01/2010

Description

This item indicates the version of CS input fields after they have been updated or recoded. This data item is recorded the first time the CS input fields are entered and should be updated each time the CS input fields are modified.

Rationale

Over time, the input codes and instructions for CS items may change. This item identifies the correct interpretation of input CS items.

Instructions for Coding

This item is autocoded by the software provider.

Codes

CS Version Input Current is a 6-digit code. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

**CS VERSION DERIVED
(CS VERSION LATEST)**

Item Length: 6
Numeric
NAACCR Item #2936
Revised 01/10

Description

This data item is recorded the first time the CS output fields are derived and should be updated each time the CS Derived items are recomputed. The CS version number is returned as part of the output of the CS algorithm.

Rationale

The CS algorithm may be re-applied to compute the CS Derived items; for example, when the data are to be used for a special study, transmitted, or when an updated CS algorithm is produced. This item identifies the specific algorithm used to obtain the CS Derived values in the data record.

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

Instructions for Coding

This item is autocoded by the software provider.

Codes

CS Version Derived is a 6-digit code. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

OVER-RIDE CS 1-19

Numeric
NAACCR Item #3750-3768
New 01/2013

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that date in a record have been reviewed and, while quite unusual are correct.

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future.

Instructions

Instructions will be provided as edits that use these items are implemented.

Over-ride CS 20 is defined, but is not to be used by CoC accredited programs for analytic cases.

| Code | Definition |
|---------------|--|
| (leave blank) | Not reviewed; or reviewed and corrected. |
| 1 | Reviewed, confirmed as reported. |

APPENDIX A

Use the table in this Appendix only for hematologic malignancies diagnosed prior to January 1, 2010. Beginning with diagnoses on that date, use *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB).

Appendix A: Definitions of Single and Subsequent Primaries for Hematologic Malignancies

Based on ICD-O-3 reportable malignancies, for use with diagnoses 01/01/2001 - 12/31/2009

Cancer registrars are often faced with multiple pathology reports in patients with hematologic malignancies, and the diagnoses reported may require different morphology codes. This is due in part to the fact that more intensive diagnostic study may yield a more specific diagnosis, and in part due to the natural histories of hematopoietic diseases, which may progress from one diagnosis into another.

The following chart, provided to aid the registrar in determining single versus subsequent primaries, employs the following guidelines:

- 1 “Lymphoma” is a general term for hematopoietic solid malignancies of the lymphoid series. “Leukemia” is a general term for liquid malignancies of either the lymphoid or the myeloid series. While it is recognized that some malignancies occur predominantly (or even exclusively) in liquid or solid form, because so many malignancies can potentially arise as either leukemias or lymphomas (or both), all hematopoietic malignancies are assumed to have this potential.
- 2 Malignancies of the lymphoid series are considered to be different from those of the myeloid series. Therefore, a lymphoid malignancy arising after diagnosis of a myeloid malignancy (or myelodysplastic or myeloproliferative disorder) would be considered a subsequent primary; however, a myeloid malignancy diagnosed after a previous myeloid malignancy would not count as a subsequent primary. Histiocytic malignancies are considered different from both lymphoid and myeloid malignancies.
- 3 Hodgkin lymphoma is considered to be different from non-Hodgkin lymphoma (NHL). Among the NHLs, B-cell malignancies are considered different from T-cell/NK cell malignancies. Therefore, a B-cell malignancy arising later in the course of a patient previously diagnosed with a T-cell malignancy would be considered a subsequent primary; however, a T-cell malignancy diagnosed later in the same patient would not be considered a subsequent primary.
- 4 The sequence of diagnoses affects whether a diagnosis represents a subsequent primary. In some cases, the order of occurrence of the two diagnoses being compared is a factor in the decision whether the second diagnosis is a new primary.

We gratefully acknowledge the assistance of Drs. Charles Lynch, Charles Platz, and Fred Dick of the University of Iowa. Dr. Tim Cote of the SEER Program, Jennifer Seiffert, MLIS, CTR, and Annette Hurlbut, RHIT, CTR for their assistance with this project.

To use the table, assign the ICD-O-3 code to the first diagnosis and find the row containing that code. Assign the ICD-O-3 code for the second diagnosis and find the column containing that code. In the cell at the intersection of the first diagnosis row and second diagnosis column, a “**S**” symbol indicates that the two diagnoses are most likely the **same** disease process (prepare/update a single abstract) and a “**D**” indicates that they are most likely **different** disease processes (prepare more than one abstract).

Note 1: If one of the two diagnoses is an NOS (not otherwise specified) term and the other is more specific and determined to be the same disease process, code the more specific diagnosis regardless of the sequence. For example, if a diagnosis of non-Hodgkin lymphoma, NOS is followed by a diagnosis of follicular lymphoma, assign the morphology code for the follicular lymphoma.

Note 2: The table “Single versus Subsequent Primaries of Lymphatic and Hematopoietic Diseases” (pages X-X) and the “Complete Diagnostic Terms for Table (based on ICD-O-3)” (page X) display only the ICD-O-3 primary (boldfaced) term associated with the code. Refer to the *International Classification of Disease, Third Edition (ICDO-3)* for a complete list of related terms and synonyms.

Source: SEER Program, NCI E-mail: seerweb@ims.nci.nih.gov

SECOND DX ACROSS

FIRST DX DOWN

| | | 1. 9590 Malignant lymphoma, NOS | 2. 9591 NHL, NOS | 3. 9596 Composite HD/NHL | 4. 9650-9667 Hodgkin lymphoma | 5. 9670-9671 ML, small B lymph | 6. 9673 Mantle cell lymph | 7. 9675-9684 ML, diffuse large B-cell | 8. 9687 Burkitt lymphoma | 9. 9689, 9699 Marg zn, B-cl lym | 10. 9690-9698 Follicular lymphoma |
|-----------------------------------|------------|---------------------------------|------------------|--------------------------|-------------------------------|--------------------------------|---------------------------|---------------------------------------|--------------------------|---------------------------------|-----------------------------------|
| 1. Malignant lymphoma, NOS | 9590 | S | S | S | S | S | S | S | S | S | |
| 2. NHL, NOS | 9591 | S | S | D | D | S | S | S | S | S | |
| 3. Composite HD/NHL | 9596 | S | S | S | S | S | S | S | S | S | |
| 4. Hodgkin lymphoma | 9650-9667 | S | D | D | S | D | D | D | D | D | |
| 5. ML, small B lymphocytic | 9670-9671 | S | S | D | D | S | D | S | D | D | |
| 6. Mantle cell lymphoma | 9673 | S | S | D | D | D | S | D | D | D | |
| 7. ML, diffuse, large B-cell | 9675-9684 | S | S | D | D | S | D | S | S | D | |
| 8. Burkitt lymphoma | 9687 | S | S | D | D | D | D | D | S | D | |
| 9. Marg zone, B-cell lymphoma | 9689, 9699 | S | S | D | D | D | D | D | D | S | |
| 10. Follicular lymphoma | 9690-9698 | S | S | D | D | D | D | S | D | S | |
| 11. Mycos fung, Sezary disease | 9700-9701 | S | S | D | D | D | D | D | D | D | |
| 12. T/NK-cell NHL | 9702-9719 | S | S | D | D | D | D | D | D | D | |
| 13. Precurs lym'blas lymph NOS | 9727 | S | S | D | D | D | D | D | D | D | |
| 14. Precurs lym'blas lymph B-cell | 9728 | S | S | D | D | D | D | D | D | D | |
| 15. Precurs lym'blas lymph T-cell | 9729 | S | S | D | D | D | D | D | D | D | |
| 16. Plasma cell tumors | 9731-9734 | D | D | D | D | D | D | D | D | D | |
| 17. Mast cell tumors | 9740-9742 | D | D | D | D | D | D | D | D | D | |
| 18. Histiocytos/Langerhans cell | 9750-9756 | D | D | D | D | D | D | D | D | D | |
| 19. Dendritic cell sarcoma | 9757-9758 | S | S | D | D | D | D | D | D | D | |
| 20. Immunoprolif disease, NOS | 9760 | S | S | D | D | S | D | S | D | D | |
| 21. Waldenstrom macroglob | 9761 | S | S | D | D | S | D | S | D | D | |
| 22. Heavy chain disease, NOS | 9762 | S | S | D | D | D | D | D | D | D | |
| 23. Immun sm intest disease | 9764 | S | S | D | D | D | D | D | D | D | |
| 24. Leuk/Acute leuk, NOS | 9800-9801 | S | S | D | D | D | D | D | S | D | |
| 25. Acute biphenotypic leukem | 9805 | S | S | D | D | S | S | S | S | S | |
| 26. Lymphocytic leukem, NOS | 9820 | S | S | D | D | D | D | D | S | D | |
| 27. BCLL/SLL | 9823 | S | S | D | D | S | D | S | D | D | |
| 28. Burkitt cell leukemia | 9826 | S | S | D | D | D | D | D | S | D | |
| 29. Adult T-cell leuk/lymph | 9827 | S | S | D | D | D | D | D | D | D | |
| 30. Polym'cyt leuk, NOS | 9832 | D | D | D | D | S | D | D | D | D | |
| 31. Polym'cyt leuk, B-cell | 9833 | D | D | D | D | S | D | D | D | D | |
| 32. Polym'cyt leuk, T-cell | 9834 | D | D | D | D | D | D | D | D | D | |
| 33. Precurs lym'cyt leuk, NOS | 9835 | S | S | D | D | D | D | D | D | D | |
| 34. Precurs B-cell leuk | 9836 | S | S | D | D | D | D | D | D | D | |
| 35. Precurs T-cell leuk | 9837 | S | S | D | D | D | D | D | D | D | |
| 36. Myeloid leukemias | 9840-9910 | D | D | D | D | D | D | D | D | D | |
| 37. Therapy related AML | 9920 | D | D | D | D | D | D | D | D | D | |
| 38. Myeloid sarcoma | 9930 | D | D | D | D | D | D | D | D | D | |
| 39. Acute panmyelosis | 9931 | D | D | D | D | D | D | D | D | D | |
| 40. Hairy cell leukemia | 9940 | D | D | D | D | D | D | D | D | D | |
| 41. Chron myelomonocyt leuk | 9945 | D | D | D | D | D | D | D | D | D | |
| 42. Juvenile myelomonocyt leuk | 9946 | D | D | D | D | D | D | D | D | D | |
| 43. NK-cell leukemia | 9948 | S | S | D | D | D | D | D | D | D | |
| 44. Polycythemia vera | 9950 | D | D | D | D | D | D | D | D | D | |
| 45. Chron myeloprolif disease | 9960 | D | D | D | D | D | D | D | D | D | |
| 46. Myelosclerosis | 9961 | D | D | D | D | D | D | D | D | D | |
| 47. Essen thrombocythem | 9962 | D | D | D | D | D | D | D | D | D | |
| 48. Chron neutrophilic leukemia | 9963 | D | D | D | D | D | D | D | D | D | |
| 49. Hypereosinophilic syndrome | 9964 | D | D | D | D | D | D | D | D | D | |
| 50. Refractory anemias | 9980-9986 | D | D | D | D | D | D | D | D | D | |
| 51. Therapy related MDS | 9987 | D | D | D | D | D | D | D | D | D | |
| 52. Myelodysplastic syndr, NOS | 9989 | D | D | D | D | D | D | D | D | D | |

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

| APPENDIX A: Definitions of Single and Subsequent Primaries for Hematologic Malignancies | | | | | | | | | | | | |
|---|------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|--------------------------------------|------------------------------|---|
| p. 355 | | | | | | | | | | | | |
| February 28, 2001 | | | | | | | | | | | | |
| SECOND DX ACROSS | | | | | | | | | | | | |
| FIRST DX DOWN | | | | | | | | | | | | |
| | | 11. 9700-9701 MF, Sezary disease | 12. 9702-9719 T/NK-cell lymphoma | 13. 9727 Precurs lym'blas lymph NOS | 14. 9728 Precurs lym'blas lymph B-cl | 15. 9729 Precurs lym'blas lymph T-cl | 16. 9731-9734 Plasma cell tumors | 17. 9740-9742 Mast cell tumors | 18. 9750-9756 Histiocytos; LCH | 19. 9757-9758 Dendritic cell sarc | 20. 9760 Immunoprolif dis | |
| 1. Malignant lymphoma, NOS | 9590 | S | S | S | S | S | S | S | S | S | S | S |
| 2. NHL, NOS | 9591 | S | S | S | S | S | D | D | D | S | S | S |
| 3. Composite HD/NHL | 9596 | S | S | S | S | S | D | D | D | D | S | S |
| 4. Hodgkin lymphoma | 9650-9667 | D | D | D | D | D | D | D | D | D | D | D |
| 5. ML, small B lymphocytic | 9670-9671 | D | D | D | D | D | D | D | D | D | D | D |
| 6. Mantle cell lymphoma | 9673 | D | D | D | D | D | D | D | D | D | D | D |
| 7. ML, diffuse, large B-cell | 9675-9684 | D | D | D | D | D | D | D | D | D | D | S |
| 8. Burkitt lymphoma | 9687 | D | D | D | D | D | D | D | D | D | D | D |
| 9. Marg zone, B-cell lymphoma | 9689, 9699 | D | D | D | D | D | D | D | D | D | D | D |
| 10. Follicular lymphoma | 9690-9698 | D | D | D | D | D | D | D | D | D | D | D |
| 11. Mycos fung, Sezary disease | 9700-9701 | S | D | D | D | D | D | D | D | D | D | D |
| 12. T/NK-cell NHL | 9702-9719 | D | S | D | D | D | D | D | D | D | D | S |
| 13. Precurs lym'blas lymph NOS | 9727 | D | D | S | S | S | D | D | D | D | D | D |
| 14. Precurs lym'blas lymph B-cell | 9728 | D | D | S | S | D | D | D | D | D | D | D |
| 15. Precurs lym'blas lymph T-cell | 9729 | D | D | S | D | S | D | D | D | D | D | D |
| 16. Plasma cell tumors | 9731-9734 | D | D | D | D | D | S | D | D | D | D | D |
| 17. Mast cell tumors | 9740-9742 | D | D | D | D | D | D | S | D | D | D | D |
| 18. Histiocytos/Langerhans cell | 9750-9756 | D | D | D | D | D | D | D | S | D | D | D |
| 19. Dendritic cell sarcoma | 9757-9758 | D | D | D | D | D | D | D | D | S | D | D |
| 20. Immunoprolif disease, NOS | 9760 | D | D | D | D | D | S | D | D | D | D | S |
| 21. Waldenstrom macroglob | 9761 | D | D | D | D | D | D | D | D | D | D | S |
| 22. Heavy chain disease, NOS | 9762 | D | D | D | D | D | D | D | D | D | D | S |
| 23. Immun sm intest disease | 9764 | D | D | D | D | D | S | D | D | D | D | S |
| 24. Leuk/Acute leuk, NOS | 9800-9801 | D | S | S | S | S | D | D | D | D | D | D |
| 25. Acute biphenotypic leukem | 9805 | S | S | S | S | S | D | D | D | D | D | D |
| 26. Lymphocytic leukem, NOS | 9820 | S | S | S | S | S | D | D | D | D | D | S |
| 27. BCLL/SLL | 9823 | D | D | D | D | D | D | D | D | D | D | S |
| 28. Burkitt cell leukemia | 9826 | D | D | D | D | D | D | D | D | D | D | D |
| 29. Adult T-cell leuk/lymph | 9827 | D | D | D | D | D | D | D | D | D | D | D |
| 30. Prolym'cyt leuk, NOS | 9832 | D | D | D | D | D | D | D | D | D | D | D |
| 31. Prolym'cyt leuk, B-cell | 9833 | D | D | D | D | D | D | D | D | D | D | D |
| 32. Prolym'cyt leuk, T-cell | 9834 | D | D | D | D | D | D | D | D | D | D | D |
| 33. Precurs lym'cyt leuk, NOS | 9835 | D | D | S | S | S | D | D | D | D | D | D |
| 34. Precurs B-cell leuk | 9836 | D | D | S | S | D | D | D | D | D | D | D |
| 35. Precurs T-cell leuk | 9837 | D | D | S | D | S | D | D | D | D | D | D |
| 36. Myeloid leukemias | 9840-9910 | D | D | D | D | D | D | D | D | D | D | D |
| 37. Therapy related AML | 9920 | D | D | D | D | D | D | D | D | D | D | D |
| 38. Myeloid sarcoma | 9930 | D | D | D | D | D | D | D | D | D | D | D |
| 39. Acute panmyelosis | 9931 | D | D | D | D | D | D | D | D | D | D | D |
| 40. Hairy cell leukemia | 9940 | D | D | D | D | D | D | D | D | D | D | D |
| 41. Chron myelomonocyt leuk | 9945 | D | D | D | D | D | D | D | D | D | D | D |
| 42. Juvenile myelomonocy leuk | 9946 | D | D | D | D | D | D | D | D | D | D | D |
| 43. NK-cell leukemia | 9948 | D | S | D | D | D | D | D | D | D | D | D |
| 44. Polycythemia vera | 9950 | D | D | D | D | D | D | D | D | D | D | D |
| 45. Chron myeloprolif disease | 9960 | D | D | D | D | D | D | D | D | D | D | D |
| 46. Myelosclerosis | 9961 | D | D | D | D | D | D | D | D | D | D | D |
| 47. Essen thrombocythem | 9962 | D | D | D | D | D | D | D | D | D | D | D |
| 48. Chron neutrophilic leukemia | 9963 | D | D | D | D | D | D | D | D | D | D | D |
| 49. Hypereosinophilic syndrome | 9964 | D | D | D | D | D | D | D | D | D | D | D |
| 50. Refractory anemias | 9980-9986 | D | D | D | D | D | D | D | D | D | D | D |
| 51. Therapy related MDS | 9987 | D | D | D | D | D | D | D | D | D | D | D |
| 52. Myelodysplastic syndr, NOS | 9989 | D | D | D | D | D | D | D | D | D | D | D |

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

| February 28, 2001 PAGE 3 SECOND DX ACROSS FIRST DX DOWN | | 21. 9761 Waldenstrom | 22. 9762 Heavy chain dis | 23. 9764 Imm sm intest dis | 24. 9800-9801 Leuk/Acu leuk NOS | 25. 9805 Acute biphenotypic leuk | 26. 9820 Lym'cyt leuk, NOS | 27. 9823 BCLL/SLL | 28. 9826 Burkitt leukemia | 29. 9827 Adult T-cell leuk/lym | 30. 9832 Prolym leuk, NOS |
|--|------------|-------------------------|-----------------------------|-------------------------------|------------------------------------|-------------------------------------|-------------------------------|----------------------|------------------------------|-----------------------------------|------------------------------|
| 1. Malignant lymphoma, NOS | 9590 | S | S | S | S | S | S | S | S | S | S |
| 2. NHL, NOS | 9591 | S | S | S | S | S | S | S | S | S | D |
| 3. Composite HD/NHL | 9596 | S | S | S | S | D | S | S | S | S | D |
| 4. Hodgkin lymphoma | 9650-9667 | D | D | D | D | D | D | D | D | D | D |
| 5. ML, small B lymphocytic | 9670-9671 | S | D | D | D | S | S | S | D | D | S |
| 6. Mantle cell lymphoma | 9673 | D | D | D | D | S | D | D | D | D | D |
| 7. ML, diffuse, large B-cell | 9675-9684 | S | S | S | D | S | S | S | D | D | S |
| 8. Burkitt lymphoma | 9687 | D | D | D | S | S | S | D | S | D | D |
| 9. Marg zone, B-cell lymphoma | 9689, 9699 | D | D | D | D | S | D | D | D | D | D |
| 10. Follicular lymphoma | 9690-9698 | D | D | D | D | S | D | D | D | D | D |
| 11. Mycos fung, Sezary disease | 9700-9701 | D | D | D | D | S | S | D | D | D | D |
| 12. T/NK-cell NHL | 9702-9719 | D | D | D | D | S | S | D | D | D | D |
| 13. Precurs lym'blas lymph NOS | 9727 | D | D | D | S | S | S | D | D | D | D |
| 14. Precurs lym'blas lymph B-cell | 9728 | D | D | D | S | S | S | D | D | D | D |
| 15. Precurs lym'blas lymph T-cell | 9729 | D | D | D | S | S | S | D | D | D | D |
| 16. Plasma cell tumors | 9731-9734 | D | D | D | D | D | D | D | D | D | D |
| 17. Mast cell tumors | 9740-9742 | D | D | D | D | D | D | D | D | D | D |
| 18. Histiocytos/Langerhans cell | 9750-9756 | D | D | D | D | D | D | D | D | D | D |
| 19. Dendritic cell sarcoma | 9757-9758 | D | D | D | D | D | D | D | D | D | D |
| 20. Immunoprolif disease, NOS | 9760 | S | S | S | D | D | D | D | D | D | D |
| 21. Waldenstrom macroglob | 9761 | S | D | D | D | D | S | S | D | D | D |
| 22. Heavy chain disease, NOS | 9762 | D | S | S | D | D | S | S | D | D | D |
| 23. Immun sm intest disease | 9764 | D | S | S | D | D | D | D | D | D | D |
| 24. Leuk/Acute leuk, NOS | 9800-9801 | D | D | D | S | S | S | D | S | S | D |
| 25. Acute biphenotypic leukem | 9805 | D | D | D | S | S | S | S | S | S | S |
| 26. Lymphocytic leukem, NOS | 9820 | S | S | D | S | S | S | S | S | S | S |
| 27. BCLL/SLL | 9823 | D | D | D | D | S | S | S | D | D | S |
| 28. Burkitt cell leukemia | 9826 | D | D | D | S | S | S | D | S | D | D |
| 29. Adult T-cell leuk/lymph | 9827 | D | D | D | D | S | S | D | D | S | D |
| 30. Prolym'cyt leuk, NOS | 9832 | D | D | D | D | S | S | S | D | D | S |
| 31. Prolym'cyt leuk, B-cell | 9833 | D | D | D | D | S | S | S | D | D | S |
| 32. Prolym'cyt leuk, T-cell | 9834 | D | D | D | D | S | S | D | D | S | S |
| 33. Precurs lym'cyt leuk, NOS | 9835 | D | D | D | S | S | S | D | D | D | D |
| 34. Precurs B-cell leuk | 9836 | D | D | D | S | S | S | D | D | D | D |
| 35. Precurs T-cell leuk | 9837 | D | D | D | S | S | S | D | D | D | D |
| 36. Myeloid leukemias | 9840-9910 | D | D | D | S | S | D | D | D | D | D |
| 37. Therapy related AML | 9920 | D | D | D | S | S | D | D | D | D | D |
| 38. Myeloid sarcoma | 9930 | D | D | D | S | S | D | D | D | D | D |
| 39. Acute panmyelosis | 9931 | D | D | D | S | S | D | D | D | D | D |
| 40. Hairy cell leukemia | 9940 | D | D | D | S | S | D | D | D | D | D |
| 41. Chron myelomonocyt leuk | 9945 | D | D | D | S | S | D | D | D | D | D |
| 42. Juvenile myelomonocy leuk | 9946 | D | D | D | S | S | D | D | D | D | D |
| 43. NK-cell leukemia | 9948 | D | D | D | S | S | S | D | D | D | D |
| 44. Polycythemia vera | 9950 | D | D | D | S | D | D | D | D | D | D |
| 45. Chron myeloprolif disease | 9960 | D | D | D | S | S | D | D | D | D | D |
| 46. Myelosclerosis | 9961 | D | D | D | S | S | D | D | D | D | D |
| 47. Essen thrombocythem | 9962 | D | D | D | S | D | D | D | D | D | D |
| 48. Chron neutrophilic leukemia | 9963 | D | D | D | S | D | D | D | D | D | D |
| 49. Hypereosinophilic syndrome | 9964 | D | D | D | S | D | D | D | D | D | D |
| 50. Refractory anemias | 9980-9986 | D | D | D | S | S | D | D | D | D | D |
| 51. Therapy related MDS | 9987 | D | D | D | S | S | D | D | D | D | D |
| 52. Myelodysplastic syndr, NOS | 9989 | D | D | D | S | S | D | D | D | D | D |

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

| February 28, 2001 PAGE 4 SECOND DX ACROSS FIRST DX DOWN | | 31. 9833 Prolym leuk, B-cell | 32. 9834 Prolym leuk, T-cell | 33. 9835 Precurs leuk, NOS | 34. 9836 Precurs leuk, B-cell | 35. 9837 Precurs leuk, T-cell | 36. 9840-9910 Myeloid leukemias | 37. 9920 Therapy rel AML | 38. 9930 Myeloid sarcoma | 39. 9931 Acute panmyelosis | 40. 9940 Hairy cell leukemia | 41. 9945 Chr myelomono leu |
|--|------------|---------------------------------|---------------------------------|-------------------------------|----------------------------------|----------------------------------|------------------------------------|-----------------------------|-----------------------------|-------------------------------|---------------------------------|-------------------------------|
| 1. Malignant lymphoma, NOS | 9590 | S | S | S | S | S | S | S | S | S | S | S |
| 2. NHL, NOS | 9591 | D | D | S | S | S | D | D | D | D | D | D |
| 3. Composite HD/NHL | 9596 | D | D | S | S | S | D | D | D | D | D | D |
| 4. Hodgkin lymphoma | 9650-9667 | D | D | D | D | D | D | D | D | D | D | D |
| 5. ML, small B lymphocytic | 9670-9671 | S | D | D | D | D | D | D | D | D | D | D |
| 6. Mantle cell lymphoma | 9673 | D | D | D | D | D | D | D | D | D | D | D |
| 7. ML, diffuse, large B-cell | 9675-9684 | S | D | D | D | D | D | D | D | D | D | D |
| 8. Burkitt lymphoma | 9687 | D | D | D | D | D | D | D | D | D | D | D |
| 9. Marg zone, B-cell lymphoma | 9689, 9699 | D | D | D | D | D | D | D | D | D | D | D |
| 10. Follicular lymphoma | 9690-9698 | D | D | D | D | D | D | D | D | D | D | D |
| 11. Mycos fung, Sezary disease | 9700-9701 | D | D | D | D | D | D | D | D | D | D | D |
| 12. T/NK-cell NHL | 9702-9719 | D | D | D | D | D | D | D | D | D | D | D |
| 13. Precurs lym'blas lymph NOS | 9727 | D | D | S | S | S | D | D | D | D | D | D |
| 14. Precurs lym'blas lymph B-cell | 9728 | D | D | S | S | D | D | D | D | D | D | D |
| 15. Precurs lym'blas lymph T-cell | 9729 | D | D | S | D | S | D | D | D | D | D | D |
| 16. Plasma cell tumors | 9731-9734 | D | D | D | D | D | D | D | D | D | D | D |
| 17. Mast cell tumors | 9740-9742 | D | D | D | D | D | D | D | D | D | D | D |
| 18. Histiocytos/Langerhans cell | 9750-9756 | D | D | D | D | D | D | D | D | D | D | D |
| 19. Dendritic cell sarcoma | 9757-9758 | D | D | D | D | D | D | D | D | D | D | D |
| 20. Immunoprolif disease, NOS | 9760 | D | D | D | D | D | D | D | D | D | D | D |
| 21. Waldenstrom macroglob | 9761 | D | D | D | D | D | D | D | D | D | D | D |
| 22. Heavy chain disease, NOS | 9762 | D | D | D | D | D | D | D | D | D | D | D |
| 23. Immun sm intest disease | 9764 | D | D | D | D | D | D | D | D | D | D | D |
| 24. Leuk/Acute leuk, NOS | 9800-9801 | D | D | S | S | S | S | S | S | D | D | S |
| 25. Acute biphenotypic leukem | 9805 | S | S | S | S | S | S | S | S | S | S | S |
| 26. Lymphocytic leukem, NOS | 9820 | S | S | S | S | S | D | D | D | D | S | D |
| 27. BCLL/SLL | 9823 | S | D | D | D | D | D | D | D | D | D | D |
| 28. Burkitt cell leukemia | 9826 | D | D | D | D | D | D | D | D | D | D | D |
| 29. Adult T-cell leuk/lymph | 9827 | D | D | D | D | D | D | D | D | D | D | D |
| 30. Prolym'cyt leuk, NOS | 9832 | S | S | D | D | D | D | D | D | D | D | D |
| 31. Prolym'cyt leuk, B-cell | 9833 | S | D | D | D | D | D | D | D | D | D | D |
| 32. Prolym'cyt leuk, T-cell | 9834 | D | S | D | D | D | D | D | D | D | D | D |
| 33. Precurs lym'cyt leuk, NOS | 9835 | D | D | S | S | S | D | D | D | D | D | D |
| 34. Precurs B-cell leuk | 9836 | D | D | S | S | D | D | D | D | D | D | D |
| 35. Precurs T-cell leuk | 9837 | D | D | S | D | S | D | D | D | D | D | D |
| 36. Myeloid leukemias | 9840-9910 | D | D | D | D | D | S | S | S | S | D | S |
| 37. Therapy related AML | 9920 | D | D | D | D | D | S | S | S | S | D | S |
| 38. Myeloid sarcoma | 9930 | D | D | D | D | D | S | S | S | S | D | S |
| 39. Acute panmyelosis | 9931 | D | D | D | D | D | S | S | S | S | D | S |
| 40. Hairy cell leukemia | 9940 | D | D | D | D | D | D | D | D | D | S | D |
| 41. Chron myelomonocyt leuk | 9945 | D | D | D | D | D | S | S | S | S | D | S |
| 42. Juvenile myelomonocy leuk | 9946 | D | D | D | D | D | S | S | S | S | D | S |
| 43. NK-cell leukemia | 9948 | D | D | D | D | D | D | D | D | D | D | D |
| 44. Polycythemia vera | 9950 | D | D | D | D | D | D | D | D | D | D | D |
| 45. Chron myeloprolif disease | 9960 | D | D | D | D | D | S | S | S | S | D | S |
| 46. Myelosclerosis | 9961 | D | D | D | D | D | S | S | S | S | D | S |
| 47. Essen thrombocythem | 9962 | D | D | D | D | D | S | S | S | S | D | S |
| 48. Chron neutrophilic leukemia | 9963 | D | D | D | D | D | S | S | S | S | D | S |
| 49. Hypereosinophilic syndrome | 9964 | D | D | D | D | D | S | S | S | S | D | S |
| 50. Refractory anemias | 9980-9986 | D | D | D | D | D | S | S | S | S | D | S |
| 51. Therapy related MDS | 9987 | D | D | D | D | D | S | S | S | S | D | S |
| 52. Myelodysplastic syndr, NOS | 9989 | D | D | D | D | D | S | S | S | S | D | S |

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

SINGLE VERSUS SUBSEQUENT PRIMARIES OF LYMPHATIC AND HEMATOPOIETIC DISEASES

| February 28, 2001 PAGE 5 SECOND DX ACROSS FIRST DX DOWN | | 42. 9946 Juv myelomono leu | 43. 9948 NK-cell leukemia | 44. 9950 Polycythemia vera | 45. 9960 Chr myeloprolif dis | 46. 9961 Myeloclerosis | 47. 9962 Ess thrombocythem | 48. 9963 Chr neutrophil leu | 49. 9964 Hypereosin syndr | 50. 9980-9986 Refract anemias | 51. 9987 Therapy rel MDS | 52. 9989 Myelodys syn NOS |
|--|------------|-------------------------------|------------------------------|-------------------------------|---------------------------------|---------------------------|-------------------------------|--------------------------------|------------------------------|----------------------------------|-----------------------------|------------------------------|
| 1. Malignant lymphoma, NOS | 9590 | S | S | D | D | D | D | D | D | D | D | D |
| 2. NHL, NOS | 9591 | D | D | D | D | D | D | D | D | D | D | D |
| 3. Composite HD/NHL | 9596 | D | D | D | D | D | D | D | D | D | D | D |
| 4. Hodgkin lymphoma | 9650-9667 | D | D | D | D | D | D | D | D | D | D | D |
| 5. ML, small B lymphocytic | 9670-9671 | D | D | D | D | D | D | D | D | D | D | D |
| 6. Mantle cell lymphoma | 9673 | D | D | D | D | D | D | D | D | D | D | D |
| 7. ML, diffuse, large B-cell | 9675-9684 | D | D | D | D | D | D | D | D | D | D | D |
| 8. Burkitt lymphoma | 9687 | D | D | D | D | D | D | D | D | D | D | D |
| 9. Marg zone, B-cell lymphoma | 9689, 9699 | D | D | D | D | D | D | D | D | D | D | D |
| 10. Follicular lymphoma | 9690-9698 | D | D | D | D | D | D | D | D | D | D | D |
| 11. Mycos fung, Sezary disease | 9700-9701 | D | D | D | D | D | D | D | D | D | D | D |
| 12. T/NK-cell NHL | 9702-9719 | D | D | D | D | D | D | D | D | D | D | D |
| 13. Precurs lym'blas lymph NOS | 9727 | D | D | D | D | D | D | D | D | D | D | D |
| 14. Precurs lym'blas lymph B-cell | 9728 | D | D | D | D | D | D | D | D | D | D | D |
| 15. Precurs lym'blas lymph T-cell | 9729 | D | D | D | D | D | D | D | D | D | D | D |
| 16. Plasma cell tumors | 9731-9734 | D | D | D | D | D | D | D | D | D | D | D |
| 17. Mast cell tumors | 9740-9742 | D | D | D | D | D | D | D | D | D | D | D |
| 18. Histiocytos/Langerhans cell | 9750-9756 | D | D | D | D | D | D | D | D | D | D | D |
| 19. Dendritic cell sarcoma | 9757-9758 | D | D | D | D | D | D | D | D | D | D | D |
| 20. Immunoprolif disease, NOS | 9760 | D | D | D | D | D | D | D | D | D | D | D |
| 21. Waldenstrom macroglob | 9761 | D | D | D | D | D | D | D | D | D | D | D |
| 22. Heavy chain disease, NOS | 9762 | D | D | D | D | D | D | D | D | D | D | D |
| 23. Immun sm intest disease | 9764 | D | D | D | D | D | D | D | D | D | D | D |
| 24. Leuk/Acute leuk, NOS | 9800-9801 | S | D | D | S | S | D | S | S | D | S | S |
| 25. Acute biphenotypic leukem | 9805 | S | S | D | S | S | D | D | D | S | S | S |
| 26. Lymphocytic leukem, NOS | 9820 | D | S | D | D | D | D | D | D | D | D | D |
| 27. BCLL/SLL | 9823 | D | D | D | D | D | D | D | D | D | D | D |
| 28. Burkitt cell leukemia | 9826 | D | D | D | D | D | D | D | D | D | D | D |
| 29. Adult T-cell leuk/lymph | 9827 | D | D | D | D | D | D | D | D | D | D | D |
| 30. Prolym'cyt leuk, NOS | 9832 | D | D | D | D | D | D | D | D | D | D | D |
| 31. Prolym'cyt leuk, B-cell | 9833 | D | D | D | D | D | D | D | D | D | D | D |
| 32. Prolym'cyt leuk, T-cell | 9834 | D | D | D | D | D | D | D | D | D | D | D |
| 33. Precurs lym'cyt leuk, NOS | 9835 | D | D | D | D | D | D | D | D | D | D | D |
| 34. Precurs B-cell leuk | 9836 | D | D | D | D | D | D | D | D | D | D | D |
| 35. Precurs T-cell leuk | 9837 | D | D | D | D | D | D | D | D | D | D | D |
| 36. Myeloid leukemias | 9840-9910 | S | D | D | S | S | S | S | S | D | S | S |
| 37. Therapy related AML | 9920 | S | D | D | D | S | D | D | D | D | S | S |
| 38. Myeloid sarcoma | 9930 | S | D | D | S | S | S | S | D | D | S | S |
| 39. Acute panmyelosis | 9931 | S | D | D | D | S | D | D | D | D | S | S |
| 40. Hairy cell leukemia | 9940 | D | D | D | D | D | D | D | D | D | D | D |
| 41. Chron myelomonocyt leuk | 9945 | S | D | D | S | S | D | S | D | D | S | S |
| 42. Juvenile myelomonocy leuk | 9946 | S | D | D | D | S | D | D | D | D | S | S |
| 43. NK-cell leukemia | 9948 | D | S | D | D | D | D | D | D | D | D | D |
| 44. Polycythemia vera | 9950 | D | D | S | S | S | D | D | D | D | D | D |
| 45. Chron myeloprolif disease | 9960 | D | D | D | S | S | S | S | D | D | D | D |
| 46. Myeloclerosis | 9961 | S | D | D | S | S | S | S | D | D | S | S |
| 47. Essen thrombocythem | 9962 | D | D | D | S | S | S | S | D | D | D | D |
| 48. Chron neutrophilic leukemia | 9963 | D | D | D | S | S | S | S | D | D | D | D |
| 49. Hypereosinophilic syndrome | 9964 | S | D | D | S | S | D | D | S | D | D | D |
| 50. Refractory anemias | 9980-9986 | S | D | D | S | S | D | D | D | S | S | S |
| 51. Therapy related MDS | 9987 | S | D | D | S | S | D | D | D | S | S | S |
| 52. Myelodysplastic syndr, NOS | 9989 | S | D | D | S | S | D | D | D | S | S | S |

Codes: S--one primary only; D--presumably a subsequent primary

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov

APPENDIX A: Definitions of Single and Subsequent Primaries for Hematologic Malignancies

- 1 9590 Malignant lymphoma, NOS
- 2 9591 Malignant lymphoma, non-Hodgkin, NOS
- 3 9596 Composite Hodgkin and non-Hodgkin lymphoma
- 4 9650-9667 Hodgkin lymphoma (all subtypes)
- 5 9670-9671 Malignant lymphoma, small B lymphocytic
- 6 9673 Mantle cell lymphoma
- 7 9675-9684 Malignant lymphoma, diffuse large B-cell
- 8 9687 Burkitt lymphoma
- 9 9689, 9699 Marginal zone B-cell lymphoma
- 10 9690-9698 Follicular lymphoma
- 11 9700-9701 Mycosis fungoides and Sezary syndrome
- 12 9702-9719 T/NK-cell non-Hodgkin lymphoma
- 13 9727 Precursor cell lymphoblastic lymphoma, NOS
- 14 9728 Precursor B-cell lymphoblastic lymphoma
- 15 9729 Precursor T-cell lymphoblastic lymphoma
- 16 9731-9734 Plasma cell tumors
- 17 9740-9742 Mast cell tumors
- 18 9750-9756 Histiocytosis/Langerhans cell histiocytosis
- 19 9757-9758 Dendritic cell sarcoma
- 20 9760 Immunoproliferative disease, NOS
- 21 9761 Waldenstrom macroglobulinemia
- 22 9762 Heavy chain disease, NOS
- 23 9764 Immunoproliferative small intestinal disease
- 24 9800-9801 Leukemia, NOS/Acute leukemia, NOS
- 25 9805 Acute biphenotypic leukemia
- 26 9820 Lymphoid leukemia, NOS
- 27 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
- 28 9826 Burkitt cell leukemia
- 29 9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)
- 30 9832 Prolymphocytic leukemia, NOS
- 31 9833 Prolymphocytic leukemia, B-cell type
- 32 9834 Prolymphocytic leukemia, T-cell type
- 33 9835 Precursor cell lymphoblastic leukemia, NOS
- 34 9836 Precursor B-cell lymphoblastic leukemia
- 35 9837 Precursor T-cell lymphoblastic leukemia
- 36 9840-9910 Myeloid leukemias
- 37 9920 Therapy related acute myelogenous leukemia
- 38 9930 Myeloid sarcoma
- 39 9931 Acute panmyelosis with myelofibrosis
- 40 9940 Hairy cell leukemia
- 41 9945 Chronic myelomonocytic leukemia, NOS
- 42 9946 Juvenile myelomonocytic leukemia
- 43 9948 Aggressive NK-cell leukemia
- 44 9950 Polycythemia vera
- 45 9960 Chronic myeloproliferative disease, NOS
- 46 9961 Myelosclerosis with myeloid metaplasia
- 47 9962 Essential thrombocythemia
- 48 9963 Chronic neutrophilic leukemia
- 49 9964 Hypereosinophilic syndrome
- 50 9980-9986 Refractory anemias
- 51 9987 Therapy related myelodysplastic syndrome, NOS
- 52 9989 Myelodysplastic syndrome, NOS

Version 1.01. Codes corrected for terms in rows 7 and 9 on pages 2-5.

SEER Program, NCI. E-mail: seerweb@ims.nci.nih.gov 02/28/2001

APPENDIX B: Site-Specific Surgery Codes

Note: The histologies specified in this section apply only to cases diagnosed in 2010 or later. Please consult *FORDS: Revised for 2009* for applicable histologies for cases diagnosed prior to that date.

ORAL CAVITY**Lip C00.0–C00.9, Base of Tongue C01.9, Other Parts of Tongue C02.0–C02.9,
Gum C03.0–C03.9, Floor of Mouth C04.0–C04.9, Palate C05.0–C05.9,
Other Parts of Mouth C06.0–C06.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from surgical events 10–14.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26–27 WITH

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

30 Wide excision, NOS

Code 30 includes:

Hemiglossectomy

Partial glossectomy

40 Radical excision of tumor, NOS

41 Radical excision of tumor ONLY

42 Combination of 41 WITH resection in continuity with mandible (marginal, segmental, hemi-, or total resection)

43 Combination of 41 WITH resection in continuity with maxilla (partial, subtotal, or total resection)

Codes 40–43 include:

Total glossectomy

Radical glossectomy

Specimen sent to pathology from surgical events 20–43.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 12/4/02, 01/10, 02/10, 01/16)

PAROTID AND OTHER UNSPECIFIED GLANDS**Parotid Gland C07.9, Major Salivary Glands C08.0–C08.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Less than total parotidectomy, NOS; less than total removal of major salivary gland, NOS
 - 31 Facial nerve spared
 - 32 Facial nerve sacrificed
 - 33 Superficial lobe ONLY
 - 34 Facial nerve spared
 - 35 Facial nerve sacrificed
 - 36 Deep lobe (Total)
 - 37 Facial nerve spared
 - 38 Facial nerve sacrificed
- 40 Total parotidectomy, NOS; total removal of major salivary gland, NOS
 - 41 Facial nerve spared
 - 42 Facial nerve sacrificed
- 50 Radical parotidectomy, NOS; radical removal of major salivary gland, NOS
 - 51 WITHOUT removal of temporal bone
 - 52 WITH removal of temporal bone
 - 53 WITH removal of overlying skin (requires graft or flap coverage)
- 80 Parotidectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16)

PHARYNX**Tonsil C09.0–C09.9, Oropharynx C10.0–C10.9, Nasopharynx C11.0–C11.9
Pyramidal Sinus C12.9, Hypopharynx C13.0–C13.9, Pharynx C14.0**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Stripping

No specimen sent to pathology from surgical events 10–15.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26–27 WITH

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

28 Stripping

30 Pharyngectomy, NOS

31 Limited/partial pharyngectomy; tonsillectomy, bilateral tonsillectomy

32 Total pharyngectomy

40 Pharyngectomy WITH laryngectomy OR removal of contiguous bone tissue, NOS (does NOT include total mandibular resection)

41 WITH Laryngectomy (laryngopharyngectomy)

42 WITH bone

43 WITH both 41 and 42

50 Radical pharyngectomy (includes total mandibular resection), NOS

51 WITHOUT laryngectomy

52 WITH laryngectomy

Specimen sent to pathology from surgical events 20–52.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

ESOPHAGUS**C15.0–C15.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY

- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision

- 30 Partial esophagectomy

- 40 Total esophagectomy, NOS

- 50 Esophagectomy, NOS WITH laryngectomy and/or gastrectomy, NOS
 - 51 WITH laryngectomy
 - 52 WITH gastrectomy, NOS
 - 53 Partial gastrectomy
 - 54 Total gastrectomy
 - 55 Combination of 51 WITH any of 52–54

- 80 Esophagectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS

- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16)

STOMACH**C16.0–C16.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Gastrectomy, NOS (partial, subtotal, hemi-)
 - 31 Antrectomy, lower (distal-less than 40% of stomach)***
 - 32 Lower (distal) gastrectomy (partial, subtotal, hemi-)
 - 33 Upper (proximal) gastrectomy (partial, subtotal, hemi-)

Code 30 includes:

Partial gastrectomy, including a sleeve resection of the stomach
 Billroth I: anastomosis to duodenum (duodenostomy)
 Billroth II: anastomosis to jejunum (jejunostomy)

- 40 Near-total or total gastrectomy, NOS
 - 41 Near-total gastrectomy
 - 42 Total gastrectomy

A total gastrectomy may follow a previous partial resection of the stomach.

- 50 Gastrectomy, NOS WITH removal of a portion of esophagus
 - 51 Partial or subtotal gastrectomy
 - 52 Near total or total gastrectomy

Codes 50–52 are used for gastrectomy resection when only portions of esophagus are included in procedure.

- 60 Gastrectomy with a resection in continuity with the resection of other organs, NOS***
 - 61 Partial or subtotal gastrectomy, in continuity with the resection of other organs***
 - 62 Near total or total gastrectomy, in continuity with the resection of other organs***
 - 63 Radical gastrectomy, in continuity with the resection of other organs***

Codes 60–63 are used for gastrectomy resections with organs other than esophagus. Portions of esophagus may or may not be included in the resection.

80 Gastrectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

*** Incidental splenectomy NOT included

COLON
C18.0–C18.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 27 Excisional biopsy
 - 26 Polypectomy, NOS
 - 28 Polypectomy-endoscopic
 - 29 Polypectomy-surgical excision
 - Any combination of 20 or 26–29 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Partial colectomy, segmental resection
 - 32 Plus resection of contiguous organ; example: small bowel, bladder
- 40 Subtotal colectomy/hemicolectomy (total right or left colon and a portion of transverse colon)
 - 41 Plus resection of contiguous organ; example: small bowel, bladder
- 50 Total colectomy (removal of colon from cecum to the rectosigmoid junction; may include a portion of the rectum)
 - 51 Plus resection of contiguous organ; example: small bowel, bladder
- 60 Total proctocolectomy (removal of colon from cecum to the rectosigmoid junction, including the entire rectum)
 - 61 Plus resection of contiguous organ; example: small bowel, bladder
- 70 Colectomy or coloproctectomy with resection of contiguous organ(s), NOS (where there is not enough information to code 32, 41, 51, or 61)

Code 70 includes: Any colectomy (partial, hemicolectomy, or total) WITH a resection of any other organs in continuity with the primary site. Other organs may be partially or totally removed. Other organs may include, but are not limited to, oophorectomy, partial proctectomy, rectal mucosectomy, or pelvic exenteration.
- 80 Colectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

RECTOSIGMOID**C19.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
- Combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Wedge or segmental resection; partial proctosigmoidectomy, NOS
 - 31 Plus resection of contiguous organs; example: small bowel, bladder

Procedures coded 30 include, but are not limited to:

- Anterior resection
- Hartmann operation
- Low anterior resection (LAR)
- Partial colectomy, NOS
- Rectosigmoidectomy, NOS
- Sigmoidectomy
- 40 Pull through WITH sphincter preservation (colo-anal anastomosis)
- 50 Total proctectomy
- 51 Total colectomy
- 55 Total colectomy WITH ileostomy, NOS
 - 56 Ileorectal reconstruction
 - 57 Total colectomy WITH other pouch; example: Koch pouch

- 60 Total proctocolectomy, NOS
- 65 Total proctocolectomy WITH ileostomy, NOS
- 66 Total proctocolectomy WITH ileostomy and pouch
Removal of the colon from cecum to the rectosigmoid or a portion of the rectum.
- 70 Colectomy or proctocolectomy resection in continuity with other organs; pelvic exenteration
- 80 Colectomy, NOS; Proctectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

RECTUM**C20.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10-14.

- 20 Local tumor excision, NOS
 - 27 Excisional biopsy
 - 26 Polypectomy
 - Any combination of 20 or 26-27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
 - 28 Curette and fulguration
- 30 Wedge or segmental resection; partial proctectomy, NOS

Procedures coded 30 include, but are not limited to:

- Anterior resection
- Hartmann's operation
- Low anterior resection (LAR)
- Transsacral rectosigmoidectomy
- Total mesorectal excision (TME)

- 40 Pull through WITH sphincter preservation (coloanal anastomosis)

- 50 Total proctectomy

Procedure coded 50 includes, but is not limited to:

- Abdominoperineal resection (Miles Procedure)

- 60 Total proctocolectomy, NOS
- 70 Proctectomy or proctocolectomy with resection in continuity with other organs; pelvic exenteration
- 80 Proctectomy, NOS

Specimen sent to pathology from surgical events 20-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

ANUS

C21.0–C21.8

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY

- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Thermal Ablation

No specimen sent to pathology from surgical events 10–15.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision

- 60 Abdominal perineal resection, NOS (APR; Miles procedure)
 - 61 APR and sentinel node excision
 - 62 APR and unilateral inguinal lymph node dissection
 - 63 APR and bilateral inguinal lymph node dissection

The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).

Specimen sent to pathology from surgical events 20–63.

- 90 Surgery, NOS

- 99 Unknown if surgery performed; death certificate ONLY

LIVER AND INTRAHEPATIC BILE DUCTS**C22.0–C22.1**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Alcohol (Percutaneous Ethanol Injection-PEI)
 - 16 Heat-Radio-frequency ablation (RFA)
 - 17 Other (ultrasound, acetic acid)

No specimen sent to pathology from surgical events 10–17.

- 20 Wedge or segmental resection, NOS
 - 21 Wedge resection
 - 22 Segmental resection, NOS
 - 23 One
 - 24 Two
 - 25 Three
 - 26 Segmental resection AND local tumor destruction
- 30 Lobectomy, NOS
 - 36 Right lobectomy
 - 37 Left lobectomy
 - 38 Lobectomy AND local tumor destruction
- 50 Extended lobectomy, NOS (extended: resection of a single lobe plus a segment of another lobe)
 - 51 Right lobectomy
 - 52 Left lobectomy
 - 59 Extended lobectomy AND local tumor destruction
- 60 Hepatectomy, NOS
 - 61 Total hepatectomy and transplant
- 65 Excision of a bile duct (for an intra-hepatic bile duct primary only)
 - 66 Excision of an intrahepatic bile duct PLUS partial hepatectomy
- 75 Extrahepatic bile duct and hepatectomy WITH transplant

Specimen sent to pathology from surgical events 20–75.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/11, 01/16)

PANCREAS**C25.0–C25.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 25 Local excision of tumor, NOS
- 30 Partial pancreatectomy, NOS; example: distal
- 35 Local or partial pancreatectomy and duodenectomy
 - 36 WITHOUT distal/partial gastrectomy
 - 37 WITH partial gastrectomy (Whipple)
- 40 Total pancreatectomy
- 60 Total pancreatectomy and subtotal gastrectomy or duodenectomy
- 70 Extended pancreatoduodenectomy
- 80 Pancreatectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

LARYNX
C32.0–C32.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Stripping

No specimen sent to pathology from surgical events 10–15.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
 - 28 Stripping
- 30 Partial excision of the primary site, NOS; subtotal/partial laryngectomy NOS; hemilaryngectomy NOS
 - 31 Vertical laryngectomy
 - 32 Anterior commissure laryngectomy
 - 33 Supraglottic laryngectomy
- 40 Total or radical laryngectomy, NOS
 - 41 Total laryngectomy ONLY
 - 42 Radical laryngectomy ONLY
- 50 Pharyngolaryngectomy
- 80 Laryngectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16)

LUNG
C34.0–C34.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS
Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).
- 15 Local tumor destruction, NOS
 - 12 Laser ablation or cryosurgery
 - 13 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)**No specimen sent to pathology from surgical events 12–13 and 15.**
- 20 Excision or resection of less than one lobe, NOS
 - 23 Excision, NOS
 - 24 Laser excision
 - 25 Bronchial sleeve resection ONLY
 - 21 Wedge resection
 - 22 Segmental resection, including lingulectomy
- 30 Resection of lobe or bilobectomy, but less than the whole lung (partial pneumonectomy, NOS)
 - 33 Lobectomy WITH mediastinal lymph node dissection**The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).**
- 45 Lobe or bilobectomy extended, NOS
 - 46 WITH chest wall
 - 47 WITH pericardium
 - 48 WITH diaphragm
- 55 Pneumonectomy, NOS
 - 56 WITH mediastinal lymph node dissection (radical pneumonectomy)**The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).**
- 65 Extended pneumonectomy
 - 66 Extended pneumonectomy plus pleura or diaphragm
- 70 Extended radical pneumonectomy
The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).
- 80 Resection of lung, NOS
Specimen sent to pathology from surgical events 20–80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16)

**HEMATOPOIETIC/RETICULOENDOTHELIAL/
IMMUNOPROLIFERATIVE/MYELOPROLIFERATIVE DISEASE**

C42.0, C42.1, C42.3, C42.4 (with any histology)

or

M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992 (with any site)

Code

- 98 All hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease sites and/or histologies, WITH or WITHOUT surgical treatment.

Surgical procedures for hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

BONES, JOINTS, AND ARTICULAR CARTILAGE C40.0–C41.9
PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM C47.0–C47.9
CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES C49.0–C49.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

- 15 Local tumor destruction

No specimen sent to pathology from surgical event 15.

- 25 Local excision
- 26 Partial resection
- 30 Radical excision or resection of lesion WITH limb salvage
- 40 Amputation of limb
 - 41 Partial amputation of limb
 - 42 Total amputation of limb
- 50 Major amputation, NOS
 - 51 Forequarter, including scapula
 - 52 Hindquarter, including ilium/hip bone
 - 53 Hemipelvectomy, NOS
 - 54 Internal hemipelvectomy

Specimen sent to pathology from surgical events 25–54.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

SPLEEN**Spleen C42.2**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

- 21 Partial splenectomy
- 22 Total splenectomy
- 80 Splenectomy, NOS

Specimen sent to pathology for surgical events 21-80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

SKIN
C44.0–C44.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
 - 31 Shave biopsy followed by a gross excision of the lesion
 - 32 Punch biopsy followed by a gross excision of the lesion
 - 33 Incisional biopsy followed by a gross excision of the lesion
 - 34 Mohs surgery, NOS
 - 35 Mohs with 1-cm margin or less
 - 36 Mohs with more than 1-cm margin
- 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS. **Margins MUST be microscopically negative.**
 - 46 WITH margins more than 1 cm and less than or equal to 2 cm
 - 47 WITH margins greater than 2 cm**If the excision or reexcision has microscopically confirmed negative margins less than 1 cm OR the margins are more than 1 cm but are not microscopically confirmed; use the appropriate code, 20–36.**
- 60 Major amputation

Specimen sent to pathology from surgical events 20–60.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

BREAST
C50.0–C50.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction, NOS

No specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

- 20 Partial mastectomy, NOS; less than total mastectomy, NOS
 - 21 Partial mastectomy WITH nipple resection
 - 22 Lumpectomy or excisional biopsy
 - 23 Reexcision of the biopsy site for gross or microscopic residual disease
 - 24 Segmental mastectomy (including wedge resection, quadrantectomy, tylectomy)

Procedures coded 20–24 remove the gross primary tumor and some of the breast tissue (breast-conserving or preserving). There may be microscopic residual tumor.

- 30 Subcutaneous mastectomy

A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or overlying skin. It is performed to facilitate immediate breast reconstruction. Cases coded 30 may be considered to have undergone breast reconstruction.

- 40 Total (simple) mastectomy
 - 41 WITHOUT removal of uninvolved contralateral breast
 - 43 With reconstruction NOS
 - 44 Tissue
 - 45 Implant
 - 46 Combined (Tissue and Implant)
 - 42 WITH removal of uninvolved contralateral breast
 - 47 With reconstruction NOS
 - 48 Tissue
 - 49 Implant
 - 75 Combined (Tissue and Implant)

A total (simple) mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done, but sentinel lymph nodes may be removed.

For single primaries only, code removal of the involved contralateral breast under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) and/or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

If the contralateral breast reveals a second primary, each breast is abstracted separately. The surgical procedure is coded 41 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

Reconstruction that is planned as part of first course treatment is coded 43-49 or 75, whether it is done at the time of mastectomy or later.

- 76 Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma.

- 50 Modified radical mastectomy
 - 51 WITHOUT removal of uninvolved contralateral breast
 - 53 Reconstruction, NOS
 - 54 Tissue
 - 55 Implant
 - 56 Combined (Tissue and Implant)
 - 52 WITH removal of uninvolved contralateral breast
 - 57 Reconstruction, NOS
 - 58 Tissue
 - 59 Implant
 - 63 Combined (Tissue and Implant)

Removal of all breast tissue, the nipple, the areolar complex, and variable amounts of breast skin in continuity with the axilla. The specimen may or may not include a portion of the pectoralis major muscle

If contralateral breast reveals a second primary, it is abstracted separately. The surgical procedure is coded 51 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

For single primaries only, code removal of involved contralateral breast under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

- 60 Radical mastectomy, NOS
 - 61 WITHOUT removal of uninvolved contralateral breast
 - 64 Reconstruction, NOS
 - 65 Tissue
 - 66 Implant
 - 67 Combined (Tissue and Implant)
 - 62 WITH removal of uninvolved contralateral breast
 - 68 Reconstruction, NOS
 - 69 Tissue
 - 73 Implant
 - 74 Combined (Tissue and Implant)
- 70 Extended radical mastectomy
 - 71 WITHOUT removal of uninvolved contralateral breast
 - 72 WITH removal of uninvolved contralateral breast

- 80 Mastectomy, NOS

Specimen sent to pathology for surgical events coded 20-80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

CERVIX UTERI**C53.0–C53.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

For invasive cancers, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Loop Electrocautery Excision Procedure (LEEP)
 - 16 Laser ablation
 - 17 Thermal ablation

No specimen sent to pathology from surgical events 10–17.

- 20 Local tumor excision, NOS
 - 26 Excisional biopsy, NOS
 - 27 Cone biopsy
 - 24 Cone biopsy WITH gross excision of lesion
 - 29 Trachelectomy; removal of cervical stump; cervicectomy
 - Any combination of 20, 24, 26, 27 or 29 WITH
 - 21 Electrocautery
 - 22 Cryosurgery
 - 23 Laser ablation or excision
 - 25 Dilatation and curettage; endocervical curettage (for in situ only)
 - 28 Loop electrocautery excision procedure (LEEP)
- 30 Total hysterectomy (simple, pan-) WITHOUT removal of tubes and ovaries
Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.
- 40 Total hysterectomy (simple, pan-) WITH removal of tubes and/or ovary
Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.
- 50 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy
 - 51 Modified radical hysterectomy
 - 52 Extended hysterectomy
 - 53 Radical hysterectomy; Wertheim procedure
 - 54 Extended radical hysterectomy
- 60 Hysterectomy, NOS, WITH or WITHOUT removal of tubes and ovaries
 - 61 WITHOUT removal of tubes and ovaries
 - 62 WITH removal of tubes and ovaries

- 70 Pelvic exenteration
71 Anterior exenteration
Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- 72 Posterior exenteration
Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- 73 Total exenteration
Includes removal of all pelvic contents and pelvic lymph nodes.
- 74 Extended exenteration
Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events 20–74.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

CORPUS UTERI**C54.0–C55.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

For invasive cancers, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Loop Electocautery Excision Procedure (LEEP)
 - 16 Thermal ablation

No specimen sent to pathology from surgical events 10–16.

- 20 Local tumor excision, NOS; simple excision, NOS
 - 24 Excisional biopsy
 - 25 Polypectomy
 - 26 Myomectomy
 Any combination of 20 or 24–26 WITH
 - 21 Electrocautery
 - 22 Cryosurgery
 - 23 Laser ablation or excision
- 30 Subtotal hysterectomy/supracervical hysterectomy/fundectomy WITH or WITHOUT removal of tube(s) and ovary(ies).
 - 31 WITHOUT tube(s) and ovary(ies)
 - 32 WITH tube(s) and ovary(ies)
- 40 Total hysterectomy (simple, pan-) WITHOUT removal of tube(s) and ovary(ies)
Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.
- 50 Total hysterectomy (simple, pan-) WITH removal of tube(s) and/or ovary(ies)
Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.
- 60 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy
 - 61 Modified radical hysterectomy
 - 62 Extended hysterectomy
 - 63 Radical hysterectomy; Wertheim procedure
 - 64 Extended radical hysterectomy

- 65 Hysterectomy, NOS, WITH or WITHOUT removal of tube(s) and ovary(ies)
66 WITHOUT removal of tube(s) and ovary(ies)
67 WITH removal of tube(s) and ovary(ies)
- 75 Pelvic exenteration
76 Anterior exenteration
Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- 77 Posterior exenteration
Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- 78 Total exenteration
Includes removal of all pelvic contents and pelvic lymph nodes.
- 79 Extended exenteration
Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events 20–79.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

OVARY**C56.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

17 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 17.

25 Total removal of tumor or (single) ovary, NOS

26 Resection of ovary (wedge, subtotal, or partial) ONLY, NOS; unknown if hysterectomy done

27 WITHOUT hysterectomy

28 WITH hysterectomy

35 Unilateral (salpingo-)oophorectomy; unknown if hysterectomy done

36 WITHOUT hysterectomy

37 WITH hysterectomy

50 Bilateral (salpingo-)oophorectomy; unknown if hysterectomy done

51 WITHOUT hysterectomy

52 WITH hysterectomy

55 Unilateral or bilateral (salpingo-)oophorectomy WITH OMENTECTOMY, NOS; partial or total; unknown if hysterectomy done

56 WITHOUT hysterectomy

57 WITH hysterectomy

60 Debulking; cytoreductive surgery, NOS

61 WITH colon (including appendix) and/or small intestine resection (not incidental)

62 WITH partial resection of urinary tract (not incidental)

63 Combination of 61 and 62

Debulking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debulking is usually followed by another treatment modality such as chemotherapy.

70 Pelvic exenteration, NOS

71 Anterior exenteration

Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.

72 Posterior exenteration

Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.

73 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

74 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

80 (Salpingo-)oophorectomy, NOS

Specimen sent to pathology from surgical events 25–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

PROSTATE**C61.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Do not code an orchiectomy in this field. For prostate primaries, orchiectomies are coded in the data item *Hematologic Transplant and Endocrine Procedures* (NAACCR Item #3250).

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 18 Local tumor destruction or excision, NOS
- 19 Transurethral resection (TURP), NOS, and no specimen sent to pathology or unknown if sent

Unknown whether a specimen was sent to pathology for surgical events coded 18 or 19 (principally for cases diagnosed prior to January 1, 2003).

- 10 Local tumor destruction, NOS
 - 14 Cryoprostatectomy
 - 15 Laser ablation
 - 16 Hyperthermia
 - 17 Other method of local tumor destruction

No specimen sent to pathology from surgical events 10–17.

- 20 Local tumor excision, NOS
 - 21 Transurethral resection (TURP), NOS, with specimen sent to pathology
 - 22 TURP—cancer is incidental finding during surgery for benign disease
 - 23 TURP—patient has suspected/known cancer
- Any combination of 20–23 WITH
 - 24 Cryosurgery
 - 25 Laser
 - 26 Hyperthermia
- 30 Subtotal, segmental, or simple prostatectomy, which may leave all or part of the capsule intact
- 50 Radical prostatectomy, NOS; total prostatectomy, NOS
Excised prostate, prostatic capsule, ejaculatory ducts, seminal vesicle(s) and may include a narrow cuff of bladder neck.
- 70 Prostatectomy WITH resection in continuity with other organs; pelvic exenteration
Surgeries coded 70 are any prostatectomy WITH resection in continuity with any other organs. The other organs may be partially or totally removed. Procedures may include, but are not limited to, cystoprostatectomy, radical cystectomy, and prostatectomy.
- 80 Prostatectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 12/4/02, 01/10, 02/10, 1/11, 01/16)

TESTIS**C62.0–C62.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

12 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 12.

20 Local or partial excision of testicle

30 Excision of testicle WITHOUT cord

40 Excision of testicle WITH cord or cord not mentioned (radical orchiectomy)

80 Orchiectomy, NOS (unspecified whether partial or total testicle removed)

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

KIDNEY, RENAL PELVIS, AND URETER
Kidney C64.9, Renal Pelvis C65.9, Ureter C66.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-99922)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Thermal ablation

No specimen sent to pathology from this surgical event 10–15.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Partial or subtotal nephrectomy (kidney or renal pelvis) or partial ureterectomy (ureter)

Procedures coded 30 include, but are not limited to:

 - Segmental resection
 - Wedge resection

- 40 Complete/total/simple nephrectomy—for kidney parenchyma
Nephroureterectomy
Includes bladder cuff for renal pelvis or ureter.
- 50 Radical nephrectomy
May include removal of a portion of vena cava, adrenal gland(s), Gerota's fascia, perinephric fat, or partial/total ureter.
- 70 Any nephrectomy (simple, subtotal, complete, partial, simple, total, radical) in continuity with the resection of other organ(s) (colon, bladder)
The other organs, such as colon or bladder, may be partially or totally removed.
- 80 Nephrectomy, NOS
Ureterectomy, NOS

Specimen sent to pathology from surgical events 20–80.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16)

BLADDER**C67.0–C67.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
- 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser
 - 15 Intravesical therapy
 - 16 Bacillus Calmette-Guerin (BCG) or other immunotherapy
- Also code the introduction of immunotherapy in the immunotherapy items. If immunotherapy is followed by surgery of the type coded 20-80 code that surgery instead and code the immunotherapy only as immunotherapy.**

No specimen sent to pathology from surgical events 10–16.

- 20 Local tumor excision, NOS
- 26 Polypectomy
 - 27 Excisional biopsy
- Combination of 20 or 26–27 WITH
- 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
- 25 Laser excision
- 30 Partial cystectomy
- 50 Simple/total/complete cystectomy
- 60 Complete cystectomy with reconstruction
- 61 Radical cystectomy PLUS ileal conduit
 - 62 Radical cystectomy PLUS continent reservoir or pouch, NOS
 - 63 Radical cystectomy PLUS abdominal pouch (cutaneous)
 - 64 Radical cystectomy PLUS in situ pouch (orthotopic)
- When the procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).**
- 70 Pelvic exenteration, NOS
- 71 Radical cystectomy including anterior exenteration
- For females, includes removal of bladder, uterus, ovaries, entire vaginal wall, and entire urethra. For males, includes removal of the prostate. When a procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).**
- 72 Posterior exenteration
- For females, also includes removal of vagina, rectum and anus. For males, also includes prostate, rectum and anus.**
- 73 Total exenteration
- Includes all tissue and organs removed for an anterior and posterior exenteration.**

74 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

80 Cystectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

BRAIN**Meninges C70.0–C70.9, Brain C71.0–C71.9,****Spinal Cord, Cranial Nerves and Other Parts of Central Nervous System C72.0–C72.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Do not code laminectomies for spinal cord primaries.

Codes

00 None; no surgery of primary site; autopsy ONLY

10 Tumor destruction, NOS

No specimen sent to pathology from surgical event 10.

Do not record stereotactic radiosurgery (SRS), Gamma knife, Cyber knife, or Linac radiosurgery as surgical tumor destruction. All of these modalities are recorded in the radiation treatment fields.

20 Local excision of tumor, lesion or mass; excisional biopsy

21 Subtotal resection of tumor, lesion or mass in brain

22 Resection of tumor of spinal cord or nerve

30 Radical, total, gross resection of tumor, lesion or mass in brain

40 Partial resection of lobe of brain, when the surgery can not be coded as 20-30.

55 Gross total resection of lobe of brain (lobectomy)

Codes 30 - 55 are not applicable for spinal cord or spinal nerve primary sites.

Specimen sent to pathology from surgical events 20–55.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

THYROID GLAND**C73.9**

(Except for M9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

00 None; no surgery of primary site; autopsy ONLY

13 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 13.

25 Removal of less than a lobe, NOS

26 Local surgical excision

27 Removal of a partial lobe ONLY

20 Lobectomy and/or isthmectomy

21 Lobectomy ONLY

22 Isthmectomy ONLY

23 Lobectomy WITH isthmus

30 Removal of a lobe and partial removal of the contralateral lobe

40 Subtotal or near total thyroidectomy

50 Total thyroidectomy

80 Thyroidectomy, NOS

Specimen sent to pathology from surgical events 20–80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

LYMPH NODES**C77.0–C77.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded to 19 (principally for cases diagnosed prior to January 1, 2003).

- 15 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 15.

- 25 Local tumor excision, NOS
Less than a full chain, includes an excisional biopsy of a single lymph node.
- 30 Lymph node dissection, NOS
 - 31 One chain
 - 32 Two or more chains
- 40 Lymph node dissection, NOS PLUS splenectomy
 - 41 One chain
 - 42 Two or more chains
- 50 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)
 - 51 One chain
 - 52 Two or more chains
- 60 Lymph node dissection, NOS and partial/total removal of adjacent organ(s) PLUS splenectomy
(Includes staging laparotomy for lymphoma.)
 - 61 One chain
 - 62 Two or more chains

Specimen sent to pathology for surgical events 25-62.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

ALL OTHER SITES

C14.2–C14.8, C17.0–C17.9, C23.9, C24.0–C24.9, C26.0–C26.9, C30.0–C 30.1, C31.0–C31.9, C33.9, C37.9, C38.0–C38.8, C39.0–C39.9, C48.0–C48.8, C51.0–C51.9, C52.9, C57.0–C57.9, C58.9, C60.0–C60.9, C63.0–C63.9, C68.0–C68.9, C69.0–C69.9, C74.0–C74.9, C75.0–C75.9

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy
 - Any combination of 20 or 26–27 WITH
 - 21 Photodynamic therapy (PDT)
 - 22 Electrocautery
 - 23 Cryosurgery
 - 24 Laser ablation
 - 25 Laser excision
- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation
 - 41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be “debulking”
- 60 Radical surgery

Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs.

Specimen sent to pathology from surgical events 20–60.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

UNKNOWN AND ILL-DEFINED PRIMARY SITES**C76.0–C76.8, C80.9**

(Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992)

Code

98 All unknown and ill-defined disease sites, WITH or WITHOUT surgical treatment.

Surgical procedures for unknown and ill-defined primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

APPENDIX C:
***FORDS* Page Revisions**

FORDS: An Evolving Data Manual

Following the initial release of *FORDS* in July 2002, the manual has undergone a series of modifications and revisions. All revisions have been made to the online edition of the manual and have been available to registries effective the date of revision.

This edition contains all the necessary documentation to support changes in case reporting to accommodate the standard data item changes implemented in 2013. The changes in the January 2010 release involved so much of this document that they are not itemized here. See *FORDS: Revised for 2009* for documentation of changes from 2003 through 2009 (see <http://www.facs.org/cancer/coc/fordsmanual.html> for a link). This appendix now contains changes introduced since the initial January 2010 release of *FORDS: Revised for 2010*. Spelling and grammar corrections are generally not cited below.

Specific questions regarding these revisions may be directed to the editor of *FORDS: Revised for 2016*, Kathleen K. Thoburn, BA, CTR (kthoburn@facs.org). All other *FORDS*-related coding questions should be directed to the CANSWER Forum at <http://cancerbulletin.facs.org/forums/>.

CHANGES TO *FORDS* SECTION ONE

2010

CANCER IDENTIFICATION: Primary Site

02/01/2010

Instructions for assigning primary site and morphology codes to hematopoietic and lymphoid tumors now specify “and lymphoid” and designate the applicable histology range as M-9590-9992.

CANCER IDENTIFICATION: Morphology

02/01/2010

Instructions for assigning histology codes now specify they apply to “solid tumors”.

CANCER IDENTIFICATION: Morphology - Grade/Differentiation

05/01/2010

Deleted breast, prostate and kidney from the 3-grade conversion instructions, because separate instructions exist for them.

FIRST COURSE OF TREATMENT: Surgery

02/01/2010

Second of duplicated “Reason for No Surgery of the Primary Site” deleted from list.

2011

AMBIGUOUS TERMS AT DIAGNOSIS

01/01/2011

Added sentence: Words or phrases that appear to be synonyms of these terms do not constitute a diagnosis. For example, “likely” alone does not constitute a diagnosis.

Exception clarified: If a cytology is identified only with an ambiguous term, do not interpret it as a diagnosis of cancer.

CANCER IDENTIFICATION

01/01/2011

Section coverage clarified: The following instructions apply to Primary Site (NAACCR Item #400), Laterality (NAACCR Item #410), Histology (NAACCR Item #522), Behavior Code (NAACCR Item #523), Grade/Differentiation (NAACCR Item #440), Grade Path Value (NAACCR Item #441) and Grade Path System (NAACCR Item #449).

CANCER IDENTIFICATION: Laterality

01/01/2011

Added sentences: "Midline" in this context refers to the point where the "right" and "left" sides of paired organs come into direct contact and a tumor forms at that point. Most paired sites can not develop midline tumors. For example, skin of the trunk can have a midline tumor, but the breasts can not.

CANCER IDENTIFICATION: Morphology - Grade/Differentiation, Grade Path Value, Grade Path System

01/01/2011

Section largely reworded.

CANCER IDENTIFICATION: Revising the Original Diagnosis

01/01/2011

Section clarified by adding the word "grade" to the sentence: Change the primary site, laterality, histology, grade and stage as the information becomes more complete. Also sentence added to first example: If first course surgery was performed, the surgery codes should be reviewed.

FIRST COURSE OF TREATMENT: Radiation

01/01/2011

Added sentence to *Treatment Volume* description: If two distinct volumes are radiated, and one of those includes the primary site, record the radiation involving the primary site in all radiation fields.

TREATMENT, PALLIATIVE, AND PROPHYLACTIC CARE

01/01/2011

Clarified palliative care description: This treatment qualifies the patient as analytic if it is given as part of planned first course treatment.

COMORBIDITIES AND COMPLICATIONS

01/01/2011

Revised section to reflect the fact that ICD-10-CM will be adopted by most United States hospitals during 2011.

2012**AMBIGUOUS TERMS AT DIAGNOSIS**

01/01/2012

Changed first sentence to read "As part of the registry case-finding activities, all diagnostic reports should be reviewed to confirm whether a particular case should be included". Replaced "pathology" with "diagnostic."

CLASS OF CASE

01/01/2012

Third paragraph under "Analytic Cases" changed to present tense for grammatical consistency.

Second sentence in “Nonanalytic Cases” was modified to read, “The CoC does not require registries in accredited programs to accession, abstract, or follow these cases, but the program or central registry may require them.”

Dropped “considered” from the following sentence: “A network clinic or outpatient center belonging to the facility is part of the facility.”

Explanation added to “Modifications to Class of Case in 2010”: “Treatment in staff physician offices is now coded ‘treated elsewhere’ because the hospital has no more responsibility over this treatment than it would if the patient were treated in another hospital.”

CANCER IDENTIFICATION

01/01/2012

Replaced the entire “Morphology: Grade” section with rules to determine when to code grade information in CS special grades, *Grade Path System* and *Grade Path Value* or *Grade/Differentiation*.

Removed redundant reference to the *SEER Multiple Primary and Histology Coding Rules* in the “Multiple Primaries” section.

AJCC TNM STAGING

01/01/2012

Added to first paragraph: “Use the rules in the current *AJCC Cancer Staging Manual* to assign AJCC T, N, M and Stage Group values”.

Added to the second non-bulleted paragraph: “CoC rules for recording AJCC staging changed in 2008”.

COLLABORATIVE STAGE DATA COLLECTION SYSTEM

01/01/2012

Changed section label to the current name of the system.

Removed extended description of the system, and changed the first paragraph to read: “The current *Collaborative Stage Data Collection System* (CS) is to be used for cases diagnosed on or after January 1, 2004. It is not to be used for cases diagnosed prior to that date. All CS items identified in FORDS are required to be completed for *Class of Case* 10-22”.

Reworded first paragraph under “Using CS Derived Values”: “Some differences in the ways that the CS algorithm operates and how the AJCC stage assignment rules are made can result in dissimilarities between the derived values for some patients and the direct-coded stages. Because of those differences, the CS Derived AJCC values must never be copied into the equivalent direct-coded AJCC fields. The dissimilarities of most interest to registrars are those that might explain discrepancies between the derived AJCC T, N, M, and Stage Group values and the values recorded for the same cases when directly coded using the AJCC instructions, as described in the next paragraph.”

04/09/2012

Corrected *Class of Case* range for CS code requirements to 00-22.

AMBIGUOUS TERMS AT DIAGNOSIS

01/01/2012

Dropped “considered” from the following sentence: “While “consistent with” can indicate involvement, “neoplasm” without specification of malignancy is not diagnostic except for non-malignant primary intracranial and central nervous system tumors.”

FIRST COURSE OF TREATMENT

01/01/2012

Added the following sentence to the first paragraph: “Maintenance treatment given as part of the first course of planned treatment (for example, for leukemia) is first course treatment, and cases receiving that treatment are analytic.”

In the section “Relationships among Surgical Items”, added: “When multiple first course procedures coded under the same item are performed for a primary, the most extensive or definitive is the last performed, and the code represents the cumulative effect of the separate procedures. Do not rely on your registry software to accumulate separate surgeries into the correct code.” (This was previously written under the primary site section, though it should apply to all surgery items.

Moved the third bullet under that statement from paragraph to bullet form.

In the section “Relationships among Radiation Items”, removed bullets that described relationships between *Regional Treatment Modality* and the former *Radiation* item (the latter item does not appear in **FORDS**).

In the paragraph following the table “Clarification of Systemic Therapy Terms,” removed a parenthetical phrase that described one way of grouping chemotherapeutic items; that list did not match the grouping in the *SEER*Rx Interactive Drug Database*.

Added the following sentence under “Other Treatment”: “Consult the most recent version of the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* for instructions for coding care of specific hematopoietic neoplasms in this item.”

COMORBIDITIES AND COMPLICATIONS

01/01/2012

Dropped “considered” from the following sentence: “All are secondary diagnoses.”

Changed wording of sentence referring to the timing of ICD-10-CM implementation to “Most hospitals in the United States are expected to implement use of ICD-10-CM in the near future.”

OUTCOMES

01/01/2012

Removed the sentence: “Reappearance of a tumor of the same histology in the same primary site during the time period defined by the *SEER Multiple Primary and Histology Coding Rules* does not constitute a recurrence.” That statement was incorrect.

2013**CASE ELIGIBILITY**

01/01/2013

Added phrase to the first title so it now reads: “Tumors Required by the CoC to be Accessioned, Abstracted, Followed and Submitted to the National Cancer Data Base (NCDB)”.

Added instruction: “Gastro-intestinal stromal tumors (GIST) and thymomas are frequently non-malignant. However, they must be abstracted and assigned a Behavior Code of 3 if they are noted to have multiple foci, metastasis or positive lymph nodes.”

Under “Examples of Diagnostic Terms”, in the second bullet the word “mammogram” was replaced with “pathology”.

CANCER IDENTIFICATION

01/01/2013

“Soft Tissue” was added to the table “Special Grades Coded in the Collaborative Stage Data Collection System”.

Added instructions and a table of CS schema that require Grade/Differentiation to be coded.

PATIENT ADDRESS AND RESIDENCY RULES

01/01/2013

Added at new section, “Coding Country and State”.

COMORBIDITIES AND COMPLICATIONS / SECONDARY DIAGNOSES

01/01/2013

Section expanded to include new Secondary Diagnosis #1-10 items.

FIRST COURSE OF TREATMENT

01/01/2013

In radiation section, the word “volume” in the definition of boost treatment was changed to “field”.

CASE ADMINISTRATION

01/01/2013

Added Over-ride CS 1-19 to list of override items that must be in the facility’s database.

Added CS Versions to the list of code versions used.

2015

CASE ELIGIBILITY

01/01/2015

Added Exception 2, and renumbered the remaining exceptions. Now carcinoid tumors of the appendix (C18.1) formerly coded 8240/1 must be coded 8240/3.

CLASS OF CASE

01/01/2015

Sentence changed to indicate no Class of Case 00 cases need to be followed: “Analytic cases *Class of Case 00* are not required to be staged or followed, regardless of the year of diagnosis.”

CANCER IDENTIFICATION

01/01/2015

Removed introductory reference to *Grade Path Value* and *Grade Path System*, which are no longer required.

01/01/2015

Under *Morphology: Histology Code*, updated reference to the *SEER 2007 Multiple Primary and Histology Coding Rules*, and added reference to the *SEER Hematopoietic and Lymphatic Neoplasm Coding Manual*.

01/01/2015

Replaced entire *Morphology: Grade* section.

PATIENT ADDRESS AND RESIDENCY RULES

01/01/2015

Under *Coding Country and State*, modified grammar in “State and country codes also include some custom codes, which are included in Appendix E.”

AJCC TNM STAGING

01/01/2015

Revised statements identifying AJCC registry staging requirements: “Clinical and pathologic staging components and stage groups should be recorded to the extent they are available.”
Pathologic staging is required as well as clinical.

01/01/2015

Modified grammar in “If either clinical or pathologic staging was applied for a pediatric tumor, enter the appropriate codes and do not code 88.”

FIRST COURSE OF TREATMENT

01/01/2015

In *Relationships among Surgical Items* corrected the code range in “Codes 10 through 19 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.”

01/01/2015

In *Systemic Therapy* added clarification that six drugs were reclassified in 2013 from chemotherapy to BRM/immunotherapy; no code change is applied for pre-2013 diagnoses.

01/01/2015

Updated the paragraph following the section described above to apply both to chemotherapy and hormone therapy: “Chemotherapy and hormone therapy agents are administered in treatment cycles, either singly or in a combination regimen of two or more drugs.... Refer to the *SEER*Rx Interactive Drug Database* (<http://seer.cancer.gov/>) for a list of systemic therapy agents.”

OUTCOMES

01/01/2015

Clarified that *Class of Case* 00 cases no longer need to be followed.

01/01/2015

Added definitions of local, trocar, regional and distant recurrence.

2016

CASE ELIGIBILITY

01/01/2016

Added larynx (LIN III), and squamous intraepithelial neoplasia excluding cervix (SIN III) to Exception 4.

UNIQUE PATIENT IDENTIFIERS CODES

01/01/2016

Added sentence to emphasize that Accession number should never be changed:
“Once cases are submitted to RQRS or the NCDB, accession numbers are not to be changed for any reason. Even if there is a clerical error, or if cases are found in an out-of-order fashion when case

finding (i.e., find an old case after abstraction of a newer one), the accession number serves as a permanent identifier for a patient at your facility. NCDB does not accommodate any requests for accession number changes for cases already submitted.”

AJCC TNM STAGING

01/01/2016

Added new coding rules for use of code 88:

- “If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are considered as “impossible diagnoses” in the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.”

Added verbiage to introduce the new T, N, M categories:

“Beginning in 2016, new T, N, and M categories were implemented that include ‘c’ and ‘p’ designations to enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual. For example, the new category of cN0 for the TNM Path N [890] data item is limited to in situ tumors only in 2016.

COLLABORATIVE STAGE DATA COLLECTION SYSTEM

01/01/2016

Added statement about retirement of Collaborative Stage and delineated diagnosis year-specific requirement of Collaborative Stage data items:

“For cases diagnosed beginning January 1, 2016, the Collaborative Stage Data Collection System (CS) has been retired. The current Collaborative Stage Data Collection System (CS) is to be used for staging cases diagnosed on or after January 1, 2004 through December 31, 2015. It is not to be used for cases diagnosed prior to, or after those that dates. For cases diagnosed from 2004-2015 all CS items identified in FORDS are required to be completed for Class of Case 00-22. See the interactive application at <http://seer.cancer.gov/csreqstatus/application.html> for the specific Site-Specific Factors required by CoC by site and histology.

The following data items were considered as Collaborative Stage input data items for the purposes of Collaborative Stage, but are now are continued to be required for AJCC staffing and research purposes. They are required for all cases diagnosed in 2004 and later:

- Regional Nodes Positive [820]
- Regional Nodes Examined [830]
- Lymph-vascular Invasion [1182]
- CS Site-specific Factors [2861-2880, 2890-2930]
- CS Version Input Original [2935]
- CS Version Input Current [2937]

Note: CoC’s requirements for the Site-specific Factors have not changed from 2015; the data items of CS Version Input Original and Current continue to be required to accommodate continued collection of the SSFs.”

CASE ADMINISTRATION

01/01/2016

Under Administrative Tracking, updated URL for complete list of FINs on ACoS website:
<https://www.facs.org/quality-programs/cancer/accredited/info/fin>

Under Code Versions Used, specified that CS Version Derived (NAACCR Item # 2936 is required
“for cases diagnosed 2004 through 2015”.

CHANGES TO *FORDS* SECTION TWO: PATIENT IDENTIFICATION

2011**Military Record Number Suffix** (NAACCR Item #2310)

01/01/2011

Item deleted from **FORDS****First Name** (NAACCR Item #2240)

01/01/2011

Modified instructions: Blanks, spaces, hyphens, and apostrophes are allowed. Do not use
other punctuation. This field may be updated if the name changes.

Middle Name (NAACCR Item #2250)

01/01/2011

Modified instructions: Blanks, spaces, hyphens, and apostrophes are allowed. Do not use
other punctuation. This field may be updated if the name changes.

State at Diagnosis (NAACCR Item #80)

01/01/2011

Code for Canada corrected: CD

State -- Current (NAACCR Item #1820)

01/01/2011

Code for Canada corrected: CD

Following Physician (NAACCR Item #2470)

01/01/2011

Item deleted from **FORDS****Primary Surgeon** (NAACCR Item #2480)

01/01/2011

Item deleted from **FORDS****Physician #3** (NAACCR Item #2490)

01/01/2011

Item deleted from **FORDS****Physician #4** (NAACCR Item #2500)

01/01/2011

Item deleted from **FORDS**

2012**Patient Address at Diagnosis (Number and Street)**

01/01/2012

Added label “Examples” to example grid.

Patient Address at Diagnosis–Supplemental

01/01/2012

Added label “Examples” to example grid.

State at Diagnosis

01/01/2012

Relabeled United States and Canadian abbreviations list for consistency.

Patient Address–Current (Number and Street)

01/01/2012

Added label “Examples” to example grid.

Patient Address Current– Supplemental

01/01/2012

Added label “Examples” to example grid.

State–Current

01/01/2012

Added label “Examples” to example grid.

Place of Birth

01/01/2012

Added label “Examples” to example grid.

Added example (000 , Place of birth in United States, no other detail known).

Race 1-5

01/01/2012

Redefined code 21, Chamorro/Chamoru

Comorbidities and Complications (1-10)

01/01/2012

Removed code range Z23001-Z2493 from allowable code range.

Added “or ICD-10-CM” to the code definition instructions.

NPI—Physician #4

01/01/2012

Third bullet: changed “radiation” to “medical” oncologist.

2013**Sequence Number**

01/01/2013

Word “malignant” in first, second and fourth bullets corrected to “invasive”.

Address at DX – Country

01/01/2013

New item. Corresponds to other Addr at DX items (state, postal code). Pre-2013 cases should be converted by the registry's software.

Address Current – Country

01/01/2013

New item. Corresponds to Address Current – State. Pre-2013 cases should be converted by the registry's software.

Place of Birth

01/01/2013

Deleted item. Replaced by Birthplace-State and Birthplace-Country, which should be converted from it. Codes are not the same.

Birthplace-State

01/01/2013

New item. Along with Birthplace-Country, replaced Place of Birth. Historic data should be converted by software.

Birthplace-Country

01/01/2013

New item. Along with Birthplace-State, replaced Place of Birth. Historic data should be converted by software.

Comorbidities and Complications #1**Comorbidities and Complications #2****Comorbidities and Complications #3****Comorbidities and Complications #4****Comorbidities and Complications #5****Comorbidities and Complications #6****Comorbidities and Complications #7****Comorbidities and Complications #8****Comorbidities and Complications #9****Comorbidities and Complications #10**

01/01/2013

In the past, these items were updated to permit coding of ICD-10-CM values in addition to ICD-9-CM values. Because those values have more characters than are available in these items (7 compared to 5), new Secondary Diagnosis #1-10 items have been introduced for use. All references to ICD-10-CM were removed from these items; however, already-coded ICD-10-CM data will be accepted for cases diagnosed prior to 2013.

Secondary Diagnosis #1**Secondary Diagnosis #2****Secondary Diagnosis #3****Secondary Diagnosis #4****Secondary Diagnosis #5****Secondary Diagnosis #6****Secondary Diagnosis #7****Secondary Diagnosis #8****Secondary Diagnosis #9****Secondary Diagnosis #10**

01/01/2013

These items are used to record secondary diagnoses when they are recorded in ICD-10-CM, rather than using Comorbidities and Complications #1-10.

2015

County at Diagnosis (NAACCR Item #90)

01/01/2015

Changed instruction: If the patient is a non-U.S. resident, use code 999. Also changed the example for 999.

01/01/2015

Removed instruction for coding country in this field.

Birthplace—State (NAACCR Item #252)

01/01/2015

Corrected header to indicate the item was added (not revised) in 2013.

Spanish Origin—All Sources (NAACCR #190)

01/01/2015

Corrected bullet by adding the word “not”: Persons of Spanish or Hispanic origin may be of any race, but these categories are generally **not** used for Native Americans, Filipinos, or others who may have Spanish names.

Sex (NAACCR Item #220)

01/01/2015

Updated code 4 to Transsexual, NOS; Added code 5 Transsexual, natal male; Added code 6 Transsexual, natal female.

Added instruction: Natality for transsexuals was added for use in 2015, but may be applied for earlier diagnoses.

- Comorbidities and Complications #2** (NAACCR Item #3120)
- Comorbidities and Complications #3** (NAACCR Item #3130)
- Comorbidities and Complications #4** (NAACCR Item #3140)
- Comorbidities and Complications #5** (NAACCR Item #3150)
- Comorbidities and Complications #6** (NAACCR Item #3160)
- Comorbidities and Complications #7** (NAACCR Item #3161)
- Comorbidities and Complications #8** (NAACCR Item #3162)
- Comorbidities and Complications #9** (NAACCR Item #3163)
- Comorbidities and Complications #10** (NAACCR Item #3164)

01/01/2015

Updated coding instructions.

- Secondary Diagnosis #2** (NAACCR Item #3782)
- Secondary Diagnosis #3** (NAACCR Item #3784)
- Secondary Diagnosis #4** (NAACCR Item #3786)
- Secondary Diagnosis #5** (NAACCR Item #3788)
- Secondary Diagnosis #6** (NAACCR Item #3790)
- Secondary Diagnosis #7** (NAACCR Item #3792)
- Secondary Diagnosis #8** (NAACCR Item #3794)
- Secondary Diagnosis #9** (NAACCR Item #3796)
- Secondary Diagnosis #10** (NAACCR Item #3798)

01/01/2015

Deleted bullet that belonged only to **Secondary Diagnosis #1** (NAACCR Item #3780): If no ICD-10-CM secondary diagnoses were documented, then code 0000000 in this data item, and leave the remaining *Secondary Diagnosis* data items blank.

2016**Sex** (NAACCR Item #220)

01/01/2016

Updated Label for code 3 from “Other (hermaphrodite)” to “Other (intersex, disorders of sexual development/DSD)”

Added instruction: “The definition of code 3 was updated to “Other (intersex, disorders of sexual development/DSD)” in 2016”.

CHANGES TO *FORDS* SECTION TWO: CANCER IDENTIFICATION

2010**Class of Case** (NAACCR Item #610)

05/01/2010

Second sentence in description modified to read: “Analytic cases are grouped according to the location of diagnosis and first course of treatment.”

Added “or a decision not to treat” to description of code 22.

Date of Initial Diagnosis (NAACCR Item #390)

02/01/2010

Deleted two sentences from final paragraph: “The *Date of Diagnosis Flag* (NAACCR Item #391) is used to explain why *Date of Diagnosis* is not a known date. See *Date of Diagnosis Flag* for an illustration of the relationships among these items.”

Date of Diagnosis Flag (NAACCR Item #391)

02/01/2010

Item deleted. Because *Date of Initial Diagnosis* must always have a year estimated if the exact date is not known, this item will never be used.

Laterality (NAACCR Item #410)

05/01/2010

Changed third bullet to read: “Where the right and left sides of paired sites are contiguous (come into contact) and the lesion is at the point of contact of the right and left sides, use code 5, midline. Note that ‘midline of the right breast’ is coded 1, right; midline in this usage indicates the primary site is C50.8 (overlapping sites).”

Histology (NAACCR Item #522)

03/10/2010

Deleted exception to sixth bullet for consistency with Multiple Primary and Histology rules.

Date Conclusive DX Flag (NAACCR Item #448)

05/01/2010

Corrected item name (from Date of Conclusive DX Flag).

2011**Class of Case** (NAACCR Item #610)

01/01/2011

Added instruction: If the hospital has purchased a physician practice, it will be necessary to determine whether the practice is now legally considered part of the hospital (their activity is coded as the hospital's) or not. If the practice is not legally part of the hospital, it will be necessary to determine whether the physicians involved are staff physicians or not, as with any other physician. Added clarification to codes 13 and 21: "part of first course treatment was done elsewhere".

Added "treatment plan only" to code 30 examples.

Added to definition of code 31: or hospital provided care that facilitated treatment elsewhere (for example, stent placement)

Added to code 32: (active disease)

Added to code 33: (disease not active)

Facility Referred From (NAACCR Item #2410)

01/01/2011

Item deleted from **FORDS**

Facility Referred To (NAACCR Item #2420)

01/01/2011

Item deleted from **FORDS**

Date of First Contact (NAACCR Item #580)

01/01/2011

Clarified first instruction (added "first course"): Record the date the patient first had contact with the facility as either an inpatient or outpatient for diagnosis and/or first course treatment of a reportable tumor.

Added instruction: For analytic cases (Class of Case 00-22), the *Date of First Contact* is the date the patient became analytic. For non-analytic cases, it is the date the patient first qualified for the *Class of Case* that causes the case to be abstracted.

Date of Initial Diagnosis (NAACCR Item #390)

01/01/2011

Clarified instruction: Use the date treatment was started as the date of diagnosis if the patient receives a first course of treatment before a diagnosis is documented.

Modified examples

Grade/Differentiation (NAACCR Item #440)

01/01/2011

Added instruction: Code the grade or differentiation from the pathology report prior to any neoadjuvant treatment. If there is no pathology report prior to neoadjuvant treatment, assign code 9.

Grade Path System (NAACCR Item #449)

01/01/2011

Replaced detailed instructions with: Refer to the current *CS Manual* for coding instructions.

Grade Path Value (NAACCR Item #441)

01/01/2011

Replaced detailed instructions with: Refer to the current *CS Manual* for coding instructions.

Lymph-Vascular Invasion (NAACCR Item #1182)

01/01/2011

Replaced detailed instructions with: Refer to the current *CS Manual* for coding instructions.

Diagnostic Confirmation (NAACCR Item #490)

01/01/2011

Added new first instruction to Solid Tumor instructions: See the section following this one for Coding Hematopoietic or Lymphoid Tumors (9590-9992).

Added sentence to cytology coding instruction: CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.

Ambiguous Terminology Diagnosis (NAACCR Item #442)

01/01/2011

Added instruction: Leave blank for cases diagnosed prior to January 1, 2007.

Date Conclusive DX Flag (NAACCR Item #448)

01/01/2011

Replaced detailed instructions with: Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.

Date of Mult Tumors Flag (NAACCR Item #439)

01/01/2011

Replaced detailed instructions with: Apply the instructions in the current version of *Multiple Primary Histology and Coding Rules* to code this item.

2012**Class of Case**

01/01/2012

Modified second sentence of third bullet: "If it is not known that the patient actually went somewhere else, code *Class of Case 10*".

Added to eighth bullet: "Treatment provided in a staff physician's office is provided 'elsewhere'. That is because care given in a physician's office is not within the hospital's realm of responsibility."

Added bullet: "'In-transit' care is care given to a patient who is temporarily away from the patient's usual practitioner for continuity of care. If these cases are abstracted, they are *Class of Case 31*. If a patient begins first course radiation or chemotherapy elsewhere and continues at the reporting facility, and the care is not in-transit, then the case is analytic (*Class of Case 21*)".

Modified label for analytic codes: "Initial diagnosis at reporting facility or in a staff physician's office."

Added more examples.

Behavior Code

01/01/2012

Added "malignant" to first bullet.

Added new bullet (second): "Code 3 if any *malignant* metastasis to nodes or tissue beyond the primary is present."

In table, modified descriptions of terminologies for “in situ”, and added “carcinoma” specification for several.

Grade/Differentiation

01/01/2012

Added new bullet: “See “Morphology: Grade” in the “Cancer Identification” of *Section I* for determining whether a particular grade is coded as *Grade/Differentiation* NAACCR Item #440), *Grade Path System* (NAACCR Item #449) and *Grade Path Value* (NAACCR Item #441), or as a site-specific special grade in the **Collaborative Stage Data Collection System**”.

Added bullet: “Do not code ‘high grade dysplasia’ as *Grade/Differentiation*; the term ‘grade’ has a different meaning in that context.”

Modified a bullet to read: “Codes 5–8 define T-cell or B-cell origin for leukemias and lymphomas. Do not use codes 1-4 for these cases.”

Deleted bullet that said: “See Section I to convert other solid tumor grade systems to *Grade/Differentiation*”.

Deleted bullet that said: “If *Grade Path System* (NAACCR Item #449) and *Grade Path Value* (NAACCR Item #441) are coded, *Grade/Differentiation* (NAACCR Item #440) must not be 9”. That rule no longer holds.

Grade Path System

01/01/2012

Added bullet: “See ‘Morphology: Grade’ in the ‘Cancer Identification’ of *Section I* for determining whether a particular grade is coded as *Grade/Differentiation* NAACCR Item #440), *Grade Path System* (NAACCR Item #449) and *Grade Path Value* (NAACCR Item #441), or as a site-specific special grade in the **Collaborative Stage Data Collection System**.”

Grade Path Value

01/01/2012

Added the word “value” to the description: “Describes the grade value assigned according to the grading system in *Grade Path System* (NAACCR Item #449)”.

Added bullet: “See ‘Morphology: Grade’ in the ‘Cancer Identification’ of *Section I* for determining whether a particular grade is coded as *Grade/Differentiation* NAACCR Item #440), *Grade Path System* (NAACCR Item #449) and *Grade Path Value* (NAACCR Item #441), or as a site-specific special grade in the **Collaborative Stage Data Collection System**.”

Diagnostic Confirmation

01/01/2012

Removed reference to multiple myeloma in definition of code 5 for solid tumors.

Ambiguous Terminology Diagnosis

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and Histology Coding Rules*. Instructions for distinguishing between “60 or fewer days” and “more than 60 days” clarified from that source.

Date of Conclusive Diagnosis

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and*

*Histology Coding Rules.***Date of Conclusive DX Flag**

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and Histology Coding Rules*.

Date of Multiple Primary Tumors

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and Histology Coding Rules*.

Date of Mult Tumors Flag

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and Histology Coding Rules*.

Type of Multiple Tumors Reported as One Primary

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and Histology Coding Rules*.

Multiplicity Counter

01/01/2012

This item should now be coded according to FORDS, rather than the *SEER Multiple Primary and Histology Coding Rules*. Codes 00 and 89 were added. Note also that some site- and histology-specific instructions have changed since that manual was produced.

2013**Laterality**

01/01/2013

Added as 3rd bullet: "If both lungs have nodules or tumors and the lung of origin is not known, assign code 4."

Behavior Code

01/01/21013

Added: "Gastro-intestinal stromal tumors (GIST) and thymomas are frequently non-malignant. However, they must be abstracted and assigned a Behavior Code of 3 if they are noted to have multiple foci, metastasis or positive lymph nodes."

Grade/Differentiation

01/01/2013

Deleted 4 bullets that were instances of other bullets.

Diagnostic Confirmation

01/01/2013

Reworded the Rationale to better apply to CoC programs: "This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases."

Reordered instructions so tables do not span pages.

Reworded bullet for code 8 in the hematopoietic instructions so first sentence reads “Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes.” Copied entire bullet to solid tumor instructions.

Ambiguous Terminology Diagnosis

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

Date of Conclusive Diagnosis

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

Date Conclusive DX Flag

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

Date of Multiple Tumors

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

Date of Mult Tumors Flag

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

Type of Multiple Tumors Reported As One Primary

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

Multiplicity Counter

01/01/2013

Item deleted. Use older codes for cases diagnosed prior to 2013.

2015

Class of Case (NAACCR Item #610)

01/01/2015

New bullet: Physicians who are not employed by the hospital but are under contract with it or have routine admitting privileges there are described in codes 10-12 and 41 as physicians with admitting privileges. Treatment provided in the office of a physician with admitting privileges is provided “elsewhere”. That is because care given in the physician’s office is not within the hospital’s realm of responsibility.

01/01/2015

Modified wording in bullet: If the hospital purchases a physician practice ...

01/01/2015

Added wording to last bullet: “In-transit” care is care given to a patient who is temporarily away from the patient’s usual practitioner for continuity of care. If these cases are abstracted, they are *Class of Case 31*. **Monitoring of oral medication started elsewhere is coded *Class of Case 31***. If a patient begins first course radiation or chemotherapy **infusion** elsewhere and continues at the reporting facility, and the care is not in-transit, then the case is analytic (*Class of Case 21*).

01/01/2015

Modified wording for *Class of Case* codes 10, 11, 12, and 41.

01/01/2015

Changes to examples for 00, 13, 11, 42 and 31.

Behavior Code (NAACCR Item #523)

01/01/2015

Added “only” to this definition of code 2: Noninvasive (carcinoma **only**)

Grade/Differentiation (NAACCR Item #440)

01/01/2015

New instruction: See “Morphology: Grade” in the “Cancer Identification” of *Section I* for instructions for coding this item for cases diagnosed in 2014 or subsequently. Consult the applicable version of **FORDS** for cases for instructions for cases diagnosed prior to 2014.

Diagnostic Confirmation (NAACCR Item #490)

01/01/15

Corrected header to show that changes to the item were made in 2013.

2016

Regional Lymph Nodes Examined (NAACCR Item #830)

01/01/2016

Added sentence to Description:

“In 2016 use of CS was discontinued, however this data item continued to be required.”

Added sentence to Instructions:

“When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual use the AJCC definition.”

Regional Lymph Nodes Positive (NAACCR Item #820)

01/01/2016

Added sentence to Description:

“In 2016 use of CS was discontinued, however this data item continued to be required.”

Added sentence to Instructions:

“When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual use the AJCC definition.”

CHANGES TO *FORDS* SECTION TWO: STAGE OF DISEASE AT DIAGNOSIS

2010

Clinical Stage (Prefix/Suffix) Descriptor (NAACCR Item #980)

02/01/2010

Code 4 removed and the following instruction added: “Previous editions of **FORDS** included a code 4 for y-classification, and a note that it was not applicable for clinical stage. Code 4 has been removed from the list of valid codes”.

05/01/2010

Code 6 removed; it was a combination of code 4 (removed 02/10/2010) and another code.

Site-Specific Factor 1 (NAACCR Item #2880)

02/01/2010

BileDuctsIntrahepatic schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Kaposi Sarcoma schema added to table.

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 2 (NAACCR Item #2890)

02/01/2010

BileDuctsIntrahepatic schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 3 (NAACCR Item #2900)

02/01/2010

SkinEyelid SSF3 name changed to “Clinical Status of Lymph Nodes”.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 4 (NAACCR Item #2910)

02/01/2010

Added instruction: Prostate SSF4 (Prostate Apex Involvement) does not show on this table, because it is considered obsolete in 2010. However, it is required for cases diagnosed through 2009, as it was required in CSv1, even if it is abstracted in CSv2.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 5 (NAACCR Item #2920)

02/01/2010

Melanoma Choroid and MelanomaCiliaryBody schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 6 (NAACCR Item #2930)

02/01/2010

SkinEyelid, MelanomaChoroid, and MelanomaCiliaryBody schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 7 (NAACCR Item #2861)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 8 (NAACCR Item #2862)

02/01/2010

SkinEyelid schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 9 (NAACCR Item #2863)

02/01/2010

SkinEyelid schema deleted from table.

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

Site C30.1 (middle ear) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 10 (NAACCR Item #2864)

02/01/2010

TongueBase, PalateSoft, SkinEyelid, GISTPeritoneum, MelanomaChoroid, and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 11 (NAACCR Item #2865)

02/01/2010

MelanomaChoroid, MelanomaCiliaryBody and MerkelCellVulva schema added to table.

Site C03.1 (Gum, Lower) added to Head and Neck site codes in table footnote.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 12 (NAACCR Item #2866)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 13 (NAACCR Item #2867)

02/01/2010

MelanomaChoroid and MelanomaCiliaryBody schema added to table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 14 (NAACCR Item #2868)

02/01/2010

SkinEyelid schema deleted from table.

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 15 (NAACCR Item #2869)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 16 (NAACCR Item #2870)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 17 (NAACCR Item #2871)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 18 (NAACCR Item #2872)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 19 (NAACCR Item #2873)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 20 (NAACCR Item #2874)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 21 (NAACCR Item #2875)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 22 (NAACCR Item #2876)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 23 (NAACCR Item #2877)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 24 (NAACCR Item #2878)

03/01/2010

Added “abstracted in CSv2” to SSF requirements in the table.

Site-Specific Factor 25 (NAACCR Item #2879)

02/01/2010

GISTPeritoneum schema deleted from table.

2011**Clinical M** (NAACCR Item #960)

01/01/2011

Added sentence to Rationale: Effective January 1, 2008 the CoC requires that AJCC clinical TNM staging be recorded in its accredited cancer program cancer registries.

Corrected code: 0I+ (was I+), represents M0(i+)

Clinical Stage Group (NAACCR Item #970)

01/01/2011

Revised fourth bullet: If the value does not fill all 4 characters, then record the value to the left and leave the remaining spaces blank.

Clinical Stage (Prefix/Suffix) Descriptor (NAACCR Item #980)

01/01/2011

Corrected Allowable Values: 0-3, 5, 9

Pathologic Stage Group (NAACCR Item #910)

01/01/2011

Revised fifth bullet: If the value does not fill all 4 characters, then record the value to the left and leave the remaining spaces blank.

All CS items

01/01/2011

Changed references from “Collaborative Staging” to “Collaborative Stage”

CS Lymph Nodes Eval (NAACCR Item #2840)

01/01/2011

Changed item name from *CS Reg Nodes Eval* for consistency with Collaborative Stage.

CS Site-Specific Factor 2 (NAACCR Item #2890)

01/01/2011

Added new schema and SSF: MyelomaPlasmaCellDisorder, Durie-Salmon Staging System

CS Site-Specific Factor 3 (NAACCR Item #2900)

01/01/2011

Added new schema and SSF: MyelomaPlasmaCellDisorder, Multiple Myeloma Terminology

CS Site-Specific Factor 10 (NAACCR Item #2864)

01/01/2011

Added new SSF for BileDuctsIntrahep schema: Tumor Growth Pattern

CS Site-Specific Factor 13 (NAACCR Item #2867)

01/01/2011

Added new SSF for Testis: Postorchiectomy Alpha Fetoprotein (AFP) Range

CS Site-Specific Factor 15 (NAACCR Item #2869)

01/01/2011

Added new SSF for Breast: HER2: Summary result of testing

Added new SSF for Testis: Postorchiectomy Human Chorionic Gonadotropin (hCG) Range

CS Site-Specific Factor 16 (NAACCR Item #2870)

01/01/2011

Added new SSF for Testis: Postorchiectomy Lactate Dehydrogenase (LDH) Range

Site-Specific Factor (SSF) 1-25

01/01/2011

Updated 2010 reference in table instructions: For tumors abstracted in CS v02.03 or diagnosed in 2011 ...

Corrected histology and/or primary site for applicable schema as shown in the following table.

Neither schema names nor the associated SSF names are affected. Only the changed sites and histologies are listed below.

| Schema Name | Site | Histology |
|---------------------|------|--|
| Head and Neck (all) | | 8000-8713, 8800-9136, 9141-9582, 9700-9701 |
| Esophagus | | 8000-8934, 8940-9136, 9141-9582, 9700-9701 |
| EsophagusGEJunction | | 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701 |
| Stomach | | 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701 |
| SmallIntestine | | 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701 |

| | | |
|---------------------|---|--|
| Colon | | 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701 |
| Appendix | | 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701 |
| Rectum | | 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701 |
| Liver | C22.1 | 8170-8175 |
| | C22.0 | 8000-8157, 8162-8175, 8190-9136, 9141-9582, 9700-9701 |
| CysticDuct | | 8000-9136, 9141-9582,9700-9701 |
| BileDuctsIntrahepat | C22.0 | 8160-8161, 8180 |
| | C22.1 | 8000-8162, 8180-9136, 9141-9582, 9700-9701 |
| BileDuctsPerihilar | | 8000-9136, 9141-9582, 9700-9701 |
| Lung | | 8000-9136, 9141-9582, 9700-9701 |
| HeartMediastinum | | 8000-9136, 9141-9582, 9700-9701 |
| Pleura | | 8000-9136, 9141-9582, 9700-9701 |
| Bone | | 8000-9136, 9141-9582, 9700-9701 |
| Skin | | 8000-8246, 8248-8713, 8800-9136, 9141-9582 |
| SkinEyelid | | 8000-8713, 8800-9136, 9141-9508, 9510-9514, 9520-9582 |
| SoftTissue | | 8000-9136, 9141-9582, 9700-9701 |
| Retroperitoneum | | 8000-8934, 8940-9136, 9141-9582, 9700-9701 |
| Peritoneum | C48.1-2,8 | Male: 8800-8921, 8940-9055, 9120-9136, 9141-9582 |
| | | Female: 8580-8589, 8680-8921, 9120-9136, 9141-9582, 9700-9701 |
| Breast | | 8000-9136, 9141-9582, 9700-9701 |
| Vagina | | 8000-9136, 9141-9582, 9700-9701 |
| Cervix | | 8000-9136, 9141-9582, 9700-9701 |
| CorpusAdenosarcoma | | 8933 |
| CorpusSarcoma | | 8800-8932, 8934-8974, 8982-9136, 9141-9582 |
| Ovary | | 8000-9136, 9141-9582, 9700-9701 |
| FallopianTube | | 8000-9136, 9141-9582, 9700-9701 |
| Placenta | | 8000-9136, 9141-9582, 9700-9701 |
| Prostate | | 8000-9136, 9141-9582, 9700-9701 |
| Testis | | 8000-9136, 9141-9582, 9700-9701 |
| Scrotum | | 8000-8246, 8248-8713, 8800-9136, 9141-9582 |
| Penis | | 8000-8246, 8248-8713, 8800-9136, 9141-9582 |
| KidneyParenchema | | 8000-9136, 9141-9582, 9700-9701 |
| KidneyRenalPelvis | | 8000-9136, 9141-9582, 9700-9701 |
| Bladder | | 8000-9136, 9141-9582, 9700-9701 |
| Urethra | | 8000-9136, 9141-9582, 9700-9701 |
| Conjunctiva | | 8000-8713, 8800-9136, 9141-9508, 9510-9514, 9520-9582 |
| LacrimalGland | | 8000-8713, 8800-9136, 9141-9508, 9520-9582, 9700-9701 |
| LacrimalSac | | 8000-8713, 8800-9136, 9141-9508, 9520-9582, 9700-9701 |
| Brain | | 8000-9136, 9141-9582, 9700-9701 |
| CNSOther | | 8000-9136, 9141-9582, 9700-9701 |
| Thyroid | | 8000-9136, 9141-9582, 9700-9701 |
| IntracranialGland | | 8000-9136, 9141-9582, 9700-9701 |
| Lymphoma | C00.0-44.0; C44.2-68.9; C69.1-4,8-C80.9 | 9590-9699, 9702-9729, 9735, 9737-9738 |
| | C00.0-41.9; C42.2-3,5-44.0; C44.2-68.9; C69.1-4,8-C80.9 | 9811-9818, 9823, 9827, 9837 |
| HemeRetic | C00.0-80.9 | 9740-9809, 9840-9992 |
| | C42.0,1,4 | 9811-9818, 9823, 9827, 9837 |

| | | |
|--|--|-----------------------------|
| | C00.0-44.0; C44.2-68.9; C69.1-4,8-C80.9 | 9733, 9820, 9826, 9231-9836 |
|--|--|-----------------------------|

Derived AJCC-6 Stage Group (NAACCR Item #3000)

01/01/2011

Replaced “M” in final instruction with “Stage Group”

Derived AJCC-7 Stage Group (NAACCR Item #3430)

01/01/2011

Replaced “M” in final instruction with “Stage Group”

2012**RX Date—DX/Stg Proc Flag**

01/01/2012

Corrected NAACCR Item #1281.

Surgical Diagnostic and Staging Procedure

01/01/2012

Reworded description: “Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.”

Added new bullet (second): “Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy”.

Surgical Diagnostic and Staging Procedure

01/01/2012

Reworded description: “Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.”

Added new bullet (second): “Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy”.

CS Site-Specific Factor 1-25

01/01/2012

Removed detailed list of SSFs required to be coded, and replaced it with the following bullet:
“Refer to the CS coding instructions on the Collaborative Stage web site at <http://www.cancerstaging.org> for the current list of CS Site Specific Factors *required* to be abstracted by CoC. Registries are *encouraged* to code other prognostic site specific factors used by the facility.

2015**Surgical Diagnostic and Staging Procedure** (NAACCR #1350)

Surgical Diagnostic and Staging Procedure at This Facility (NAACCR #740)

01/01/2015

Added clarifying instruction: If a needle biopsy preceded an excisional biopsy or more extensive surgery, even if no tumor remained at the time of surgery, both the needle biopsy (*Surgical Diagnostic and Staging Procedure*) and the *Surgical Procedure of the Primary Site* are to be reported. Surgical margins must be examined to determine whether a biopsy intended as incisional is excisional instead, and margins cannot be evaluated for a needle biopsy.

Pathologic T (NAACCR Item #880)

Pathologic N (NAACCR Item #890)

Pathologic M (NAACCR Item #900)

Pathologic Stage Group (NAACCR Item #910)

01/01/2015

Removed bullet: these items are required, not “recommended”, in 2015.

Added bullet: items are required for Class of Case 10-22.

2016

Surgical Diagnostic and Staging Procedure (NAACCR #1350)

01/01/2016

Reworded 8th bullet for clarity

- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* data item (NAACCR Item #1290).

Surgical Diagnostic and Staging Procedure at this Facility (NAACCR #740)

01/01/2016

Reworded 8th bullet for clarity

- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* data item (NAACCR Item #1290).

Tumor Size Summary (NAACCR #756)

Mets at Diagnosis – Bone (NAACCR #1112)

Mets at Diagnosis – Brain (NAACCR #1113)

Mets at Diagnosis – Distant Lymph Nodes (NAACCR #1114)

Mets at Diagnosis – Liver (NAACCR #1115)

Mets at Diagnosis – Lung (NAACCR #1116)

Mets at Diagnosis – Other (NAACCR #1117)

01/01/2016

Added new data items to FORDS

Clinical T (NAACCR #940)

01/01/2016

Added the following to rationale:

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Replaced Code Table:

| Code | Definition | Code | Definition | Code | Definition |
|---------|---------------|------|------------|------|----------------|
| (blank) | Not recorded | c1B | cT1b | c3 | cT3 |
| cX | cTX | c1B1 | cT1b1 | c3A | cT3a |
| c0 | cT0 | c1B2 | cT1b2 | c3B | cT3b |
| pA | pTa | c1C | cT1c | c3C | cT3c |
| pIS | pTis | c1D | cT1d | c3D | cT3d |
| pISU | pTispu | c2 | cT2 | c4 | cT4 |
| pISD | pTispd | c2A | cT2a | c4A | cT4a |
| c1MI | cT1mi, cT1mic | c2A1 | cT2a1 | c4B | cT4b |
| c1 | cT1 | c2A2 | cT2a2 | c4C | cT4c |
| c1A | cT1a | c2B | cT2b | c4D | cT4d |
| c1A1 | cT1a1 | c2C | cT2c | c4E | cT4e |
| c1A2 | cT1a2 | c2D | cT2d | 88 | Not applicable |

Clinical N (NAACCR #950)

01/01/2016

Added the following to rationale:

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of 'c' and 'p' to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Replaced Code Table:

| Code | Definition | Code | Definition | Code | Definition |
|---------|--------------|------|------------|------|------------|
| (blank) | Not recorded | c1B | cN1b | c3A | cN3a |
| cX | cNX | c1C | cN1c | c3B | cN3b |
| c0 | cN0 | c2 | cN2 | c3C | cN3c |
| c0A | cN0a | c2A | cN2a | c4 | cN4 |

| Code | Definition |
|------|------------|
| c0B | cN0b |
| c1 | cN1 |
| c1A | cN1a |

| Code | Definition |
|------|------------|
| c2B | cN2b |
| c2C | cN2c |
| c3 | cN3 |

| Code | Definition |
|------|----------------|
| 88 | Not applicable |

Clinical M (NAACCR #960)

01/01/2016

Added the following to rationale:

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Replaced Code Table:

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| c0 | cM0 |
| c0I+ | cM0(i+) |
| c1 | cM1 |
| c1A | cM1a |
| c1B | cM1b |
| c1C | cM1c |
| c1D | cM1d |
| c1E | cM1e |

| Code | Definition |
|------|----------------|
| p1 | pM1 |
| p1A | pM1a |
| p1B | pM1b |
| p1C | pM1c |
| p1D | pM1d |
| p1E | pM1e |
| 88 | Not applicable |

Clinical Stage Group (NAACCR #970)

01/01/2016

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Clinical Stage (Prefix/Suffix) Descriptor (NAACCR #980)

01/01/2016

Added the following bullets to Instructions:

If the tumor is not staged according to the AJCC manual, leave this data item blank.

Staged By (Clinical Stage) (NAACCR #990)

01/01/2016

Added expanded version of data item to FORDS

Pathologic T (NAACCR #880)

01/01/2016

Revised rationale:

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of 'c' and 'p' to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual.

Revised 3rd bullet under Instructions:

- If the managing physician has not recorded pathologic T, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Replaced Code Table:

| Code | Definition |
|---------|----------------|
| (blank) | Not recorded |
| pX | pTX |
| p0 | pT0 |
| pA | pTa |
| pIS | pTis |
| pISU | pTispu |
| pISD | pTispd |
| p1MI | pT1mi, pT1 mic |
| p1 | pT1 |
| p1A | pT1a |

| Code | Definition |
|------|------------|
| p1B | pT1b |
| p1B1 | pT1b1 |
| p1B2 | pT1b2 |
| p1C | pT1c |
| p1D | pT1d |
| p2 | pT2 |
| p2A | pT2a |
| p2A1 | pT2a1 |
| p2A2 | pT2a2 |
| p2B | pT2b |

| Code | Definition |
|------|------------|
| p3 | pT3 |
| p3A | pT3a |
| p3B | pT3b |
| p3C | pT3c |
| p3D | pT3d |
| p4 | pT4 |
| p4A | pT4a |
| p4B | pT4b |
| p4C | pT4c |
| p4D | pT4d |

| | |
|------|-------|
| p1A1 | pT1a1 |
| p1A2 | pT1a2 |

| | |
|-----|------|
| p2C | pT2c |
| p2D | pT2d |

| | |
|-----|----------------|
| p4E | pT4e |
| 88 | Not applicable |

Pathologic N (NAACCR #890)

01/01/2016

Revised rationale:

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual.

Revised 3rd bullet under Instructions:

- If the managing physician has not recorded pathologic T, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Replaced Code Table:

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| pX | pNX |
| c0 | cN0 |
| p0 | pN0 |
| p0I- | pN0i- |
| p0I+ | pN0i+ |
| p0M- | pN0m- |
| p0M+ | pN0m+ |
| p1MI | pN1mi |

| Code | Definition |
|------|------------|
| p0A | pN0a |
| p0B | pN0b |
| p1 | pN1 |
| p1A | pN1a |
| p1B | pN1b |
| p1C | pN1c |
| p2 | pN2 |
| p2A | pN2a |
| p2B | pN2b |

| Code | Definition |
|------|----------------|
| p2C | pN2c |
| p3 | pN3 |
| p3A | pN3a |
| p3B | pN3b |
| p3C | pN3c |
| p4 | pN4 |
| 88 | Not applicable |

Pathologic M (NAACCR #900)

01/01/2016

Revised rationale:

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Beginning in 2016, new T, N, and M categories were implemented the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. These new categories have been generated by adding the prefixes of ‘c’ and ‘p’ to existing valid clinical and pathologic T, N, and M categories respectively, and modifying, adding and deleting specific categories. The new categories enable registrars to comply with AJCC clinical and pathologic staging/classification timeframe rules while abstracting. The new categories will be used for cases of all diagnosis years abstracted using NAACCR version 16-compliant (and later) software. Please note that not all possible categories were added in 2016, only those addressing prominent issues. Additional T, N, and M categories will be added and use of existing categories and will be expanded with the implementation of the AJCC 8th Edition Manual.

Revised 3rd bullet under Instructions:

- If the managing physician has not recorded pathologic T, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Replaced Code Table:

| Code | Definition |
|---------|--------------|
| (blank) | Not recorded |
| c0 | cM0 |
| c0I+ | cM0(i+) |
| p1 | pM1 |
| p1A | pM1a |
| p1B | pM1b |

| Code | Definition |
|------|------------|
| p1C | pM1c |
| p1D | pM1d |
| p1E | pM1e |
| c1 | cM1 |
| c1A | cM1a |
| c1B | cM1b |

| Code | Definition |
|------|----------------|
| c1C | cM1c |
| c1D | cM1d |
| c1E | cM1e |
| 88 | Not applicable |

Pathologic Stage Group (NAACCR #910)

01/01/2016

Revised Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. Effective January 1, 2015 the CoC requires that AJCC pathologic TNM staging be recorded in its accredited cancer program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Added the following bullets to Instructions:

- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical and pathologic T, N, and M as well as stage group.
- For in situ tumors that are not staged according to the AJCC manual code 88 for clinical and pathologic T, N, and M as well as stage group.

Pathologic Stage (Prefix/Suffix) Descriptor (NAACCR #920)

01/01/2016

Revised 2nd bullet under Instructions:

- If the managing physician has not recorded the descriptor, registrars *will* code this item based on the best available information, without necessarily requiring additional contact with the physician(s).

Added the following bullet to Instructions:

- If the tumor is not staged using AJCC rules, leave this data item blank.

Staged By (Pathologic Stage) (NAACCR #930)

01/01/2016

Added expanded version of data item to FORDS

SEER Summary Stage 2000 (NAACCR #759)

01/01/2016

Added data item to FORDS

CS Tumor Size (NAACCR #2800)

CS Extension (NAACCR #2810)

CS Tumor Size/Ext Eval (NAACCR #2820)

CS Lymph Nodes (NAACCR #2830)

CS Lymph Nodes Eval (NAACCR #2840)

CS Mets at Dx (NAACCR #2850)

CS Mets at Dx - Bone (NAACCR #2851)

CS Mets at Dx - Brain (NAACCR #2852)

CS Mets at Dx - Liver (NAACCR #2853)

CS Mets at Dx - Lung (NAACCR #2854)

CS Mets Eval (NAACCR #2860)

01/01/2016

Added the following to Rationale:

Effective for cases diagnosed January 1, 2016 and later, this data item is no longer required by CoC for accredited cancer program cancer registries.

CS Site-Specific Factor 1-24 (NAACCR #2880-2878)

01/01/2016

Revised Rationale:

For cases diagnosed from 2004 through 2015, site-specific factors are used to record additional staging information needed by Collaborative Stage to derive TNM and/or SEER Summary Stage codes for particular site-histology schema.

Effective for cases diagnosed January 1, 2016 and later site-specific factors are used to record additional staging information needed to assign AJCC clinical and pathologic stage, to document biomarkers and prognostic factors of clinical significance, and for research purposes. This data item is required by CoC for accredited cancer program cancer registries on a sites-specific basis for cases diagnosed January 1, 2016 and later.

CS Site-Specific Factor 25 (NAACCR #2879)

01/01/2016

Revised Rationale:

CS Site-Specific Factor 25 is used to discriminate between CS staging schema (for cases diagnosed from 2004 through 2015 only) or between AJCC chapters for cases where site and histology alone are insufficient to identify the tumor type or location to identify the applicable staging method. Use of this item is limited to specific subsites and histologies as shown below.

Derived AJCC-6 T (NAACCR #2940)**Derived AJCC-6 T Descript (NAACCR #2950)****Derived AJCC-6 N (NAACCR #2960)****Derived AJCC-6 N Descript (NAACCR #2970)****Derived AJCC-6 M (NAACCR #2980)****Derived AJCC-6 M Descript (NAACCR #2990)****Derived AJCC-6 Stage Group (NAACCR #3000)****Derived AJCC-7 T (NAACCR #3400)****Derived AJCC-7 T Descript (NAACCR #3402)****Derived AJCC-7 N (NAACCR #3410)****Derived AJCC-7 N Descript (NAACCR #3412)****Derived AJCC-7 M (NAACCR #3420)****Derived AJCC-7 M Descript (NAACCR #3422)****Derived AJCC-7 Stage Group (NAACCR #3430)****Derived SS1977 (NAACCR #3010)****Derived SS2000 (NAACCR #3020)**

01/01/2016

Added following sentence to Rationale:

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

CHANGES TO *FORDS* SECTION TWO: FIRST COURSE OF TREATMENT**2010****Approach - Surgery of the Primary Site at This Facility (NAACCR Item #668)**

05/01/2010

Changed term “laparoscopic” to “endoscopic” in instructions and codes.

Added new bullet: “If both robotic and endoscopic surgery were used, code to robotic (codes 1 or 2).”

Surgical Margins of the Primary Site (NAACCR Item #1320)

02/01/2010

Changed list of lymphoma histologies to be coded 9 when sited to lymph nodes to “9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971.”

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 9 to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Scope of Regional Lymph Node Surgery (NAACCR Item #1292)

02/01/2010

Changed list of lymphoma histologies to be coded 9 when sited to lymph nodes to “9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971.”

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 9 to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Scope of Regional Lymph Node Surgery at This Facility (NAACCR Item #672)

02/01/2010

Changed list of lymphoma histologies to be coded 9 when sited to lymph nodes to “9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971.”

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 9 to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Surgical Procedure/Other Site (NAACCR Item #1294)

02/01/2010

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 1 if treated surgically to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Surgical Procedure/Other Site at This Facility (NAACCR Item #674)

02/01/2010

Changed list of hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease histologies that are coded 1 if treated surgically to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Number of Treatments to this Volume (NAACCR Item #1520)

05/01/2010

Changed code range for number of treatments to 001-998 (from 091-998).

Changed examples to 3-digit codes (from 2).

Rx Date Rad Ended Flag (NAACCR Item #3221)

02/01/2010

Modified fourth bullet to read “Code 11 if no radiation is planned or given, or if it is not yet completed.”

Modified definition of code 11 to read “No proper value is applicable in this context (for example, radiation has not been completed).”

03/01/2010

Above changes were incorrect (NCDB apologizes).

Modified fourth bullet by removing “if it is not yet completed”

Modified definition of code 11 to read “No proper value is applicable in this context (for example, no radiation was administered).”

2011

RX Summ -- Treatment Status (NAACCR Item #1285)

01/01/2011

Added instruction: Use code 0 when treatment is refused or the physician decides not to treat for any reason such as the presence of comorbidities.

Approach - Surgery of the Primary Site at This Facility (NAACCR Item #668)

01/01/2011

Changed term “endoscopic” to “endoscopic or laparoscopic” in instructions and codes.

Radiation Treatment Volume (NAACCR Item #1540)

01/01/2011

Added bullet: If two discrete volumes are treated and one of those includes the primary site, record the treatment to the primary site.

Added example for TBI (total body irradiation).

Regional Treatment Modality (NAACCR Item #1570)

01/01/2011

Added examples for PUVA and I-125

Number of Treatments to This Volume (NAACCR Item #1520)

01/01/2011

Added example for Mammosite®

Radiation/Surgery Sequence (NAACCR Item #1380)

01/01/2011

Clarified that at least two courses of radiation must be given to assign code 4.

Systemic/Surgery Sequence (NAACCR Item #1639)

01/01/2011

Clarified that at least two courses of systemic therapy must be given to assign code 4.

Other Treatment (NAACCR Item #1420)

01/01/2011

Added instruction: Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)

2012**Date 1st Crs Fx Flag**

01/01/2012

Clarified definition of code 11: “No proper value is applicable in this context (that is, no treatment was given or autopsy only)”.

Surgical Procedure of Primary Site

01/01/2012

Added sentence to seventh bullet: “Do not rely on registry software to perform this task for you.”

Surgical Procedure of Primary Site at This Facility

01/01/2012

Added sentence to seventh bullet: “Do not rely on registry software to perform this task for you.”

Scope of Regional Lymph Node Surgery

01/01/2012

Added bullet: “If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.”

Revised code-specific instructions to capture sentinel lymph node biopsies and regional lymph node biopsies in a clinically-relevant manner based on surgical notes.

Scope of Regional Lymph Node Surgery at This Facility

01/01/2012

Added bullet: “If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.”

Revised code-specific instructions to capture sentinel lymph node biopsies and regional lymph node biopsies in a clinically-relevant manner based on surgical notes.

04/09/2012

Corrected and clarified examples for codes 0, 2 and 9.

Surgical Procedure/Other Site

01/01/2012

Added bullet: “If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.”

Surgical Procedure/Other Site at This Facility

01/01/2012

Added bullet: “If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.”

Corrected item name and NAACCR number in the last bullet: “*Palliative Care at This Facility* (NAACCR Item #3280)”.

Reason for No Surgery of Primary Site

01/01/2012

Added NAACCR item number (1340).

Radiation/Surgery Sequence

01/01/2012

Added bullet: “If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies”.

Definition of code 4 clarified: “At least two courses of radiation therapy are given before and at least two more after surgery to the primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).”

Added code 7: “Surgery both before and after radiation”, defined as “Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s)”.

Location of Radiation Treatment

01/01/2012

Added sentence: “In this context, ‘regional’ is used to distinguish from ‘boost’; it does not refer to ‘regional’ as used to identify stage or disease spread.”

Radiation Treatment Volume

01/01/2012

Deleted the word “regional” from description.

Added “whole-body” to first example for code 33.

Number of Treatments to This Volume

01/01/2012

Added example of prostate primary treated with a single administration of seeds.

Date Radiation Ended

01/01/2012

Corrected item name in final sentence: “*RX Date–Rad Ended Flag.*”

Rx Date Systemic Flag

01/01/2012

Corrected NAACCR item number in final sentence (3231).

Chemotherapy at This Facility

01/01/2102

Corrected item name and number in last bullet: “*Palliative Care at This Facility* (NAACCR Item #3280).”

Date Hormone Therapy Started

01/01/2012

Corrected NAACCR item number (1230).

Corrected NAACCR item number for Hormone Therapy (1400) in first bullet.

Hematologic Transplant and Endocrine Procedures

01/01/2012

Added bullet: “Use code 88 if a bone marrow or stem cell harvest was undertaken, but was not followed by a rescue or re-infusion as part of first course treatment.”

Systemic/Surgery Sequence

01/01/2012

Added bullet: “If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies”.

Definition of code 4 clarified: “At least two courses of systemic therapy were given before and at least two more after a surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.”

Added code 7: “Systemic therapy both before and after radiation”, defined as “Systemic therapy was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s)”.

Other Treatment

01/01/2012

Added “certain” to the following sentence in the first bullet: “In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY.”

Added the following sentence to the first bullet: “Consult the most recent version of the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* for instructions for coding care of specific hematopoietic neoplasms in this item.”

Other Treatment at This Facility

01/01/2012

Corrected item name and NAACCR item number in sixth bullet: “*Palliative Care at This Facility* (NAACCR Item #3280).”

Added “certain” to the following sentence in the first bullet: “In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY.”

Added the following sentence to the first bullet: “Consult the most recent version of the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* for instructions for coding care of specific hematopoietic neoplasms in this item.”

2013

Approach-Surgery of the Primary Site at This Facility

01/01/2013

Changed wording of 3rd bullet to read “For ablation procedures, assign code 3”. Formerly, specified ablation of skin tumors.

Surgical Margins of the Primary Site

01/01/2013

Added wording to the 5th bullet so it reads “code 9 if the pathology report makes no mention of margins or no tissue was sent to pathology.”

Scope of Regional Lymph Node Surgery

01/01/2013

Corrected site code reference in second example (previous omitted the “C” for “C50.1”).

Surgical Procedure/Other Site

01/01/2013

Reversed sequence of first two bullets.

Reason for No Surgery of Primary Site

01/01/2013

Second bullet: Added wording to the 2nd bullet so it now reads “Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include surgery of the primary site, or if the option of “no treatment” was accepted by the patient.”

Moved “diagnosed at autopsy” from code 9 to code 1.

Reason for No Radiation

01/01/2013

Added modifier “alternative treatment” to “options” in the 2nd and 7th bullets.

Moved “diagnosed at autopsy” from code 9 to code 1.

Chemotherapy

01/01/2013

Second bullet: Added wording to the 2nd bullet so it now reads “Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include chemotherapy, or if the option of “no treatment” was accepted by the patient.”

Chemotherapy at This Facility

01/01/2013

Third bullet: Added wording to the 3rd bullet so it now reads “Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include chemotherapy, or if the option of “no treatment” was accepted by the patient.”

Hormone Therapy

01/01/2013

Fifth bullet: Added wording to the 5th bullet so it now reads “Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include hormone therapy, or if the option of “no treatment” was accepted by the patient.”

Hormone Therapy at This Facility

01/01/2013

Sixth bullet: Added wording to the 6th bullet so it now reads “Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include hormone therapy, or if the option of “no treatment” was accepted by the patient.”

Immunotherapy

01/01/2013

Second bullet: Added wording to the 2nd bullet so it now reads “Code00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include immunotherapy, or if the option of “no treatment” was accepted by the patient.”

Immunotherapy at This Facility

01/01/2013

Third bullet: Added wording to the 2nd bullet so it now reads “Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include immunotherapy, or if the option of “no treatment” was accepted by the patient.”

Hematologic Transplant and Endocrine Procedures

01/01/2013

Fifth bullet: Added wording to the 2nd bullet so it now reads “Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include a transplant or endocrine procedure, or if the option of “no treatment” was accepted by the patient.”

2015

Date 1st Crs Rx Flag (NAACCR Item #1271)

01/01/2015

Added “at all” to instruction: Code 12 if the *Date of First Course of Treatment* can not be determined at all, but the patient did receive first course treatment.

New instruction: Code 12 if a decision not to treat was made, but the date is totally unknown.

New instruction: Code 12 if a decision to use active surveillance was made, but the date is totally unknown.

Removed “no treatment was given or” for definition of code 11.

Surgical Procedure of Primary Site (NAACCR #1290)**Surgical Procedure of Primary Site at This Facility** (NAACCR # 670)

01/01/2015

Added clarifying instruction: If a needle biopsy preceded an excisional biopsy or more extensive surgery, even if no tumor remained at the time of surgery, both the needle biopsy (*Surgical Diagnostic and Staging Procedure*) and the *Surgical Procedure of the Primary Site* are to be reported. Surgical margins must be examined to determine whether a biopsy intended as incisional is excisional instead, and margins cannot be evaluated for a needle biopsy.

Approach—Surgery of the Primary Site at This Facility (NAACCR Item #668)

01/01/2015

Revised instructions and code definitions to emphasize “minimally invasive” terminology.

Scope of Regional Lymph Node Surgery (NAACCR Item #1292)

01/01/2015

Corrected typo in definition of code 1: Review the operative **report to confirm** whether an excisional biopsy or aspiration of regional lymph nodes was actually performed. If additional procedures were performed on the lymph nodes, use the appropriate code 2-7.

Radiation Treatment Volume (NAACCR Item #1540)

01/01/2015

Corrected grammar in definition of code 08: The primary target is one or both of the maxillary sinuses, the ethmoidal, and/or the frontal sinuses. In some cases, the adjacent lymph node regions may be irradiated.

Regional Treatment Modality (NAACCR Item #1570)

01/01/2015

Added advisory bullet: Note: do not confuse a radioiodine *scan* with treatment. Only treatment is recorded in this item.

Regional Dose: cGy (NAACCR Item #1510)**Boost Dose: cGy** (NAACCR Item #3210)

01/01/2015

Added instruction: For photon treatment, dosage is reported in cGe units (Cobalt Gray Equivalent) rather than cGy. Please record 100x cGe for Regional Dose: cGy (note that it is necessary to multiply cGe by 100 to code this).

Chemotherapy (NAACCR Item #1390)**Chemotherapy at This Facility** (NAACCR Item #700)**Immunotherapy** (NAACCR Item #1410)**Immunotherapy at This Facility** (NAACCR Item #720)

01/01/2015

Added information about six drugs that changed category in 2013 from Chemotherapy to BRM/Immunotherapy.

Other Treatment at This Facility (NAACCR Item # 730)

01/01/2015

Added instruction: Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)

Rx Date—Other Flag (NAACCR Item #1251)

01/01/2015

Added code 15: Other therapy is planned as part of the first course of treatment, but had not been started at the time of the most recent follow-up.

2016**Surgical Procedure of Primary Site (NAACCR #1290)****Surgical Procedure of Primary Site at This Facility (NAACCR # 670)**

01/01/2016

Revised 6th bullet under Instructions:

- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350) data item and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* data item (NAACCR Item #1290).

Regional Dose: cGy (NAACCR #1510)**Boost Dose: cGy (NAACCR #3210)**

01/01/2016

Revised 3rd bullet under Instructions (revised “photon” to “proton”):

- For proton treatment, dosage is reported in cGe units (Cobalt Gray Equivalent) rather than cGy. Please record 100x cGe for *Regional Dose: cGy* (note that it is necessary to multiply cGe by 100 to code this).

Chemotherapy (NAACCR #1390)**Chemotherapy at this Facility (NAACCR #700)**

01/01/2016

Added bullet under Instructions:

- If chemotherapy was provided as a radiosensitizer or radioprotectant DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer.

CHANGES TO FORDS SECTION TWO: OUTCOMES

2011**Following Registry**

01/01/2011

Item deleted from **FORDS**.**2012****Date of First Recurrence**

01/01/2012

Deleted second bullet.

2013**Type of First Recurrence**

01/01/2013

Added to ninth bullet: “If one of these is controlled by drugs (for example, Gleevec for CML), the patient is in remission”

2015**Type of First Recurrence** (NAACCR Item #1880)

01/01/2015

Clarified bullet: Codes 00 through 70 are hierarchical; record the highest-numbered applicable response, with the following limits.. The first time a patient converts from disease status (70) to disease-free, change the code to 00. Then the first time a patient converts from 00 to a recurrence, then record the proper code for the recurrence. No further changes (other than corrections) should be made.

Date of Last Contact or Death (NAACCR #1750)**Vital Status** (NAACCR Item #1760)

01/01/2015

Added bullet: Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.

CHANGES TO FORDS SECTION TWO: CASE ADMINISTRATION

2010**Override Hospseq/Site** (NAACCR Item #1988)

02/01/2010

Changed the wording of the second bullet to read “Lymph node primary sites (C77.0-C77.9) for histologies other than lymphomas, or hematopoietic primary sites (C42.0-C42.4) for histologies not in range for hematopoietic diseases. (That combination is most likely a metastatic lesion. Check whether the lesion could be a manifestation of one of the patient's other cancers.)”

2011**Morphology Coding System Original** (NAACCR Item #480)

01/01/2011

Corrected instruction: For cases diagnosed on or after January 1, 2010, this data item must be coded 8. [Formerly, it said 2000].

2012**Facility Identification Number (FIN)**

01/01/2012

Added bullet: “Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific FIN in their data for submission to the National Cancer Data Base.”

Added bullet: “Facilities that merge are legally a single hospital. Consult NCDB for instructions for recording the FIN for newly-merged programs.”

NPI-Reporting Facility

01/01/2012

Added bullet: “Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number in their data for submission to the National Cancer Data Base.”

Added bullet: “Facilities that merge are legally a single hospital. Use the NPI number for the merged hospital.”

Archive FIN

01/01/2012

Added bullet: “Facilities that are part of an Integrated Network Cancer Program (INCP) *must* use the hospital-specific FIN for the Archive FIN in their data for submission to the National Cancer Data Base.”

Added bullet: “Programs that are not part of a merged facility or an INCP will use their hospital’s FIN as the Archive FIN.”

NPI-Archive FIN

01/01/2012

Added bullet: “Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number for the NPI-Archive FIN in their data for submission to the National Cancer Data Base.”

Date Case Completed-CoC

01/01/2012

For Class of Case 00, the items that must be completed were reworded to “NPI number for the facility the patient was referred to OR a treating physician”.

For Class of Case 20-22, the items that must be completed were reworded to “NPI number for the facility the patient was referred to or from OR the physician who diagnosed or treated the patient”.

Override Site/TNM Stage Group

01/01/2012

Under “EDITS Use”, changed reference to AJCC Staging Manual to specify the “applicable” version.

ICD Revision Comorbidities and Complications

01/01/2012

Changed “Rationale” to read “This item is necessary to interpret the meaning of particular codes for *Comorbidities and Complications* (secondary diagnoses); there is some overlap between specific codes.”

Added “-CM” to edition labels in the “Definitions”.

ICD-O-2 Conversion Flag

01/01/2012

Corrected Allowable Codes to 0-6 or blank

ICD Revision Cormorbidities and Complications

01/01/2012

Revised Rationale: “This item is necessary to interpret the meaning of particular codes for *Comorbidities and Complications* (secondary diagnoses); there is some overlap between specific codes”.

Corrected labels for codes to specify that they indicate ICD-9-CM and ICD-10-CM.

2013

ICD Revision Secondary Diagnosis

01/01/2013

Changed name from *ICD Revision Comorbidities and Complications*

Expanded instructions to handle movement from use of ICD-9-CM *Comorbidities and Complications* to ICD-10-CM *Secondary Diagnoses*. CMS requires implementation of ICD-10-CM during 2014, but some programs are testing the system before that.

Over-ride CS 1-19

01/01/2013

New items. These 19 items were introduced for the Collaborative Stage Data Coding System (CS) for use with rare but not impossible code combinations if they fail an edit. Definitions will be provided as edits are released that use them. (Over-ride CS 20 is defined but not to be used by CoC accredited programs).

2016**Derived AJCC–Flag (NAACCR #3030)****Derived SS1977–Flag (NAACCR #3040)****Derived SS2000–Flag (NAACCR #3050)****CS Version Derived (NAACCR #2936)**

01/01/2016

Added following sentence to Rationale:

Effective for cases diagnosed January 1, 2016 and later this data item is no longer required by CoC for accredited cancer program cancer registries, and should no longer be derived and recorded in the hospital registry database.

CHANGES TO FORDS: APPENDIX B

2010**Section cover page**

02/01/2010

Added the following note: “The February 2010 updates changed the histologies that apply to these site-specific surgery codes. Those changes apply only to cases diagnosed in 2010 or later. Please consult *FORDS: Revised for 2009* for applicable histologies for cases diagnosed prior to that date”.

Rectum

05/01/2010

Corrected notation to indicate that codes 20-80 (rather than 20-28) send material to pathology.

Lung

02/01/2010

Corrected notation to indicate that codes 20-80 (rather than 20-25) send material to pathology.

Breast

05/01/2010

Changed explanatory note for code 30 to read: “A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or

overlying skin. It is performed to facilitate immediate breast reconstruction. Cases coded 30 may be considered to have undergone breast reconstruction.”

Corrected indentation of subcodes under codes 40, 50 and 60.

Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease

02/01/2010

Changed list of included histologies to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

Every site other than Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease

02/01/2010

Changed list of excluded histologies to “9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.”

2011

Liver and Intrahepatic Bile Ducts

01/01/2011

Reworded description of code 66: Excision of an intrahepatic bile duct PLUS partial hepatectomy

Reworded description of code 75: Extrahepatic bile duct and hepatectomy WITH transplant

Breast

01/01/2011

Added phrase to mastectomy description: A total (simple) mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done, but sentinel lymph nodes may be removed.

Added new code 76: Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma.

Added “41 or” to this sentence about contralateral primaries: The surgical procedure is coded 41 or 51 for the first primary.

Prostate

01/01/2011

Clarified code 19: Transurethral resection (TURP), NOS, and no specimen sent to pathology or unknown if sent

Clarified code 21: Transurethral resection (TURP), NOS, with specimen sent to pathology

2012

Bladder

01/01/2012

Added note to code 16: “Also code the introduction of immunotherapy in the immunotherapy items. If immunotherapy is followed by surgery of the type coded 20-80 code that surgery instead and code the immunotherapy only in the immunotherapy items.”

Please note: Changes made in 2010 to the bladder instructions were omitted in Appendix C at that time, and were noted only in the *Preface*. These changes provided instructions for coding pelvic exenteration differentially based on the sex of the patient.

Code 71 note reads: “For females, includes removal of bladder, uterus, ovaries, entire vaginal wall, and entire urethra. For males, includes removal of the prostate. When a procedure is described as a

pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).” A companion note for codes 60-64 reads: “When the procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).”

Code 72 note reads: “For females, also includes removal of vagina, rectum and anus. For males, also includes prostate, rectum and anus.”

Code 73 note reads: “Includes all tissue and organs removed for an anterior and posterior exenteration.”

Code 74 note reads: “Includes pelvic blood vessels or bony pelvis.”

2013

Breast

01/01/2013

Deleted sentence from instruction after code 63: “If only sentinel lymph nodes are removed, the procedure should be coded as a simple mastectomy.” The purpose is to avoid possible conflict with the instructions for coding Scope of Regional Lymph Node Surgery.

Removed irrelevant “41 or” from second instruction following code 63.

2015

Skin

01/01/2015

Modified explanation about margins (codes 45-47): If the excision does not have microscopically clinically negative margins during surgery greater than 1 cm, use the appropriate code, 20–36.

2016

All Sites

Revised Histology Exceptions to reflect 2015 Heme conversion

Skin

01/01/2016

Revised explanation about margins (codes 45-47) for further clarification:

If the excision or reexcision has microscopically confirmed negative margins less than 1 cm OR the margins are more than 1 cm but are not microscopically confirmed; use the appropriate code, 20–36.

CHANGES TO *FORDS*: APPENDIX D

2011

The “referred to” and “referred from” sections of the table were modified as follows:

| | | |
|--|------------------------|------|
| Referred To Class of Case 00 [Must have a facility or at least one Physician] | NPI-Inst Referred To | 2425 |
| | NPI-Primary Surgeon | 2485 |
| | NPI-Physician #3 | 2495 |
| | NPI-Physician #4 | 2505 |
| Referred From | NPI-Inst Referred From | 2415 |

| | | |
|---|---------------------|------|
| Class of Case 20-22 [Must have a facility or at least one Physician] | NPI-Primary Surgeon | 2485 |
| | NPI-Physician #3 | 2495 |
| | NPI-Physician #4 | 2505 |

2012

The final section of the table was modified such that all cases that received first course care “elsewhere” have at least one entry for the NPI of the facility or physician elsewhere. *Class of Case* 11 through 13 are affected in this modification. Also, *NPI-Inst Referred To* and *NPI-Managing Physician* were added to the list of equivalent options for representing that information.

| | | |
|---|--|------|
| Referred To or From Class of Case 11-13, 20-22 [Must have at least one facility or at least one Physician] | NPI-Inst Referred From | 2415 |
| | NPI-Inst Referred To | 2425 |
| | NPI-Managing Physician (if that person diagnosed the patient and the other options do not apply) | 2465 |
| | NPI-Primary Surgeon | 2485 |
| | NPI-Physician #3 | 2495 |
| | NPI-Physician #4 | 2505 |

2013

The following items for Diagnostic information are required only for cases diagnosed in 2010-2012: Ambiguous Terminology, Date Conclusive DX, Date Conclusive DX Flag, Mult Tum Rpt as One Prim, Date of Multiple Tumors, Date of Mult Tumors Flag, and Multiplicity Counter.

2015

Deleted from the table:

- ICD Revision Comorbidities and Complications
- Birth Place
- Date of Diagnosis Flag
- Grade Path Value
- Grade Path System
- Ambiguous Terminology DX
- Date of Conclusive DX
- Date Conclusive DX Flag
- Mult Tum Rpt as One Prim
- Date of Multiple Tumors
- Date of Mult Tumors Flag
- Multiplicity Counter

Added to the table:

- Addr at DX—Country
- Secondary Diagnosis #1-10
- Address Current – Country
- Birthplace—State
- Birthplace--Country

Changed explanation for “Referred To”: Class of Case 00 [Must have a facility **OR** at least one Physician]

Changed explanation for “Referred To or From: Class of Case 11-13, 20-22 [Must have at least one facility **OR** at least one Physician]

CHANGES TO *FORDS*: APPENDIX E

2013

New Appendix. Tables of state and country for coding the following items: Birthplace-State, Birthplace-Country, Address at DX-State, Address at DX-Country, Address Current-State, Address Current-Country. Three tables are included for Preferred (detailed) codes, General codes (when no preferred code applies), and Obsolete codes (codes that may have been generated in conversion, not to be used for cases coded beginning in 2013).

2015

The country codes for Czechoslovakia and Yugoslavia were changed from X CZ and X YG, respectively, to CSK and YUG, and moved from Obsolete to General codes. These codes were updated in historic data by the conversion to NAACCR v15 layout and codes.

2016**Country and State label and code revisions:**

01/01/2016

Brunei Darussalam, BND, XX to Brunei, BRN, XX

Central America, ZZC, XX to Central America, ZZC, YY

Czechoslovakia, CSK, XX to Czechoslovakia, CSK, YY

Yugoslavia, YUG, XX to Yugoslavia, YUG, YY

St. Martin, MAF, XX added

Congo, COG, XX added

Slovakia, SWK, XX to Slovakia, SVK, XX

Vanuatu, VLT, XX to Vanuatu, VUT, XX

Palestine Territory, Occupied, PSE, XX to Palestine, PSE, XX

Zaire (Congo-Leopoldville, Belgian Congo, Congo/Kinshasa), COD, XX to

Congo, Democratic Republic of, COD, XX

Indonesia (Dutch East Indies), IDN, XX to Indonesia, IDN, XX

Northern Ireland (Ulster), NIR, XX to Northern Ireland, NIR, XX

Palau (Trust Territory of Pacific Islands), PLW, PW to Palau, PLW, PW

Tokelau Islands (New Zealand), TKL, XX TO Tokelau, TKL, XX

APPENDIX D:

***FORDS* Items Required to Be Complete
to Enter *Date Case Completed* – *CoC* for
Cases Diagnosed in 2016**

See *Date Case Completed–CoC* (NAACCR Item #2092) for instructions.

| Category | FORDS Items | NAACCR Item # |
|--|--------------------------------------|---------------|
| Identification Class of Case 00-22 | Addr at DX–City | 70 |
| | Addr at DX–State | 80 |
| | Addr at DX–Postal Code | 100 |
| | County at DX | 90 |
| | Addr at DX--Country | 102 |
| | Date of 1 st Contact | 580 |
| | Date of 1 st Contact Flag | 581 |
| | Class of Case | 610 |
| | Primary Payer at DX | 630 |
| | NPI Archive FIN | 3105 |
| | Archive FIN | 3100 |
| | Accession Number | 500 |
| | Sequence Number | 560 |
| | Abstracted By | 570 |
| | Comorbidities and Complications #1 | 3110 |
| | Comorbidities and Complications #2 | 3120 |
| | Comorbidities and Complications #3 | 3130 |
| | Comorbidities and Complications #4 | 3140 |
| | Comorbidities and Complications #5 | 3150 |
| | Comorbidities and Complications #6 | 3160 |
| | Comorbidities and Complications #7 | 3161 |
| | Comorbidities and Complications #8 | 3162 |
| | Comorbidities and Complications #9 | 3163 |
| | Comorbidities and Complications #10 | 3164 |
| | Secondary Diagnosis #1 | 3780 |
| | Secondary Diagnosis #2 | 3782 |
| | Secondary Diagnosis #3 | 3784 |
| | Secondary Diagnosis #4 | 3786 |
| | Secondary Diagnosis #5 | 3788 |
| | Secondary Diagnosis #6 | 3790 |
| | Secondary Diagnosis #7 | 3792 |
| | Secondary Diagnosis #8 | 3794 |
| | Secondary Diagnosis #9 | 3796 |
| | Secondary Diagnosis #10 | 3798 |
| | Override Acsn/Class/Seq | 1985 |
| | CoC Coding System - Current | 2140 |
| | CoC Coding System - Original | 2150 |
| | Vendor Name | 2170 |
| | ICD-O-3 Conversion Flag | 2116 |
| | Date of Last Contact or Death | 1750 |
| | Date of Last Contact Flag | 1751 |
| | City/Town – Current | 1810 |
| | State – Current | 1820 |
| Postal Code – Current | 1830 | |
| Address Current--Country | 1832 | |
| Last Name | 2230 | |
| First Name | 2240 | |
| Middle Name | 2250 | |

| | | | |
|---|--|------------------------------|-----|
| | Medical Record Number | 2300 | |
| | Social Security Number | 2320 | |
| | Patient Address (Number and Street) at Diagnosis | 2330 | |
| | Patient Address at Diagnosis – Supplemental | 2335 | |
| | Patient Address (Number and Street) – Current | 2350 | |
| | Patient Address–Current - Supplemental | 2335 | |
| | Telephone | 2360 | |
| Demographic Class of Case 00-22 | Race 1 | 160 | |
| | Race 2 | 161 | |
| | Race 3 | 162 | |
| | Race 4 | 163 | |
| | Race 5 | 164 | |
| | Spanish/Hispanic Origin | 190 | |
| | Sex | 220 | |
| | Age at Diagnosis | 230 | |
| | Date of Birth | 240 | |
| | Date of Birth Flag | 241 | |
| | | | |
| | | Birthplace--State | 252 |
| | | Birthplace--Country | 254 |
| | | Race Coding System – Current | 170 |
| | Race Coding System – Original | 180 | |
| Diagnostic Class of Case 00-22 | Date of Diagnosis | 390 | |
| | Primary Site | 400 | |
| | Laterality | 410 | |
| | Histologic Type ICD-O-3 | 522 | |
| | Behavior Code ICD-O-3 | 523 | |
| | Grade | 440 | |
| | Diagnostic Confirmation | 490 | |
| | Sequence Number - Hosp | 560 | |
| | RX Hosp–DX/Stg Proc | 740 | |
| | Regional Nodes Positive | 820 | |
| | Regional Nodes Examined | 830 | |
| | Site Coding System – Current | 450 | |
| | Site Coding System – Original | 460 | |
| | Morph Coding System – Current | 470 | |
| | Morph Coding System – Original | 480 | |
| | Override HospSeq/DxConf | 1986 | |
| | Override CoC Site/Type | 1987 | |
| | Override HospSeq/Site | 1988 | |
| | Override Site/TNM-StgGrp | 1989 | |
| | Override Age/Site/Morph | 1990 | |
| | Override SeqNo/DxConf | 2000 | |
| | Override Site/Lat/SeqNo | 2010 | |
| | Override Surg/DxConf | 2020 | |
| | Override Site/Type | 2030 | |
| | Override Histology | 2040 | |
| | Override Leuk, Lymphoma | 2070 | |
| | Override Site/Behavior | 2071 | |
| | Override Site/Lat/Morph | 2074 | |
| Staging Class of Case 10-22 | TNM Edition Number | 1060 | |
| | TNM Path T | 880 | |
| | TNM Path N | 890 | |

| | | |
|---|---|------|
| | TNM Path M | 900 |
| | TNM Path Stage Group | 910 |
| | TNM Path Descriptor | 920 |
| | TNM Path Staged By | 930 |
| | TNM Clin T | 940 |
| | TNM Clin N | 950 |
| | TNM Clin M | 960 |
| | TNM Clin Stage Group | 970 |
| | TNM Clin Descriptor | 980 |
| | TNM Clin Staged By | 990 |
| | Lymph-vascular Invasion | 1182 |
| | CS Tumor Size | 2800 |
| | CS Extension | 2810 |
| | CS Tumor Size/Ext Eval | 2820 |
| | CS Lymph Nodes | 2830 |
| | CS Lymph Nodes Eval | 2840 |
| | CS Mets at DX | 2850 |
| | CS Mets Eval | 2860 |
| | CS Mets at Dx-Bone | 2851 |
| | CS Mets at Dx-Brain | 2852 |
| | CS Mets at Dx-Liver | 2853 |
| | CS Mets at Dx-Lung | 2854 |
| | Site-Specific Factors 1-25 – if required for case | |
| | Derived SS1977 | 3010 |
| | Derived SS2000 | 3020 |
| | Derived AJCC–Flag | 3030 |
| | Derived SS1977–Flag | 3040 |
| | Derived SS2000–Flag | 3050 |
| | CS Version Input Current | 2937 |
| | CS Version Original | 2935 |
| | CS Version Derived | 2936 |
| | Derived AJCC 6 T | 2940 |
| | Derived AJCC 6 T Descript | 2950 |
| | Derived AJCC 6 N | 2960 |
| | Derived AJCC 6 N Descript | 2970 |
| | Derived AJCC 6 M | 2980 |
| | Derived AJCC 6 M Descript | 2990 |
| | Derived AJCC 6 Stage Grp | 3000 |
| | Derived AJCC 7 T | 3400 |
| | Derived AJCC 7 T Descript | 3402 |
| | Derived AJCC 7 N | 3410 |
| | Derived AJCC 7 N Descript | 3412 |
| | Derived AJCC 7 M | 3420 |
| | Derived AJCC 7 M Descript | 3422 |
| | Derived AJCC 7 Stage Grp | 3430 |
| Hospital-Specific Treatment Class of Case 10-22 | RX Hosp–Surg App 2010 | 668 |
| | Surgical Procedure of Primary Site at This Facility | 670 |
| | Scope of Regional Lymph Node Surgery at This Facility | 672 |
| | Surgical Procedure / Other Site at This Facility | 674 |
| | Chemotherapy at This Facility | 700 |
| | Hormone Therapy at This Facility | 710 |
| | Immunotherapy at This Facility | 720 |
| | Other Treatment at This Facility | 730 |

| | | |
|----------------------------------|---|------|
| | Palliative Care at This Facility | 3280 |
| | Date of First Course of Treatment | 1270 |
| | Date of 1 st Crs Flag | 1271 |
| | Date of First Surgical Procedure | 1200 |
| | RX Date–Surgery Flag | 1201 |
| | Date of the Most Definitive Resection of the Primary Site | 3170 |
| | RX Date–Mst Defn Srg Flag | 3171 |
| | Date of Surgical Discharge | 3180 |
| | RX Date–Surg Disch Flag | 3181 |
| | Date Radiation Started | 1210 |
| | RX Date–Radiation Flag | 1211 |
| | Date Radiation Ended | 3220 |
| | RX Date–Rad Ended Flag | 3221 |
| | Date Systemic Therapy Started | 3230 |
| | Date Chemotherapy Started | 1220 |
| | RX Date–Chemo Flag | 1221 |
| | Date Hormone Therapy Started | 1230 |
| | RX Date–Hormone Flag | 1231 |
| | Date Immunotherapy Started | 1240 |
| | RX Date–BRM Flag | 1241 |
| | Date Other Treatment Started | 1250 |
| | RX Date–Other Flag | 1251 |
| | RX Summ–Treatment Status | 1285 |
| | NPI- Managing Physician | 2465 |
| | NPI-Following Physician | 2475 |
| | NPI-Primary Surgeon | 2485 |
| | NPI-Physician #3 | 2495 |
| | NPI-Physician #4 | 2505 |
| Summary Treatment | Surgical Procedure of Primary Site | 1290 |
| Class of Case 10, 12, 14, 20, 22 | Scope of Regional Lymph Node Surgery | 1292 |
| | Surgical Procedure / Other Site | 1294 |
| | Surgical Margins of the Primary Site | 1320 |
| | Reason for No Surgery of Primary Site | 1340 |
| | Surgical Diagnostic and Staging Procedure | 1350 |
| | Palliative Care | 3270 |
| | Radiation / Surgery Sequence | 1380 |
| | Hematological Transplant and Endocrine Procedures | 3250 |
| | Chemotherapy | 1390 |
| | Hormone Therapy | 1400 |
| | Immunotherapy | 1410 |
| | Other Treatment | 1420 |
| | Reason for No Radiation | 1430 |
| | Rx Coding System–Current | 1460 |
| | Regional Dose: cGy | 1510 |
| | Number of Treatments to This Volume | 1520 |
| | Radiation Treatment Volume | 1540 |
| | Location of Radiation Treatment | 1550 |
| | Regional Treatment Modality | 1570 |
| | Boost Treatment Modality | 3200 |
| | Boost Dose: cGy | 3210 |
| | Systemic / Surgery Sequence | 1639 |
| Referred To | NPI-Inst Referred To | 2425 |
| Class of Case 00 | NPI-Primary Surgeon | 2485 |

| | | |
|---|--|------|
| [Must have a facility OR at least one Physician] | NPI-Physician #3 | 2495 |
| | NPI-Physician #4 | 2505 |
| Referred To or From Class of Case 11-13, 20-22 [Must have at least one facility OR at least one Physician] | NPI-Inst Referred From | 2415 |
| | NPI-Inst Referred To | 2425 |
| | NPI-Managing Physician (if that person diagnosed the patient and the other options do not apply) | 2465 |
| | NPI-Primary Surgeon | 2485 |
| | NPI-Physician #3 | 2495 |
| | NPI-Physician #4 | 2505 |

(Revised 01/12, 01/14, 01/15)

APPENDIX E:
Country and State Codes

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| United States (state and armed forces codes) | | |
| Alabama | USA | AL |
| Alaska | USA | AK |
| Arizona | USA | AZ |
| Arkansas | USA | AR |
| Armed Forces Americas | USA | AA |
| Armed Forces Canada, Europe, Middle East, Africa | USA | AE |
| Armed Forces Pacific | USA | AP |
| California | USA | CA |
| Colorado | USA | CO |
| Connecticut | USA | CT |
| Delaware | USA | DE |
| District of Columbia | USA | DC |
| Florida | USA | FL |
| Georgia | USA | GA |
| Hawaii | USA | HI |
| Idaho | USA | ID |
| Illinois | USA | IL |
| Indiana | USA | IN |
| Iowa | USA | IA |
| Kansas | USA | KS |
| Kentucky | USA | KY |
| Louisiana | USA | LA |
| Maine | USA | ME |
| Maryland | USA | MD |
| Massachusetts | USA | MA |
| Michigan | USA | MI |
| Minnesota | USA | MN |
| Mississippi | USA | MS |
| Missouri | USA | MO |
| Montana | USA | MT |
| Nebraska | USA | NE |
| Nevada | USA | NV |
| New Hampshire | USA | NH |
| New Jersey | USA | NJ |
| New Mexico | USA | NM |
| New York | USA | NY |
| North Carolina | USA | NC |
| North Dakota | USA | ND |
| Ohio | USA | OH |
| Oklahoma | USA | OK |
| Oregon | USA | OR |
| Pennsylvania | USA | PA |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Rhode Island | USA | RI |
| South Carolina | USA | SC |
| South Dakota | USA | SD |
| Tennessee | USA | TN |
| Texas | USA | TX |
| Utah | USA | UT |
| Vermont | USA | VT |
| Virginia | USA | VA |
| Washington | USA | WA |
| West Virginia | USA | WV |
| Wisconsin | USA | WI |
| Wyoming | USA | WY |
| Canada (province and territory codes) | | |
| Alberta | CAN | AB |
| British Columbia | CAN | BC |
| Manitoba | CAN | MB |
| New Brunswick | CAN | NB |
| Newfoundland and Labrador | CAN | NL |
| Northwest Territories | CAN | NT |
| Nova Scotia | CAN | NS |
| Nunavut | CAN | NU |
| Ontario | CAN | ON |
| Prince Edward Island | CAN | PE |
| Quebec | CAN | QC |
| Saskatchewan | CAN | SK |
| Yukon Territory | CAN | YT |
| Afghanistan | AFG | XX |
| Aland Islands | ALA | XX |
| Albania | ALB | XX |
| Algeria | DZA | XX |
| American Samoa | ASM | AS |
| Andorra | AND | XX |
| Angola (Sao Tome, Principe, Cabinda) | AGO | XX |
| Anguilla | AIA | XX |
| Antarctica | ATA | XX |
| Antigua and Barbuda | ATG | XX |
| Argentina | ARG | XX |
| Armenia | ARM | XX |
| Aruba | ABW | XX |
| Australia | AUS | XX |
| Australia and Australian New Guinea | AUS | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Austria | AUT | XX |
| Azerbaijan | AZE | XX |
| Bahamas | BHS | XX |
| Bahrain | BHR | XX |
| Bangladesh (East Pakistan) | BGD | XX |
| Barbados | BRB | XX |
| Belgium | BEL | XX |
| Belize (British Honduras) | BLZ | XX |
| Benin | BEN | XX |
| Bermuda | BMU | XX |
| Bhutan | BTN | XX |
| Bolivia, Plurinational State of | BOL | XX |
| Bonaire, Saint Eustatius and Saba | BES | XX |
| Bosnia and Herzegovina | BIH | XX |
| Botswana | BWA | XX |
| Bouvet Island | BVT | XX |
| Brazil | BRA | XX |
| British Indian Ocean Territory | IOT | XX |
| Virgin Islands, British | VGB | XX |
| Brunei | BRN | XX |
| Bulgaria | BGR | XX |
| Burkina Faso | BFA | XX |
| Burma (Myanmar) | MMR | XX |
| Burundi (Urundi) | BDI | XX |
| Byelorussia (Byelorussian SSR, White Russia) | BLR | XX |
| Cambodia | KHM | XX |
| Cameroon | CMR | XX |
| Panama (Canal Zone) | PAN | XX |
| Cape Verde | CPV | XX |
| Cayman Islands | CYM | XX |
| Central African Republic | CAF | XX |
| Ceylon (Sri Lanka) | LKA | XX |
| Chad | TCD | XX |
| Chile | CHL | XX |
| China (Peoples Republic of China) | CHN | XX |
| Christmas Island | CXR | XX |
| Cocos (Keeling) Islands | CCK | XX |
| Colombia | COL | XX |
| Comoros | COM | XX |
| Congo | COG | XX |
| Congo, Democratic Republic of | COD | XX |
| Cook Islands | COK | XX |
| Costa Rica | CRI | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Cote d'Ivoire | CIV | XX |
| Croatia | HRV | XX |
| Cuba | CUB | XX |
| Curacao | CUW | XX |
| Cyprus | CYP | XX |
| Czech Republic | CZE | XX |
| Denmark, Faroe Islands | DNK | XX |
| Djibouti | DJI | XX |
| Dominica | DMA | XX |
| Dominican Republic | DOM | XX |
| Ecuador | ECU | XX |
| Egypt (United Arab Republic) | EGY | XX |
| El Salvador | SLV | XX |
| England | ENG | XX |
| Equatorial Guinea | GNQ | XX |
| Eritrea | ERI | XX |
| Estonian SSR (Estonia) | EST | XX |
| Ethiopia | ETH | XX |
| Falkland Islands (Malvinas) | FLK | XX |
| Faroe Islands | FRO | XX |
| Fiji | FJI | XX |
| Finland | FIN | XX |
| France, Corsica, Monaco | FRA | XX |
| French Guiana | GUF | XX |
| French Polynesia | PYF | XX |
| French Southern Territories | ATF | XX |
| Gabon | GAB | XX |
| Gambia | GMB | XX |
| Georgia | GEO | XX |
| Germany (East and West) | DEU | XX |
| Ghana | GHA | XX |
| Gibraltar | GIB | XX |
| Greece | GRC | XX |
| Greenland | GRL | XX |
| Grenada | GRD | XX |
| Guadeloupe | GLP | XX |
| Guam | GUM | GU |
| Guatemala | GTM | XX |
| Guernsey | GGY | XX |
| Guinea | GIN | XX |
| Guinea Bissau | GNB | XX |
| Guyana (British Guiana) | GUY | XX |
| Haiti | HTI | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Heard Island and McDonald Islands | HMD | XX |
| Honduras | HND | XX |
| Hong Kong | HKG | XX |
| Hungary | HUN | XX |
| Iceland | ISL | XX |
| India | IND | XX |
| Indonesia (Dutch East Indies) | IDN | XX |
| Iran (Persia) | IRN | XX |
| Iraq | IRQ | XX |
| Ireland (Eire) (Ireland NOS, Republic of Ireland) | IRL | XX |
| Isle of Man | IMN | XX |
| Israel | ISR | XX |
| Italy (Sardinia, Sicily), San Marino, Vatican City | ITA | XX |
| Jamaica | JAM | XX |
| Japan | JPN | XX |
| Jersey | JEY | XX |
| Johnston Atoll | UMI | UM |
| Jordan (Transjordan) and former Arab Palestine | JOR | XX |
| Kazakhstan | KAZ | XX |
| Kenya | KEN | XX |
| Kiribati (Canton, Enderbury, Gilbert, S Lines, Phoenix) | KIR | XX |
| Kuwait | KWT | XX |
| Kyrgyzstan | KGZ | XX |
| Laos, Lao People's Democratic Republic | LAO | XX |
| Latvian SSR (Latvia) | LVA | XX |
| Lebanon | LBN | XX |
| Lesotho | LSO | XX |
| Liberia | LBR | XX |
| Libya (Tripoli, Tripolitania, Cyrenaica), Libyan Arab Jamahiriya | LBY | XX |
| Liechtenstein | LIE | XX |
| Lithuania (Lithuanian SSR) | LTU | XX |
| Luxembourg | LUX | XX |
| Macao (Macau) | MAC | XX |
| Macedonia | MKD | XX |
| Madagascar (Malagasy Republic) | MDG | XX |
| Malawi (Nyasaland) | MWI | XX |
| Malaysia | MYS | XX |
| Mali | MLI | XX |
| Malta | MLT | XX |
| Mariana Islands (Trust Territory of Pacific Islands) | MNP | MP |
| Marshall Islands (Trust Territory Pacific Islands) | MHL | MH |
| Martinique | MTQ | XX |
| Mauritania | MRT | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Mauritius | MUS | XX |
| Mayotte | MYT | XX |
| Mexico | MEX | XX |
| Micronesia (Fed States of) (Caroline, Trust Terr of Pacific) | FSM | FM |
| Mid-East Asia NOS, Maldives | MDV | XX |
| Midway Islands, U.S. Minor Outlying Islands | UMI | UM |
| Moldova | MDA | XX |
| Monaco | MCO | XX |
| Mongolia | MNG | XX |
| Montenegro | MNE | XX |
| Montserrat | MSR | XX |
| Morocco | MAR | XX |
| Mozambique | MOZ | XX |
| Namibia | NAM | XX |
| Nampo-Shoto, Southern (Japan) | JPN | XX |
| Nauru | NRU | XX |
| Nepal, Bhutan, Sikkim | NPL | XX |
| Netherlands | NLD | XX |
| New Caledonia | NCL | XX |
| New Zealand | NZL | XX |
| Nicaragua | NIC | XX |
| Niger | NER | XX |
| Nigeria | NGA | XX |
| Niue | NIU | XX |
| Norfolk Island | NFK | XX |
| North Korea | PRK | XX |
| Northern Ireland | NIR | XX |
| Norway (Svalbard, Jan Mayen) | NOR | XX |
| Oman | OMN | XX |
| Pakistan (West Pakistan) | PAK | XX |
| Palau | PLW | PW |
| Palestine Territory, Occupied | PSE | XX |
| Panama | PAN | XX |
| Papua New Guinea | PNG | XX |
| Paraguay | PRY | XX |
| Peru | PER | XX |
| Philippines (Philippine Islands) | PHL | XX |
| Pitcairn Islands | PCN | XX |
| Poland | POL | XX |
| Portugal (Madeira Islands, Azores, Cape Verde Islands) | PRT | XX |
| Puerto Rico | PRI | PR |
| Qatar | QAT | XX |
| Republic of South Africa | ZAF | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Réunion | REU | XX |
| Romania | ROU | XX |
| Russian SFSR (Russia) | RUS | XX |
| Rwanda (Ruanda) | RWA | XX |
| Ryukyu Islands (Japan) | JPN | XX |
| Samoa | ASM | XX |
| San Marino | SMR | XX |
| Sao Tome & Principe | STP | XX |
| Saudi Arabia | SAU | XX |
| Scotland | SCT | XX |
| Senegal | SEN | XX |
| Serbia | SRB | XX |
| Seychelles | SYC | XX |
| Sierra Leone | SLE | XX |
| Singapore | SGP | XX |
| Sint-Maarten | SXM | XX |
| Slovakia | SVK | XX |
| Slovenia | SVN | XX |
| Solomon Islands | SLB | XX |
| Somalia (Somali Republic, Somaliland) | SOM | XX |
| South Georgia and the South Sandwich Islands | SGS | XX |
| South Sudan | SSD | XX |
| Spain (Canary Islands, Balearic Islands), Andorra | ESP | XX |
| St Pierre and Miquelon | SPM | XX |
| St. Barthelemy | BLM | XX |
| St. Helena, Ascension and Tristan da Cunha | SHN | XX |
| St. Kitts and Nevis | KNA | XX |
| St. Lucia | LCA | XX |
| St. Martin | MAF | XX |
| St. Vincent and the Grenadines | VCT | XX |
| Sudan | SDN | XX |
| Suriname (Dutch Guiana) | SUR | XX |
| Svalbard and Jan Mayen | SJM | XX |
| Swan Islands | UMI | UM |
| Swaziland | SWZ | XX |
| Sweden | SWE | XX |
| Switzerland | CHE | XX |
| Syria | SYR | XX |
| Taiwan (Formosa) (Republic of China) | TWN | XX |
| Tajikistan | TJK | XX |
| Tanzania (Tanganyika, Zanzibar) | TZA | XX |
| Thailand (Siam) | THA | XX |
| Tibet | CHN | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Timor-Leste | TLS | XX |
| Togo | TGO | XX |
| Tokelau | TKL | XX |
| Tonga | TON | XX |
| Trinidad and Tobago | TTO | XX |
| Tunisia | TUN | XX |
| Turkey | TUR | XX |
| Turkmenistan | TKM | XX |
| Turks and Caicos | TCA | XX |
| Tuvalu (Ellice Islands) | TUV | XX |
| U.S. Virgin Islands | VIR | VI |
| Uganda | UGA | XX |
| Ukraine | UKR | XX |
| United Arab Emirates | ARE | XX |
| Uruguay | URY | XX |
| Uzbekistan | UZB | XX |
| Vanuatu | VUT | XX |
| Holy See (Vatican City State) | VAT | XX |
| Venezuela, Bolivarian Republic of | VEN | XX |
| Vietnam (Tonkin, Annam, Cochin China) | VNM | XX |
| Wake Island | UMI | UM |
| Wales | WLS | XX |
| Wallis and Fotuna | WLF | XX |
| Western Sahara | ESH | XX |
| Yemen | YEM | XX |
| Zambia (Northern Rhodesia) | ZMB | XX |
| Zimbabwe (Rhodesia, Southern Rhodesia) | ZWE | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| General: Codes to Use In the Absence of More Specific Information | | |
| United States, NOS | USA | US |
| Canada, NOS | CAN | CD |
| Africa, NOS (Central, Equatorial) | ZZF | YY |
| Asia, NOS | ZZA | YY |
| Asian and Arab Countries | ZZA | YY |
| Atlantic/Caribbean Area | ZZN | YY |
| Baltic Republic(s), NOS (Baltic States, NOS) | ZZE | YY |
| Central America | ZZC | YY |
| Czechoslovakia | CSK | YY |
| East Asia | ZZA | YY |
| Europe, NOS (Central, Eastern, Northern, Southern, Western) | ZZE | YY |
| Latin America, NOS | ZZU | YY |
| Near East | ZZA | YY |
| North America, NOS | ZZN | YY |
| Other Atlantic/Caribbean Area (not on detailed list) | ZZN | YY |
| Other Mainland Europe (not on detailed list) | ZZE | YY |
| Other Mediterranean Isles (not on detailed list) | ZZE | YY |
| Other Pacific Area (not on first list) | ZZP | YY |
| Pacific Area, NOS | ZZP | YY |
| Pacific Islands, NOS | ZZP | YY |
| Romance-Language Countries | ZZE | YY |
| South America, NOS | ZZS | YY |
| South American Islands | ZZS | YY |
| United Kingdom, NOS | GBR | XX |
| Yugoslavia | YUG | YY |
| Not U.S., but no other information | ZZX | YY |
| Unknown, no mention in patient record | ZZU | ZZ |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Obsolete: State/Province or Country Codes That Must Not Be Used for Current Coding | | |
| (May have been assigned during conversion, so may be present in pre-2013 data) | | |
| New England and New Jersey | USA | NN |
| Maritime Provinces (New Brunswick, Newfound, Nova Scotia, PE) | CAN | MM |
| Northwest Territories, Yukon Territory | CAN | YN |
| Prairie Provinces (Alberta, Manitoba, Saskatchewan) | CAN | PP |
| African Coastal Islands (previously in South Africa, NOS) | XIF | YY |
| Arabian Peninsula | XAP | YY |
| Caucasian Republics of the USSR | XCR | YY |
| China, NOS | XCH | YY |
| East Africa | XEF | YY |
| England, Channel Islands, Isle of Man | XEN | XX |
| Ethiopia (Abyssinia), Eritrea | XET | YY |
| Germanic Countries | XGR | YY |
| Indochina | XSE | YY |
| Israel and former Jewish Palestine | XIS | YY |
| Korea (Not Specified whether North or South) | KOR | XX |
| Malaysia, Singapore, Brunei | XMS | YY |
| Melanesian Islands, Solomon Islands | XML | YY |
| Micronesian Islands | XMC | YY |
| North Africa | XNF | YY |
| North American Islands | XNI | YY |
| Other Asian Republics of the USSR | XOR | YY |
| Other Caribbean Islands | XCB | YY |
| Other West African Countries | XWF | YY |
| Polynesian Islands | XPL | YY |
| Republic of South Africa, Botswana, Lesotho, Namibia, Swaziland | XSF | YY |
| Scandinavia | XSC | YY |
| Slavic Countries | XSL | XX |
| South Africa, NOS | XSF | YY |
| Southeast Asia | XSE | YY |
| Sudanese Countries | XSD | YY |
| Ukraine and Moldavia | XUM | YY |
| West Africa, NOS (French Africa, NOS) | XWF | YY |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| United States (state and armed forces codes) | | |
| Alabama | USA | AL |
| Alaska | USA | AK |
| Arizona | USA | AZ |
| Arkansas | USA | AR |
| Armed Forces Americas | USA | AA |
| Armed Forces Canada, Europe, Middle East, Africa | USA | AE |
| Armed Forces Pacific | USA | AP |
| California | USA | CA |
| Colorado | USA | CO |
| Connecticut | USA | CT |
| Delaware | USA | DE |
| District of Columbia | USA | DC |
| Florida | USA | FL |
| Georgia | USA | GA |
| Hawaii | USA | HI |
| Idaho | USA | ID |
| Illinois | USA | IL |
| Indiana | USA | IN |
| Iowa | USA | IA |
| Kansas | USA | KS |
| Kentucky | USA | KY |
| Louisiana | USA | LA |
| Maine | USA | ME |
| Maryland | USA | MD |
| Massachusetts | USA | MA |
| Michigan | USA | MI |
| Minnesota | USA | MN |
| Mississippi | USA | MS |
| Missouri | USA | MO |
| Montana | USA | MT |
| Nebraska | USA | NE |
| Nevada | USA | NV |
| New Hampshire | USA | NH |
| New Jersey | USA | NJ |
| New Mexico | USA | NM |
| New York | USA | NY |
| North Carolina | USA | NC |
| North Dakota | USA | ND |
| Ohio | USA | OH |
| Oklahoma | USA | OK |
| Oregon | USA | OR |
| Pennsylvania | USA | PA |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Rhode Island | USA | RI |
| South Carolina | USA | SC |
| South Dakota | USA | SD |
| Tennessee | USA | TN |
| Texas | USA | TX |
| Utah | USA | UT |
| Vermont | USA | VT |
| Virginia | USA | VA |
| Washington | USA | WA |
| West Virginia | USA | WV |
| Wisconsin | USA | WI |
| Wyoming | USA | WY |
| Canada (province and territory codes) | | |
| Alberta | CAN | AB |
| British Columbia | CAN | BC |
| Manitoba | CAN | MB |
| New Brunswick | CAN | NB |
| Newfoundland and Labrador | CAN | NL |
| Northwest Territories | CAN | NT |
| Nova Scotia | CAN | NS |
| Nunavut | CAN | NU |
| Ontario | CAN | ON |
| Prince Edward Island | CAN | PE |
| Quebec | CAN | QC |
| Saskatchewan | CAN | SK |
| Yukon Territory | CAN | YT |
| Afghanistan | AFG | XX |
| Aland Islands | ALA | XX |
| Albania | ALB | XX |
| Algeria | DZA | XX |
| American Samoa | ASM | AS |
| Andorra | AND | XX |
| Angola (Sao Tome, Principe, Cabinda) | AGO | XX |
| Anguilla | AIA | XX |
| Antarctica | ATA | XX |
| Antigua and Barbuda | ATG | XX |
| Argentina | ARG | XX |
| Armenia | ARM | XX |
| Aruba | ABW | XX |
| Australia | AUS | XX |
| Australia and Australian New Guinea | AUS | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Austria | AUT | XX |
| Azerbaijan | AZE | XX |
| Bahamas | BHS | XX |
| Bahrain | BHR | XX |
| Bangladesh (East Pakistan) | BGD | XX |
| Barbados | BRB | XX |
| Belgium | BEL | XX |
| Belize (British Honduras) | BLZ | XX |
| Benin | BEN | XX |
| Bermuda | BMU | XX |
| Bhutan | BTN | XX |
| Bolivia, Plurinational State of | BOL | XX |
| Bonaire, Saint Eustatius and Saba | BES | XX |
| Bosnia and Herzegovina | BIH | XX |
| Botswana | BWA | XX |
| Bouvet Island | BVT | XX |
| Brazil | BRA | XX |
| British Indian Ocean Territory | IOT | XX |
| Virgin Islands, British | VGB | XX |
| Brunei | BRN | XX |
| Bulgaria | BGR | XX |
| Burkina Faso | BFA | XX |
| Burma (Myanmar) | MMR | XX |
| Burundi (Urundi) | BDI | XX |
| Byelorussia (Byelorussian SSR, White Russia) | BLR | XX |
| Cambodia | KHM | XX |
| Cameroon | CMR | XX |
| Panama (Canal Zone) | PAN | XX |
| Cape Verde | CPV | XX |
| Cayman Islands | CYM | XX |
| Central African Republic | CAF | XX |
| Ceylon (Sri Lanka) | LKA | XX |
| Chad | TCD | XX |
| Chile | CHL | XX |
| China (Peoples Republic of China) | CHN | XX |
| Christmas Island | CXR | XX |
| Cocos (Keeling) Islands | CCK | XX |
| Colombia | COL | XX |
| Comoros | COM | XX |
| Congo | COG | XX |
| Congo, Democratic Republic of | COD | XX |
| Cook Islands | COK | XX |
| Costa Rica | CRI | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Cote d'Ivoire | CIV | XX |
| Croatia | HRV | XX |
| Cuba | CUB | XX |
| Curacao | CUW | XX |
| Cyprus | CYP | XX |
| Czech Republic | CZE | XX |
| Denmark, Faroe Islands | DNK | XX |
| Djibouti | DJI | XX |
| Dominica | DMA | XX |
| Dominican Republic | DOM | XX |
| Ecuador | ECU | XX |
| Egypt (United Arab Republic) | EGY | XX |
| El Salvador | SLV | XX |
| England | ENG | XX |
| Equatorial Guinea | GNQ | XX |
| Eritrea | ERI | XX |
| Estonian SSR (Estonia) | EST | XX |
| Ethiopia | ETH | XX |
| Falkland Islands (Malvinas) | FLK | XX |
| Faroe Islands | FRO | XX |
| Fiji | FJI | XX |
| Finland | FIN | XX |
| France, Corsica, Monaco | FRA | XX |
| French Guiana | GUF | XX |
| French Polynesia | PYF | XX |
| French Southern Territories | ATF | XX |
| Gabon | GAB | XX |
| Gambia | GMB | XX |
| Georgia | GEO | XX |
| Germany (East and West) | DEU | XX |
| Ghana | GHA | XX |
| Gibraltar | GIB | XX |
| Greece | GRC | XX |
| Greenland | GRL | XX |
| Grenada | GRD | XX |
| Guadeloupe | GLP | XX |
| Guam | GUM | GU |
| Guatemala | GTM | XX |
| Guernsey | GGY | XX |
| Guinea | GIN | XX |
| Guinea Bissau | GNB | XX |
| Guyana (British Guiana) | GUY | XX |
| Haiti | HTI | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Heard Island and McDonald Islands | HMD | XX |
| Honduras | HND | XX |
| Hong Kong | HKG | XX |
| Hungary | HUN | XX |
| Iceland | ISL | XX |
| India | IND | XX |
| Indonesia (Dutch East Indies) | IDN | XX |
| Iran (Persia) | IRN | XX |
| Iraq | IRQ | XX |
| Ireland (Eire) (Ireland NOS, Republic of Ireland) | IRL | XX |
| Isle of Man | IMN | XX |
| Israel | ISR | XX |
| Italy (Sardinia, Sicily), San Marino, Vatican City | ITA | XX |
| Jamaica | JAM | XX |
| Japan | JPN | XX |
| Jersey | JEY | XX |
| Johnston Atoll | UMI | UM |
| Jordan (Transjordan) and former Arab Palestine | JOR | XX |
| Kazakhstan | KAZ | XX |
| Kenya | KEN | XX |
| Kiribati (Canton, Enderbury, Gilbert, S Lines, Phoenix) | KIR | XX |
| Kuwait | KWT | XX |
| Kyrgyzstan | KGZ | XX |
| Laos, Lao People's Democratic Republic | LAO | XX |
| Latvian SSR (Latvia) | LVA | XX |
| Lebanon | LBN | XX |
| Lesotho | LSO | XX |
| Liberia | LBR | XX |
| Libya (Tripoli, Tripolitania, Cyrenaica), Libyan Arab Jamahiriya | LBY | XX |
| Liechtenstein | LIE | XX |
| Lithuania (Lithuanian SSR) | LTU | XX |
| Luxembourg | LUX | XX |
| Macao (Macau) | MAC | XX |
| Macedonia | MKD | XX |
| Madagascar (Malagasy Republic) | MDG | XX |
| Malawi (Nyasaland) | MWI | XX |
| Malaysia | MYS | XX |
| Mali | MLI | XX |
| Malta | MLT | XX |
| Mariana Islands (Trust Territory of Pacific Islands) | MNP | MP |
| Marshall Islands (Trust Territory Pacific Islands) | MHL | MH |
| Martinique | MTQ | XX |
| Mauritania | MRT | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Mauritius | MUS | XX |
| Mayotte | MYT | XX |
| Mexico | MEX | XX |
| Micronesia (Fed States of) (Caroline, Trust Terr of Pacific) | FSM | FM |
| Mid-East Asia NOS, Maldives | MDV | XX |
| Midway Islands, U.S. Minor Outlying Islands | UMI | UM |
| Moldova | MDA | XX |
| Monaco | MCO | XX |
| Mongolia | MNG | XX |
| Montenegro | MNE | XX |
| Montserrat | MSR | XX |
| Morocco | MAR | XX |
| Mozambique | MOZ | XX |
| Namibia | NAM | XX |
| Nampo-Shoto, Southern (Japan) | JPN | XX |
| Nauru | NRU | XX |
| Nepal, Bhutan, Sikkim | NPL | XX |
| Netherlands | NLD | XX |
| New Caledonia | NCL | XX |
| New Zealand | NZL | XX |
| Nicaragua | NIC | XX |
| Niger | NER | XX |
| Nigeria | NGA | XX |
| Niue | NIU | XX |
| Norfolk Island | NFK | XX |
| North Korea | PRK | XX |
| Northern Ireland | NIR | XX |
| Norway (Svalbard, Jan Mayen) | NOR | XX |
| Oman | OMN | XX |
| Pakistan (West Pakistan) | PAK | XX |
| Palau | PLW | PW |
| Palestine Territory, Occupied | PSE | XX |
| Panama | PAN | XX |
| Papua New Guinea | PNG | XX |
| Paraguay | PRY | XX |
| Peru | PER | XX |
| Philippines (Philippine Islands) | PHL | XX |
| Pitcairn Islands | PCN | XX |
| Poland | POL | XX |
| Portugal (Madeira Islands, Azores, Cape Verde Islands) | PRT | XX |
| Puerto Rico | PRI | PR |
| Qatar | QAT | XX |
| Republic of South Africa | ZAF | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Réunion | REU | XX |
| Romania | ROU | XX |
| Russian SFSR (Russia) | RUS | XX |
| Rwanda (Ruanda) | RWA | XX |
| Ryukyu Islands (Japan) | JPN | XX |
| Samoa | ASM | XX |
| San Marino | SMR | XX |
| Sao Tome & Principe | STP | XX |
| Saudi Arabia | SAU | XX |
| Scotland | SCT | XX |
| Senegal | SEN | XX |
| Serbia | SRB | XX |
| Seychelles | SYC | XX |
| Sierra Leone | SLE | XX |
| Singapore | SGP | XX |
| Sint-Maarten | SXM | XX |
| Slovakia | SVK | XX |
| Slovenia | SVN | XX |
| Solomon Islands | SLB | XX |
| Somalia (Somali Republic, Somaliland) | SOM | XX |
| South Georgia and the South Sandwich Islands | SGS | XX |
| South Sudan | SSD | XX |
| Spain (Canary Islands, Balearic Islands), Andorra | ESP | XX |
| St Pierre and Miquelon | SPM | XX |
| St. Barthelemy | BLM | XX |
| St. Helena, Ascension and Tristan da Cunha | SHN | XX |
| St. Kitts and Nevis | KNA | XX |
| St. Lucia | LCA | XX |
| St. Martin | MAF | XX |
| St. Vincent and the Grenadines | VCT | XX |
| Sudan | SDN | XX |
| Suriname (Dutch Guiana) | SUR | XX |
| Svalbard and Jan Mayen | SJM | XX |
| Swan Islands | UMI | UM |
| Swaziland | SWZ | XX |
| Sweden | SWE | XX |
| Switzerland | CHE | XX |
| Syria | SYR | XX |
| Taiwan (Formosa) (Republic of China) | TWN | XX |
| Tajikistan | TJK | XX |
| Tanzania (Tanganyika, Zanzibar) | TZA | XX |
| Thailand (Siam) | THA | XX |
| Tibet | CHN | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Preferred: Specific Codes for Use Where the Detail is Known | | |
| Timor-Leste | TLS | XX |
| Togo | TGO | XX |
| Tokelau | TKL | XX |
| Tonga | TON | XX |
| Trinidad and Tobago | TTO | XX |
| Tunisia | TUN | XX |
| Turkey | TUR | XX |
| Turkmenistan | TKM | XX |
| Turks and Caicos | TCA | XX |
| Tuvalu (Ellice Islands) | TUV | XX |
| U.S. Virgin Islands | VIR | VI |
| Uganda | UGA | XX |
| Ukraine | UKR | XX |
| United Arab Emirates | ARE | XX |
| Uruguay | URY | XX |
| Uzbekistan | UZB | XX |
| Vanuatu | VUT | XX |
| Holy See (Vatican City State) | VAT | XX |
| Venezuela, Bolivarian Republic of | VEN | XX |
| Vietnam (Tonkin, Annam, Cochin China) | VNM | XX |
| Wake Island | UMI | UM |
| Wales | WLS | XX |
| Wallis and Fotuna | WLF | XX |
| Western Sahara | ESH | XX |
| Yemen | YEM | XX |
| Zambia (Northern Rhodesia) | ZMB | XX |
| Zimbabwe (Rhodesia, Southern Rhodesia) | ZWE | XX |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| General: Codes to Use In the Absence of More Specific Information | | |
| United States, NOS | USA | US |
| Canada, NOS | CAN | CD |
| Africa, NOS (Central, Equatorial) | ZZF | YY |
| Asia, NOS | ZZA | YY |
| Asian and Arab Countries | ZZA | YY |
| Atlantic/Caribbean Area | ZZN | YY |
| Baltic Republic(s), NOS (Baltic States, NOS) | ZZE | YY |
| Central America | ZZC | YY |
| Czechoslovakia | CSK | YY |
| East Asia | ZZA | YY |
| Europe, NOS (Central, Eastern, Northern, Southern, Western) | ZZE | YY |
| Latin America, NOS | ZZU | YY |
| Near East | ZZA | YY |
| North America, NOS | ZZN | YY |
| Other Atlantic/Caribbean Area (not on detailed list) | ZZN | YY |
| Other Mainland Europe (not on detailed list) | ZZE | YY |
| Other Mediterranean Isles (not on detailed list) | ZZE | YY |
| Other Pacific Area (not on first list) | ZZP | YY |
| Pacific Area, NOS | ZZP | YY |
| Pacific Islands, NOS | ZZP | YY |
| Romance-Language Countries | ZZE | YY |
| South America, NOS | ZZS | YY |
| South American Islands | ZZS | YY |
| United Kingdom, NOS | GBR | XX |
| Yugoslavia | YUG | YY |
| Not U.S., but no other information | ZZX | YY |
| Unknown, no mention in patient record | ZZU | ZZ |

| Geographic Area | Country Code | State or Province Code |
|--|--------------|------------------------|
| Obsolete: State/Province or Country Codes That Must Not Be Used for Current Coding | | |
| (May have been assigned during conversion, so may be present in pre-2013 data) | | |
| New England and New Jersey | USA | NN |
| Maritime Provinces (New Brunswick, Newfound, Nova Scotia, PE) | CAN | MM |
| Northwest Territories, Yukon Territory | CAN | YN |
| Prairie Provinces (Alberta, Manitoba, Saskatchewan) | CAN | PP |
| African Coastal Islands (previously in South Africa, NOS) | XIF | YY |
| Arabian Peninsula | XAP | YY |
| Caucasian Republics of the USSR | XCR | YY |
| China, NOS | XCH | YY |
| East Africa | XEF | YY |
| England, Channel Islands, Isle of Man | XEN | XX |
| Ethiopia (Abyssinia), Eritrea | XET | YY |
| Germanic Countries | XGR | YY |
| Indochina | XSE | YY |
| Israel and former Jewish Palestine | XIS | YY |
| Korea (Not Specified whether North or South) | KOR | XX |
| Malaysia, Singapore, Brunei | XMS | YY |
| Melanesian Islands, Solomon Islands | XML | YY |
| Micronesian Islands | XMC | YY |
| North Africa | XNF | YY |
| North American Islands | XNI | YY |
| Other Asian Republics of the USSR | XOR | YY |
| Other Caribbean Islands | XCB | YY |
| Other West African Countries | XWF | YY |
| Polynesian Islands | XPL | YY |
| Republic of South Africa, Botswana, Lesotho, Namibia, Swaziland | XSF | YY |
| Scandinavia | XSC | YY |
| Slavic Countries | XSL | XX |
| South Africa, NOS | XSF | YY |
| Southeast Asia | XSE | YY |
| Sudanese Countries | XSD | YY |
| Ukraine and Moldavia | XUM | YY |
| West Africa, NOS (French Africa, NOS) | XWF | YY |



AMERICAN COLLEGE OF SURGEONS
663 N. SAINT CLAIR ST.
CHICAGO, IL 60611-321